,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,1,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line,Confirmatory,,
1,5,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H322M Non-Small Cell Lung cell line,Confirmatory,,
2,7,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H460 Non-Small Cell Lung cell line,Confirmatory,,
3,9,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HOP-62 Non-Small Cell Lung cell line,Confirmatory,,
4,13,1,1,,535138,2662,Unspecified,,,,,NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line,Confirmatory,,
5,19,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the A549/ATCC Non-Small Cell Lung cell line,Confirmatory,,
6,21,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the EKVX Non-Small Cell Lung cell line,Confirmatory,,
7,23,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the LOX IMVI Melanoma cell line,Confirmatory,,
8,25,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the M14 Melanoma cell line,Confirmatory,,
9,29,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MALME-3M Melanoma cell line,Confirmatory,,
10,31,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the UACC-62 Melanoma cell line,Confirmatory,,
11,33,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the UACC-257 Melanoma cell line,Confirmatory,,
12,35,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-2 Melanoma cell line,Confirmatory,,
13,37,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Melanoma cell line,Confirmatory,,
14,39,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-28 Melanoma cell line,Confirmatory,,
15,41,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the PC-3 Prostate cell line,Confirmatory,,
16,43,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the DU-145 Prostate cell line,Confirmatory,,
17,45,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-268 Central Nervous System cell line,Confirmatory,,
18,47,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-295 Central Nervous System cell line,Confirmatory,,
19,49,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-539 Central Nervous System cell line,Confirmatory,,
20,53,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SNB-19 Central Nervous System cell line,Confirmatory,,
21,55,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SNB-75 Central Nervous System cell line,Confirmatory,,
22,59,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the U251 Central Nervous System cell line,Confirmatory,,
23,65,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HT29 Colon cell line,Confirmatory,,
24,67,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the COLO 205 Colon cell line,Confirmatory,,
25,71,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCT-15 Colon cell line,Confirmatory,,
26,73,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the KM12 Colon cell line,Confirmatory,,
27,77,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCC-2998 Colon cell line,Confirmatory,,
28,79,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCT-116 Colon cell line,Confirmatory,,
29,81,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SW-620 Colon cell line,Confirmatory,,
30,83,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MCF7 Breast cell line,Confirmatory,,
31,85,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-435 Breast cell line,Confirmatory,,
32,87,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-N Breast cell line,Confirmatory,,
33,89,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the BT-549 Breast cell line,Confirmatory,,
34,91,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the T-47D Breast cell line,Confirmatory,,
35,93,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI/ADR-RES Breast cell line,Confirmatory,,
36,95,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-231/ATCC Breast cell line,Confirmatory,,
37,97,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HS 578T Breast cell line,Confirmatory,,
38,99,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-3 Ovarian cell line,Confirmatory,,
39,101,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the IGROV1 Ovarian cell line,Confirmatory,,
40,103,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-OV-3 Ovarian cell line,Confirmatory,,
41,105,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-4 Ovarian cell line,Confirmatory,,
42,107,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-5 Ovarian cell line,Confirmatory,,
43,109,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-8 Ovarian cell line,Confirmatory,,
44,113,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the RPMI-8226 Leukemia cell line,Confirmatory,,
45,115,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SR Leukemia cell line,Confirmatory,,
46,119,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the CCRF-CEM Leukemia cell line,Confirmatory,,
47,121,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the K-562 Leukemia cell line,Confirmatory,,
48,123,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MOLT-4 Leukemia cell line,Confirmatory,,
49,125,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Leukemia cell line,Confirmatory,,
50,129,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the A498 Renal cell line,Confirmatory,,
51,131,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the CAKI-1 Renal cell line,Confirmatory,,
52,133,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the RXF 393 Renal cell line,Confirmatory,,
53,137,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the 786-0 Renal cell line,Confirmatory,,
54,139,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the ACHN Renal cell line,Confirmatory,,
55,141,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the TK-10 Renal cell line,Confirmatory,,
56,143,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the UO-31 Renal cell line,Confirmatory,,
57,145,1,1,,535138,2662,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SN12C Renal cell line,Confirmatory,,
58,421,1,3,,17389545,2662,Inactive,,,,,Cell Viability - BJ,Confirmatory,,
59,426,1,2,,17389545,2662,Inactive,,,,,Cell Viability - Jurkat,Confirmatory,,
60,427,1,1,,17389545,2662,Inactive,,,,,Cell Viability - Hek293,Confirmatory,,
61,433,1,1,,17389545,2662,Inactive,,,,,Cell Viability - HepG2,Confirmatory,,
62,434,1,2,,17389545,2662,Inactive,,,,,Cell Viability - MRC5,Confirmatory,,
63,435,1,2,,17389545,2662,Inactive,,,,,Cell Viability - SK-N-SH,Confirmatory,,
64,445,3,1,,17389545,2662,Inconclusive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
65,530,1,1,,17389545,2662,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
66,540,1,1,,17389545,2662,Inactive,,,,,Cell Viability - N2a,Confirmatory,,
67,541,1,1,,17389545,2662,Active,,,,,Cell Viability - NIH 3T3,Confirmatory,,
68,542,1,1,,17389545,2662,Inactive,,,,,Cell Viability - HUV-EC-C,Confirmatory,,
69,543,1,1,,17389545,2662,Inconclusive,,,,,Cell Viability - H-4-II-E,Confirmatory,,
70,544,2,1,,17389545,2662,Inconclusive,,,,,Cell Viability - SH-SY5Y,Confirmatory,,
71,545,1,1,,17389545,2662,Inconclusive,,,,,Cell Viability - Renal Proximal Tubule,Confirmatory,,
72,546,1,1,,17389545,2662,Inactive,,,,,Cell Viability - Mesenchymal,Confirmatory,,
73,584,1,3,,17389545,2662,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
74,585,1,4,,17389545,2662,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
75,595,1,3,,17389545,2662,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
76,596,1,2,,17389545,2662,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
77,603,1,2,,17389545,2662,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
78,605,1,2,,17389545,2662,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
79,654,1,1,,17389545,2662,Inactive,,,,,Cellular Toxicity (caspase-3) HepG2,Confirmatory,,
80,655,1,1,,17389545,2662,Inactive,,,,,Cellular Toxicity (caspase-3) Jurkat,Confirmatory,,
81,656,1,1,,17389545,2662,Inactive,,,,,Cellular Toxicity (caspase-3) HUV-EC-C,Confirmatory,,
82,657,1,1,,17389545,2662,Inactive,,,,,Cellular Toxicity (caspase-3) SHSY5Y,Confirmatory,,
83,658,1,1,,17389545,2662,Inactive,,,,,Cellular Toxicity (caspase-3) BJ,Confirmatory,,
84,659,1,1,,17389545,2662,Inactive,,,,,Cellular Toxicity (caspase-3) MRC-5,Confirmatory,,
85,660,1,1,,17389545,2662,Inconclusive,,,,,Cellular Toxicity (caspase-3) Mesangial,Confirmatory,,
86,661,1,1,,17389545,2662,Inactive,,,,,Cellular Toxicity (caspase-3) SK-N-SH,Confirmatory,,
87,662,1,1,,17389545,2662,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
88,663,1,1,,17389545,2662,Inconclusive,,,,,Cellular Toxicity (caspase-3) H-4-II-E,Confirmatory,,
89,664,1,1,,17389545,2662,Inactive,,,,,Cellular Toxicity (caspase-3) Hek293,Confirmatory,,
90,665,1,1,,17389545,2662,Inactive,,,,,Cellular Toxicity (caspase-3) N2a,Confirmatory,,
91,666,1,1,,17389545,2662,Inactive,,,,,Cellular Toxicity (caspase-3) NIH 3T3,Confirmatory,,
92,667,1,1,,17389545,2662,Inactive,,,,,Cellular Toxicity (caspase-3) Renal Proximal Tubule,Confirmatory,,
93,875,1,2,,17389545,2662,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
94,880,2,1,,17389545,2662,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
95,880,2,1,,17389545,2662,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
96,880,2,1,,26747363,2662,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
97,880,2,1,,26747363,2662,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
98,881,2,2,,17389545,2662,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
99,884,1,2,,17389545,2662,Active,13435386.0,1576.0,15.8489,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
100,885,1,2,,17389545,2662,Inactive,13435386.0,1576.0,15.8489,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
101,886,1,2,,17389545,2662,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
102,886,1,2,,17389545,2662,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
103,887,1,2,,17389545,2662,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
104,889,1,3,,17389545,2662,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
105,892,1,2,,17389545,2662,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
106,893,1,2,,17389545,2662,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
107,893,1,2,,17389545,2662,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
108,894,2,1,,17389545,2662,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
109,894,2,1,,26747363,2662,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
110,900,1,3,,17389545,2662,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
111,902,1,2,,17389545,2662,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
112,910,1,2,,17389545,2662,Inactive,4504349.0,3043.0,,Potency,Confirmation and Secondary Assay for Modulators of Hemoglobin Beta Chain Splicing at IVS2 654 locus,Confirmatory,,
113,912,1,2,,17389545,2662,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
114,921,1,2,,17389545,2662,Inactive,,,,Potency,Cell Viability - LYMP2-001,Confirmatory,,
115,923,1,2,,17389545,2662,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
116,924,1,2,,17389545,2662,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
117,925,1,2,,17389545,2662,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
118,926,1,2,,17389545,2662,Inconclusive,38016895.0,7253.0,0.7943,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
119,927,1,3,,17389545,2662,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
120,930,1,2,,17389545,2662,Inactive,4504349.0,3043.0,,Potency,Confirmation and Secondary Assay for Modulators of Hemoglobin Beta Chain Splicing at IVS2 705 locus,Confirmatory,,
121,938,1,2,,17389545,2662,Inactive,38016895.0,7253.0,0.7943,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
122,940,1,2,,26612517,2662,Active,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
123,946,1,2,,17389545,2662,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Dead Cells,Confirmatory,,
124,947,1,2,,17389545,2662,Inconclusive,,,19.9526,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Live Cells,Confirmatory,,
125,948,1,2,,17389545,2662,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 16 hr,Confirmatory,,
126,955,1,2,,17389545,2662,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Live Cells,Confirmatory,,
127,960,1,2,,17389545,2662,Inconclusive,,,15.8489,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Dead Cells,Confirmatory,,
128,961,1,2,,17389545,2662,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Dead Cells,Confirmatory,,
129,962,1,2,,17389545,2662,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Live Cells,Confirmatory,,
130,963,1,2,,17389545,2662,Inactive,,,,Potency,Cell Viability - LYMP1-003 - Assay at 24 hr,Confirmatory,,
131,964,1,2,,17389545,2662,Inactive,,,,Potency,Cell Viability - LYMP1-003 - Assay at 40 hr,Confirmatory,,
132,965,1,2,,17389545,2662,Inactive,,,,Potency,Cell Viability - LYMP2-003,Confirmatory,,
133,966,1,2,,17389545,2662,Inactive,,,,Potency,Cell Viability - LYMP2-004,Confirmatory,,
134,967,1,2,,17389545,2662,Inactive,,,,Potency,Cell Viability - LYMP2-005,Confirmatory,,
135,968,1,2,,17389545,2662,Inactive,,,,Potency,Cell Viability - LYMP2-009,Confirmatory,,
136,969,1,2,,17389545,2662,Inactive,,,,Potency,Cell Viability - LYMP2-011,Confirmatory,,
137,970,1,2,,17389545,2662,Inactive,,,,Potency,Cell Viability - LYMP2-013,Confirmatory,,
138,971,1,2,,17389545,2662,Inactive,,,,Potency,Cell Viability - LYMP2-015,Confirmatory,,
139,972,1,2,,17389545,2662,Inactive,,,,Potency,Cell Viability - LYMP2-017,Confirmatory,,
140,973,1,2,,17389545,2662,Inactive,,,,Potency,Cell Viability - LYMP2-019,Confirmatory,,
141,974,1,2,,17389545,2662,Inactive,,,,Potency,Cell Viability - LYMP2-021,Confirmatory,,
142,975,1,2,,17389545,2662,Inactive,,,,Potency,Cell Viability - LYMP2-023,Confirmatory,,
143,976,1,2,,17389545,2662,Inactive,,,,Potency,Cell Viability - LYMP2-025,Confirmatory,,
144,977,1,2,,17389545,2662,Inactive,,,,Potency,Cell Viability - LYMP2-002,Confirmatory,,
145,978,1,2,,17389545,2662,Inactive,,,,Potency,Cell Viability - LYMP2-006,Confirmatory,,
146,979,1,2,,17389545,2662,Inactive,,,,Potency,Cell Viability - LYMP2-007,Confirmatory,,
147,980,1,2,,17389545,2662,Inactive,,,,Potency,Cell Viability - LYMP2-008,Confirmatory,,
148,981,1,2,,17389545,2662,Inactive,,,,Potency,Cell Viability - LYMP2-010,Confirmatory,,
149,982,1,2,,17389545,2662,Inactive,,,,Potency,Cell Viability - LYMP2-012,Confirmatory,,
150,983,1,2,,17389545,2662,Inactive,,,,Potency,Cell Viability - LYMP2-014,Confirmatory,,
151,984,1,2,,17389545,2662,Inactive,,,,Potency,Cell Viability - LYMP2-016,Confirmatory,,
152,985,1,2,,17389545,2662,Inactive,,,,Potency,Cell Viability - LYMP2-018,Confirmatory,,
153,986,1,2,,17389545,2662,Inactive,,,,Potency,Cell Viability - LYMP2-020,Confirmatory,,
154,987,1,2,,17389545,2662,Inactive,,,,Potency,Cell Viability - LYMP2-022,Confirmatory,,
155,988,1,2,,17389545,2662,Inactive,,,,Potency,Cell Viability - LYMP2-024,Confirmatory,,
156,989,1,2,,17389545,2662,Inactive,,,,Potency,Cell Viability - LYMP2-026,Confirmatory,,
157,993,1,2,,17389545,2662,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 24 hr,Confirmatory,,
158,994,1,2,,17389545,2662,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 40 hr,Confirmatory,,
159,995,1,2,,17389545,2662,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
160,1030,2,1,,17389545,2662,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
161,1030,2,1,,26747363,2662,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
162,1080,1,1,,26612517,2662,Active,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin EP2 receptor - Primary Counterscreens,Other,,
163,1189,1,5,,48413391,2662,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary SingleCellCall Results,Other,,
164,1195,1,2,,48415737,2662,Active,,,,,DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database,Other,,
165,1208,1,3,,48413391,2662,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Rat Bioassay Results,Other,,
166,1379,1,2,,26747363,2662,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
167,1421,1,1,,26612517,2662,Active,31881630.0,5732.0,20.0,Active Concentration,Modulators of the EP2 prostaglandin EP2 receptor - Primary Dose Response,Confirmatory,,
168,1422,1,1,,26612517,2662,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
169,1452,1,1,,17389545,2662,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
170,1454,1,1,,26747363,2662,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
171,1457,1,1,,17389545,2662,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
172,1457,1,1,,26747363,2662,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
173,1458,1,1,,17389545,2662,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
174,1458,1,1,,26747363,2662,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
175,1460,1,3,,26747363,2662,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
176,1463,1,1,,26747363,2662,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
177,1467,1,3,,26747363,2662,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
178,1468,1,1,,26747363,2662,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
179,1469,1,1,,17389545,2662,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
180,1469,1,1,,26747363,2662,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
181,1471,2,1,,17389545,2662,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
182,1471,2,1,,26747363,2662,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
183,1476,2,1,,17389545,2662,Inconclusive,281307097.0,,39.8107,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
184,1476,2,1,,26747363,2662,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
185,1477,1,1,,17389545,2662,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
186,1477,1,1,,26747363,2662,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
187,1478,2,1,,17389545,2662,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
188,1478,2,1,,26747363,2662,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
189,1479,1,2,,17389545,2662,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
190,1479,1,2,,26747363,2662,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
191,1487,1,1,,17389545,2662,Inconclusive,27436948.0,4000.0,35.4813,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
192,1490,2,1,,17389545,2662,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
193,1490,2,1,,26747363,2662,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
194,1490,2,1,,49666478,2662,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
195,1511,1,3,,49666478,2662,Inactive,487738.0,3757.0,,,Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents,Screening,,
196,1519,1,3,,26747363,2662,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
197,1527,1,3,,49666478,2662,Inactive,7381449.0,14678525.0,,,Primary biochemical high throughput screening assay to identify inhibitors of VIM-2 metallo-beta-lactamase,Screening,,
198,1529,1,1,,49666478,2662,Inactive,42794767.0,4215.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase3 Wildtype",Screening,,
199,1530,1,1,,49666478,2662,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase 2 mutant",Screening,,
200,1531,1,1,,49666478,2662,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 binding to MEK Kinase 2 Wildtype",Screening,,
201,1554,1,1,,49666478,2662,Inactive,,,,,MLPCN Ras selective lethality-BJeLR viability,Screening,,
202,1556,1,4,,49666478,2662,Inactive,27368096.0,,,,Epi-absorbance primary biochemical high throughput screening assay to identify inhibitors of IMP-1 metallo-beta-lactamase,Screening,,
203,1565,2,2,,49666478,2662,Inactive,219689097.0,162466.0,,IC50,uHTS absorbance assay for the identification of compounds that inhibit PHOSPHO1,Confirmatory,,
204,1566,2,3,,49666478,2662,Inactive,11545912.0,64127.0,,EC50,uHTS luminescence assay for the identification of compounds that inhibit NOD2,Confirmatory,,
205,1578,3,2,,49666478,2662,Inactive,5174617.0,10392.0,,EC50,uHTS luminescence assay for the identification of compounds that inhibit NOD1,Confirmatory,,
206,1580,1,1,,8150033,2662,Inconclusive,,,,,Screen for compounds that inhibit mitochondrial permeability transition (MitoPT),Other,,
207,1581,1,1,,8150033,2662,Inconclusive,,,,,Screen of Compounds to Block PAR4 - aPKC Interaction for Treatment of Neurodegeneration (Par4_PKC),Other,,
208,1582,1,1,,8150033,2662,Inconclusive,,,,,Yeast cell-based screen for Novel HDAC inhibitors using a PHO84-LacZ reporter gene (PHO84),Other,,
209,1583,1,1,,8150033,2662,Unspecified,,,,,Assay to identify inhibitors of polyglutamine-induced caspase-3 activation (CASP3),Other,,
210,1584,1,1,,8150033,2662,Inconclusive,,,,,Screen for compounds that inhibit in vitro mutant huntingtin aggregation (QA1),Other,,
211,1585,1,1,,8150033,2662,Inconclusive,,,,,"Screen for compounds that inhibit the ability of solid phase synthetic polyglutamine aggregates to elongate by incorporating solution-phase biotin-tagged, monomeric polyglutamine (QA3)",Other,,
212,1586,1,1,,8150033,2662,Inconclusive,,,,,A 2-Hybrid Test for Interactions Between Polyglutamine-Containing Proteins in the Yeast Nucleus  (Qn2Hy),Other,,
213,1587,1,1,,8150033,2662,Inconclusive,,,,,Screen for compounds that increase the expression of EAAT-2 in rat spinal cord organotypic slice cultures (X4_EAAT2),Other,,
214,1588,1,1,,8150033,2662,Inconclusive,,,,,Screen for compounds that reduce polyglutamine aggregation as measured by turbidity (QTHIO),Other,,
215,1589,1,1,,8150033,2662,Inconclusive,,,,,Screen for compounds that reduce polyglutamine (polyQ) inclusions in nerve growth factor (NGF)-treated PC12 cells (SDS),Other,,
216,1590,1,1,,8150033,2662,Inconclusive,,,,,Cellular toxicity caused by inducible expressing of N-terminal huntingtin with expanded ployglutamine repeat (Htt-N63-148Q) in PC12 cells (ROSShtt),Other,,
217,1593,1,1,,8150033,2662,Unspecified,,,,,Yeast cell-based screen for compounds that suppress polyglutamine aggregation in vivo (75Q-TubU),Other,,
218,1594,1,1,,8150033,2662,Inconclusive,,,,,Screen for compounds that decrease glutamate induced motor neuron death measured by TUNEL staining for DNA degradation (MNGlu),Other,,
219,1595,1,1,,8150033,2662,Inconclusive,,,,,Suppression of Polyglutamine Toxicity in Whole Organism Drosophila Model of SCA1 (SCA1FLYe),Other,,
220,1596,1,1,,8150033,2662,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH100),Other,,
221,1597,1,1,,8150033,2662,Inconclusive,,,,,Suppression of Polyglutamine Toxicity in Whole Organism Drosophila Model of SCA1 (SCA1FLYp),Other,,
222,1598,1,1,,8150033,2662,Inconclusive,,,,,Screen for compounds that selectively increase SMN2 splicing relative to SMN1 splicing (SMNLUC),Other,,
223,1599,1,1,,8150033,2662,Unspecified,,,,,"Screen for compounds that correct neuronal dysfunction without cell death as induced by the expression of polyglutamine-expanded, N-terminal huntingtin in C. elegans mechanosensory neurons (HDELENEU)",Other,,
224,1600,1,1,,8150033,2662,Inconclusive,,,,,Yeast Assay for Parkinson&apos;s Disease (YAPD),Other,,
225,1601,1,1,,8150033,2662,Inconclusive,,,,,Screen for compounds that suppress mutant SOD1-mediated cell death (mSODtox),Other,,
226,1602,1,1,,8150033,2662,Inconclusive,,,,,Screen for compounds that attenuate mutant SOD1 toxicity (mSOD1),Other,,
227,1603,1,1,,8150033,2662,Unspecified,,,,,Screen for compounds that selectively inhibit cytochrome c release from purified mitochondria (CytoCRel),Other,,
228,1604,1,1,,8150033,2662,Unspecified,,,,,Screen for compounds that inhibit polyglutamine induced protein aggregation (AGREG),Other,,
229,1605,1,1,,8150033,2662,Unspecified,,,,,Screening of compounds showing protective effect against cell death induced by familial amyotrophic lateral sclerosis (FALS)-linked mutantsuperoxide dismutase 1 (SOD1) (ALSOD1),Other,,
230,1606,1,1,,8150033,2662,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH20),Other,,
231,1607,1,1,,8150033,2662,Inconclusive,,,,,Screen for compounds that promote the turnover of an expanded polyglutamine androgen receptor (AR112GFP),Other,,
232,1608,1,1,,8150033,2662,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH016),Other,,
233,1609,1,1,,8150033,2662,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH08),Other,,
234,1610,1,1,,8150033,2662,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells,Other,,
235,1612,1,1,,8150033,2662,Unspecified,,,,,Screen for compounds that increase glutamate transport activity in MN-1 cell line (GluUPTAKE),Other,,
236,1613,1,1,,8150033,2662,Unspecified,,,,,Screen for compounds that inhibit protein aggregation formed by mutant SOD1 (GFPSOD1),Other,,
237,1614,1,1,,8150033,2662,Unspecified,,,,,Screen for compounds that reduce polyglutamine (polyQ) inclusions in nerve growth factor (NGF)-treated PC12 cells (GFPQ80),Other,,
238,1616,1,1,,8150033,2662,Unspecified,,,,,Yeast cell-based screen for compounds that suppress polyglutamine aggregation in vivo (75Q-TubH),Other,,
239,1621,1,2,,49666478,2662,Inactive,,,,IC50,A Cell Based Assay for the Identification of Lead Compounds with Anti-Viral Activity Against West Nile Virus,Confirmatory,,
240,1631,3,1,,49666478,2662,Inactive,33286418.0,5315.0,,Potency,qHTS Assay for Activators of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
241,1634,3,1,,49666478,2662,Inactive,33286418.0,5315.0,,Potency,qHTS Assay for Inhibitors of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
242,1654,2,2,,49666478,2662,Inactive,4758208.0,1845.0,,IC50,uHTS absorbance assay for the identification of compounds that inhibit VHR1.,Confirmatory,,
243,1656,2,2,,49666478,2662,Inactive,,,,,High Throughput Imaging Assay for Hepatic Lipid Droplet Formation,Screening,,
244,1662,1,2,,49666478,2662,Inactive,15675770.0,901648.0,,,MLPCN Streptokinase Expression Inhibition,Screening,,
245,1663,1,2,,49666478,2662,Inactive,,,,,MLPCN Platelet Activation -Dense Granule Release,Screening,,
246,1672,1,3,,49666478,2662,Inactive,6680530.0,16518.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1,Screening,,
247,1688,1,1,,17389545,2662,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
248,1700,1,2,,49666478,2662,Inactive,124263658.0,688.0,,,Primary cell-based high throughput screening assay to identify inhibitors of kruppel-like factor 5 (KLF5),Screening,,
249,1706,1,2,,49666478,2662,Inactive,73745819.0,,,,QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro),Screening,,
250,1721,1,2,,49666478,2662,Inactive,290753097.0,,,Potency,qHTS Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
251,1722,1,2,,49666478,2662,Inactive,290753097.0,,,Potency,qHTS Assay for Activators of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
252,1766,1,1,,17389545,2662,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
253,1766,1,1,,17389545,2662,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
254,1766,1,1,,26747363,2662,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
255,1766,1,1,,26747363,2662,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
256,1766,1,1,,49666478,2662,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
257,1766,1,1,,49666478,2662,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
258,1768,1,1,,17389545,2662,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
259,1768,1,1,,17389545,2662,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
260,1768,1,1,,26747363,2662,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
261,1768,1,1,,26747363,2662,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
262,1768,1,1,,49666478,2662,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
263,1768,1,1,,49666478,2662,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
264,1777,3,2,,49666478,2662,Inactive,39725940.0,4986.0,,EC50,uHTS identification of small molecule agonists of the kappa opioid receptor via a luminescent beta-arrestin assay,Confirmatory,,
265,1778,3,3,,49666478,2662,Inactive,39725940.0,4986.0,,IC50,uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay,Confirmatory,,
266,1779,2,2,,49666478,2662,Inactive,224586929.0,26191.0,,IC50,uHTS identification of small molecule inhibitors of LYP via a fluorescence intensity assay,Confirmatory,,
267,1789,1,2,,49666478,2662,Inactive,83318444.0,3320.0,,,Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90),Screening,,
268,1800,1,2,,49666478,2662,Inactive,125541954.0,,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3),Screening,,
269,1811,3,2,,46392808,2662,Active,47168469.0,,,,Experimentally measured binding affinity data derived from PDB,Other,14736236.0,
270,1813,1,2,,49666478,2662,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - inhibitors,Screening,,
271,1814,1,2,,49666478,2662,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - activators,Screening,,
272,1817,2,2,,49666478,2662,Inactive,40849930.0,5339.0,,IC50,uHTS identification of small molecule antagonists of the binding of Siah-1 and a peptide ligand via a fluorescence polarization assay.,Confirmatory,,
273,1822,1,3,,49666478,2662,Inactive,23505220.0,813594.0,,,QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (PFM18AAP).,Screening,,
274,1825,1,1,,49666478,2662,Inactive,,,,,Luminescence-based counterscreen assay for KLF5 inhibitors: cell-based high throughput screening assay to identify cytotoxic compounds using the IEC-6 intestinal epithelial cell line.,Screening,,
275,1832,2,1,,49666478,2662,Inactive,55976631.0,178296.0,,,MLPCN maternal gene expression-MEX-5 TCR-2 binding assay-Primary Screen,Screening,,
276,1845,1,2,,49666478,2662,Inactive,125541954.0,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors: biochemical high-throughput screening assay to identify compounds that cause fluorescent intercalator displacement (FID),Screening,,
277,1850,2,1,,49666478,2662,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,Confirmatory,,
278,1861,2,1,,49666478,2662,Inactive,119607128.0,2831.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify antagonists of the G-protein coupled receptor 7 (GPR7).,Screening,,
279,1863,2,1,,49666478,2662,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
280,1865,1,1,,26747363,2662,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
281,1875,2,1,,49666478,2662,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Polyadenylation,Screening,,
282,1885,2,1,,49666478,2662,Inactive,,,,,Luminescence Cell-Based/Microorganism Primary HTS to Identify Inhibitors of T.Cruzi Replication,Screening,,
283,1899,1,3,,49666478,2662,Inactive,83779224.0,,,,TR-FRET-based primary biochemical high-throughput screening assay to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization,Screening,,
284,1903,2,3,,49666478,2662,Inactive,297591903.0,29031019.0,,IC50,Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents,Confirmatory,,
285,1906,1,3,,49666478,2662,Inactive,55958172.0,,,,QFRET-based counterscreen for PFM18AAP inhibitors: biochemical high throughput screening assay to identify inhibitors of the Cathepsin L proteinase (CTSL1).,Screening,,
286,1910,1,2,,49666478,2662,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Transcriptional Activators of Hypoxia-Inducible Factor Pathway,Screening,,
287,1947,1,2,,49666478,2662,Inactive,21595511.0,226016.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the serine hydrolase family member Fam108B.,Screening,,
288,1948,1,1,,17389545,2662,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
289,1948,1,1,,26747363,2662,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
290,1950,1,3,,49666478,2662,Inactive,23893623.0,3783709.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the Epstein-Barr virus nuclear antigen 1 (EBNA-1).,Screening,,
291,1961,2,2,,49666478,2662,Inactive,33695107.0,9290.0,,EC50,Image-based HTS for Selective Agonists of GPR55,Confirmatory,,
292,1962,1,2,,49666478,2662,Inactive,68476498.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of tRNA 2'-phosphotransferase (TPT1).,Screening,,
293,1974,1,2,,49666478,2662,Inactive,4758484.0,9446.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the oxidoreductase glutathione S-transferase omega 1(GSTO1).,Screening,,
294,1979,1,1,,49666478,2662,Inactive,994798.0,,,,Fluorescence Cell-Based Primary HTS of C.albicans growth in the presence of Fluconazole and compound,Screening,,
295,1984,1,3,,49666478,2662,Inactive,118026946.0,17979.0,,IC50,Fluorescence for the identification of compounds that decrease p/CIP protein stability,Confirmatory,,
296,1986,1,2,,49666478,2662,Inactive,45357394.0,,,IC50,uHTS fluorescence assay for the identification of Human Immunodeficiency Virus Fusion Inhibitors.,Confirmatory,,
297,1987,1,2,,49666478,2662,Inactive,37589898.0,5536.0,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase 5 (PP5).,Screening,,
298,2006,3,2,,49666478,2662,Inactive,4507785.0,7329.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
299,2006,3,2,,49666478,2662,Inactive,13111961.0,10054.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
300,2006,3,2,,49666478,2662,Inactive,17390638.0,10055.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
301,2012,3,2,,49666478,2662,Inactive,45219878.0,7458.0,,IC50,uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (eIF4H),Confirmatory,,
302,2013,2,2,,49666478,2662,Inactive,33695107.0,9290.0,,IC50,Image-Based HTS for Selective Antagonists for GPR55,Confirmatory,,
303,2014,3,2,,49666478,2662,Inactive,46367787.0,26986.0,,IC50,uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (PABP),Confirmatory,,
304,2016,1,3,,49666478,2662,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ MEP2_MLPCN.,Screening,,
305,2019,1,1,,57578332,2662,Inactive,56202836.0,,30.0,EC50_MICROM,Pyrazoline SAR compounds tested via Multiplex dose response to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Cdc42 wildtype protein,Confirmatory,,
306,2020,1,1,,57578332,2662,Inactive,56202836.0,,30.0,EC50_MICROM,Pyrazoline SAR compounds tested via Multiplex dose response to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Cdc42 activated mutant,Confirmatory,,
307,2023,1,3,,49666478,2662,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ LAP4_MLPCN.,Screening,,
308,2025,1,3,,49666478,2662,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ RPL19A_MLPCN.,Screening,,
309,2029,1,3,,49666478,2662,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ CIT2_MLPCN.,Screening,,
310,2041,1,1,,57578332,2662,Inactive,164058.0,404007.0,30.0,EC50_MICROM,Pyrazoline SAR compounds tested via Multiplex dose response to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rab7 wildtype,Confirmatory,,
311,2045,1,1,,57578332,2662,Inactive,46577642.0,404009.0,30.0,EC50_MICROM,Pyrazoline SAR compounds tested via Multiplex dose response to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rab2 wildtype,Confirmatory,,
312,2047,1,1,,57578332,2662,Inactive,190938.0,3265.0,30.0,EC50_MICROM,Pyrazoline SAR compounds tested via Multiplex dose response to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype,Confirmatory,,
313,2048,1,1,,57578332,2662,Inactive,8574038.0,5879.0,43.053000000000004,EC50_MICROM,Pyrazoline SAR compounds tested via Multiplex dose response to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac1 activated mutant,Confirmatory,,
314,2050,1,1,,57578332,2662,Inactive,190938.0,3265.0,30.0,EC50_MICROM,Pyrazoline SAR compounds tested via Multiplex dose response to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras activated mutant,Confirmatory,,
315,2052,2,1,,49666478,2662,Inactive,124486680.0,16408.0,,,HTS for developing T Cell Immune Modulators,Screening,,
316,2055,1,1,,57578332,2662,Inactive,8574038.0,5879.0,30.0,EC50_MICROM,Pyrazoline SAR compounds tested via Multiplex dose response to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac1 wildtype,Confirmatory,,
317,2057,1,2,,49666478,2662,Inactive,78070770.0,4170.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.,Screening,,
318,2058,3,2,,49666478,2662,Inactive,33695097.0,2859.0,,IC50,Image-Based HTS for Selective Antagonists of GPR35,Confirmatory,,
319,2066,1,4,,49666478,2662,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ AGP1_MLPCN.,Screening,,
320,2071,2,2,,49666478,2662,Inactive,14719829.0,22861.0,,,Colorimetric  Assay for Inhibitors for NALP1,Screening,,
321,2073,2,3,,49666478,2662,Inactive,2625023.0,83589.0,,IC50,Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,Confirmatory,,
322,2073,2,3,,49666478,2662,Inactive,4502523.0,774.0,,IC50,Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,Confirmatory,,
323,2094,1,2,,49666478,2662,Inactive,67463988.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
324,2094,1,2,,49666478,2662,Inactive,67463989.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
325,2094,1,2,,49666478,2662,Inactive,166202459.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
326,2097,1,2,,49666478,2662,Inactive,21361340.0,2932.0,,,Cell-Free Homogeneous Primary HTS to Identify Inhibitors of GSK3beta Activity,Screening,,
327,2098,1,1,,49666478,2662,Inactive,62740231.0,15499.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Heat Shock Factor 1 (HSF1).,Screening,,
328,2099,1,1,,49666478,2662,Inactive,,,,,Fluorescence Biochemical Primary HTS to Identify Inhibitors of GASC-1 Activity,Screening,,
329,2100,1,1,,49666478,2662,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen,Confirmatory,,
330,2101,1,1,,17389545,2662,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
331,2101,1,1,,26747363,2662,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
332,2101,1,1,,49666478,2662,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
333,2107,1,1,,17389545,2662,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
334,2107,1,1,,26747363,2662,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
335,2112,1,1,,17389545,2662,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
336,2112,1,1,,26747363,2662,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
337,2120,1,1,,17389545,2662,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Inducers of Hypoxia Response,Confirmatory,,
338,2129,1,2,,49666478,2662,Inactive,510901.0,598.0,,,"Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).",Screening,,
339,2130,1,3,,49666478,2662,Inactive,7706645.0,51400.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).,Screening,,
340,2147,1,1,,26747363,2662,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
341,2156,2,2,,49666478,2662,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels,Screening,,
342,2174,1,3,,49666478,2662,Inactive,5453722.0,10434.0,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 1 (LYPLA1).,Screening,,
343,2177,1,3,,49666478,2662,Inactive,4581413.0,,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 2 (LYPLA2).,Screening,,
344,2216,1,3,,49666478,2662,Inactive,,,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the RanGTP-Importin-beta complex,Screening,,
345,2221,1,2,,49666478,2662,Inactive,15609874.0,888371.0,,,Fluorescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of RecA Intein Splicing Activity,Screening,,
346,2227,1,2,,49666478,2662,Inactive,2935630.0,22066.0,,,Primary cell-based high-throughput screening assay for identification of compounds that allosterically potentiate transient receptor potential cation channel C4 (TRPC4),Screening,,
347,2234,1,2,,49666478,2662,Inactive,82503229.0,3783744.0,,,"Counterscreen for inhibitors of EBNA-1: fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of the Epstein-Barr virus-encoded protein, ZTA.",Screening,,
348,2235,1,2,,49666478,2662,Inactive,56790945.0,5499.0,,,Counterscreen for inhibitors of PP5: fluorescence-based biochemical high throughput primary assay to identify inhibitors of Protein Phosphatase 1 (PP1).,Screening,,
349,2237,1,2,,49666478,2662,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that activate transient receptor potential cation channel C4 (TRPC4).,Screening,,
350,2239,1,2,,49666478,2662,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels,Screening,,
351,2240,1,1,,85789333,2662,Inactive,38156699.0,4286.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of MITF,Screening,,
352,2241,1,1,,85789333,2662,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1,Screening,,
353,2247,1,2,,49666478,2662,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that inhibit transient receptor potential cation channel C4 (TRPC4).,Screening,,
354,2275,1,1,,85789333,2662,Inconclusive,,,,,Luminescence Cell-Based Primary HTS to Measure Viability of BJeLR cells,Screening,,
355,2280,2,3,,49666478,2662,Inactive,17507875.0,172532.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of GLD-1 protein - TGE RNA interaction.,Screening,,
356,2288,1,1,,49666478,2662,Inactive,,,,Potency,qHTS Assay for Modulators of miRNAs and/orActivators of miR-21,Confirmatory,,
357,2289,1,1,,49666478,2662,Inactive,,,,Potency,qHTS Assay for Modulators of miRNAs and/or Inhibitors of miR-21,Confirmatory,,
358,2300,1,3,,49666478,2662,Inactive,216409728.0,10002.0,,,"TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).",Screening,,
359,2313,1,1,,85789333,2662,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of the Sonic Hedgehog Signaling Pathway,Screening,,
360,2314,1,2,,49666478,2662,Inactive,32400299.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
361,2314,1,2,,49666478,2662,Inactive,32400300.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
362,2315,1,2,,49666478,2662,Inactive,32400299.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
363,2315,1,2,,49666478,2662,Inactive,32400300.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
364,2322,1,1,,85789333,2662,Inactive,,,,,Luminescence Homogenous Primary HTS to Identify Inhibitors of STK33 Activity,Screening,,
365,2326,1,1,,49666478,2662,Inactive,194352380.0,,,Potency,qHTS Assay for Inhibitors of Influenza NS1 Protein Function,Confirmatory,,
366,2330,1,1,,85789333,2662,Inactive,12830367.0,65975.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33,Screening,,
367,2380,1,2,,49666478,2662,Inactive,,,,,uHTS identification of small molecules that induce b-cell replication in the MIN-6 cell line,Screening,,
368,2391,1,1,,49666478,2662,Inactive,,,,IC50,A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV),Confirmatory,,
369,2435,1,2,,49666478,2662,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).,Screening,,
370,2445,1,2,,49666478,2662,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify potentiators of Oxytocin Receptor (OXTR),Screening,,
371,2451,1,2,,26747363,2662,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
372,2451,1,2,,49666478,2662,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
373,2462,1,1,,49666478,2662,Inactive,20336315.0,10018.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
374,2462,1,1,,49666478,2662,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
375,2472,1,2,,26747363,2662,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
376,2472,1,2,,49666478,2662,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
377,2517,2,1,,17389545,2662,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
378,2517,2,1,,26747363,2662,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
379,2517,2,1,,49666478,2662,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
380,2520,1,4,,49666478,2662,Inactive,4885057.0,187.0,,,uHTS identification of small molecule agonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
381,2521,1,3,,49666478,2662,Inactive,4885057.0,187.0,,,uHTS identification of small molecule antagonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
382,2524,1,2,,49666478,2662,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of activators of human intestinal alkaline phosphatase,Screening,,
383,2528,1,2,,17389545,2662,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
384,2528,1,2,,26747363,2662,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
385,2528,1,2,,49666478,2662,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
386,2540,1,2,,49666478,2662,Inactive,262118306.0,123228.0,,,HTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 8 (SENP8),Screening,,
387,2544,1,2,,49666478,2662,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of inhibitors of human intestinal alkaline phosphatase,Screening,,
388,2546,1,1,,17389545,2662,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
389,2546,1,1,,26747363,2662,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
390,2546,1,1,,49666478,2662,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
391,2549,1,1,,17389545,2662,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
392,2549,1,1,,26747363,2662,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
393,2550,1,3,,49666478,2662,Inactive,160333370.0,22068.0,,,High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6),Screening,,
394,2551,1,1,,17389545,2662,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
395,2551,1,1,,26747363,2662,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
396,2551,1,1,,49666478,2662,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
397,2553,1,2,,49666478,2662,Inactive,160333370.0,22068.0,,,High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6),Screening,,
398,2557,1,3,,49666478,2662,Inactive,67191027.0,3676.0,,,HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library,Screening,,
399,2563,1,1,,49666478,2662,Inactive,6323930.0,855317.0,,,Fluorescence Cell-Free Homogenous Primary HTS  to Identify Inhibitors of the Ras-converting Enzyme,Screening,,
400,2599,1,2,,49666478,2662,Inactive,6166485.0,26054.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 6 (SENP6),Screening,,
401,2606,1,2,,49666478,2662,Inactive,15610807.0,885176.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the membrane-associated serine protease Rv3671c in M.tuberculosis,Screening,,
402,2629,1,1,,49666478,2662,Inactive,139472804.0,4961527.0,,,Fluorescence Polarization Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the LANA Histone H2A/H2B Interaction,Screening,,
403,2642,1,2,,49666478,2662,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels,Screening,,
404,2648,1,2,,49666478,2662,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels,Screening,,
405,2650,2,1,,49666478,2662,Inactive,49574532.0,2931.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha,Screening,,
406,2661,1,1,,49666478,2662,Inactive,23943882.0,65975.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of Serine/Threonine  Kinase 33  Activity,Screening,,
407,2662,2,1,,17389545,2662,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
408,2662,2,1,,49666478,2662,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
409,2675,1,1,,49666478,2662,Inactive,41281591.0,4154.0,,Potency,qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding,Confirmatory,,
410,2676,1,2,,49666478,2662,Inactive,85986601.0,59350.0,,Potency,qHTS Assay for Agonists of the Relaxin Receptor RXFP1,Confirmatory,,
411,2685,1,1,,49666478,2662,Inconclusive,,,,Potency,qHTS Assay for Lipid Storage Modulators in Drosophila S3 Cells,Confirmatory,,
412,2690,1,2,,49666478,2662,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide,Screening,,
413,2716,1,1,,49666478,2662,Inactive,,,,,Luminescence  Microorganism Primary HTS to Identify Inhibitors of the SUMOylation Pathway Using a Temperature Sensitive Growth Reversal Mutant Mot1-301,Screening,,
414,2717,1,2,,49666478,2662,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Cancer Stem Cells,Screening,,
415,2718,1,1,,49666478,2662,Inactive,13128862.0,8841.0,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3,Screening,,
416,2751,2,2,,49666478,2662,Inactive,153217451.0,9581.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL),Screening,,
417,2796,1,4,,49666478,2662,Inactive,4502003.0,196.0,,,Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR),Screening,,
418,2797,1,2,,49666478,2662,Inactive,4502331.0,552.0,,,Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R),Screening,,
419,2805,2,2,,49666478,2662,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of activators of mouse intestinal alkaline phosphatase,Screening,,
420,2806,2,2,,49666478,2662,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of inhibitors of mouse intestinal alkaline phosphatase,Screening,,
421,2825,1,2,,49666478,2662,Inactive,219518789.0,114548.0,,,uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast,Screening,,
422,8128,4,2,,103181002,2662,Unspecified,,,,,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,Other,14684306.0,
423,8516,4,3,,103181002,2662,Inconclusive,,,,,C24 after oral administration at 5 mg/kg,Other,14684306.0,
424,8752,7,2,,103181002,2662,Unspecified,,,,,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,Other,14684306.0,
425,9724,3,3,,103181002,2662,Unspecified,,,,,T1/2 (Half-life) was after oral administration at 5 mg/kg,Other,14684306.0,
426,9740,4,3,,103181002,2662,Inconclusive,,,,,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,Other,14684306.0,
427,23814,3,3,,103181002,2662,Unspecified,,,,,Plasma half-life was determined after intravenous administration of 10 mg/kg of compound in male rat,Other,9135032.0,
428,24142,3,3,,103181002,2662,Unspecified,,,,,Gastric toxicity of the compound.,Other,11101350.0,
429,25975,5,2,,103181002,2662,Unspecified,,,,,Pharmacokinetic parameter AUC(area under curve) was determined in male Wistar rat after 100 mg/kg oral dose of the compound,Other,12954051.0,
430,28216,3,4,,103181002,2662,Inconclusive,,,,,Half life of compound was determined at 1 mg/kg intravenous administration in rat; Not tested,Other,12877584.0,
431,28332,6,3,,103181002,2662,Unspecified,,,,,Pharmacokinetic parameter Cmax was determined in male Wistar rat after 100 mg/kg oral dose of the compound,Other,12954051.0,
432,28940,3,3,,103181002,2662,Unspecified,,,,,Partition coefficient (logP),Other,12954051.0,
433,29698,3,4,,103181002,2662,Unspecified,,,,,Pharmacokinetic parameter Tmax was determined in male Wistar rat after 100 mg/kg oral dose of the compound,Other,12954051.0,
434,46697,9,2,,103181002,2662,Active,,,1.0,IC50,In vitro potency against human Prostaglandin G/H synthase 2 in the human whole blood assay.,Confirmatory,10197970.0,
435,46698,9,1,,103181002,2662,Active,,,0.002,IC50,In vitro potency against human Prostaglandin G/H synthase 2 in transfected CHO cells.,Confirmatory,10197970.0,
436,47748,4,7,,103181002,2662,Active,,,0.021,IC50,Inhibitory activity of compound against human carbonic anhydrase II,Confirmatory,14698154.0,
437,47749,11,1,,103181002,2662,Active,,,0.021,IC50,Inhibitory activity against human carbonic anhydrase II was determined,Confirmatory,14736236.0,
438,48112,4,7,,103181002,2662,Active,,,0.29,IC50,Inhibitory activity of compound against bovine carbonic anhydrase IV,Confirmatory,14698154.0,
439,48114,11,1,,103181002,2662,Active,,,0.29,IC50,Inhibitory activity against bovine carbonic anhydrase IV was determined,Confirmatory,14736236.0,
440,48294,11,1,,103181002,2662,Active,,,0.016,IC50,Inhibitory activity against human carbonic anhydrase IX was determined,Confirmatory,14736236.0,
441,50344,4,7,,103181002,2662,Unspecified,,,50.0,IC50,Inhibitory activity of compound against human carbonic anhydrase I,Confirmatory,14698154.0,
442,50345,11,1,,103181002,2662,Unspecified,,,50.0,IC50,Inhibitory activity against human carbonic anhydrase I was determined,Confirmatory,14736236.0,
443,54531,7,6,,103181002,2662,Active,317373262.0,5742.0,1.88,IC50,In vitro inhibition of cyclooxygenase-1 by inhibition of TXB2 generation with 1 uM arachidonic acid in human platelets,Confirmatory,11844666.0,
444,54536,9,1,,103181002,2662,Active,,,0.05,IC50,In vitro inhibitory potency against U-937 microsomal COX-1,Confirmatory,10576684.0,
445,54538,9,2,,103181002,2662,Active,,,6.3,IC50,In vitro inhibitory potency against human COX-1 (HWB COX-2) by whole blood assay,Confirmatory,10576684.0,
446,54545,9,2,,103181002,2662,Active,,,0.05,IC50,Inhibition of COX-1 in U-937 (human lymphoma) cell microsomes.,Confirmatory,10576685.0,
447,54555,6,3,,103181002,2662,Active,,,0.11,IC50,In vitro inhibition of PGE-2 generation by LPS-stimulated monocytes isolated from human blood.,Confirmatory,11844666.0,
448,54559,9,2,,103181002,2662,Active,,,1.0,IC50,In vitro inhibitory potency against human COX-2 (HWB COX-2) by whole blood assay,Confirmatory,10576684.0,
449,54560,9,1,,103181002,2662,Active,,,0.002,IC50,In vitro inhibitory potency against human COX-2 in stably transfected chinese hamster ovary (CHO) cells,Confirmatory,10576684.0,
450,54711,9,3,,103181002,2662,Active,,,1.0,IC50,Inhibitory potency against PGE-2 production in the human whole blood (HWB COX-2) assay,Confirmatory,10576685.0,
451,54712,9,1,,103181002,2662,Active,,,0.002,IC50,Inhibition of PGE-2 production in CHO cells expressing human COX-2.,Confirmatory,10576685.0,
452,104510,5,3,,103181002,2662,Unspecified,,,,,Evaluated in vivo for oral dose required to produce antiinflammatory activity in the rat paw edema assay (male Wistar rat),Other,12954051.0,
453,104515,6,3,,103181002,2662,Unspecified,,,,,Evaluated in vivo for oral dose required to produce antiinflammatory activity in the rat paw edema assay (male Wistar rat),Other,12954051.0,
454,130717,6,2,,103181002,2662,Unspecified,,,,,In vivo inhibitory activity by mouse air-pouch assay at dose 2 MPK was determined.,Other,9934449.0,
455,155354,6,2,,103181002,2662,Unspecified,,,,,Compound was evaluated for its effective dose to inhibit exudate PGE-2,Other,11101350.0,
456,155356,6,2,,103181002,2662,Unspecified,,,,,Compound was evaluated for its effective dose to inhibit gastric PGE-2,Other,11101350.0,
457,160061,6,2,,103181002,2662,Active,,,19.0,IC50,Inhibitory effect on production of cyclooxygenase-1 (COX-1) thromboxane B2 (TXB2) in human platelet cells,Confirmatory,10821716.0,
458,160245,5,5,,103181002,2662,Unspecified,,,,,Evaluation for percent inhibition of prostaglandin G/H synthase 2 in human whole blood (HWB) at a concentration of 10 um,Other,15084117.0,
459,160246,5,5,,103181002,2662,Unspecified,,,,,Evaluation for percent inhibition of prostaglandin G/H synthase 2 in human whole blood (HWB) at a concentration of 1 um,Other,15084117.0,
460,160247,4,5,,103181002,2662,Unspecified,,,,,Evaluation for percent inhibition of recombinant prostaglandin G/H synthase 2 in human whole blood (HWB) at a concentration of 10 um,Other,15084117.0,
461,160248,4,5,,103181002,2662,Unspecified,,,,,Evaluation for percent inhibition of recombinant prostaglandin G/H synthase 2 in human whole blood (HWB) at a concentration of 1 um,Other,15084117.0,
462,160249,8,1,,103181002,2662,Active,,,,,Compound was tested in vitro for inhibition of human recombinant Prostaglandin G/H synthase 2,Other,9934449.0,
463,160252,3,7,,103181002,2662,Unspecified,,,,,In vitro average percent Inhibition of Prostaglandin G/H synthase 2 (COX-2) at a concentration of 1 uM in human whole blood by human whole blood assay,Other,14640557.0,
464,160257,3,7,,103181002,2662,Unspecified,,,,,In vitro average percent Inhibition of Prostaglandin G/H synthase 2 (COX-2) at a concentration of 10 uM in human whole blood by human whole blood assay,Other,14640557.0,
465,160262,3,7,,103181002,2662,Unspecified,,,,,Inhibition of Prostaglandin G/H synthase 2 (COX-2) in human whole blood at 10 uM,Other,12877584.0,
466,160264,3,6,,103181002,2662,Unspecified,,,,,In vitro inhibition of human Prostaglandin G/H synthase 2 (expressed in sf9 insect cells using baculovirus) enzyme at a concentration of 10 M,Other,12954051.0,
467,160265,3,6,,103181002,2662,Unspecified,,,,,In vitro inhibition of human Prostaglandin G/H synthase 2 (rexpressed in sf9 insect cells using baculo virus) enzyme at the concentration of 1 uM,Other,12954051.0,
468,160266,3,7,,103181002,2662,Unspecified,,,,,In vitro inhibitory activity against human recombinant prostaglandin G/H synthase 2 (COX-2) at 10 uM expressed in sf-9 cells infected with baculovirus,Other,15026050.0,
469,160269,3,7,,103181002,2662,Unspecified,,,,,In vitro percent Inhibition of recombinant human prostaglandin G/H synthase 2 (COX-2) at a concentration of 1 uM,Other,14640557.0,
470,160399,3,7,,103181002,2662,Unspecified,,,,,In vitro percent Inhibition of recombinant human prostaglandin G/H synthase 2 (COX-2) at a concentration of 10 uM,Other,14640557.0,
471,160400,3,7,,103181002,2662,Unspecified,,,,,In vitro percent inhibition of prostaglandin G/H synthase 2 (COX-2) in human whole blood at 1 uM,Other,12877584.0,
472,160431,3,7,,103181002,2662,Unspecified,,,,,Percentage of inhibition of Prostaglandin G/H synthase 2 activity in human whole blood(HWB) at 1 uM,Other,11462976.0,
473,160432,3,7,,103181002,2662,Unspecified,,,,,Percentage of inhibition of Prostaglandin G/H synthase 2 activity in human whole blood(HWB) at 10 uM,Other,11462976.0,
474,160434,8,2,,103181002,2662,Active,,,0.039810000000000005,IC50,Inhibition of human Prostaglandin G/H synthase 2,Confirmatory,11563921.0,
475,160561,7,2,,103181002,2662,Active,,,0.0007,IC50,Tested for inhibition against Prostaglandin G/H synthase 2 from mouse resident macrophages,Confirmatory,11101350.0,
476,160563,6,4,,103181002,2662,Unspecified,,,,,Inhibitory activity against Prostaglandin G/H synthase 2 from freshly harvested mouse peritoneal macrophages,Other,15081007.0,
477,160565,6,4,,103181002,2662,Unspecified,,,,,In vitro inhibitory activity against prostaglandin G/H synthase 2 using mouse peritoneal macrophage method,Other,14761182.0,
478,160566,6,4,,103181002,2662,Unspecified,,,,,In vitro inhibitory concentration against prostaglandin G/H synthase 2 using freshly harvested mouse peritoneal macrophages,Other,12565941.0,
479,160593,4,1,,103181002,2662,Unspecified,,,,,Inhibitory constant against prostaglandin G/H synthase 2 (COX-2),Other,12383007.0,
480,160595,7,2,,103181002,2662,Active,,,0.039810000000000005,IC50,Inhibitory activity against prostaglandin G/H synthase 2 (COX-2),Confirmatory,12383007.0,
481,160596,6,4,,103181002,2662,Unspecified,,,,,Ability to inhibit Prostaglandin G/H synthase 2 by using freshly harvested mouse peritoneal macrophages,Other,11206450.0,
482,160599,9,2,,103181002,2662,Active,,,1.1,IC50,In vitro inhibitory concentration against rat Prostaglandin G/H synthase 2,Confirmatory,11591502.0,
483,160730,9,5,,103181002,2662,Active,3914304.0,443460.0,0.0567,IC50,In vitro inhibition against ovine Prostaglandin G/H synthase 2,Confirmatory,12798335.0,
484,160731,9,2,,103181002,2662,Active,,,0.057,IC50,In vitro inhibitory activity against prostaglandin G/H synthase 2 (COX-2),Confirmatory,14584938.0,
485,160732,9,5,,103181002,2662,Active,3914304.0,443460.0,0.057,IC50,In vitro inhibitory activity against prostaglandin G/H synthase 2 from ovine,Confirmatory,15050635.0,
486,160740,9,2,,103181002,2662,Active,,,1.2,IC50,Compound was tested for the inhibition of human Prostaglandin G/H synthase 2 (COX-2) in human whole blood,Confirmatory,14640557.0,
487,160742,9,2,,103181002,2662,Active,,,0.0507,IC50,Inhibitory concentration against Prostaglandin G/H synthase 2,Confirmatory,11520213.0,
488,160743,9,1,,103181002,2662,Active,,,0.002,IC50,Inhibitory of human Prostaglandin G/H synthase 2 expressed in CHO cells.,Confirmatory,12643942.0,
489,160745,7,1,,103181002,2662,Unspecified,,,,,Relative free energy of binding of compound to wild-type Prostaglandin G/H synthase 2; (deltaG=RT ln IC50),Other,11412976.0,
490,161324,9,2,,103181002,2662,Active,,,5.57,IC50,In vitro inhibitory activity against canine prostaglandin G/H synthase 1.,Confirmatory,14684306.0,
491,161327,9,2,,103181002,2662,Active,,,9.73,IC50,"Biochemical index for Prostaglandin G/H synthase 1 measured as, thromboxane 2 (TXB2) levels following blood coagulation",Confirmatory,10937738.0,
492,161331,9,2,,103181002,2662,Active,,,14.0,IC50,Compound was evaluated for inhibition concentration of prostaglandin G/H synthase 1 in human blood,Confirmatory,15084117.0,
493,161333,9,5,,103181002,2662,Active,317373262.0,5742.0,15.0,IC50,Inhibition of human Prostaglandin G/H synthase 1,Confirmatory,10328307.0,
494,161336,9,5,,103181002,2662,Active,317373262.0,5742.0,6.3,IC50,In vitro potency against human Prostaglandin G/H synthase 1 (hCOX-1) in the human whole blood assay.,Confirmatory,10197970.0,
495,161337,9,2,,103181002,2662,Active,,,0.05,IC50,In vitro potency against human Prostaglandin G/H synthase 1 in U937 microsomes.,Confirmatory,10197970.0,
496,161475,9,2,,103181002,2662,Active,,,15.0,IC50,In Vitro activity of compound against human recombinant Prostaglandin G/H synthase 1,Confirmatory,10715145.0,
497,161480,9,1,,103181002,2662,Active,,,5.1,IC50,In vitro inhibitory activity against human Prostaglandin G/H synthase 1 (COX-1) in U-937 cells,Confirmatory,12877584.0,
498,161484,9,2,,103181002,2662,Active,,,6.3,IC50,In vitro inhibitory activity against human whole blood Prostaglandin G/H synthase 1,Confirmatory,10406640.0,
499,161487,9,2,,103181002,2662,Active,,,10.7,IC50,In vitro inhibitory activity against recombinant human Prostaglandin G/H synthase 1,Confirmatory,12729631.0,
500,161491,9,2,,103181002,2662,Active,,,22.9,IC50,In vitro inhibitory concentration of compound required to inhibit Prostaglandin G/H synthase 1 enzyme was determined,Confirmatory,12217369.0,
501,161494,9,2,,103181002,2662,Active,,,15.0,IC50,In vitro inhibitory concentration required to block recombinant human prostaglandin G/H synthase 1 (COX-1),Confirmatory,9135032.0,
502,161499,9,1,,103181002,2662,Active,,,5.1,IC50,Inhibition of Prostaglandin G/H synthase 1 in U-937 cells from human histiocytic lymphoma,Confirmatory,11462976.0,
503,161503,6,3,,103181002,2662,Active,,,2.0,IC50,Inhibition of arachidonic acid induced TXB2 generation in isolated human platelets (Prostaglandin G/H synthase 1 cell assay),Confirmatory,11906281.0,
504,161504,9,2,,103181002,2662,Active,,,22.9,IC50,Inhibition of human Prostaglandin G/H synthase 1,Confirmatory,11520200.0,
505,161654,9,2,,103181002,2662,Active,,,14.2,IC50,Inhibitory activity against prostaglandin G/H synthase 1,Confirmatory,10649977.0,
506,161656,9,2,,103181002,2662,Active,,,6.3,IC50,Inhibitory activity against Prostaglandin G/H synthase 1 in human whole blood,Confirmatory,10465547.0,
507,161660,9,5,,103181002,2662,Active,317373262.0,5742.0,27.0,IC50,Inhibition of human Prostaglandin G/H synthase 1,Confirmatory,11906292.0,
508,161668,9,2,,103181002,2662,Active,,,6.3,IC50,Inhibitory concentration was measured against Prostaglandin G/H synthase 1 in human whole blood,Confirmatory,12643942.0,
509,161669,9,1,,103181002,2662,Active,,,0.05,IC50,Inhibitory concentration was measured against Prostaglandin G/H synthase 1 in the sensitive U937 microsome assay,Confirmatory,12643942.0,
510,161671,6,3,,103181002,2662,Active,,,26.4,IC50,Inhibitory effect on Prostaglandin G/H synthase 1 activity was evaluated in human whole blood as TXB2 production,Confirmatory,11906281.0,
511,161687,6,4,,103181002,2662,Inconclusive,,,,,Compound was evaluated for percent inhibition of prostaglandin G/H synthase 1 in human whole blood (HWB) at a concentration of 100 um; not determined,Other,15084117.0,
512,161691,8,1,,103181002,2662,Active,,,,,Compound was tested in vitro for inhibition of human recombinant Prostaglandin G/H synthase 1,Other,9934449.0,
513,161833,3,7,,103181002,2662,Unspecified,,,,,In vitro percent Inhibition of recombinant human prostaglandin G/H synthase 1 (COX-1) at a concentration of 100 uM,Other,14640557.0,
514,161846,3,8,,103181002,2662,Inconclusive,,,,,In vitro average percent Inhibition of Prostaglandin G/H synthase 1 (COX-1) at a concentration of 100 uM in human whole blood by human whole blood assay; Not tested,Other,14640557.0,
515,161848,3,8,,103181002,2662,Unspecified,,,,,Ratio of in vitro inhibitory activity against recombinant human Prostaglandin G/H synthase 1 to that of recombinant human Prostaglandin G/H synthase 2,Other,12729631.0,
516,161987,3,7,,103181002,2662,Unspecified,,,,,Percentage of inhibition of Prostaglandin G/H synthase 1 activity in human whole blood (HWB) at 10 uM,Other,11462976.0,
517,161995,6,4,,103181002,2662,Unspecified,,,100.0,IC50,Compound was tested for the inhibition of recombinant human Prostaglandin G/H synthase 1 (COX-1),Confirmatory,14640557.0,
518,161996,6,4,,103181002,2662,Unspecified,,,,,In vitro inhibitory activity against prostaglandin G/H synthase 1 using mouse peritoneal macrophage method,Other,14761182.0,
519,162001,3,8,,103181002,2662,Unspecified,,,,,In vitro percentage inhibition against prostaglandin G/H synthase 1 using freshly harvested mouse peritoneal macrophages at 10 ug/mL concentration,Other,12565941.0,
520,162003,3,8,,103181002,2662,Unspecified,,,,,In vitro percentage inhibitory activity against prostaglandin G/H synthase 1 from freshly harvested mouse peritoneal macrophages at 10 ug/mL,Other,15081007.0,
521,162005,7,2,,103181002,2662,Active,,,0.0093,IC50,Tested for inhibition against Prostaglandin G/H synthase 1 from mouse resident macrophages,Confirmatory,11101350.0,
522,162006,6,4,,103181002,2662,Unspecified,,,,,Ability to inhibit Prostaglandin G/H synthase 1 by using freshly harvested mouse peritoneal macrophages,Other,11206450.0,
523,162011,9,2,,103181002,2662,Active,,,14.2,IC50,In vitro inhibitory concentration against rat prostaglandin G/H synthase 1,Confirmatory,11591502.0,
524,162017,10,5,,103181002,2662,Active,754286265.0,443551.0,22.9,IC50,In vitro inhibition against ovine Prostaglandin G/H synthase 1,Confirmatory,12798335.0,
525,162018,10,5,,103181002,2662,Active,754286265.0,443551.0,22.9,IC50,In vitro inhibitory activity against Prostaglandin G/H synthase 1 (COX-1),Confirmatory,14584938.0,
526,162020,10,5,,103181002,2662,Active,754286265.0,443551.0,10.7,IC50,In vitro inhibitory activity against prostaglandin G/H synthase 1 from the microsomal fraction of ram seminal vesicles,Confirmatory,15026050.0,
527,162022,10,5,,103181002,2662,Active,754286265.0,443551.0,23.0,IC50,In vitro inhibitory activity against prostaglandin G/H synthase 1 from ovine,Confirmatory,15050635.0,
528,162146,10,5,,103181002,2662,Active,754286265.0,443551.0,10.7,IC50,Inhibitory activity against prostaglandin G/H synthase 1 from ram seminal vesicles,Confirmatory,14698190.0,
529,162156,3,11,,103181002,2662,Unspecified,754286265.0,443551.0,,,In vitro inhibitory activity against prostaglandin G/H synthase 1 (COX-1) from the microsomal fraction of ram seminal vesicles at 10 uM concentration,Other,15026050.0,
530,162165,5,3,,103181002,2662,Unspecified,754286265.0,443551.0,,,Inhibitory constant against prostaglandin G/H synthase 1 (COX-1),Other,12383007.0,
531,162167,3,11,,103181002,2662,Unspecified,754286265.0,443551.0,,,In vitro selectivity ratio of Prostaglandin G/H synthase 1 to Prostaglandin G/H synthase 2,Other,12798335.0,
532,162176,8,5,,103181002,2662,Active,754286265.0,443551.0,15.1356,IC50,Inhibitory activity against prostaglandin G/H synthase 1 (COX-1),Confirmatory,12383007.0,
533,162177,9,5,,103181002,2662,Active,754286265.0,443551.0,15.33,IC50,In vitro inhibition against Prostaglandin G/H synthase 1 from ram seminal vesicles,Confirmatory,12954051.0,
534,162306,3,9,,103181002,2662,Unspecified,754286265.0,443551.0,,,In vitro inhibition of Prostaglandin G/H synthase 1 (from ram seminal vesicles) at a concentration of 10 M,Other,12954051.0,
535,162308,9,2,,103181002,2662,Active,,,14.0,IC50,Compound was tested for the inhibition of human Prostaglandin G/H synthase 1 (COX-1) in human whole blood,Confirmatory,14640557.0,
536,162312,9,2,,103181002,2662,Active,,,22.9,IC50,Inhibitory concentration against Prostaglandin G/H synthase 1,Confirmatory,11520213.0,
537,162315,7,1,,103181002,2662,Unspecified,,,,,Relative free energy of binding of compound to wild-type Prostaglandin G/H synthase 1;(deltaG=RT ln IC50),Other,11412976.0,
538,162335,9,2,,103181002,2662,Active,,,0.9,IC50,In vitro inhibitory activity against canine prostaglandin G/H synthase 2.,Confirmatory,14684306.0,
539,162339,9,2,,103181002,2662,Active,,,0.53,IC50,"Biochemical index for Prostaglandin G/H synthase 2 measured as, PGE-2 levels in lipopolysaccharide (LPS)-challenged human whole blood",Confirmatory,10937738.0,
540,162341,9,2,,103181002,2662,Active,,,1.2,IC50,Compound was evaluated for inhibition concentration of prostaglandin G/H synthase 2 in human blood,Confirmatory,15084117.0,
541,162344,9,2,,103181002,2662,Active,,,0.04,IC50,In vitro inhibitory activity against human Prostaglandin G/H synthase 2,Confirmatory,10328307.0,
542,162472,9,2,,103181002,2662,Active,,,0.054000000000000006,IC50,Compound was tested for the inhibition of recombinant human Prostaglandin G/H synthase 2 (COX-2),Confirmatory,14640557.0,
543,162482,9,2,,103181002,2662,Active,,,0.04,IC50,In Vitro activity of compound against human recombinant Prostaglandin G/H synthase 2,Confirmatory,10715145.0,
544,162484,9,2,,103181002,2662,Active,,,0.07,IC50,In vitro inhibition against human Prostaglandin G/H synthase 2,Confirmatory,12954051.0,
545,162489,9,1,,103181002,2662,Active,,,0.079,IC50,In vitro inhibitory activity against human Prostaglandin G/H synthase 2 (COX-2) in 143982 cells,Confirmatory,12877584.0,
546,162493,9,1,,103181002,2662,Active,,,0.036000000000000004,IC50,In vitro inhibitory activity against human recombinant prostaglandin G/H synthase 2 expressed in sf-9 cells infected with baculovirus,Confirmatory,15026050.0,
547,162494,9,5,,103181002,2662,Active,3915797.0,5743.0,1.0,IC50,In vitro inhibitory activity against human whole blood Prostaglandin G/H synthase 2,Confirmatory,10406640.0,
548,162498,9,2,,103181002,2662,Active,,,0.036000000000000004,IC50,In vitro inhibitory activity against recombinant human Prostaglandin G/H synthase 2,Confirmatory,12729631.0,
549,162503,9,2,,103181002,2662,Active,,,0.0567,IC50,In vitro inhibitory concentration of compound required to inhibit Prostaglandin G/H synthase 2 enzyme was determined,Confirmatory,12217369.0,
550,162507,9,2,,103181002,2662,Active,,,0.04,IC50,In vitro inhibitory concentration required to block human recombinant prostaglandin G/H synthase 2 (COX-2),Confirmatory,9135032.0,
551,162630,7,2,,103181002,2662,Active,,,0.6,IC50,In vitro percent inhibition of Prostaglandin G/H synthase 2 (COX-2) in human whole blood was determined,Confirmatory,12877584.0,
552,162635,6,4,,103181002,2662,Active,,,0.12,IC50,Inhibition of PGE-2 generation in LPS-stimulated human monocytes (Prostaglandin G/H synthase 2 cell assay),Confirmatory,11906281.0,
553,162636,9,1,,103181002,2662,Active,,,0.08,IC50,Inhibition of Prostaglandin G/H synthase 2 in 143.98.2 from human osteosarcoma cells,Confirmatory,11462976.0,
554,162644,9,2,,103181002,2662,Active,,,1.1,IC50,Inhibitory activity against prostaglandin G/H synthase 2,Confirmatory,10649977.0,
555,162646,9,5,,103181002,2662,Active,3915797.0,5743.0,1.0,IC50,Inhibition of Prostaglandin G/H synthase 2 in human whole blood,Confirmatory,10465547.0,
556,162651,9,5,,103181002,2662,Active,3915797.0,5743.0,0.23,IC50,Inhibition of human Prostaglandin G/H synthase 2,Confirmatory,11906292.0,
557,162652,9,1,,103181002,2662,Active,,,0.036000000000000004,IC50,Inhibitory activity against human Prostaglandin G/H synthase 2 expressed in sf-9 cells infected with baculovirus,Confirmatory,14698190.0,
558,162656,9,2,,103181002,2662,Active,,,0.0567,IC50,Inhibitory concentration against Prostaglandin G/H synthase 2,Confirmatory,11520200.0,
559,162659,9,2,,103181002,2662,Active,,,0.04,IC50,Inhibitory concentration against human prostaglandin G/H synthase 2 at 25 degrees.,Confirmatory,11814774.0,
560,162662,6,3,,103181002,2662,Active,,,3.6,IC50,Inhibitory effect on Prostaglandin G/H synthase 2 activity was evaluated in human whole blood as LPS-induced PGE-2 generation,Confirmatory,11906281.0,
561,166745,3,4,,103181002,2662,Unspecified,,,,,Variation of intraocular pressure in day one at a dose of 150 mg/kg by systemic administration in hypertensive rabbits,Other,14736236.0,
562,166749,3,4,,103181002,2662,Unspecified,,,,,Variation of intraocular pressure in fifth day at a dose of 150 mg/kg by systemic administration in hypertensive rabbits,Other,14736236.0,
563,166753,3,4,,103181002,2662,Unspecified,,,,,Variation of intraocular pressure in fourth day at a dose of 150 mg/kg by systemic administration in hypertensive rabbits,Other,14736236.0,
564,166757,3,4,,103181002,2662,Unspecified,,,,,Variation of intraocular pressure in second day at a dose of 150 mg/kg by systemic administration in hypertensive rabbits,Other,14736236.0,
565,166761,3,4,,103181002,2662,Unspecified,,,,,Variation of intraocular pressure in seventh day at a dose of 150 mg/kg by systemic administration in hypertensive rabbits,Other,14736236.0,
566,166902,3,4,,103181002,2662,Unspecified,,,,,Variation of intraocular pressure in sixth day at a dose of 150 mg/kg by systemic administration in hypertensive rabbits,Other,14736236.0,
567,166906,3,4,,103181002,2662,Unspecified,,,,,Variation of intraocular pressure in third day at a dose of 150 mg/kg by systemic administration in hypertensive rabbits,Other,14736236.0,
568,174679,3,4,,103181002,2662,Unspecified,,,,,"Percentage of [51Cr]- secreted in feces was determined by fecal drug-induced bleeding method in rat at 100 mg/kg, bid for 5 days",Other,12877584.0,
569,175862,6,1,,103181002,2662,Unspecified,,,,,"In vivo activity determined using minimum of four dose points, 5 animals/group in rat carrageenan edema.",Other,10715145.0,
570,175863,6,1,,103181002,2662,Unspecified,,,,,"In vivo activity determined using minimum of four dose points, 8-10 animals/group in rat adjuvant arthritis.",Other,10715145.0,
571,175864,6,1,,103181002,2662,Unspecified,,,,,In vivo activity in rat air pouch.,Other,10715145.0,
572,175865,6,1,,103181002,2662,Unspecified,,,,,In vivo activity in rat air pouch.,Other,10715145.0,
573,176212,6,2,,103181002,2662,Unspecified,,,,,Effective dose was determined in vivo in male lewis rats by rat adjuvant-induced arthritis assay,Other,9135032.0,
574,176213,6,2,,103181002,2662,Unspecified,,,,,Effective dose was determined in vivo in male Dawley rats by rat carrageenan-induced foot pad edema assay,Other,9135032.0,
575,176214,6,2,,103181002,2662,Unspecified,,,,,Effective dose was determined in vivo in male Dawley rats by rat carrageenan-induced hyperalgesia assay,Other,9135032.0,
576,177173,6,2,,103181002,2662,Unspecified,,,,,In vivo efficacy was evaluated using a carrageenan-induced rat paw edema model as ED50.,Other,10197970.0,
577,177221,3,3,,103181002,2662,Unspecified,,,,,In vivo inhibition of carrageenan-induced air pouch in rats,Other,10649977.0,
578,177223,3,3,,103181002,2662,Unspecified,,,,,Inhibition of carrageenan paw edema in rats,Other,10649977.0,
579,177358,6,2,,103181002,2662,Unspecified,,,,,In vivo inhibition of adjuvant arthritis in rats,Other,10649977.0,
580,177511,6,2,,103181002,2662,Unspecified,,,,,In vivo inhibition of carrageenan-induced hyperalgesia in rats,Other,10649977.0,
581,177520,6,2,,103181002,2662,Unspecified,,,,,In vivo inhibition of pyresis in rats,Other,10649977.0,
582,177675,6,2,,103181002,2662,Unspecified,,,,,Inhibition of carrageenan induced rat paw oedema.,Other,12643942.0,
583,178666,4,2,,103181002,2662,Unspecified,,,,,Antiinflammatory activity was determined by measuring adjuvant-induced arthritis in rats using therapeutic method; dose administered daily once,Other,14761182.0,
584,178667,4,2,,103181002,2662,Unspecified,,,,,Antiinflammatory activity was determined by measuring adjuvant-induced arthritis in rats using therapeutic method; dose administered daily twice,Other,14761182.0,
585,178739,8,1,,103181002,2662,Unspecified,,,,,Effective dose was evaluated by rat adjuvant arthritis model.,Other,9934449.0,
586,178934,4,2,,103181002,2662,Unspecified,,,,,Effective dose required for the inhibition of adjuvant arthritis in Sprague-Darley rats,Other,11206450.0,
587,180547,6,2,,103181002,2662,Unspecified,,,,,The compound was tested in vivo for activity against adjuvant-induced arthritis in rat after peroral administration after peroral administration,Other,11906292.0,
588,180548,6,2,,103181002,2662,Unspecified,,,,,The compound was tested in vivo for activity against carrageenan induced paw edema in rat after peroral administration,Other,11906292.0,
589,181152,8,1,,103181002,2662,Unspecified,,,,,Hemoglobin levels in the different assays ranged from 11.5-14.7 g/dl.,Other,10649977.0,
590,182047,3,3,,103181002,2662,Unspecified,,,,,In vivo inhibition of contralateral paw swelling after oral treatment for 28 days (1 mg/kg od) was determined by adjuvabt arthritis in rat,Other,12877584.0,
591,182758,3,3,,103181002,2662,Unspecified,,,,,In vivo inhibitory activity against carrageenan induced paw edema in Sprague-Darley rats after oral administration of the compound,Other,11206450.0,
592,183004,3,4,,103181002,2662,Unspecified,,,,,"Analgesic activity at 30 min post drug administration (50 mg/kg, ip)using the 4% NaCl-induced abdominal constriction assay in rat.",Other,11520200.0,
593,183006,3,4,,103181002,2662,Unspecified,,,,,"Analgesic activity at 60 min post drug administration (50 mg/kg, ip)using the 4% NaCl-induced abdominal constriction assay in rat.",Other,11520200.0,
594,183015,3,3,,103181002,2662,Unspecified,,,,,Analgesic activity was determined in rat using 4% sodium chloride-induced abdominal constriction assay at a duration of 30 min following a 1 mg/kg intraperitoneal dose,Other,14584938.0,
595,183016,3,3,,103181002,2662,Unspecified,,,,,Analgesic activity was determined in rat using 4% sodium chloride-induced abdominal constriction assay at a duration of 60 min following a 1 mg/kg intraperitoneal dose,Other,14584938.0,
596,183112,6,2,,103181002,2662,Unspecified,,,,,Inhibitory activity against carrageenan induced rat paw edema after peroral administration,Other,11520200.0,
597,183113,6,2,,103181002,2662,Unspecified,,,,,Inhibitory activity against carrageenan induced rat paw edema after peroral administration after 5 hours,Other,11520200.0,
598,183305,3,3,,103181002,2662,Unspecified,,,,,Anti-inflammatory activity at 3h post drug administration using the carrageenan-induced rat paw edema assay,Other,11520200.0,
599,183306,3,3,,103181002,2662,Unspecified,,,,,Anti-inflammatory activity at 5 hr post drug administration using the carrageenan-induced rat paw edema assay,Other,11520200.0,
600,183502,3,3,,103181002,2662,Unspecified,,,,,Antiinflammatory activity in vivo by carrageenan paw edema assay in rat at a dose of 3 mg/kg,Other,11591502.0,
601,183637,4,3,,103181002,2662,Unspecified,,,,,Anti-inflammatory activity in vivo by carrageenan paw edema assay in rat at a dose of 30 mg/kg,Other,11591502.0,
602,183650,3,3,,103181002,2662,Unspecified,,,,,Inhibition of carrageenan-induced rat foot oedema following 3 mg/kg administration.,Other,14761182.0,
603,183701,3,3,,103181002,2662,Unspecified,,,,,Evaluated in vivo for antiinflammatory activity at 30 mg/kg oral dose in the carrageenan-induced rat paw edema (male Wistar rat),Other,12954051.0,
604,184044,3,3,,103181002,2662,Unspecified,,,,,In vivo analgesic activity of compound was determined by inflammatory hyperalgesia model at 3 mg/kg perorally in rat,Other,12877584.0,
605,184173,3,3,,103181002,2662,Unspecified,,,,,In vivo anti-inflammatory activity by air pouch model at 1 mg/kg perorally in rat.,Other,12877584.0,
606,184174,3,3,,103181002,2662,Unspecified,,,,,In vivo anti-inflammatory activity determined by rat carrageenan paw edema method at 10 mg/kg perorally,Other,12877584.0,
607,184177,3,4,,103181002,2662,Unspecified,,,,,In vivo antiinflammatory activity against rat carrageenan-induced foot paw edema model at 3 hr following a 1 mg/kg oral dose,Other,14584938.0,
608,184179,3,4,,103181002,2662,Unspecified,,,,,In vivo antiinflammatory activity against rat carrageenan-induced foot paw edema model at 5 hr following a 1 mg/kg oral dose,Other,14584938.0,
609,185799,3,3,,103181002,2662,Unspecified,,,,,Inhibitory effect of compound on carrageenan-induced rat paw edema administered p.o. at 10 mg/kg,Other,15081007.0,
610,185800,3,3,,103181002,2662,Unspecified,,,,,Inhibitory effect of compound on carrageenan-induced rat paw edema administered p.o. at 3 mg/kg,Other,15081007.0,
611,190164,3,3,,103181002,2662,Unspecified,,,,,The compound was tested in vivo for gastric ulcerogenic activity in rat after peroral administration,Other,11906292.0,
612,190377,3,3,,103181002,2662,Unspecified,,,,,Percent ulceration was determined in rats at a dose of 200 mg/kg (10 animals),Other,9135032.0,
613,193928,3,3,,103181002,2662,Unspecified,,,,,"% Inhibition (Analgesic) in rat 4% NaCl induced abdominal contriction assay, 30 min after intraperitoneal administration of 50 mg/kg of compound",Other,11520213.0,
614,193929,3,3,,103181002,2662,Unspecified,,,,,"% Inhibition (Analgesic) in rat 4% NaCl induced abdominal contriction assay, 60 min after intraperitoneal administration of 50 mg/kg of compound",Other,11520213.0,
615,193930,3,3,,103181002,2662,Unspecified,,,,,"% Inhibition (antiinflammatory) on carrageenan rat paw edema, 3 hours after oral administration of 50 mg/kg compound",Other,11520213.0,
616,193931,3,3,,103181002,2662,Unspecified,,,,,"% Inhibition (antiinflammatory) on carrageenan rat paw edema, 5 hours after oral administration 50 mg/kg of compound",Other,11520213.0,
617,194462,3,3,,103181002,2662,Unspecified,,,,,In vivo inhibition of Carrageenan-induced rat paw edema was determined in male Sprague-Dawley rat at a dose of 10 mg/kg,Other,11462976.0,
618,194620,3,3,,103181002,2662,Unspecified,,,,,Inhibition of PGE 2 production in air-pouch model in male Lewis-rat at a dose of 0.3 mg/kg,Other,11462976.0,
619,194621,3,3,,103181002,2662,Unspecified,,,,,Inhibition of PGE 2 production in air-pouch model in male Lewis-rat at a dose of 1 mg/kg,Other,11462976.0,
620,196175,3,3,,103181002,2662,Unspecified,,,,,Effect on non perforated ulcers(NPU) at the dose of 100 mg/kg.,Other,10649977.0,
621,196178,3,3,,103181002,2662,Unspecified,,,,,Effect on perforated ulcers(PU) at the dose of 100 mg/kg.,Other,10649977.0,
622,223071,6,2,,103181002,2662,Active,,,6.67,IC50,Analysis of TXB2 as a function of COX-1 activity in heparinized human whole blood.,Confirmatory,10715145.0,
623,223079,6,2,,103181002,2662,Active,,,0.16399999999999998,IC50,In vitro assay for PGE-2 production as a function of COX-2 inhibition in whole human blood cultured with lipopolysaccharide (LPS),Confirmatory,10715145.0,
624,224764,3,7,,103181002,2662,Unspecified,,,,,Compound was evaluated for percent inhibition of recombinant prostaglandin G/H synthase 1 in human whole blood (HWB) at a concentration of 100 um,Other,15084117.0,
625,225286,4,2,,103181002,2662,Unspecified,,,,,Effective dose for inhibition of edema after oral administration (95% confidence limits),Other,11101350.0,
626,225287,4,2,,103181002,2662,Unspecified,,,,,Effective dose for inhibition of edema of the non injected paw in rat,Other,11101350.0,
627,226197,9,3,,103181002,2662,Active,,,1.0,IC50,Inhibitory concentration was measured against Cyclooxygenase-2 in human whole blood,Confirmatory,12643942.0,
628,228024,6,2,,103181002,2662,Active,,,0.0079,IC50,Inhibitory effect on production of cyclooxygenase-2 (COX-2) prostaglandin E2 (PGE2) in human IL1-beta stimulated synovial cells,Confirmatory,10821716.0,
629,229164,3,7,,103181002,2662,Unspecified,,,,,Selectivity of IC50 COX-2/COX-1 was determined; Not determined,Other,14640557.0,
630,229282,3,5,,103181002,2662,Unspecified,,,,,Ratio of IC50 of COX-1 to that of COX-2.,Other,14684306.0,
631,229414,3,10,,103181002,2662,Unspecified,3915797.0,5743.0,,,Selectivity ratio for COX-1 over COX-2,Other,11906292.0,
632,229414,3,10,,103181002,2662,Unspecified,317373262.0,5742.0,,,Selectivity ratio for COX-1 over COX-2,Other,11906292.0,
633,229415,3,6,,103181002,2662,Unspecified,,,,,Selectivity ratio (COX-1/COX-2),Other,11906281.0,
634,229532,4,3,,103181002,2662,Unspecified,,,,,Ratio of IC50 values at Cyclooxygenase-1 and Cyclooxygenase-2,Other,10406640.0,
635,232419,3,6,,103181002,2662,Unspecified,,,,,Ratio of inhibition of COX-1 to COX-2,Other,10821716.0,
636,232500,3,7,,103181002,2662,Unspecified,,,,,Selectivity ratio of COX-1/COX-2,Other,10649977.0,
637,232766,3,8,,103181002,2662,Unspecified,,,,,Selectivity index of IC50 (COX-1) to that of IC50 (COX-2) was determined,Other,12217369.0,
638,232767,3,9,,103181002,2662,Unspecified,3914304.0,443460.0,,,Selectivity index of IC50 against COX-1 to the IC50 against COX-2,Other,14584938.0,
639,232767,3,9,,103181002,2662,Unspecified,754286265.0,443551.0,,,Selectivity index of IC50 against COX-1 to the IC50 against COX-2,Other,14584938.0,
640,232913,3,7,,103181002,2662,Unspecified,,,,,Ratio of cox-1/cox-2 was determined,Other,11520200.0,
641,233868,3,8,,103181002,2662,Unspecified,,,,,Selectivity expressed as IC50 COX-1/IC50 COX-2,Other,15050635.0,
642,234313,4,7,,103181002,2662,Unspecified,,,,,Selectivity of IC50 COX-2/COX-1 was determined,Other,14640557.0,
643,234556,3,8,,103181002,2662,Unspecified,,,,,Selectivity against COX-2 over COX-1,Other,14761182.0,
644,234657,3,9,,103181002,2662,Unspecified,,,,,Tested for COX-2 selectivity over COX-1 using freshly harvested mouse peritoneal macrophages,Other,11206450.0,
645,234761,3,10,,103181002,2662,Unspecified,3915797.0,5743.0,,,Ratio of inhibitory activity against COX-1 and COX-2,Other,10937738.0,
646,234761,3,10,,103181002,2662,Unspecified,317373262.0,5742.0,,,Ratio of inhibitory activity against COX-1 and COX-2,Other,10937738.0,
647,234963,3,11,,103181002,2662,Unspecified,548484.0,29527.0,,,Selectivity towards COX-2 versus COX-1,Other,11591502.0,
648,234963,3,11,,103181002,2662,Unspecified,3914292.0,24693.0,,,Selectivity towards COX-2 versus COX-1,Other,11591502.0,
649,234974,3,5,,103181002,2662,Unspecified,,,,,Selectivity as log (IC50[COX-1]/IC50[COX-2]).,Other,12383007.0,
650,235863,3,7,,103181002,2662,Unspecified,,,,,In vitro selectivity against COX-1 to that of COX-2 was determined,Other,12954051.0,
651,238536,9,5,,103181002,2662,Unspecified,115449.0,759.0,50.0,Ki,Inhibitory activity against human carbonic anhydrase I (hCAI),Confirmatory,15686931.0,
652,238574,8,5,,103181002,2662,Active,115456.0,760.0,0.021,Ki,Inhibitory activity against human carbonic anhydrase II (hCAII),Confirmatory,15686931.0,
653,238575,8,5,,103181002,2662,Active,115465.0,762.0,0.88,Ki,Inhibitory activity against human carbonic anhydrase IV (hCAIV),Confirmatory,15686931.0,
654,238597,8,1,,103181002,2662,Active,5915863.0,280741.0,0.29,Ki,Inhibitory activity against bovine carbonic anhydrase IV (bCAIV),Confirmatory,15686931.0,
655,238957,9,5,,103181002,2662,Unspecified,115449.0,759.0,50.0,Ki,Inhibitory activity against human carbonic anhydrase I at 0.09 uM,Confirmatory,15546717.0,
656,238986,9,5,,103181002,2662,Active,115456.0,760.0,21.0,Ki,Inhibitory activity against human carbonic anhydrase II at 0.01 uM,Confirmatory,15546717.0,
657,238987,9,5,,103181002,2662,Active,83300925.0,768.0,16.0,Ki,Inhibitory activity against human carbonic anhydrase IX at 0.09 uM,Confirmatory,15546717.0,
658,239145,9,5,,103181002,2662,Active,729004.0,,1.01,Ki,Inhibitory activity against alpha carbonic anhydrase (Co-Cam) from Methanosarcina thermophila,Confirmatory,15546717.0,
659,239146,9,5,,103181002,2662,Active,729004.0,,0.14,Ki,Inhibitory activity against alpha carbonic anhydrase (Zn-Cam) from Methanosarcina thermophila,Confirmatory,15546717.0,
660,239250,10,1,,103181002,2662,Active,74515025.0,,38.5,Ki,Inhibitory activity against beta carbonic anhydrase (Cab) from Methanobacterium thermoautotrophicum,Confirmatory,15546717.0,
661,239789,3,11,,103181002,2662,Unspecified,129900.0,19224.0,,,Ratio of IC50 of Prostaglandin G/H synthase 1 and Prostaglandin G/H synthase 2,Other,15857149.0,
662,239789,3,11,,103181002,2662,Unspecified,548483.0,19225.0,,,Ratio of IC50 of Prostaglandin G/H synthase 1 and Prostaglandin G/H synthase 2,Other,15857149.0,
663,239790,3,9,,103181002,2662,Unspecified,3914304.0,443460.0,,,In vitro selectivity for Prostaglandin G/H synthase 1 and Prostaglandin G/H synthase 2,Other,15267236.0,
664,239790,3,9,,103181002,2662,Unspecified,754286265.0,443551.0,,,In vitro selectivity for Prostaglandin G/H synthase 1 and Prostaglandin G/H synthase 2,Other,15267236.0,
665,239794,3,10,,103181002,2662,Unspecified,3914304.0,443460.0,,,Ratio of IC50 for prostaglandin G/H synthase 1 and prostaglandin G/H synthase 2,Other,15537365.0,
666,239794,3,10,,103181002,2662,Unspecified,754286265.0,443551.0,,,Ratio of IC50 for prostaglandin G/H synthase 1 and prostaglandin G/H synthase 2,Other,15537365.0,
667,239795,4,9,,103181002,2662,Unspecified,3914304.0,443460.0,,,Ratio of IC50 for Cyclooxygenase-1 and Cyclooxygenase-2,Other,15603969.0,
668,239795,4,9,,103181002,2662,Unspecified,754286265.0,443551.0,,,Ratio of IC50 for Cyclooxygenase-1 and Cyclooxygenase-2,Other,15603969.0,
669,241083,10,1,,103181002,2662,Active,754286265.0,443551.0,33.1,IC50,Inhibition of ovine Prostaglandin G/H synthase 1,Confirmatory,15267236.0,
670,241084,10,1,,103181002,2662,Active,3914304.0,443460.0,0.07,IC50,Inhibition of ovine Prostaglandin G/H synthase 2,Confirmatory,15267236.0,
671,241126,10,1,,103181002,2662,Active,754286265.0,443551.0,33.1,IC50,In vitro inhibitory concentration against ovine Cyclooxygenase-1,Confirmatory,15603969.0,
672,241127,10,1,,103181002,2662,Active,3914304.0,443460.0,0.07,IC50,In vitro inhibitory concentration against ovine Cyclooxygenase-2,Confirmatory,15603969.0,
673,241307,8,5,,103181002,2662,Active,317373262.0,5742.0,1.689,IC50,Inhibition of human cyclooxygenase-1 expressed in COS cells,Confirmatory,15454242.0,
674,241308,8,5,,103181002,2662,Active,3915797.0,5743.0,0.068,IC50,Inhibition of human cyclooxygenase-2 expressed in COS cells,Confirmatory,15454242.0,
675,241382,10,1,,103181002,2662,Active,754286265.0,443551.0,33.1,IC50,In vitro inhibition of ovine prostaglandin G/H synthase 1,Confirmatory,15537365.0,
676,241383,10,1,,103181002,2662,Active,3914304.0,443460.0,0.07,IC50,In vitro inhibition of ovine prostaglandin G/H synthase 2,Confirmatory,15537365.0,
677,241488,10,1,,103181002,2662,Active,754286265.0,443551.0,33.1,IC50,In vitro inhibitory concentration against ovine Prostaglandin G/H synthase 1,Confirmatory,15341950.0,
678,241489,10,1,,103181002,2662,Active,3914304.0,443460.0,0.07,IC50,In vitro inhibitory concentration against ovine Prostaglandin G/H synthase 2,Confirmatory,15341950.0,
679,241608,9,5,,103181002,2662,Active,317373262.0,5742.0,14.0,IC50,In vitro inhibition of Prostaglandin G/H synthase 1 in human whole blood,Confirmatory,15546727.0,
680,241609,9,5,,103181002,2662,Active,3915797.0,5743.0,1.2,IC50,In vitro inhibition of Prostaglandin G/H synthase 2 in human whole blood,Confirmatory,15546727.0,
681,241917,10,1,,103181002,2662,Active,129900.0,19224.0,5.1,IC50,In vitro inhibitory activity against Prostaglandin G/H synthase 1 in murine J774 cells,Confirmatory,15857149.0,
682,241918,10,1,,103181002,2662,Active,548483.0,19225.0,0.079,IC50,In vitro inhibitory activity against Prostaglandin G/H synthase 2 in murine J774 cells,Confirmatory,15857149.0,
683,241924,9,5,,103181002,2662,Active,2499600.0,1432.0,0.81,IC50,Inhibitory concentration against p38 alpha MAP kinase calculated by CoMFA model; FlexX score=-12.4 kcal/mol,Confirmatory,15990304.0,
684,242132,9,5,,103181002,2662,Active,317373262.0,5742.0,14.0,IC50,In vitro inhibitory concentration against Prostaglandin G/H synthase 1 (COX-1) in human whole blood,Confirmatory,15916445.0,
685,242133,9,5,,103181002,2662,Active,3915797.0,5743.0,1.2,IC50,In vitro inhibitory concentration against Prostaglandin G/H synthase 2 (COX-2) in human whole blood,Confirmatory,15916445.0,
686,242224,9,5,,103181002,2662,Active,3914304.0,443460.0,2.05,IC50,Inhibitory concentration against Prostaglandin G/H synthase 2 from sheep placenta at 100 uM,Confirmatory,15780608.0,
687,243090,3,5,,103181002,2662,Unspecified,,,,,Ratio of inhibition of carbonic anhydrase IV in human to that of carbonic anhydrase IV in bovine,Other,15686931.0,
688,243602,3,10,,103181002,2662,Unspecified,548484.0,29527.0,,,Anti-inflammatory activity in rat paw edema assay at 50 mg/kg,Other,15780608.0,
689,243653,3,7,,103181002,2662,Unspecified,548483.0,19225.0,,,Percentage inhibition of Prostaglandin G/H synthase 2 in murine J774 cells at 1 uM,Other,15857149.0,
690,243659,3,7,,103181002,2662,Unspecified,548483.0,19225.0,,,Percentage inhibition of Prostaglandin G/H synthase 2 in murine J774 cells at 10 uM,Other,15857149.0,
691,243778,3,9,,103181002,2662,Unspecified,3915797.0,5743.0,,,In vitro inhibition of Prostaglandin G/H synthase 2 in human whole blood at 1 uM,Other,15546727.0,
692,243785,3,9,,103181002,2662,Unspecified,317373262.0,5742.0,,,In vitro inhibition of Prostaglandin G/H synthase 1 in human whole blood at 30 uM,Other,15546727.0,
693,243786,3,9,,103181002,2662,Unspecified,3915797.0,5743.0,,,In vitro inhibition of Prostaglandin G/H synthase 2 in human whole blood at 10 uM,Other,15546727.0,
694,243850,3,9,,103181002,2662,Unspecified,754286265.0,443551.0,,,Percent inhibition against Prostaglandin G/H synthase 1 from ram seminal vesicles at 100 uM,Other,15780608.0,
695,243903,3,10,,103181002,2662,Unspecified,317373262.0,5742.0,,,Percentage inhibition activity at a concentration of 10 uM against cyclooxygenase 1 with the compound dissolved in DMSO,Other,15993594.0,
696,243904,3,10,,103181002,2662,Unspecified,3915797.0,5743.0,,,Percentage inhibition activity at a concentration of 10 uM against cyclooxygenase 2 with the compound dissolved in DMSO,Other,15993594.0,
697,244091,3,10,,103181002,2662,Unspecified,3915797.0,5743.0,,,Ratio of IC50 for human COX-1 and COX-2,Other,15454242.0,
698,244091,3,10,,103181002,2662,Unspecified,317373262.0,5742.0,,,Ratio of IC50 for human COX-1 and COX-2,Other,15454242.0,
699,244252,3,10,,103181002,2662,Unspecified,3915797.0,5743.0,,,Selectivity for Prostaglandin G/H synthase 2 (COX-2) and Prostaglandin G/H synthase 1 (COX-1) in human whole blood as r\\atio of IC50,Other,15916445.0,
700,244252,3,10,,103181002,2662,Unspecified,317373262.0,5742.0,,,Selectivity for Prostaglandin G/H synthase 2 (COX-2) and Prostaglandin G/H synthase 1 (COX-1) in human whole blood as r\\atio of IC50,Other,15916445.0,
701,244381,3,10,,103181002,2662,Unspecified,3914304.0,443460.0,,,Ratio of IC50 for Prostaglandin G/H synthase 1 and Prostaglandin G/H synthase 2,Other,15341950.0,
702,244381,3,10,,103181002,2662,Unspecified,754286265.0,443551.0,,,Ratio of IC50 for Prostaglandin G/H synthase 1 and Prostaglandin G/H synthase 2,Other,15341950.0,
703,246823,6,8,,103181002,2662,Unspecified,548484.0,29527.0,,,Reduced Freund's complete adjuvant (FCA)-induced arthritis in rats,Other,15454242.0,
704,249060,6,7,,103181002,2662,Unspecified,548484.0,29527.0,,,Inhibitory oral dose in carrageenan induced rat paw edema assay,Other,15267236.0,
705,249062,6,8,,103181002,2662,Unspecified,548484.0,29527.0,,,Inhibitory dose against carrageenan-induced rat paw edema at 3 hr after oral dose,Other,15537365.0,
706,251780,3,10,,103181002,2662,Unspecified,548484.0,29527.0,,,Percent inhibition of anti-inflammatory activity in carrageenan induced rat paw edema at 3 hr,Other,15267236.0,
707,251920,3,3,,103181002,2662,Unspecified,,,,,Percent inhibition of analgesic activity in a rat model 4% NaCl-induced abdominal constriction assay at 30 min,Other,15267236.0,
708,251921,3,3,,103181002,2662,Unspecified,,,,,Percent inhibition of analgesic activity in a rat model 4% NaCl-induced abdominal constriction assay at 60 min,Other,15267236.0,
709,252036,3,3,,103181002,2662,Unspecified,,,,,Percent inhibition of 4% sodium chloride-induced abdominal constriction in rat after 30 min of 50 mg/kg oral dose of the compound,Other,15537365.0,
710,252037,3,3,,103181002,2662,Unspecified,,,,,Percent inhibition of 4% sodium chloride-induced abdominal constriction in rat after 60 min of 50 mg/kg oral dose of the compound,Other,15537365.0,
711,254247,8,5,,103181002,2662,Active,115456.0,760.0,0.021,Ki,Inhibition of cloned human carbonic anhydrase II,Confirmatory,16134940.0,
712,254248,8,5,,103181002,2662,Active,83300925.0,768.0,0.016,Ki,Inhibition of catalytic domain of human recombinant carbonic anhydrase IX,Confirmatory,16134940.0,
713,254687,4,10,,103181002,2662,Unspecified,115449.0,759.0,10.0,IC50,Inhibitory concentration against carbonic anhydrase I,Confirmatory,16220969.0,
714,254699,8,5,,103181002,2662,Active,115456.0,760.0,0.021,IC50,Inhibitory concentration against carbonic anhydrase II,Confirmatory,16220969.0,
715,254700,8,5,,103181002,2662,Active,83300925.0,768.0,0.016,IC50,Inhibitory concentration against carbonic anhydrase IX,Confirmatory,16220969.0,
716,254798,8,5,,103181002,2662,Active,3915797.0,5743.0,0.0068,IC50,Inhibitory concentration against COX-2; (valus obtained by Kato et al.),Confirmatory,16250658.0,
717,254882,11,2,,103181002,2662,Active,3915797.0,5743.0,0.006,IC50,Inhibitory concentration against COX-2 upon incubation for 15 minutes at 37 degree C,Confirmatory,16250658.0,
718,258729,8,5,,103181002,2662,Unspecified,115449.0,759.0,50.0,Ki,Inhibitory activity against cloned human CA1,Confirmatory,16290146.0,
719,258730,8,5,,103181002,2662,Active,115456.0,760.0,0.021,Ki,Inhibitory activity against cloned human CA2,Confirmatory,16290146.0,
720,258731,8,5,,103181002,2662,Active,5915863.0,280741.0,0.29,Ki,Inhibitory activity against CA4 isolated from bovine lung microsomes,Confirmatory,16290146.0,
721,258732,8,5,,103181002,2662,Active,83300925.0,768.0,0.016,Ki,Inhibitory activity against cloned human CA9,Confirmatory,16290146.0,
722,258733,8,5,,103181002,2662,Active,5915866.0,771.0,0.018000000000000002,Ki,Inhibitory activity against cloned human CA12,Confirmatory,16290146.0,
723,261404,9,5,,103181002,2662,Active,754286265.0,443551.0,33.1,IC50,Inhibitory activity against ovine COX1,Confirmatory,16509583.0,
724,261405,9,5,,103181002,2662,Active,3914304.0,443460.0,0.07,IC50,Inhibitory activity against ovine COX2,Confirmatory,16509583.0,
725,261408,3,10,,103181002,2662,Unspecified,3914304.0,443460.0,,,In vitro COX2 selectivity index (IC50 COX1/IC50 COX2),Other,16509583.0,
726,261408,3,10,,103181002,2662,Unspecified,754286265.0,443551.0,,,In vitro COX2 selectivity index (IC50 COX1/IC50 COX2),Other,16509583.0,
727,261409,6,2,,103181002,2662,Unspecified,,,,,"Anti-inflammatory activity against carrageenan-induced edema in Sprague-Dawley rat paw after 3 hrs of 30 mg/kg, po",Other,16509583.0,
728,261412,3,3,,103181002,2662,Unspecified,,,,,"Inhibitory activity against 4% NaCl-induced abdominal constriction in Sprague-Dawley rat after 30 min of 5 mg/kg, po",Other,16509583.0,
729,261413,3,3,,103181002,2662,Unspecified,,,,,"Inhibitory activity against 4% NaCl-induced abdominal constriction in Sprague-Dawley rat after 60 min of 5 mg/kg, po",Other,16509583.0,
730,269462,4,7,,103181002,2662,Unspecified,317373262.0,5742.0,,,Inhibition of microsomal COX1,Other,16730986.0,
731,269464,3,9,,103181002,2662,Unspecified,3915797.0,5743.0,,,Inhibition of human recombinant COX2 expressed in sf9 cells infected with baculovirus,Other,16730986.0,
732,269466,6,2,,103181002,2662,Unspecified,,,,,Anti-inflammatory activity in orally dosed Wistar rat assessed as reduction of carrageenan-induced paw edema,Other,16730986.0,
733,270013,8,5,,103181002,2662,Active,754286265.0,443551.0,0.0037,IC50,Inhibition of COX1,Confirmatory,16806914.0,
734,270014,8,5,,103181002,2662,Active,3915797.0,5743.0,0.0022,IC50,Inhibition of COX2,Confirmatory,16806914.0,
735,270015,3,10,,103181002,2662,Unspecified,3915797.0,5743.0,,,"Selectivity index, IC50 for COX1 over IC50 for COX2",Other,16806914.0,
736,270015,3,10,,103181002,2662,Unspecified,317373262.0,5742.0,,,"Selectivity index, IC50 for COX1 over IC50 for COX2",Other,16806914.0,
737,270016,5,3,,103181002,2662,Inconclusive,,,,,"Anti-inflammatory activity against carrageenan-induced paw edema in Sprague-Dawley rat at 3 mg/kg, iv after 3 hrs",Other,16806914.0,
738,270017,5,3,,103181002,2662,Inconclusive,,,,,"Anti-inflammatory activity against carrageenan-induced paw edema in Sprague-Dawley rat at 3 mg/kg, iv after 5 hrs",Other,16806914.0,
739,270018,3,3,,103181002,2662,Inconclusive,,,,,"Gastric toxicity in rat at 20 mg/kg, iv",Other,16806914.0,
740,271283,7,6,,103181002,2662,Active,317373262.0,5742.0,20.03,IC50,Inhibition of COX1 assessed as TBX2 production in human whole blood,Confirmatory,16814546.0,
741,271284,7,6,,103181002,2662,Active,3915797.0,5743.0,0.33,IC50,Inhibition of COX2 assessed as LPS-stimulated PGE2 production in human whole blood leukocyte,Confirmatory,16814546.0,
742,271285,3,10,,103181002,2662,Unspecified,3915797.0,5743.0,,,"Selectivity index, IC50 for COX1/IC50 for COX2 in human whole blood",Other,16814546.0,
743,271285,3,10,,103181002,2662,Unspecified,317373262.0,5742.0,,,"Selectivity index, IC50 for COX1/IC50 for COX2 in human whole blood",Other,16814546.0,
744,271286,9,5,,103181002,2662,Active,754286265.0,443551.0,26.61,IC50,Inhibition of ovine COX1,Confirmatory,16814546.0,
745,271287,9,5,,103181002,2662,Active,3914304.0,443460.0,0.44,IC50,Inhibition of ovine COX2,Confirmatory,16814546.0,
746,271288,3,10,,103181002,2662,Unspecified,3914304.0,443460.0,,,"Selectivity index, IC50 for ovine COX1/IC50 for ovine COX2",Other,16814546.0,
747,271288,3,10,,103181002,2662,Unspecified,754286265.0,443551.0,,,"Selectivity index, IC50 for ovine COX1/IC50 for ovine COX2",Other,16814546.0,
748,275265,3,3,,103181002,2662,Active,,,,,"Inhibition of Freund's complete adjuvant-induced arthritis in Lewis rat at 5 mg/kg, po",Other,17201408.0,
749,280834,9,5,,103181002,2662,Active,3915797.0,5743.0,1.3,IC50,Activity of COX2 in human heparinized blood assessed as inhibition of LPS-induced PGE2 production after 24 hrs,Confirmatory,17335184.0,
750,280835,9,5,,103181002,2662,Active,317373262.0,5742.0,14.0,IC50,Inhibition of COX1 in human whole blood assessed as TxB2 production after 1 hr,Confirmatory,17335184.0,
751,281535,6,3,,103181002,2662,Active,,,13.5,IC50,Inhibition of COX1 expressed in CHO cells assessed as inhibition of arachidonic acid-stimulated PGE2 production by enzyme immunoassay,Confirmatory,15566290.0,
752,281536,6,3,,103181002,2662,Active,,,0.036000000000000004,IC50,Inhibition of COX2 expressed in CHO cells assessed as inhibition of arachidonic acid-stimulated PGE2 production by enzyme immunoassay,Confirmatory,15566290.0,
753,281537,3,3,,103181002,2662,Unspecified,,,,,Selectivity for COX2 over COX1,Other,15566290.0,
754,281538,6,4,,103181002,2662,Unspecified,,,10.0,IC50,Inhibition of 5LOX in human whole blood assessed as inhibition of calcium ionophore A 23187-stimulated 5HETE production by HPLC analysis,Confirmatory,15566290.0,
755,281539,6,2,,103181002,2662,Unspecified,,,50.4,IC50,Antiproliferative activity against androgen-sensitive human LNCaP cells after 72 hrs by MTT test,Confirmatory,15566290.0,
756,281540,6,2,,103181002,2662,Active,,,47.0,IC50,Antiproliferative activity against androgen-independent human PC3 cells after 72 hrs by MTT test,Confirmatory,15566290.0,
757,281544,3,4,,103181002,2662,Unspecified,,,,,Cell cycle arrest in human LNCaP cells by accumulation at subG1 phase at 10 uM after 72 hrs by FACS flow cytometry,Other,15566290.0,
758,281545,3,4,,103181002,2662,Unspecified,,,,,Cell cycle arrest in human LNCaP cells by accumulation at G1 phase at 10 uM after 72 hrs by FACS flow cytometry,Other,15566290.0,
759,281546,3,4,,103181002,2662,Unspecified,,,,,Cell cycle arrest in human LNCaP cells by accumulation at S phase at 10 uM after 72 hrs by FACS flow cytometry,Other,15566290.0,
760,281547,3,4,,103181002,2662,Unspecified,,,,,Cell cycle arrest in human LNCaP cells by accumulation at G2M phase at 10 uM after 72 hrs by FACS flow cytometry,Other,15566290.0,
761,281549,3,4,,103181002,2662,Unspecified,,,,,Cell cycle arrest in human LNCaP cells by accumulation at subG1 phase at 50 uM after 72 hrs by FACS flow cytometry,Other,15566290.0,
762,281550,3,4,,103181002,2662,Unspecified,,,,,Cell cycle arrest in human LNCaP cells by accumulation at G1 phase at 50 uM after 72 hrs by FACS flow cytometry,Other,15566290.0,
763,281551,3,4,,103181002,2662,Unspecified,,,,,Cell cycle arrest in human LNCaP cells by accumulation at S phase at 50 uM after 72 hrs by FACS flow cytometry,Other,15566290.0,
764,281552,3,4,,103181002,2662,Unspecified,,,,,Cell cycle arrest in human LNCaP cells by accumulation at G2M phase at 50 uM after 72 hrs by FACS flow cytometry,Other,15566290.0,
765,281557,3,4,,103181002,2662,Unspecified,,,,,Cell cycle arrest in human PC3 cells by accumulation at subG1 phase at 50 uM after 72 hrs by FACS flow cytometry,Other,15566290.0,
766,281558,3,4,,103181002,2662,Unspecified,,,,,Cell cycle arrest in human PC3 cells by accumulation at G1 phase at 50 uM after 72 hrs by FACS flow cytometry,Other,15566290.0,
767,281559,3,4,,103181002,2662,Unspecified,,,,,Cell cycle arrest in human PC3 cells by accumulation at S phase at 50 uM after 72 hrs by FACS flow cytometry,Other,15566290.0,
768,281560,3,4,,103181002,2662,Unspecified,,,,,Cell cycle arrest in human PC3 cells by accumulation at G2M phase at 50 uM after 72 hrs by FACS flow cytometry,Other,15566290.0,
769,282431,9,5,,103181002,2662,Active,317373262.0,5742.0,2.6,IC50,Inhibition of COX1 in human whole blood assessed as inhibition of calcium ionophore A-23187-stimulated platelet aggregation by measuring TXB2 production,Confirmatory,15615524.0,
770,282432,9,5,,103181002,2662,Active,3915797.0,5743.0,0.35,IC50,Inhibition of COX2 in human whole blood assessed as inhibition of LPS-stimulated PGE2 production,Confirmatory,15615524.0,
771,282433,3,3,,103181002,2662,Unspecified,,,,,Selectivity ratio of IC50 for human COX1 to IC50 for human COX2,Other,15615524.0,
772,289278,9,5,,103181002,2662,Active,754286265.0,443551.0,19.03,IC50,Inhibition of ovine COX1 by measuring PGE2,Confirmatory,17604631.0,
773,289279,9,5,,103181002,2662,Active,3915797.0,5743.0,0.035,IC50,Inhibition of human recombinant COX2 by measuring PGE2,Confirmatory,17604631.0,
774,289280,3,3,,103181002,2662,Unspecified,,,,,Selectivity for ovine COX1 over human recombinant COX2,Other,17604631.0,
775,293131,3,3,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in rat at 50 mg/kg, po",Other,17150356.0,
776,293132,3,3,,103181002,2662,Unspecified,,,,,Toxicity in rat assessed as ulcerogenic potential,Other,17150356.0,
777,293935,6,7,,103181002,2662,Unspecified,548483.0,19225.0,25.0,IC50,Inhibition of mouse COX2,Confirmatory,17258905.0,
778,293936,9,5,,103181002,2662,Active,754286265.0,443551.0,0.21,IC50,Inhibition of ovine COX1,Confirmatory,17258905.0,
779,293937,5,3,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema in Sprague-Dawley rat at 50 mg/kg, po after 3 hrs",Other,17258905.0,
780,293938,5,3,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema in Sprague-Dawley rat at 50 mg/kg, po after 5 hrs",Other,17258905.0,
781,297561,3,9,,103181002,2662,Unspecified,6686268.0,1559.0,,,Metabolic stability in presence of human recombinant CYP2C9 at 1 uM after 30 mins,Other,17696334.0,
782,297562,3,9,,103181002,2662,Unspecified,317373262.0,5742.0,,,Inhibition of human recombinant COX1 by measuring PGE2 formation at 100 uM,Other,17696334.0,
783,297563,3,9,,103181002,2662,Unspecified,3915797.0,5743.0,,,Inhibition of human recombinant COX2 by measuring PGE2 formation at 100 uM,Other,17696334.0,
784,301223,9,5,,103181002,2662,Active,754286265.0,443551.0,33.1,IC50,Inhibition of ovine COX1 by enzyme immuno assay,Confirmatory,17764958.0,
785,301224,9,5,,103181002,2662,Active,3914304.0,443460.0,0.07,IC50,Inhibition of ovine COX2 by enzyme immuno assay,Confirmatory,17764958.0,
786,301225,3,3,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for ovine COX1 to IC50 for ovine COX2",Other,17764958.0,
787,301578,9,5,,103181002,2662,Unspecified,134047703.0,761.0,154.0,Ki,Inhibition of human recombinant CA 3 assessed as CO2 hydration by stopped flow kinetic assay,Confirmatory,17826101.0,
788,302411,6,5,,103181002,2662,Active,,,10.0,IC50,Inhibition of recombinant CYP2C9 by fluorescence inhibition assay,Confirmatory,17915853.0,
789,302412,9,5,,103181002,2662,Active,129900.0,19224.0,3.7,IC50,Inhibition of COX1 in mouse J774 cells assessed as arachidonic acid-induced PGE2 levels by radio immunoassay,Confirmatory,17915854.0,
790,302413,9,5,,103181002,2662,Active,548483.0,19225.0,0.06,IC50,Inhibition of COX2 in LPS-stimulated J774 cells assessed as inhibition of PGE2 levels by radioimmunoassay,Confirmatory,17915854.0,
791,302414,5,9,,103181002,2662,Unspecified,548483.0,19225.0,,,Inhibition of COX2 in LPS-stimulated J774 cells assessed as inhibition of PGE2 levels at 10 uM by radioimmunoassay,Other,17915854.0,
792,302415,5,9,,103181002,2662,Unspecified,548483.0,19225.0,,,Inhibition of COX2 in LPS-stimulated J774 cells assessed as inhibition of PGE2 levels at 1 uM by radioimmunoassay,Other,17915854.0,
793,302416,3,3,,103181002,2662,Unspecified,,,,,Selectivity ratio of IC50 for mouse COX1 to IC50 for mouse COX2,Other,17915854.0,
794,302417,9,5,,103181002,2662,Active,3915797.0,5743.0,0.54,IC50,Inhibition of COX2 in LPS-induced monocyte assessed as PGE2 production in human whole blood,Confirmatory,17915854.0,
795,302418,9,5,,103181002,2662,Active,317373262.0,5742.0,12.5,IC50,Inhibition of COX1 in human whole blood assessed as TXB2 production,Confirmatory,17915854.0,
796,302419,3,3,,103181002,2662,Unspecified,,,,,Selectivity ratio of IC50 for COX1 to IC50 for COX2 by human whole blood assay,Other,17915854.0,
797,302423,3,3,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced hyperalgesia in rat assessed as paw pressure in rat at 10 mg/kg, po after 30 mins",Other,17915854.0,
798,302424,3,3,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced hyperalgesia in rat assessed as paw pressure in rat at 10 mg/kg, po after 120 mins",Other,17915854.0,
799,302425,3,3,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced hyperalgesia in rat assessed as paw pressure in rat at 10 mg/kg, po after 60 mins",Other,17915854.0,
800,302427,3,3,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema in rat at 10 mg/kg, po",Other,17915854.0,
801,303267,6,4,,103181002,2662,Unspecified,,,,,Inhibition of human recombinant COX2 expressed in insect sf9 cells assessed as arachidonic acid-stimulated reactive oxygen species at 10 uM after 30 mins,Other,17950600.0,
802,304223,9,5,,103181002,2662,Active,317373262.0,5742.0,14.0,IC50,Inhibition of COX1 in human whole blood assessed as effect on A23187-induced thromboxane B2 production,Confirmatory,17994684.0,
803,304224,9,5,,103181002,2662,Active,3915797.0,5743.0,1.2,IC50,Inhibition of COX2 in human whole blood assessed as effect on LPS-induced thromboxane B2 production,Confirmatory,17994684.0,
804,304225,4,3,,103181002,2662,Unspecified,,,,,Selectivity for human COX2 over human COX1,Other,17994684.0,
805,309449,9,2,,103181002,2662,Active,,,24.3,IC50,Inhibition of COX1,Confirmatory,17822894.0,
806,309450,9,2,,103181002,2662,Active,,,0.06,IC50,Inhibition of COX2,Confirmatory,17822894.0,
807,309451,3,3,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for COX2 to IC50 for COX1",Other,17822894.0,
808,312224,3,3,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po after 4 hrs relative to celecoxib",Other,18072726.0,
809,312225,3,3,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po after 6 hrs relative to celecoxib",Other,18072726.0,
810,312226,3,3,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po after 7 hrs relative to celecoxib",Other,18072726.0,
811,312227,3,3,,103181002,2662,Unspecified,,,,,Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema after 4 hrs,Other,18072726.0,
812,312228,3,3,,103181002,2662,Unspecified,,,,,Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema after 4 hrs,Other,18072726.0,
813,312229,3,3,,103181002,2662,Unspecified,,,,,"Analgesic activity in acute model Wistar rat assessed as reversal of carrageenan-induced hind paw edema at 10 mg/kg, po after 60 mins by mechanical hyperalgesia test relative to celecoxib",Other,18072726.0,
814,312230,3,3,,103181002,2662,Unspecified,,,,,"Analgesic activity in acute model Wistar rat assessed as reversal of carrageenan-induced hind paw edema at 10 mg/kg, po after 120 mins by mechanical hyperalgesia test relative to celecoxib",Other,18072726.0,
815,312231,3,3,,103181002,2662,Unspecified,,,,,"Analgesic activity in acute model Wistar rat assessed as reversal of carrageenan-induced hind paw edema at 10 mg/kg, po after 180 mins by mechanical hyperalgesia test relative to celecoxib",Other,18072726.0,
816,312232,3,3,,103181002,2662,Unspecified,,,,,"Analgesic activity in acute model Wistar rat assessed as reversal of carrageenan-induced hind paw edema at 30 mg/kg, po after 60 mins by mechanical hyperalgesia test relative to celecoxib",Other,18072726.0,
817,312233,3,3,,103181002,2662,Unspecified,,,,,"Analgesic activity in acute model Wistar rat assessed as reversal of carrageenan-induced hind paw edema at 30 mg/kg, po after 120 mins by mechanical hyperalgesia test relative to celecoxib",Other,18072726.0,
818,312234,3,3,,103181002,2662,Unspecified,,,,,"Analgesic activity in acute model Wistar rat assessed as reversal of carrageenan-induced hind paw edema at 30 mg/kg, po after 180 mins by mechanical hyperalgesia test relative to celecoxib",Other,18072726.0,
819,312235,3,3,,103181002,2662,Unspecified,,,,,"Analgesic activity in chronic model Wistar rat assessed as reversal of carrageenan-induced hind paw edema at 10 mg/kg, po after 30 mins by mechanical hyperalgesia test relative to celecoxib",Other,18072726.0,
820,312236,3,3,,103181002,2662,Unspecified,,,,,"Analgesic activity in chronic model Wistar rat assessed as reversal of carrageenan-induced hind paw edema at 10 mg/kg, po after 60 mins by mechanical hyperalgesia test relative to celecoxib",Other,18072726.0,
821,312237,3,3,,103181002,2662,Unspecified,,,,,"Analgesic activity in chronic model Wistar rat assessed as reversal of carrageenan-induced hind paw edema at 10 mg/kg, po after 120 mins by mechanical hyperalgesia test relative to celecoxib",Other,18072726.0,
822,312238,3,3,,103181002,2662,Unspecified,,,,,"Analgesic activity in chronic model Wistar rat assessed as reversal of carrageenan-induced hind paw edema at 10 mg/kg, po after 180 mins by mechanical hyperalgesia test relative to celecoxib",Other,18072726.0,
823,312239,3,3,,103181002,2662,Unspecified,,,,,"Analgesic activity in chronic model Wistar rat assessed as reversal of carrageenan-induced hind paw edema at 30 mg/kg, po after 30 mins by mechanical hyperalgesia test relative to celecoxib",Other,18072726.0,
824,312240,3,3,,103181002,2662,Unspecified,,,,,"Analgesic activity in chronic model Wistar rat assessed as reversal of carrageenan-induced hind paw edema at 30 mg/kg, po after 60 mins by mechanical hyperalgesia test relative to celecoxib",Other,18072726.0,
825,312241,3,3,,103181002,2662,Unspecified,,,,,"Analgesic activity in chronic model Wistar rat assessed as reversal of carrageenan-induced hind paw edema at 30 mg/kg, po after 120 mins by mechanical hyperalgesia test relative to celecoxib",Other,18072726.0,
826,312242,3,3,,103181002,2662,Unspecified,,,,,"Analgesic activity in chronic model Wistar rat assessed as reversal of carrageenan-induced hind paw edema at 30 mg/kg, po after 180 mins by mechanical hyperalgesia test relative to celecoxib",Other,18072726.0,
827,312243,3,3,,103181002,2662,Unspecified,,,,,"Inhibition of ethanol-induced gastric mucosal damage in Wistar rat at 30 mg/kg, po",Other,18072726.0,
828,312244,3,3,,103181002,2662,Unspecified,,,,,"Inhibition of ethanol-induced gastric mucosal damage in Wistar rat at 15 mg/kg, po",Other,18072726.0,
829,312245,3,3,,103181002,2662,Unspecified,,,,,"Inhibition of ethanol-induced gastric mucosal damage in Wistar rat at 60 mg/kg, po",Other,18072726.0,
830,312247,3,3,,103181002,2662,Unspecified,,,,,"Increase in body weight in acetic acid-induced chronic gastric ulcer Wistar rat at 30 mg/kg, po",Other,18072726.0,
831,312249,3,3,,103181002,2662,Unspecified,,,,,"Effect on acetic acid-induced chronic gastric ulcer Wistar rat assessed as area of ulcer at 30 mg/kg, po",Other,18072726.0,
832,312250,3,3,,103181002,2662,Unspecified,,,,,"Inhibition of ethanol-induced gastric mucosal damage in Wistar rat assessed as ulcer index at 30 mg/kg, po",Other,18072726.0,
833,312251,3,3,,103181002,2662,Unspecified,,,,,"Inhibition of ethanol-induced gastric mucosal damage in Wistar rat assessed as ulcer index at 15 mg/kg, po",Other,18072726.0,
834,312252,3,3,,103181002,2662,Unspecified,,,,,"Inhibition of ethanol-induced gastric mucosal damage in Wistar rat assessed as ulcer index at 60 mg/kg, po",Other,18072726.0,
835,313334,5,8,,103181002,2662,Unspecified,754286265.0,443551.0,,,Inhibition of ovine COX1 at 10 uM,Other,17937989.0,
836,313335,9,5,,103181002,2662,Active,754286265.0,443551.0,13.0,IC50,Inhibition of ovine COX1,Confirmatory,17937989.0,
837,313336,5,8,,103181002,2662,Unspecified,3914304.0,443460.0,,,Inhibition of ovine COX2 at 10 uM,Other,17937989.0,
838,313337,9,5,,103181002,2662,Active,3914304.0,443460.0,0.04,IC50,Inhibition of ovine COX2,Confirmatory,17937989.0,
839,313338,4,3,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Albino rat assessed as reduction of carrageenan-induced paw edema volume at 10 mg/kg, po after 2 hrs",Other,17937989.0,
840,313339,4,3,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Albino rat assessed as reduction of carrageenan-induced paw edema volume at 10 mg/kg, po after 4 hrs",Other,17937989.0,
841,314261,9,5,,103181002,2662,Active,754286265.0,443551.0,24.3,IC50,Inhibition of ovine COX1 by chemiluminescent assay,Confirmatory,18226898.0,
842,314262,9,5,,103181002,2662,Active,3914304.0,443460.0,0.06,IC50,Inhibition of ovine COX2 by chemiluminescent assay,Confirmatory,18226898.0,
843,314263,3,3,,103181002,2662,Unspecified,,,,,Selectivity for ovine COX2 over ovine COX1,Other,18226898.0,
844,315991,9,5,,103181002,2662,Active,317373262.0,5742.0,23.47,IC50,Inhibition of COX1 in human whole blood assessed as effect on A-23187-stimulated TxB2 production,Confirmatory,18063374.0,
845,315992,9,5,,103181002,2662,Active,3915797.0,5743.0,0.3,IC50,Inhibition of COX2 in human whole blood assessed as effect on LPS-stimulated PGE2 production,Confirmatory,18063374.0,
846,315993,3,3,,103181002,2662,Unspecified,,,,,Selectivity for human COX2 over human COX1 by human whole blood assay,Other,18063374.0,
847,321895,9,5,,103181002,2662,Active,754286265.0,443551.0,33.1,IC50,Inhibition of ovine COX1 by enzyme immunoassay,Confirmatory,18096394.0,
848,321896,9,5,,103181002,2662,Active,3914304.0,443460.0,0.07,IC50,Inhibition of ovine COX2 by enzyme immunoassay,Confirmatory,18096394.0,
849,321897,3,3,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for ovine COX1 to IC50 for ovine COX2",Other,18096394.0,
850,323716,9,5,,103181002,2662,Active,754286265.0,443551.0,33.1,IC50,Inhibition of ovine COX1 by enzyme immuno assay,Confirmatory,18023187.0,
851,323717,9,5,,103181002,2662,Active,3914304.0,443460.0,0.07,IC50,Inhibition of ovine COX2 by enzyme immuno assay,Confirmatory,18023187.0,
852,323718,3,3,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for ovine COX1 to IC50 for ovine COX2",Other,18023187.0,
853,323719,6,2,,103181002,2662,Unspecified,,,,,Antiinflammatory activity against carrageenan-induced foot paw edema in orally dosed rat after 3 hrs,Other,18023187.0,
854,330496,6,7,,103181002,2662,Unspecified,754286265.0,443551.0,100.0,IC50,Inhibition of ovine COX1 by enzyme immuno assay,Confirmatory,18272371.0,
855,330497,9,5,,103181002,2662,Active,3914304.0,443460.0,1.71,IC50,Inhibition of ovine COX2 by enzyme immuno assay,Confirmatory,18272371.0,
856,330498,4,3,,103181002,2662,Unspecified,,,,,Selectivity ratio of IC50 for ovine COX1 to IC50 for ovine COX2,Other,18272371.0,
857,330499,3,9,,103181002,2662,Unspecified,126407.0,240.0,,,Inhibition of LOX5 from human PBML cells at 10 uM by enzyme immuno assay,Other,18272371.0,
858,330500,3,9,,103181002,2662,Unspecified,125987838.0,239.0,,,Inhibition of LOX12 from human platelets at 10 uM by enzyme immuno assay,Other,18272371.0,
859,330501,3,10,,103181002,2662,Unspecified,126397.0,100009114.0,,,Inhibition of LOX15 from rabbit reticulocytes at 10 uM by enzyme immuno assay,Other,18272371.0,
860,340786,3,3,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for human COX1 to IC50 for human COX2 by whole blood assay",Other,18598017.0,
861,342462,3,3,,103181002,2662,Unspecified,,,,,Half life in rat plasma,Other,18570365.0,
862,342463,3,3,,103181002,2662,Unspecified,,,,,Half life in human plasma,Other,18570365.0,
863,344873,9,5,,103181002,2662,Active,754286265.0,443551.0,7.7,IC50,Inhibition of ovine COX1 by enzyme immuno assay,Confirmatory,18930406.0,
864,344874,9,5,,103181002,2662,Active,3914304.0,443460.0,0.07,IC50,Inhibition of ovine COX2 by enzyme immuno assay,Confirmatory,18930406.0,
865,344875,7,2,,103181002,2662,Unspecified,,,,,Antiinflammatory activity against po dosed carrageenan-induced rat foot paw edema after 3 hrs,Other,18930406.0,
866,346079,3,5,,103181002,2662,Unspecified,,,,,Inhibition of IgE-specific antigen-induced PGF2-alpha release in rat MC9 cells at 0.0005 uM,Other,19178292.0,
867,346080,3,5,,103181002,2662,Unspecified,,,,,Inhibition of IgE-specific antigen-induced PGF2-alpha release in rat MC9 cells at 0.40 uM,Other,19178292.0,
868,346084,3,5,,103181002,2662,Unspecified,,,,,Inhibition of arachidonic acid-induced PGF2-alpha release in rat MC9 cells at 0.0005 uM,Other,19178292.0,
869,346085,3,4,,103181002,2662,Unspecified,,,,,Inhibition of arachidonic acid-induced PGF2alpha release in rat MC9 cells at 0.30 uM,Other,19178292.0,
870,346087,3,4,,103181002,2662,Inactive,,,,,Inhibition of IgE-specific antigen-induced LBT4 release in rat MC9 cells,Other,19178292.0,
871,347221,9,5,,103181002,2662,Active,166897622.0,282022.0,8.0,IC50,Inhibition of COX1 in bovine platelets assessed as formation of 12-hydroxyheptadecatrienoic acid by HPLC,Confirmatory,19097798.0,
872,347222,9,5,,103181002,2662,Active,3915797.0,5743.0,0.8,IC50,Inhibition of COX2 in LPS-stimulated human blood,Confirmatory,19097798.0,
873,347224,3,3,,103181002,2662,Unspecified,,,,,Ratio of IC50 for COX1 in bovine platelets to IC50 for COX2 in human blood,Other,19097798.0,
874,347225,6,2,,103181002,2662,Unspecified,,,500.0,IC50,Antioxidant activity assessed as hydroxyl radical scavenging activity,Confirmatory,19097798.0,
875,347226,3,3,,103181002,2662,Unspecified,,,,,Antioxidant activity assessed as hydroxyl radical scavenging activity at 100 uM,Other,19097798.0,
876,347228,3,5,,103181002,2662,Unspecified,,,,,Inhibition of TNF-alpha-stimulated adhesion of human MM6 cells to BAEC at 40 uM by static assay relative to control,Other,19097798.0,
877,349605,8,5,,103181002,2662,Unspecified,115449.0,759.0,50.0,Ki,Inhibition of human recombinant carbonic anhydrase 1 by stopped flow CO2 hydration assay,Confirmatory,19338333.0,
878,349606,8,5,,103181002,2662,Active,115456.0,760.0,0.021,Ki,Inhibition of human recombinant carbonic anhydrase 2 by stopped flow CO2 hydration assay,Confirmatory,19338333.0,
879,349607,9,5,,103181002,2662,Active,614098993.0,886987.0,10.35,Ki,Inhibition of Mycobacterium tuberculosis recombinant carbonic anhydrase 1 encoded by Rv1284 by stopped flow CO2 hydration assay,Confirmatory,19338333.0,
880,349608,6,2,,103181002,2662,Active,,,7.76,Ki,Inhibition of full length Mycobacterium tuberculosis H37Rv recombinant carbonic anhydrase 3 expressed in Escherichia coli BL21 by stopped flow CO2 hydration assay,Confirmatory,19338333.0,
881,353527,3,3,,103181002,2662,Unspecified,,,,,Antiinflammatory activity in rat assessed as inhibition of carrageenan induced paw edema at 10 mg/kg after 1 hr relative to control,Other,19286379.0,
882,353528,3,3,,103181002,2662,Unspecified,,,,,Antiinflammatory activity in rat assessed as inhibition of carrageenan induced paw edema at 10 mg/kg after 2 hrs relative to control,Other,19286379.0,
883,353529,3,3,,103181002,2662,Unspecified,,,,,Antiinflammatory activity in rat assessed as inhibition of carrageenan induced paw edema at 10 mg/kg after 3 hrs relative to control,Other,19286379.0,
884,353530,3,3,,103181002,2662,Unspecified,,,,,Antiinflammatory activity in rat assessed as inhibition of carrageenan induced paw edema at 10 mg/kg after 4 hrs relative to control,Other,19286379.0,
885,362870,11,1,,103181002,2662,Active,,,0.0005200000000000001,IC50,Inhibition of COX2,Confirmatory,17714833.0,
886,363325,3,7,,103181002,2662,Unspecified,,,,,Inhibition of COX1 at 13.1 uM,Other,17937972.0,
887,363326,6,2,,103181002,2662,Active,,,48.0,IC50,Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay,Confirmatory,17937972.0,
888,363508,9,5,,103181002,2662,Active,129900.0,19224.0,3.7,IC50,Inhibition of COX1 in arachidonic acid-stimulated mouse J774 cells assessed as inhibition of PGE2 production after 15 mins by radioimmunoassay,Confirmatory,18752957.0,
889,363509,9,5,,103181002,2662,Active,548483.0,19225.0,0.06,IC50,Inhibition of COX2 in LPS-stimulated mouse J774 cells assessed as inhibition of PGE2 production after 15 mins by radioimmunoassay,Confirmatory,18752957.0,
890,363510,3,10,,103181002,2662,Unspecified,548483.0,19225.0,,,Inhibition of COX2 in LPS-stimulated mouse J774 cells assessed as inhibition of PGE2 production at 10 uM after 15 mins by radioimmunoassay,Other,18752957.0,
891,363511,3,10,,103181002,2662,Unspecified,548483.0,19225.0,,,Inhibition of COX2 in LPS-stimulated mouse J774 cells assessed as inhibition of PGE2 production at 1 uM after 15 mins by radioimmunoassay,Other,18752957.0,
892,363512,3,4,,103181002,2662,Unspecified,,,,,Selectivity ratio of IC50 for COX1 in arachidonic acid-stimulated mouse J774 cells to IC50 for COX2 in LPS-stimulated mouse J774 cells,Other,18752957.0,
893,363513,9,5,,103181002,2662,Active,317373262.0,5742.0,16.0,IC50,Inhibition of COX1 in human whole blood assessed as inhibition of LPS-stimulated PGE2 production by radioimmunoassay,Confirmatory,18752957.0,
894,363514,9,5,,103181002,2662,Active,3915797.0,5743.0,0.54,IC50,Inhibition of COX2 in human whole blood assessed as inhibition of TXB2 production by radioimmunoassay,Confirmatory,18752957.0,
895,363515,3,3,,103181002,2662,Unspecified,,,,,Selectivity ratio of IC50 for human COX1 to IC50 for human COX2 by whole blood assay,Other,18752957.0,
896,363519,3,3,,103181002,2662,Unspecified,,,,,"Analgesic activity against carrageenan-induced hyperalgesia in rat assessed as paw pressure at 10 mg/kg, po after 30 mins",Other,18752957.0,
897,363520,3,3,,103181002,2662,Unspecified,,,,,"Analgesic activity against carrageenan-induced hyperalgesia in rat assessed as paw pressure at 10 mg/kg, po after 60 mins",Other,18752957.0,
898,363700,3,3,,103181002,2662,Unspecified,,,,,"Analgesic activity against carrageenan-induced hyperalgesia in rat assessed as paw pressure at 10 mg/kg, po after 120 mins",Other,18752957.0,
899,363702,3,3,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema in rat assessed as paw volume at 10 mg/kg, po administered 4 hrs post carrageenan challenge measured after 60 mins",Other,18752957.0,
900,363801,3,10,,103181002,2662,Unspecified,166897622.0,282022.0,,,Inhibition of bovine COX1 at 10 uM,Other,17976864.0,
901,363802,9,5,,103181002,2662,Active,3915797.0,5743.0,1.0,IC50,Inhibition of human COX2,Confirmatory,17976864.0,
902,363807,3,3,,103181002,2662,Unspecified,,,,,Antioxidant activity assessed as hydroxyl radical scavenging activity at 100 uM,Other,17976864.0,
903,367820,8,5,,103181002,2662,Unspecified,115449.0,759.0,50.0,Ki,Inhibition of human recombinant CA1 by stopped-flow CO2 hydrase assay,Confirmatory,19124253.0,
904,367821,8,5,,103181002,2662,Active,115456.0,760.0,0.021,Ki,Inhibition of human recombinant CA2 by stopped-flow CO2 hydrase assay,Confirmatory,19124253.0,
905,367822,8,5,,103181002,2662,Active,1709238.0,855692.0,0.10800000000000001,Ki,Inhibition of Saccharomyces cerevisiae recombinant CA expressed in Escherichia coli by stopped-flow CO2 hydrase assay,Confirmatory,19124253.0,
906,368225,9,5,,103181002,2662,Active,754286265.0,443551.0,7.7,IC50,Inhibition of ovine COX1 by enzyme immuno assay,Confirmatory,19136259.0,
907,368226,9,5,,103181002,2662,Active,3915797.0,5743.0,0.12,IC50,Inhibition of human recombinant COX2 by enzyme immuno assay,Confirmatory,19136259.0,
908,368228,6,2,,103181002,2662,Unspecified,,,,,Antiinflammatory activity in orally dosed rat assessed as inhibition of carrageenan-induced paw edema after 3 hrs,Other,19136259.0,
909,369088,9,2,,103181002,2662,Active,,,7.7,IC50,Inhibition of COX1 by enzyme immunoassay,Confirmatory,19157881.0,
910,369089,9,2,,103181002,2662,Active,,,0.07,IC50,Inhibition of COX2 by enzyme immunoassay,Confirmatory,19157881.0,
911,369090,3,3,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for COX1 to IC50 COX2",Other,19157881.0,
912,369271,8,5,,103181002,2662,Unspecified,115449.0,759.0,50.0,Ki,Inhibition of human recombinant carbonic anhydrase 1 by stopped flow CO2 hydrase assay,Confirmatory,19193158.0,
913,369272,8,5,,103181002,2662,Active,115456.0,760.0,0.021,Ki,Inhibition of human recombinant carbonic anhydrase 2 by stopped flow CO2 hydrase assay,Confirmatory,19193158.0,
914,369273,8,5,,103181002,2662,Active,116241278.0,765.0,0.094,Ki,Inhibition of human full length recombinant carbonic anhydrase 6 by stopped flow CO2 hydrase assay,Confirmatory,19193158.0,
915,369274,8,5,,103181002,2662,Active,83300925.0,768.0,0.016,Ki,Inhibition of human recombinant carbonic anhydrase 9 catalytic domain by stopped flow CO2 hydrase assay,Confirmatory,19193158.0,
916,369275,8,5,,103181002,2662,Active,30580362.0,80733.0,0.045,Ki,Inhibition of mouse recombinant carbonic anhydrase 15 by stopped flow CO2 hydrase assay,Confirmatory,19193158.0,
917,379225,9,5,,103181002,2662,Active,548483.0,19225.0,0.0005099999999999999,IC50,Inhibition of LPS-induced COX2 activity in C57BL/6J mouse peritoneal macrophages by RIA,Confirmatory,17125227.0,
918,382418,3,7,,103181002,2662,Unspecified,,,,,Inhibition of COX1 at 3 uM,Other,17467123.0,
919,382419,3,7,,103181002,2662,Unspecified,,,,,Inhibition of COX2 at 3 uM,Other,17467123.0,
920,382813,9,5,,103181002,2662,Active,3915797.0,5743.0,0.3,IC50,Inhibition of human recombinant COX2,Confirmatory,17532544.0,
921,382814,9,5,,103181002,2662,Unspecified,317373262.0,5742.0,100.0,IC50,Inhibition of human platelet COX1,Confirmatory,17532544.0,
922,382815,3,3,,103181002,2662,Unspecified,,,,,Selectivity for human recombinant COX2 over human platelet COX1,Other,17532544.0,
923,386623,4,8,,103181002,2662,Unspecified,313104181.0,6580.0,,,Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy,Other,18788725.0,
924,387743,6,2,,103181002,2662,Unspecified,,,,,Antiinflammatory activity against po dosed carrageenan-induced rat foot paw edema model,Other,18789699.0,
925,392037,3,7,,103181002,2662,Unspecified,,,,,Inhibition of COX2 at 1 uM,Other,18262309.0,
926,392038,3,7,,103181002,2662,Unspecified,,,,,Inhibition of COX2 at 10 uM,Other,18262309.0,
927,392039,3,7,,103181002,2662,Unspecified,,,,,Inhibition of COX1 at 1 uM,Other,18262309.0,
928,392040,9,2,,103181002,2662,Active,,,1.2,IC50,Inhibition of COX2,Confirmatory,18262309.0,
929,392041,9,2,,103181002,2662,Active,,,14.0,IC50,Inhibition of COX1,Confirmatory,18262309.0,
930,392042,3,3,,103181002,2662,Unspecified,,,,,Selectivity ratio of IC50 for COX1 to IC50 for COX2,Other,18262309.0,
931,392046,9,1,,103181002,2662,Active,,,47.0,GI50,Anticancer activity against human PC3 cells,Confirmatory,18262309.0,
932,393211,3,9,,103181002,2662,Unspecified,3915797.0,5743.0,,,Inhibition of COX2 in LPS-stimulated human whole blood assessed as inhibition of PGE2 production at 10 uM by radioimmunoassay,Other,19200742.0,
933,393213,3,10,,103181002,2662,Unspecified,548483.0,19225.0,,,Inhibition of COX2 in LPS-stimulated mouse J774 cells assessed as inhibition of PGE2 production by radioimmunoassay,Other,19200742.0,
934,393214,3,10,,103181002,2662,Unspecified,266649.0,18126.0,,,Inhibition of iNOS in LPS-stimulated mouse J774 cells assessed as inhibition of nitric oxide generation at 10 uM,Other,19200742.0,
935,393818,9,5,,103181002,2662,Active,166897622.0,282022.0,7.7,IC50,Inhibition of bovine COX1 by enzyme immunoassay,Confirmatory,19296694.0,
936,393819,9,5,,103181002,2662,Active,3915797.0,5743.0,0.12,IC50,Inhibition of human recombinant COX2 by enzyme immunoassay,Confirmatory,19296694.0,
937,393822,6,2,,103181002,2662,Unspecified,,,,,Antiinflammatory activity against carrageenan-induced foot paw edema in po dosed rat after 3 hrs,Other,19296694.0,
938,403703,11,2,,103181002,2662,Unspecified,317373262.0,5742.0,100.0,IC50,Inhibition of human COX1 expressed in sf9 cells,Confirmatory,16252917.0,
939,403704,9,5,,103181002,2662,Active,3915797.0,5743.0,0.08,IC50,Inhibition of human COX2 expressed in sf9 cells,Confirmatory,16252917.0,
940,404304,3,10,,103181002,2662,Unspecified,308153583.0,1244.0,,,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,Other,18457386.0,
941,404464,3,10,,103181002,2662,Active,117020.0,,,,Inhibition of COX2-dependent PGE2 production in IL1B stimulated human A549 cells in presence of arachidonic acid,Other,18498150.0,
942,404466,3,10,,103181002,2662,Active,117020.0,,,,Inhibition of COX2-dependent PGE2 production in IL1B stimulated human A549 cells,Other,18498150.0,
943,404470,3,3,,103181002,2662,Unspecified,,,,,"Inhibition of PGE2 production in carrageenan-stimulated rat air pouch model at 2 mg/kg, ip after 6 hrs",Other,18498150.0,
944,404474,3,3,,103181002,2662,Unspecified,,,,,"Inhibition of carrageenan-induced paw edema in Sprague-Dawley rat administered 2 hrs before carrageenan challenge at 25 mg/kg, po",Other,18498150.0,
945,404479,6,2,,103181002,2662,Inactive,,,,IC50,Inhibition of LTB4 production in mouse MC9 cells,Confirmatory,18498150.0,
946,404480,6,2,,103181002,2662,Active,,,0.4,IC50,Inhibition of PGF2alpha production in mouse MC9 cells,Confirmatory,18498150.0,
947,404481,6,2,,103181002,2662,Active,,,0.3,IC50,Inhibition of PGF2apha production in arachidonic acid-stimulated mouse MC9 cells,Confirmatory,18498150.0,
948,404496,6,1,,103181002,2662,Unspecified,,,,,"Plasma concentration in adjuvant-induced arthritis Lewis rat model at 5 mg/kg, po after 4 hrs",Other,18498150.0,
949,404499,6,1,,103181002,2662,Unspecified,,,,,"Plasma concentration in adjuvant-induced arthritis Lewis rat model at 5 mg/kg, po after 16 hrs",Other,18498150.0,
950,404507,3,3,,103181002,2662,Active,,,,,"Reduction in synovitis damage in Freund's adjuvant-induced arthritis Lewis rat model at 5 mg/kg, po for 11 days",Other,18498150.0,
951,404510,3,3,,103181002,2662,Active,,,,,"Reduction in cartilage damage in Freund's adjuvant-induced arthritis Lewis rat model at 5 mg/kg, po for 11 days",Other,18498150.0,
952,406720,6,2,,103181002,2662,Unspecified,,,,,Antiinflammatory activity in po dosed rat assessed as inhibition of carrageenan-induced paw edema after 3 hrs,Other,18513975.0,
953,406721,3,7,,103181002,2662,Unspecified,,,,,Inhibition of COX1 at 100 uM,Other,18513975.0,
954,406722,3,7,,103181002,2662,Unspecified,,,,,Inhibition of COX2 at 100 uM,Other,18513975.0,
955,408271,8,2,,103181002,2662,Unspecified,,,,,Antiinflammatory activity against carrageenan-induced paw edema in sc dosed Albino rat assessed as inhibition of paw edema volume measured 4 hrs after carrageenan challenge,Other,18430576.0,
956,408272,4,3,,103181002,2662,Unspecified,,,,,"Toxicity in Albino rat assessed as gastric-ulcerogenic effect at 30 uM/kg, po twice daily for 3 days",Other,18430576.0,
957,408273,3,3,,103181002,2662,Unspecified,,,,,Antiinflammatory activity in sc dosed Albino rat assessed as protection against carrageenan-induced paw edema measured 4 hrs after carrageenan challenge,Other,18430576.0,
958,408274,3,3,,103181002,2662,Unspecified,,,,,Antiinflammatory activity in sc dosed Albino rat assessed as protection against carrageenan-induced paw edema measured 4 hrs after carrageenan challenge relative to indomethacin,Other,18430576.0,
959,408486,6,2,,103181002,2662,Unspecified,,,,IC50,Inhibition of recombinant Curvularia lunata trihydroxynaphthalene reductase,Confirmatory,18482840.0,
960,410033,9,5,,103181002,2662,Active,754286265.0,443551.0,7.7,IC50,Inhibition of ovine COX1 by enzyme immuno assay,Confirmatory,18945614.0,
961,410034,9,5,,103181002,2662,Active,3914304.0,443460.0,0.07,IC50,Inhibition of ovine COX2 by enzyme immuno assay,Confirmatory,18945614.0,
962,410035,6,2,,103181002,2662,Unspecified,,,10.0,IC50,Inhibition of potato LOX5 by enzyme immuno assay,Confirmatory,18945614.0,
963,410036,6,2,,103181002,2662,Unspecified,,,,,Antiinflammatory activity against carrageenan-induced orally dosed rat assessed paw edema after 3 hrs,Other,18945614.0,
964,411998,3,3,,103181002,2662,Unspecified,,,,,"Analgesic activity in Swiss mouse assessed as inhibition of acetic acid-induced abdominal constriction at 100 umol/kg, po administered 1 hr before acetic acid challenge",Other,19059783.0,
965,411999,7,2,,103181002,2662,Unspecified,,,,,Analgesic activity in po dosed Swiss mouse assessed as inhibition of acetic acid-induced abdominal constriction administered 1 hr before acetic acid challenge,Other,19059783.0,
966,412000,3,3,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 100 umol/kg, po measured 3 hrs post carrageenan challenge",Other,19059783.0,
967,412001,7,2,,103181002,2662,Unspecified,,,,,Antiinflammatory activity in po dosed Wistar rat assessed as inhibition of carrageenan-induced paw edema measured 3 hrs post carrageenan challenge,Other,19059783.0,
968,412002,9,5,,103181002,2662,Active,3915797.0,5743.0,2.9,IC50,Inhibition of PGHS2 in human whole blood assessed as inhibition of TXB2 production by radioimmunoassay,Confirmatory,19059783.0,
969,412003,3,9,,103181002,2662,Unspecified,317373262.0,5742.0,,,Inhibition of PGHS1 in human whole blood assessed as inhibition of TXB2 production at 100 uM by radioimmunoassay,Other,19059783.0,
970,412148,3,3,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in carrageenan-induced Wistar rat paw edema model assessed as increase in paw volume at 20 mg/kg, po measured 3 hrs after carrageenan challenge relative to control",Other,19010670.0,
971,412149,3,3,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in carrageenan-induced Wistar rat paw edema model assessed as increase in paw volume at 20 mg/kg, po measured 5 hrs after carrageenan challenge relative to control",Other,19010670.0,
972,413193,3,10,,103181002,2662,Active,7387730.0,9536.0,,,Inhibition of mPGES1 in human A549 cells assessed as inhibition of IL-1-beta-induced PGE2 formation at 5 uM by cell-intact assay,Other,19053751.0,
973,413195,3,9,,103181002,2662,Unspecified,3915797.0,5743.0,,,Inhibition of human recombinant COX2 assessed as remaining activity at 5 uM relative to control,Other,19053751.0,
974,414955,8,5,,103181002,2662,Unspecified,115449.0,759.0,50.0,Ki,Inhibition of human recombinant carbonic anhydrase 1 by stopped flow CO2 hydration method,Confirmatory,19317447.0,
975,414956,8,5,,103181002,2662,Active,115456.0,760.0,0.021,Ki,Inhibition of human recombinant carbonic anhydrase 2 by stopped flow CO2 hydration method,Confirmatory,19317447.0,
976,414961,4,3,,103181002,2662,Active,,,10.35,Ki,Inhibition of Mycobacterium tuberculosis H37Rv recombinant beta-carbonic anhydrase 1 expressed in Escherichia coli BL21 by stopped flow CO2 hydration method,Confirmatory,19317447.0,
977,420789,3,3,,103181002,2662,Unspecified,,,,,"Analgesic activity in Albino mouse assessed as inhibition of acetic acid-induced writhing at 300 umol/kg, po administered 1 hr before acetic acid challenge and measured 10 mins after acetic acid challenge",Other,19144452.0,
978,420790,3,3,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Albino mouse assessed as inhibition of carrageenan-induced paw edema at 300 umol/kg, po administered 1 hr before carrageenan challenge and measured 3 hrs after carrageenan challenge",Other,19144452.0,
979,420791,3,3,,103181002,2662,Unspecified,,,,,"Gastrointestinal toxicity in Albino mouse assessed ulcer index at 300 mg/kg, po",Other,19144452.0,
980,427122,8,5,,103181002,2662,Active,74656605.0,3636621.0,1.0170000000000001,Ki,Inhibition of Candida albicans recombinant Nce103 by stopped-flow CO2 hydration assay,Confirmatory,19450983.0,
981,427123,4,3,,103181002,2662,Active,,,3.056,Ki,Inhibition of Cryptococcus neoformans recombinant Can2 by stopped-flow CO2 hydration assay,Confirmatory,19450983.0,
982,427124,7,2,,103181002,2662,Active,,,0.021,Ki,Inhibition of Helicobacter pylori beta-carbonic anhydrase by stopped-flow CO2 hydration assay,Confirmatory,19450983.0,
983,427125,8,5,,103181002,2662,Unspecified,115449.0,759.0,50.0,Ki,Inhibition of human recombinant carbonic anhydrase 1 by stopped-flow CO2 hydrase method,Confirmatory,19450983.0,
984,427144,9,5,,103181002,2662,Active,754286265.0,443551.0,24.3,IC50,Inhibition of ovine COX1 by chemiluminescence assay,Confirmatory,19596198.0,
985,427145,9,5,,103181002,2662,Active,3914304.0,443460.0,0.06,IC50,Inhibition of ovine COX2 by chemiluminescence assay,Confirmatory,19596198.0,
986,427146,3,3,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for ovine COX1 to IC50 for ovine COX2",Other,19596198.0,
987,432203,3,3,,103181002,2662,Unspecified,,,,,Selectivity ratio of IC50 for ovine COX1 to IC50 for ovine COX2,Other,19457595.0,
988,432204,9,5,,103181002,2662,Active,754286265.0,443551.0,33.1,IC50,Inhibition of ovine COX1 by enzyme-immuno assay,Confirmatory,19457595.0,
989,432205,9,5,,103181002,2662,Active,3914304.0,443460.0,0.07,IC50,Inhibition of ovine COX2 by enzyme-immuno assay,Confirmatory,19457595.0,
990,432545,8,5,,103181002,2662,Active,3915797.0,5743.0,0.068,IC50,Inhibition of human COX2 expressed in african green monkey COS cells assessed as inhibition of arachidonic acid-stimulated PGE2 production treated 1 hr before arachidonic acid challenge by enzyme immunoassay,Confirmatory,19520573.0,
991,432546,8,5,,103181002,2662,Active,317373262.0,5742.0,1.689,IC50,Inhibition of human COX1 expressed in african green monkey COS cells assessed as inhibition of arachidonic acid-stimulated PGE2 treated 1 hr before arachidonic acid challenge by enzyme immunoassay,Confirmatory,19520573.0,
992,432547,3,3,,103181002,2662,Unspecified,,,,,Selectivity ratio of IC50 for human COX1 to IC50 for human COX2 expressed in african green monkey COS cells,Other,19520573.0,
993,432548,8,5,,103181002,2662,Active,3915797.0,5743.0,0.063,IC50,Inhibition of human COX2 expressed in baculovirus-infected SF9 cells assessed as inhibition of arachidonic acid-stimulated PGE2 production treated 1 hr before arachidonic acid challenge by enzyme immunoassay,Confirmatory,19520573.0,
994,432549,8,5,,103181002,2662,Unspecified,317373262.0,5742.0,1.0,IC50,Inhibition of human COX1 expressed in baculovirus-infected SF9 cells assessed as inhibition of arachidonic acid-stimulated PGE2 production treated 1 hr before arachidonic acid challenge by enzyme immunoassay,Confirmatory,19520573.0,
995,432550,3,3,,103181002,2662,Unspecified,,,,,Selectivity ratio of IC50 for human COX1 to IC50 for human COX2 expressed in baculovirus-infected SF9 cells,Other,19520573.0,
996,432551,8,5,,103181002,2662,Active,3915797.0,5743.0,0.336,IC50,Inhibition of COX2 in human whole blood assessed as inhibition of lipopolysaccharide-stimulated PGE2 production after 24 hrs by enzyme immunoassay,Confirmatory,19520573.0,
997,432552,8,5,,103181002,2662,Active,317373262.0,5742.0,10.193999999999999,IC50,Inhibition of COX1 in human whole blood assessed as inhibition of lipopolysaccharide-induced TxB2 production after 30 min by enzyme immunoassay,Confirmatory,19520573.0,
998,432553,3,3,,103181002,2662,Unspecified,,,,,Selectivity ratio of IC50 for COX1 to IC50 for COX2 in human whole blood,Other,19520573.0,
999,432561,3,4,,103181002,2662,Unspecified,,,,,Ratio of drug level in brain to blood in rat,Other,19520573.0,
1000,434955,1,2,,49666478,2662,Inactive,,,,IC90,Screen to Identify Novel Compounds That Sensitize Mycobacterium Tuberculosis to Beta-lactam Antibiotics,Confirmatory,,
1001,434959,1,1,,85789333,2662,Inactive,,,,,Fluorescence Cell-Based Primary HTS to Measure Inhibition of Y box Binding Protein 1 Expression,Screening,,
1002,434962,1,2,,49666478,2662,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify inhibitors of insulin-degrading enzyme (IDE),Screening,,
1003,434973,1,3,,49666478,2662,Inactive,120538355.0,57337.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 7 (SENP7),Screening,,
1004,434989,1,1,,49666478,2662,Inactive,222080095.0,3061.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
1005,435003,1,3,,49666478,2662,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of T-cell specific antigen receptor-induced NF-kB activation,Screening,,
1006,435005,1,1,,49666478,2662,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Beta Cell Apoptosis.,Screening,,
1007,435022,2,2,,49666478,2662,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of B-cell specific antigen receptor-induced NF-kB activation,Screening,,
1008,435030,1,2,,49666478,2662,Inactive,15645703.0,899625.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
1009,435030,1,2,,49666478,2662,Inactive,15646160.0,899738.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
1010,436563,7,5,,103181002,2662,Unspecified,115449.0,759.0,50.0,Ki,Inhibition of human recombinant CA1 by stopped-flow CO2 assay,Confirmatory,19520577.0,
1011,436564,7,5,,103181002,2662,Active,115456.0,760.0,0.021,Ki,Inhibition of human recombinant CA2 by stopped-flow CO2 assay,Confirmatory,19520577.0,
1012,436565,7,1,,103181002,2662,Active,,,0.0342,Ki,Inhibition of cloned Stylophora pistillata alpha-CA expressed in human HEK293 cells by stopped-flow CO2 assay,Confirmatory,19520577.0,
1013,436656,3,3,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced foot paw edema in rat assessed as reduction in paw size at 20 mg/kg, sc administered 30 mins before carrageenan challenge measured after 3 hrs relative to control",Other,19527932.0,
1014,437749,7,5,,103181002,2662,Active,115456.0,760.0,0.021,Ki,Inhibition of human recombinant CA2 by stopped-flow hydration assay,Confirmatory,19846301.0,
1015,437750,11,5,,103181002,2662,Active,614098999.0,887836.0,0.713,Ki,Inhibition of full length Mycobacterium tuberculosis H37Rv recombinant carbonic anhydrase 2 encoded by RV3588c by stopped flow CO2 hydration assay,Confirmatory,19846301.0,
1016,443489,8,5,,103181002,2662,Active,754286265.0,443551.0,8.32,IC50,Inhibition of ovine COX-1 assessed as inhibition of transformation of AA to PGH2 by EIA,Confirmatory,19880317.0,
1017,443490,8,5,,103181002,2662,Active,3914304.0,443460.0,0.113,IC50,Inhibition of ovine COX-2 assessed as inhibition of transformation of AA to PGH2 by EIA,Confirmatory,19880317.0,
1018,443491,5,2,,103181002,2662,Unspecified,,,73.4,IC50,Inhibition of potato LOX-5 assessed as inhibition of hydroperoxide production after 5 mins by EIA,Confirmatory,19880317.0,
1019,443492,3,3,,103181002,2662,Unspecified,,,,,Selectivity ratio of IC50 for ovine COX-1 to IC50 for ovine COX-2,Other,19880317.0,
1020,447528,8,5,,103181002,2662,Active,754286265.0,443551.0,7.7,IC50,Inhibition of ovine COX1 by enzyme immunoassay,Confirmatory,19500994.0,
1021,447529,8,5,,103181002,2662,Active,3915797.0,5743.0,0.12,IC50,Inhibition of human recombinant COX2 by enzyme immunoassay,Confirmatory,19500994.0,
1022,447532,3,3,,103181002,2662,Unspecified,,,,,Selectivity ratio of IC50 for ovine COX1 to IC50 for human COX2,Other,19500994.0,
1023,447533,8,2,,103181002,2662,Unspecified,,,,,Antiinflammatory activity in po dosed rat assessed as inhibition of carrageenan-induced paw edema after 3 hrs,Other,19500994.0,
1024,448077,8,5,,103181002,2662,Active,754286265.0,443551.0,24.3,IC50,Inhibition of ovine COX1 by chemiluminescent enzyme assay,Confirmatory,19560931.0,
1025,448078,8,5,,103181002,2662,Active,3914304.0,443460.0,0.06,IC50,Inhibition of ovine COX2 by chemiluminescent enzyme assay,Confirmatory,19560931.0,
1026,448079,3,3,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for ovine COX1 to IC50 for ovine COX2",Other,19560931.0,
1027,449728,1,2,,49666478,2662,Inactive,,,,,Counterscreen for inhibitors of AddAB: absorbance-based bacterial cell-based high throughput screening assay to identify inhibitors of bacterial viability,Screening,,
1028,449762,1,2,,49666478,2662,Inactive,,,,IC50,High Throughput Screening Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in 7H9 Media,Confirmatory,,
1029,449763,1,3,,49666478,2662,Inactive,,,,,uHTS identification of small molecule activators of the apoptotic arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
1030,453626,3,9,,103181002,2662,Unspecified,754286265.0,443551.0,,,Inhibition of ovine COX1 at 5 uM,Other,19884011.0,
1031,453627,3,9,,103181002,2662,Unspecified,3915797.0,5743.0,,,Inhibition of human recombinant COX2 at 5 uM,Other,19884011.0,
1032,453634,4,10,,103181002,2662,Active,7387730.0,9536.0,,,Inhibition of mPGES1 in IL1-beta induced human A549 cells assessed as PGE2 production at 5 uM preincubated for 10 mins,Other,19884011.0,
1033,453640,3,11,,103181002,2662,Unspecified,3915797.0,5743.0,,,Inhibition of COX2 in IL1-beta induced human A549 cells assessed as reduction of 6-keto-PGF1-alpha formation up to 5 uM preincubated for 15 mins by ELISA,Other,19884011.0,
1034,456475,8,5,,103181002,2662,Active,129900.0,19224.0,5.1,IC50,Inhibition of COX1-dependent PGE2 production in LPS-stimulated mouse J774 cells by RIA,Confirmatory,19957931.0,
1035,456476,8,5,,103181002,2662,Active,548483.0,19225.0,0.079,IC50,Inhibition of COX2-dependent PGE2 production in LPS-stimulated mouse J774 cells by RIA,Confirmatory,19957931.0,
1036,456477,9,5,,103181002,2662,Unspecified,548483.0,19225.0,95.0,IC50,Inhibition of COX2-dependent PGE2 production in LPS-stimulated mouse J774 cells at 10 uM by RIA,Confirmatory,19957931.0,
1037,456478,8,5,,103181002,2662,Unspecified,548483.0,19225.0,80.0,IC50,Inhibition of COX2-dependent PGE2 production in LPS-stimulated mouse J774 cells at 1 uM by RIA,Confirmatory,19957931.0,
1038,456479,3,3,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for mouse COX1 to IC50 for mouse COX2",Other,19957931.0,
1039,456480,8,5,,103181002,2662,Active,317373262.0,5742.0,12.5,IC50,Inhibition of COX1 in human whole blood assessed as thromboxane B2 production by RIA,Confirmatory,19957931.0,
1040,456481,8,5,,103181002,2662,Active,3915797.0,5743.0,0.54,IC50,Inhibition of COX2 in human whole blood assessed as inhibition of LPS-induced PGE2 production by RIA,Confirmatory,19957931.0,
1041,456482,3,3,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for human COX1 to IC50 for human COX2",Other,19957931.0,
1042,456486,3,3,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema rat inflammatory model assessed as paw pressure at 20 mg/kg, po after 30 mins",Other,19957931.0,
1043,456487,3,3,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema rat inflammatory model assessed as paw pressure at 20 mg/kg, po after 60 mins",Other,19957931.0,
1044,456488,3,3,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema rat inflammatory model assessed as paw pressure at 20 mg/kg, po after 120 mins",Other,19957931.0,
1045,456489,5,1,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema rat inflammatory model assessed as paw volume at 20 mg/kg, po after 60 mins",Other,19957931.0,
1046,456491,3,3,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema rat inflammatory model assessed as suppression of paw edema at 20 mg/kg, po after 60 mins",Other,19957931.0,
1047,456498,3,3,,103181002,2662,Unspecified,,,,,Analgesic activity against zymosan-induced hyperalgesia in mouse assessed maximum effect measured up to 2 hrs,Other,19957931.0,
1048,456499,3,3,,103181002,2662,Unspecified,,,,,Analgesic activity against zymosan-induced hyperalgesia in mouse assessed maximum effect measured up to 6 hrs,Other,19957931.0,
1049,457535,3,9,,103181002,2662,Unspecified,3915797.0,5743.0,,,Inhibition of COX2 in human THP1 cells at 10 uM by enzyme immunoassay,Other,20056549.0,
1050,457537,3,4,,103181002,2662,Inactive,,,,,Antiinflammatory activity in human THP1 cells assessed as inhibition of LPS-induced TNFalpha release at 10 uM by ELISA,Other,20056549.0,
1051,457928,8,5,,103181002,2662,Active,754286265.0,443551.0,7.7,IC50,Inhibition of ovine COX1 by enzyme immunoassay,Confirmatory,20097072.0,
1052,457929,8,5,,103181002,2662,Active,3915797.0,5743.0,0.12,IC50,Inhibition of human recombinant COX2 by enzyme immunoassay,Confirmatory,20097072.0,
1053,457930,3,3,,103181002,2662,Unspecified,,,,,Selectivity ratio of IC50 for ovine COX1 to IC50 for human recombinant COX2,Other,20097072.0,
1054,457933,6,2,,103181002,2662,Unspecified,,,,,Antiinflammatory activity in po dosed rat assessed as inhibition of carrageenan-induced paw edema,Other,20097072.0,
1055,458547,8,5,,103181002,2662,Active,754286265.0,443551.0,24.3,IC50,Inhibition of ovine COX1 by enzyme chemiluminescent enzyme assay,Confirmatory,20061161.0,
1056,458548,8,5,,103181002,2662,Active,3914304.0,443460.0,0.06,IC50,Inhibition of ovine COX2 by enzyme chemiluminescent enzyme assay,Confirmatory,20061161.0,
1057,458549,3,3,,103181002,2662,Unspecified,,,,,Selectivity for ovine COX2 over ovine COX1,Other,20061161.0,
1058,459696,3,3,,103181002,2662,Active,,,,,Inhibition of Brucella suis CA1 expressed in Escherichia coli BL21(DE3) by stopped-flow CO2-hydration assay,Other,20158185.0,
1059,460652,5,2,,103181002,2662,Unspecified,,,50.0,EC50,Cytotoxicity against LPS and IFN-gamma-stimulated human THP1 cells after 24 hrs,Confirmatory,20138770.0,
1060,460653,4,4,,103181002,2662,Inactive,,,,,Inhibition of MCP1 release in human THP1 cells after 24 hrs by ELISA,Other,20138770.0,
1061,460654,5,4,,103181002,2662,Active,,,5.0,IC50,Antineurotoxicity in human SH-SY5Y cells assessed as inhibition human THP1 cell supernatant-induced cytotoxicity compound pretreated 24 to 48 hrs to THP1 cells measured after 72 hrs of supernatant addition,Confirmatory,20138770.0,
1062,460655,5,2,,103181002,2662,Unspecified,,,,IC50,Inhibition of phagocyte respiratory burst in human HL60 cells after 6 to 7 days by luminol-induced chemiluminescence,Confirmatory,20138770.0,
1063,460897,3,9,,103181002,2662,Unspecified,754286265.0,443551.0,,,Inhibition of ovine COX1 at 10 uM,Other,20138770.0,
1064,460898,3,9,,103181002,2662,Unspecified,3915797.0,5743.0,,,Inhibition of human COX2 at 10 uM,Other,20138770.0,
1065,460899,3,3,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat acute inflammatory model assessed as inhibition of formalin-induced paw edema at 20 mg/kg, po administered 1 hr before formalin challenge measured after 1 hr by plethysmometer relative to control",Other,20138770.0,
1066,460900,3,3,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat acute inflammatory model assessed as inhibition of formalin-induced paw edema at 20 mg/kg, po administered 1 hr before formalin challenge measured after 2 hrs by plethysmometer relative to control",Other,20138770.0,
1067,460901,3,3,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat acute inflammatory model assessed as inhibition of formalin-induced paw edema at 20 mg/kg, po administered 1 hr before formalin challenge measured after 3 hrs by plethysmometer relative to control",Other,20138770.0,
1068,460902,3,3,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat acute inflammatory model assessed as inhibition of formalin-induced paw edema at 20 mg/kg, po administered 1 hr before formalin challenge measured after 4 hrs by plethysmometer relative to control",Other,20138770.0,
1069,460903,3,3,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat sub-acute inflammatory model assessed as inhibition of formalin-induced paw edema at 20 mg/kg, po administered daily for 7 days by plethysmometer relative to control",Other,20138770.0,
1070,460904,3,3,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat sub-acute inflammatory model assessed as inhibition of turpentine oil-induced granuloma pouch exudate volume at 20 mg/kg, po 1 hr before turpentine oil challenge for 7 days assessed measured on day 8",Other,20138770.0,
1071,460906,3,3,,103181002,2662,Unspecified,,,,,"Gastrointestinal toxicity in Wistar albino rat assessed as ulceration at 100 mg/kg/day, po administered twice daily for 3 days",Other,20138770.0,
1072,460908,6,2,,103181002,2662,Unspecified,,,,,Antiinflammatory activity in po dosed Wistar albino rat acute inflammatory model assessed as inhibition of formalin-induced paw edema administered 1 hr before formalin challenge measured after 3 hrs by plethysmometer,Other,20138770.0,
1073,461096,5,2,,103181002,2662,Active,,,10.0,IC50,Inhibition of potato tuber 5LOX by polarographic method,Confirmatory,20045317.0,
1074,463079,1,2,,49666478,2662,Inactive,,,,,Fluorescence-based counterscreen for orexin 1 receptor (OX1R) antagonists: cell-based assay to identify antagonists of the parental CHO cell line,Screening,,
1075,463082,1,1,,49666478,2662,Active,270133071.0,7941.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH),Screening,,
1076,463104,1,2,,49666478,2662,Inactive,,,,,uHTS identification of small molecule activators of the adaptive arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
1077,463111,1,1,,49666478,2662,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate regulator of G-protein signaling 4 (RGS4),Screening,,
1078,463141,1,2,,49666478,2662,Inactive,14790119.0,836.0,,,Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3,Screening,,
1079,463165,1,1,,49666478,2662,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit regulator of   G-protein signaling 4 (RGS4),Screening,,
1080,463190,1,2,,49666478,2662,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10-1 yeast via a luminescent assay,Screening,,
1081,463195,1,2,,49666478,2662,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10 yeast via a luminescent assay,Screening,,
1082,463210,1,2,,49666478,2662,Inactive,55960760.0,,,,Counterscreen for procaspase-3 activators: absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-7,Screening,,
1083,463212,1,1,,49666478,2662,Inactive,285814664.0,855751.0,,,uHTS identification of small molecule inhibitors of tim23-1 yeast via a luminescent assay,Screening,,
1084,463230,1,2,,49666478,2662,Active,270133071.0,7941.0,,,Fluorescence polarization-based biochemical high throughput confirmation assay for inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH; PLA2G7),Screening,,
1085,463254,1,1,,49666478,2662,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
1086,471115,3,3,,103181002,2662,Unspecified,,,,,Selectivity ratio of IC50 for COX1 to IC50 for COX2 in human whole blood,Other,19791801.0,
1087,471116,8,5,,103181002,2662,Active,317373262.0,5742.0,2.6,IC50,Inhibition of COX1 in human whole blood assessed as TXB2 production by enzyme immunoassay,Confirmatory,19791801.0,
1088,471117,8,5,,103181002,2662,Active,3915797.0,5743.0,0.35,IC50,Inhibition of COX2 in LPS-stimulated human whole blood assessed as PGE2 production by enzyme immunoassay,Confirmatory,19791801.0,
1089,471118,3,3,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity against gamma carrageenan-induced pleurisy in Wistar rat assessed as inhibition of exudate production in pleural cavity at 5 mg/kg, ip administered 30 mins before gamma carrageenan challenge measured after 4 hrs",Other,19791801.0,
1090,471119,3,3,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity against gamma carrageenan-induced pleurisy in Wistar rat assessed as inhibition of exudate production in pleural cavity at 10 mg/kg, ip administered 30 mins before gamma carrageenan challenge measured after 4 hrs",Other,19791801.0,
1091,471360,3,3,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity against gamma carrageenan-induced pleurisy in Wistar rat assessed as inhibition of exudate production in pleural cavity at 20 mg/kg, ip administered 30 mins before gamma carrageenan challenge measured after 4 hrs",Other,19791801.0,
1092,471362,3,3,,103181002,2662,Active,,,,,"Antiinflammatory activity against gamma carrageenan-induced pleurisy in Wistar rat assessed as decrease in exudate volume in pleural cavity at 10 mg/kg, ip administered 30 mins before gamma carrageenan challenge measured after 4 hrs",Other,19791801.0,
1093,471363,3,3,,103181002,2662,Active,,,,,"Antiinflammatory activity against gamma carrageenan-induced pleurisy in Wistar rat assessed as decrease in exudate volume in pleural cavity at 20 mg/kg, ip administered 30 mins before gamma carrageenan challenge measured after 4 hrs",Other,19791801.0,
1094,477295,3,3,,103181002,2662,Unspecified,,,,,"Octanol-water partition coefficient, log P of the compound",Other,20106561.0,
1095,479548,7,5,,103181002,2662,Active,3914304.0,443460.0,0.07,IC50,Inhibition of ovine COX2 assessed as inhibition of PGF2a formation after 20 mins by Ellman's method,Confirmatory,20387815.0,
1096,479549,7,5,,103181002,2662,Active,754286265.0,443551.0,33.1,IC50,Inhibition of ovine COX1 assessed as inhibition of PGF2a formation after 20 mins by Ellman's method,Confirmatory,20387815.0,
1097,479550,3,3,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for ovine COX1 to IC50 for ovine COX2",Other,20387815.0,
1098,479869,5,2,,103181002,2662,Active,,,17.5,GI50,Growth inhibition of human NCI60 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20387815.0,
1099,484274,8,5,,103181002,2662,Unspecified,118157.0,,126.0,IC50,Inhibition of Trypanosoma cruzi cruzaine preincubated for 5 mins before substrate addition by fluorescence assay in absence of Triton X-100,Confirmatory,20426472.0,
1100,484275,8,5,,103181002,2662,Unspecified,118157.0,,400.0,IC50,Inhibition of Trypanosoma cruzi cruzaine preincubated for 5 mins before substrate addition by fluorescence assay in presence of 0.01% Triton X-100,Confirmatory,20426472.0,
1101,484278,3,3,,103181002,2662,Unspecified,,,,,Colloidal aggregation in fed state simulated intestinal fluid by dynamic light scattering assay in presence of 0.6% DMSO,Other,20426472.0,
1102,484381,3,3,,103181002,2662,Unspecified,,,,,Colloidal aggregation in fed state simulated intestinal fluid assessed as colloid radius at 120 uM by dynamic light scattering assay in presence of 1% DMSO,Other,20426472.0,
1103,485270,1,1,,49666478,2662,Inactive,222080095.0,3061.0,,,FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
1104,485272,1,1,,49666478,2662,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS),Screening,,
1105,485273,2,1,,49666478,2662,Inactive,4507793.0,7334.0,,,uHTS identification of UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay,Screening,,
1106,485275,1,3,,49666478,2662,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors,Screening,,
1107,485281,1,1,,26747363,2662,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
1108,485281,1,1,,49666478,2662,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
1109,485290,1,1,,17389545,2662,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1110,485290,1,1,,26747363,2662,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1111,485294,1,1,,49666478,2662,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
1112,485297,1,1,,49666478,2662,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
1113,485298,1,1,,49666478,2662,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
1114,485313,1,2,,49666478,2662,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
1115,485314,1,1,,49666478,2662,Inactive,4505931.0,5423.0,,Potency,qHTS Assay for Inhibitors of DNA Polymerase Beta,Confirmatory,,
1116,485317,1,2,,49666478,2662,Inactive,54112432.0,2671.0,,,HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS,Screening,,
1117,485341,1,1,,49666478,2662,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
1118,485344,1,1,,49666478,2662,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists,Screening,,
1119,485346,1,1,,49666478,2662,Inactive,88702791.0,4194.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
1120,485346,1,1,,49666478,2662,Inactive,89993689.0,4193.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
1121,485347,1,2,,49666478,2662,Inactive,4503385.0,1813.0,,,HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators,Screening,,
1122,485349,1,1,,49666478,2662,Inactive,71902540.0,472.0,,Potency,qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia,Confirmatory,,
1123,485350,1,2,,92124698,2662,Inactive,126642418.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme BasE,Screening,,
1124,485353,2,1,,49666478,2662,Inactive,30124074.0,1489680.0,,,qHTS of Yeast-based Assay for SARS-CoV PLP,Confirmatory,,
1125,485358,1,1,,49666478,2662,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists,Screening,,
1126,485364,1,1,,49666478,2662,Inactive,15149312.0,8345881.0,,Potency,qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins,Confirmatory,,
1127,485367,1,2,,49666478,2662,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
1128,488197,8,5,,103181002,2662,Inconclusive,126407.0,240.0,,IC50,Inhibition of 5-lipoxygenase in human whole blood assessed as inhibition of LTB4 production by HPLC method,Confirmatory,20451397.0,
1129,488198,8,5,,103181002,2662,Inconclusive,126407.0,240.0,,IC50,Inhibition of 5-lipoxygenase in human whole blood assessed as inhibition of 5-hydroxyeicosatetraenoic acid production by HPLC method,Confirmatory,20451397.0,
1130,488201,8,5,,103181002,2662,Active,317373262.0,5742.0,13.1,IC50,Inhibition of COX1 in human whole blood assessed as inhibition of 12-hydroxyheptadecatrienoic acid production by HPLC method,Confirmatory,20451397.0,
1131,488203,8,5,,103181002,2662,Active,3915797.0,5743.0,0.8,IC50,Inhibition of COX2 in human whole blood assessed as inhibition of 12-hydroxyheptadecatrienoic acid production by HPLC method,Confirmatory,20451397.0,
1132,488204,3,3,,103181002,2662,Unspecified,,,,,Selectivity ratio of IC50 for COX2-mediated 12-hydroxyheptadecatrienoic acid production in human whole blood to IC50 for COX1-mediated 12-hydroxyheptadecatrienoic acid production in human whole blood,Other,20451397.0,
1133,488205,5,2,,103181002,2662,Active,,,44.0,IC50,Cytotoxicity against mouse L1210 cells after 72 hrs by MTT assay,Confirmatory,20451397.0,
1134,488207,5,2,,103181002,2662,Unspecified,,,50.2,IC50,Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,20451397.0,
1135,488209,5,2,,103181002,2662,Active,,,48.5,IC50,Cytotoxicity against human PC3 cells after 72 hrs by MTT assay,Confirmatory,20451397.0,
1136,488837,1,1,,49666478,2662,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
1137,488839,1,1,,49665790,2662,Inactive,20072248.0,8851.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1138,488839,1,1,,49665790,2662,Inactive,48146199.0,1020.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1139,488847,1,3,,49666478,2662,Inactive,148539876.0,156.0,,,RNA aptamer-based HTS for inhibitors of GRK2,Screening,,
1140,488862,1,1,,49665790,2662,Inactive,,,,,Inhibitors of Prion Protein 5' UTR mRNA Measured in Cell-Based System Using Plate Reader - 2078-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1141,488890,1,2,,49666478,2662,Inactive,,,,IC50,"Elucidation of physiology of non-replicating, drug-tolerant Mycobacterium tuberculosis",Confirmatory,,
1142,488895,1,2,,49665790,2662,Inactive,90111653.0,948321.0,,,High Throughput Screen for Tat Transport Inhibitors Measured in Microorganism System Using Plate Reader - 2093-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1143,488896,1,1,,49665790,2662,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1144,488899,1,1,,49665790,2662,Inactive,40807040.0,4286.0,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1145,488922,1,2,,49666478,2662,Inactive,7706135.0,,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9,Screening,,
1146,488965,1,2,,49665790,2662,Inactive,218891639.0,,,,Fluorescent Biochemical Primary HTS to Identify Inhibitors of P. aeruginosa PvdQ acylase Measured in Biochemical System Using Plate Reader and Imaging Combination - 2091-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1147,488966,1,1,,49665790,2662,Inactive,,,,IC50,Primary and Confirmatory Screening for Inhibitors of Bacterial Capsule Biogenesis,Confirmatory,,
1148,488975,1,2,,49666478,2662,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT),Screening,,
1149,488977,1,2,,49666478,2662,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT),Screening,,
1150,489030,2,1,,49666478,2662,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of inhibitors of Apaf-1,Screening,,
1151,489031,2,1,,49666478,2662,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of activators of Apaf-1,Screening,,
1152,489468,3,10,,103181002,2662,Unspecified,548483.0,19225.0,,,Inhibition of COX-2-mediated PGE2 production in LPS-induced mouse RAW 264.7 cells at 10 uM after 24 hrs by EIA,Other,20554444.0,
1153,492302,3,4,,103181002,2662,Unspecified,,,,,"Antinociceptive activity in Swiss mouse assessed as inhibition of acetic acid-induced abdominal constrictions at 100 umol/kg, po administered 40 mins before acetic acid challenge measured for 25 mins relative to control",Other,20598893.0,
1154,492305,3,4,,103181002,2662,Unspecified,,,,,"Analgesic activity against formalin-induced acute pain in Swiss mouse assessed inhibition of nociception at 100 umol/kg, po administered 40 mins before formalin challenge measured for 15 to 30 mins relative to control",Other,20598893.0,
1155,492306,3,4,,103181002,2662,Unspecified,,,,,"Analgesic activity in Swiss mouse assessed as increase in latency of paw licking at 100 umol/kg, po after 60 mins measured for 60 seconds by hot plate test (Rvb = 4.9 +/- 0.5 seconds)",Other,20598893.0,
1156,492308,3,4,,103181002,2662,Unspecified,,,,,"Analgesic activity in Swiss mouse assessed as increase in latency of paw licking at 100 umol/kg, po after 90 mins measured for 60 seconds by hot plate test (Rvb = 5.9 +/- 0.8 seconds)",Other,20598893.0,
1157,492310,3,4,,103181002,2662,Unspecified,,,,,"Analgesic activity in Swiss mouse assessed as increase in latency of paw licking at 100 umol/kg, po after 120 mins measured for 60 seconds by hot plate test (Rvb = 5.6 +/- 0.5 seconds)",Other,20598893.0,
1158,492312,3,4,,103181002,2662,Unspecified,,,,,"Analgesic activity in Swiss mouse assessed as increase in latency of paw licking at 100 umol/kg, po after 150 mins measured for 60 seconds by hot plate test (Rvb = 5.1 +/- 0.4 seconds)",Other,20598893.0,
1159,492314,3,4,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity against zymosan A-induced peritonitis in Swiss mouse assessed as inhibition of granulocyte infiltration in to peritoneal cavity at 100 mg/kg, po administered 40 mins before zymosan A challenge measured after 6 hrs relative to control",Other,20598893.0,
1160,492315,3,4,,103181002,2662,Unspecified,,,,,"Antiedematogenic activity in Swiss mouse assessed as decrease of capsaicin-induced paw edema weight at 100 umol/kg, po administered 40 mins before capsaicin challenge measured after 30 mins relative to control",Other,20598893.0,
1161,492316,3,4,,103181002,2662,Unspecified,,,,,"Antiedematogenic activity in Swiss mouse assessed as inhibition of capsaicin-induced paw edema at 100 umol/kg, po administered 40 mins before capsaicin challenge measured after 30 mins relative to control",Other,20598893.0,
1162,492947,1,1,,49666478,2662,Inactive,4501969.0,154.0,,Potency,qHTS assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
1163,492953,1,1,,49665790,2662,Inactive,296080766.0,5049.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (PAFAH1B2)",Screening,,
1164,492956,1,1,,49665790,2662,Inactive,4758878.0,5051.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet activating factor acetylhydrolase 2 (PAFAH2),Screening,,
1165,492961,1,1,,17389545,2662,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase: hit validation,Confirmatory,,
1166,492967,1,2,,99301981,2662,Inactive,47566732.0,,,,A screen for compounds that inhibit the CapD enzyme of Bacillus anthracis,Other,,
1167,492972,1,1,,49665790,2662,Inactive,225543099.0,5050.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1B, catalytic subunit 3 (PAFAH1B3)",Screening,,
1168,493005,1,1,,49665790,2662,Inactive,5454140.0,7251.0,,Potency,qHTS Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
1169,493008,1,1,,49665790,2662,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1170,493008,1,1,,49665790,2662,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1171,493008,1,1,,49665790,2662,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1172,493008,1,1,,49665790,2662,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1173,493011,1,1,,49666478,2662,Inactive,21955158.0,200315.0,,,uHTS identification of APOBEC3A DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
1174,493012,1,1,,49666478,2662,Inactive,13399304.0,60489.0,,,uHTS identification of APOBEC3G DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
1175,493014,1,1,,49666478,2662,Inactive,,,,Potency,qHTS Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
1176,493017,1,1,,103853303,2662,Active,,5743.0,,,Wombat Data for BeliefDocking,Other,10937738.0,
1177,493033,1,2,,92124698,2662,Inactive,614089026.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme MbtI,Other,,
1178,493036,1,2,,49666478,2662,Inactive,110611243.0,4923.0,,,Image-Based HTS for Selective Agonists for NTR1,Screening,,
1179,493056,1,1,,49666478,2662,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Enhancers,Screening,,
1180,493084,1,1,,49666478,2662,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Agonists.,Screening,,
1181,493087,1,1,,49665790,2662,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify activators of insulin-degrading enzyme (IDE),Screening,,
1182,493091,1,1,,49665790,2662,Inactive,10864009.0,58190.0,,,uHTS Colorimetric assay for identification of inhibitors of Scp-1,Screening,,
1183,493098,1,1,,49665790,2662,Inactive,37187860.0,1235.0,,,uHTS identification of small molecule antagonists of the CCR6 receptor via a luminescent beta-arrestin assay,Screening,,
1184,493131,1,1,,49665790,2662,Inactive,6679827.0,14282.0,,,Activator for delta FosB/delta FosB homodimer Measured in Biochemical System Using Plate Reader - 2072-01_Activator_SinglePoint_HTS_Activity,Screening,,
1185,493160,1,1,,49665790,2662,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of inhibitors of hexokinase domain containing  I (HKDC1),Screening,,
1186,493162,1,2,,99301981,2662,Inactive,335756.0,,,,A screen for compounds that inhibit processive DNA synthesis of vaccinia virus,Other,,
1187,493187,1,2,,49665790,2662,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of activators of hexokinase domain containing  I (HKDC1),Screening,,
1188,493244,1,1,,49665790,2662,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1189,493244,1,1,,49665790,2662,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1190,493244,1,1,,49665790,2662,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1191,493244,1,1,,49665790,2662,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1192,493883,6,5,,103181002,2662,Unspecified,115449.0,759.0,50.0,Ki,Inhibition of human recombinant carbonic anhydrase 1 after 15 mins by stopped-flow CO2 hydration assay,Confirmatory,20605094.0,
1193,493884,6,5,,103181002,2662,Active,115456.0,760.0,0.021,Ki,Inhibition of human recombinant carbonic anhydrase 2 after 15 mins by stopped-flow CO2 hydration assay,Confirmatory,20605094.0,
1194,493885,9,2,,103181002,2662,Unspecified,134047703.0,761.0,70.0,Ki,Inhibition of human recombinant carbonic anhydrase 3 after 15 mins by stopped-flow CO2 hydration assay,Confirmatory,20605094.0,
1195,493886,6,5,,103181002,2662,Active,115465.0,762.0,0.88,Ki,Inhibition of human recombinant carbonic anhydrase 4 after 15 mins by stopped-flow CO2 hydration assay,Confirmatory,20605094.0,
1196,493887,6,5,,103181002,2662,Active,461680.0,763.0,0.794,Ki,Inhibition of human recombinant carbonic anhydrase 5a after 15 mins by stopped-flow CO2 hydration assay,Confirmatory,20605094.0,
1197,493888,6,5,,103181002,2662,Active,8928041.0,11238.0,0.09300000000000001,Ki,Inhibition of human recombinant carbonic anhydrase 5b after 15 mins by stopped-flow CO2 hydration assay,Confirmatory,20605094.0,
1198,493889,6,5,,103181002,2662,Active,116241278.0,765.0,0.094,Ki,Inhibition of human recombinant carbonic anhydrase 6 after 15 mins by stopped-flow CO2 hydration assay,Confirmatory,20605094.0,
1199,493890,6,5,,103181002,2662,Active,1168744.0,766.0,2.17,Ki,Inhibition of human recombinant carbonic anhydrase 7 after 15 mins by stopped-flow CO2 hydration assay,Confirmatory,20605094.0,
1200,493891,6,5,,103181002,2662,Active,83300925.0,768.0,0.016,Ki,Inhibition of human recombinant carbonic anhydrase 9 after 15 mins by stopped-flow CO2 hydration assay,Confirmatory,20605094.0,
1201,493892,6,5,,103181002,2662,Active,5915866.0,771.0,0.018000000000000002,Ki,Inhibition of human recombinant carbonic anhydrase 12 after 15 mins by stopped-flow CO2 hydration assay,Confirmatory,20605094.0,
1202,493893,6,5,,103181002,2662,Active,30580350.0,377677.0,0.098,Ki,Inhibition of human recombinant carbonic anhydrase 13 after 15 mins by stopped-flow CO2 hydration assay,Confirmatory,20605094.0,
1203,493894,6,5,,103181002,2662,Active,8928036.0,23632.0,0.6890000000000001,Ki,Inhibition of human recombinant carbonic anhydrase 14 after 15 mins by stopped-flow CO2 hydration assay,Confirmatory,20605094.0,
1204,493895,6,5,,103181002,2662,Active,30580362.0,80733.0,0.045,Ki,Inhibition of mouse recombinant carbonic anhydrase 15 after 15 mins by stopped-flow CO2 hydration assay,Confirmatory,20605094.0,
1205,494634,7,5,,103181002,2662,Unspecified,754286265.0,443551.0,115.9,IC50,Inhibition of sheep COX1 by enzyme immunoassay,Confirmatory,20576432.0,
1206,494635,7,5,,103181002,2662,Active,3915797.0,5743.0,0.065,IC50,Inhibition of human COX2 by enzyme immunoassay,Confirmatory,20576432.0,
1207,494636,2,3,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for sheep COX1 to IC50 for human COX2",Other,20576432.0,
1208,494637,5,2,,103181002,2662,Unspecified,,,,,Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced paw edema after 3 hrs,Other,20576432.0,
1209,497105,2,3,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of turpentine oil-induced granuloma at 20 mg/kg, po qd for 7 days post turpentine oil challenge measured on day 8",Other,20609589.0,
1210,497127,6,5,,103181002,2662,Unspecified,115449.0,759.0,50.0,Ki,Inhibition of wild type human recombinant carbonic anhydrase 1 expressed in Escherichia coli BL21 (DE3) after 15 mins by CO2 hydration method,Confirmatory,20624682.0,
1211,497128,2,3,,103181002,2662,Unspecified,,,52.3,Ki,Inhibition of human recombinant carbonic anhydrase 1 Phe91Asn mutant expressed in Escherichia coli BL21 (DE3) after 15 mins by CO2 hydration method,Confirmatory,20624682.0,
1212,497129,6,5,,103181002,2662,Active,115456.0,760.0,0.021,Ki,Inhibition of human recombinant carbonic anhydrase 2 after 15 mins by CO2 hydration method,Confirmatory,20624682.0,
1213,497201,4,3,,103181002,2662,Unspecified,,,70.0,IC50,Antiinflammatory activity in human THP1 cells assessed as reduction in LPS and IFN-gamma-induced MCP level after 24 hrs,Confirmatory,20609589.0,
1214,497202,4,2,,103181002,2662,Active,,,5.0,IC50,Neuroprotective activity against LPS and IFN-gamma-stimulated neurotoxin production in human THP1 cell assessed as inhibition of THP1 cell secretion-induced toxicity to human SH-SY5Y cells after 72 hrs by MTT assay,Confirmatory,20609589.0,
1215,497208,2,9,,103181002,2662,Unspecified,754286265.0,443551.0,,,Inhibition of ovine COX1 at 10 uM,Other,20609589.0,
1216,497209,2,9,,103181002,2662,Unspecified,3915797.0,5743.0,,,Inhibition of human COX2 at 10 uM,Other,20609589.0,
1217,497215,2,3,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of formalin-induced paw edema at 20 mg/kg, po administered 1 hr prior to formalin challenge measured after 1 hr relative to control",Other,20609589.0,
1218,497216,2,3,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of formalin-induced paw edema at 20 mg/kg, po administered 1 hr prior to formalin challenge measured after 2 hrs relative to control",Other,20609589.0,
1219,497217,2,3,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of formalin-induced paw edema at 20 mg/kg, po administered 1 hr prior to formalin challenge measured after 3 hrs relative to control",Other,20609589.0,
1220,497218,2,3,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of formalin-induced paw edema at 20 mg/kg, po administered 1 hr prior to formalin challenge measured after 4 hrs relative to control",Other,20609589.0,
1221,497219,2,3,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat sub-acute inflammatory model assessed as inhibition of formalin-induced paw edema at 20 mg/kg, po administered 1 hr prior to formalin challenge measured on day 1 relative to control",Other,20609589.0,
1222,497220,2,3,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat sub-acute inflammatory model assessed as inhibition of formalin-induced paw edema at 20 mg/kg, po administered 1 hr prior to formalin challenge measured on day 8 relative to control",Other,20609589.0,
1223,497221,5,2,,103181002,2662,Unspecified,,,,,Antiinflammatory activity in po dosed Wistar albino rat assessed as inhibition of formalin-induced paw edema after 3 hrs relative to control,Other,20609589.0,
1224,497222,2,3,,103181002,2662,Unspecified,,,,,"Toxicity in Wistar albino rat assessed as ulcerogenic activity at 300 mg/kg, po qd for 3 days",Other,20609589.0,
1225,497271,4,2,,103181002,2662,Unspecified,,,50.0,EC50,Cytotoxicity against human THP1 cells assessed as reduction in cell viability,Confirmatory,20609589.0,
1226,501378,7,5,,103181002,2662,Unspecified,754286265.0,443551.0,115.9,IC50,Inhibition of ovine COX1 by EIA,Confirmatory,20655211.0,
1227,501379,7,5,,103181002,2662,Active,3915797.0,5743.0,0.065,IC50,Inhibition of human recombinant COX2 by EIA,Confirmatory,20655211.0,
1228,501380,2,3,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for ovine COX1 to IC50 for human recombinant COX2",Other,20655211.0,
1229,501698,2,3,,103181002,2662,Inactive,,,,,"Antiinflammatory activity in rat assessed as inhibition of FCA-induced hypersensitivity at 20 and 50 mg/kg, po bid for 5 days",Other,20673717.0,
1230,503311,2,5,,103181002,2662,Unspecified,,,,,Antiproliferative activity against human PC3 cells at 10 uM after 120 hrs by MTT assay relative to DMSO,Other,16680159.0,
1231,504326,1,2,,49665790,2662,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1232,504326,1,2,,49665790,2662,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1233,504327,1,1,,17389545,2662,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
1234,504327,1,1,,26747363,2662,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
1235,504327,1,1,,49666478,2662,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
1236,504329,1,1,,49665790,2662,Inactive,227977143.0,23308111.0,,IC50,Discovery of Small Molecule Probes for H1N1 Influenza NS1A,Confirmatory,,
1237,504332,1,1,,17389545,2662,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
1238,504332,1,1,,26747363,2662,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
1239,504332,1,1,,49666478,2662,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
1240,504333,1,1,,49666478,2662,Inactive,6683500.0,29994.0,,Potency,qHTS Assay for Inhibitors of BAZ2B,Confirmatory,,
1241,504339,1,1,,49665790,2662,Inactive,162330054.0,,,Potency,qHTS Assay for Inhibitors of JMJD2A-Tudor Domain,Confirmatory,,
1242,504357,1,1,,49665790,2662,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1243,504357,1,1,,49665790,2662,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1244,504406,1,1,,49666478,2662,Inactive,15610945.0,886142.0,,,Inhibitors of Mycobacterium tuberculosis UDP-galactopyranose mutase (UGM) enzyme - High throughput screening using Fluorescent polarization assay Measured in Biochemical System Using Plate Reader - 2105-01_Inhibitor_SinglePoint_HTS_Activity_Set6,Screening,,
1245,504408,2,1,,49666478,2662,Inactive,,,,,Heat Shock Factor-1 (HSF-1) Measured in Cell-Based System Using Plate Reader - 2038-01_Activator_SinglePoint_HTS_Activity,Screening,,
1246,504411,1,1,,49665790,2662,Inactive,218931251.0,221955.0,,,"Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of human diacylglycerol lipase, beta (DAGLB)",Screening,,
1247,504414,1,1,,49665790,2662,Inactive,9966877.0,57120.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1248,504414,1,1,,49665790,2662,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1249,504423,1,1,,49665790,2662,Inactive,312275222.0,,,,C-LANA FP assay Measured in Biochemical System Using Plate Reader - 2117-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1250,504441,1,1,,49665790,2662,Inactive,6978787.0,25255.0,,,Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1251,504444,1,1,,49665790,2662,Inconclusive,224028257.0,4780.0,25.929000000000002,Potency,Nrf2 qHTS screen for inhibitors,Confirmatory,,
1252,504454,1,3,,49665790,2662,Inactive,4501969.0,154.0,,,HTS for Beta-2AR agonists via FAP method,Screening,,
1253,504462,1,1,,49665790,2662,Inactive,47132611.0,23192.0,,,uHTS fluorescent assay for identification of inhibitors of ATG4B,Screening,,
1254,504466,1,1,,49666478,2662,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
1255,504467,1,1,,49666478,2662,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
1256,504490,1,2,,49665790,2662,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction That Mediate GPCR Degradation and Recycling,Screening,,
1257,504523,1,1,,49665790,2662,Inactive,45269145.0,9817.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1258,504523,1,1,,49665790,2662,Inactive,224028257.0,4780.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1259,504558,1,1,,49665790,2662,Inactive,23893668.0,3783750.0,,,Inhibitors of Epstein-Barr LMP1 inducible NF-kappaB luciferase reporter Measured in Cell-Based System Using Plate Reader - 2122-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1260,504577,2,2,,49665790,2662,Inactive,6325022.0,855842.0,,,HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
1261,504582,2,1,,49665790,2662,Inactive,124809271.0,811941.0,,,In vivo-based yeast HTS to detect compounds rescuing yeast growth/survival of Plasmodium Falciparum HSP40-mediated toxicity Measured in Whole Organism System Using Plate Reader - 2120-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1262,504621,1,1,,49665790,2662,Inactive,124809506.0,811999.0,,,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1263,504634,1,1,,49665790,2662,Inactive,13236497.0,3361.0,,,Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
1264,504648,1,1,,49665790,2662,Inconclusive,,,29.0929,Potency,Nrf2 qHTS screen for inhibitors: counterscreen for cytotoxicity,Confirmatory,,
1265,504651,1,1,,49666478,2662,Inactive,4503383.0,1812.0,,,Potentiators of Human D1 Dopamine Receptor: qHTS,Screening,,
1266,504652,1,1,,49666478,2662,Inactive,4503383.0,1812.0,,,Antagonist of Human D 1 Dopamine Receptor: qHTS,Screening,,
1267,504660,1,1,,49666478,2662,Inactive,4503383.0,1812.0,,,Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS,Screening,,
1268,504690,1,3,,49665790,2662,Inactive,12381848.0,,,,uHTS identification of small molecule inhibitors of Plasmodium falciparum Glucose-6-phosphate dehydrogenase via a fluorescence intensity assay,Screening,,
1269,504692,2,2,,49665790,2662,Inactive,13236497.0,3361.0,,,Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
1270,504700,1,1,,49665790,2662,Inactive,46909587.0,5567.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
1271,504700,1,1,,49665790,2662,Inactive,47132585.0,5577.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
1272,504707,1,1,,49665790,2662,Inactive,6755076.0,18749.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
1273,504707,1,1,,49665790,2662,Inactive,115496662.0,615074.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
1274,504720,1,1,,49665790,2662,Inactive,16130689.0,947252.0,,,uHTS identification of MazEF TA System activators  via a fluorescence-based single-stranded RNase assay,Screening,,
1275,504734,1,1,,49665790,2662,Inactive,194068499.0,54106.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.,Screening,,
1276,504749,1,3,,17389545,2662,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1277,504749,1,3,1.0,17389545,2662,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1278,504749,1,3,2.0,17389545,2662,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1279,504749,1,3,3.0,17389545,2662,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1280,504749,1,3,4.0,17389545,2662,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1281,504749,1,3,5.0,17389545,2662,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1282,504749,1,3,6.0,17389545,2662,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1283,504749,1,3,7.0,17389545,2662,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1284,504749,1,3,8.0,17389545,2662,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1285,504749,1,3,9.0,17389545,2662,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1286,504749,1,3,10.0,17389545,2662,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1287,504749,1,3,11.0,17389545,2662,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1288,504749,1,3,12.0,17389545,2662,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1289,504749,1,3,13.0,17389545,2662,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1290,504749,1,3,14.0,17389545,2662,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1291,504749,1,3,15.0,17389545,2662,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1292,504749,1,3,16.0,17389545,2662,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1293,504749,1,3,17.0,17389545,2662,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1294,504749,1,3,18.0,17389545,2662,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1295,504749,1,3,19.0,17389545,2662,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1296,504749,1,3,20.0,17389545,2662,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1297,504749,1,3,21.0,17389545,2662,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1298,504749,1,3,22.0,17389545,2662,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1299,504749,1,3,23.0,17389545,2662,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1300,504749,1,3,24.0,17389545,2662,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1301,504749,1,3,25.0,17389545,2662,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1302,504749,1,3,26.0,17389545,2662,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1303,504749,1,3,27.0,17389545,2662,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1304,504749,1,3,28.0,17389545,2662,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1305,504749,1,3,29.0,17389545,2662,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1306,504749,1,3,30.0,17389545,2662,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1307,504749,1,3,31.0,17389545,2662,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1308,504749,1,3,32.0,17389545,2662,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1309,504749,1,3,33.0,17389545,2662,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1310,504749,1,3,34.0,17389545,2662,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1311,504749,1,3,35.0,17389545,2662,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1312,504749,1,3,36.0,17389545,2662,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1313,504749,1,3,37.0,17389545,2662,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1314,504749,1,3,38.0,17389545,2662,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1315,504749,1,3,39.0,17389545,2662,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1316,504749,1,3,40.0,17389545,2662,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1317,504749,1,3,41.0,17389545,2662,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1318,504749,1,3,42.0,17389545,2662,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1319,504749,1,3,43.0,17389545,2662,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1320,504749,1,3,44.0,17389545,2662,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1321,504749,1,3,45.0,17389545,2662,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1322,504749,1,3,46.0,17389545,2662,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1323,504749,1,3,47.0,17389545,2662,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1324,504749,1,3,48.0,17389545,2662,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1325,504749,1,3,49.0,17389545,2662,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1326,504749,1,3,50.0,17389545,2662,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1327,504749,1,3,51.0,17389545,2662,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1328,504749,1,3,52.0,17389545,2662,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1329,504749,1,3,53.0,17389545,2662,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1330,504749,1,3,54.0,17389545,2662,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1331,504749,1,3,55.0,17389545,2662,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1332,504749,1,3,56.0,17389545,2662,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1333,504749,1,3,57.0,17389545,2662,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1334,504749,1,3,58.0,17389545,2662,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1335,504749,1,3,59.0,17389545,2662,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1336,504749,1,3,60.0,17389545,2662,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1337,504749,1,3,61.0,17389545,2662,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1338,504766,2,1,,49665790,2662,Inactive,5016090.0,190.0,,,"Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)",Screening,,
1339,504770,1,2,,92124698,2662,Inactive,9657380.0,2612528.0,,,A screen for compounds that inhibit replication of Vibrio cholerae chromosome II,Other,,
1340,504775,1,1,,49665790,2662,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity,Screening,,
1341,504803,1,1,,49665790,2662,Inactive,121945198.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1),Screening,,
1342,504810,1,2,,49666478,2662,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
1343,504812,1,2,,49666478,2662,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
1344,504832,1,1,,17389545,2662,Active,,,15.1014,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
1345,504832,1,1,,49666478,2662,Inconclusive,,,11.6891,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
1346,504834,1,1,,17389545,2662,Active,,,5.3582,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
1347,504834,1,1,,49666478,2662,Active,,,5.8584,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
1348,504842,1,1,,49666478,2662,Inactive,4090929.0,10576.0,,Potency,Inhibitors of TCP-1 ring complex (TRiC) of Methanococcus maripaludis (MmCpn): qHTS,Confirmatory,,
1349,504845,1,1,,49665790,2662,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
1350,504847,1,1,,17389545,2662,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
1351,504847,1,1,,26747363,2662,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
1352,504847,1,1,,49665790,2662,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
1353,504865,1,1,,17389545,2662,Inconclusive,118600387.0,7398.0,44.6684,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
1354,504865,1,1,,26747363,2662,Inconclusive,118600387.0,7398.0,50.1187,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
1355,504884,1,2,,49665790,2662,Inactive,115347926.0,1175052.0,,,Inhibitors of Y. pestis Topo-I using cleavage product accumulation Measured in Biochemical System Using Plate Reader - 2123-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1356,504891,1,1,,49665790,2662,Inactive,5453898.0,5300.0,,Potency,qHTS Assay to Find Inhibitors of Pin1,Confirmatory,,
1357,504894,1,1,,49665790,2662,Inactive,553160.0,,,Potency,Activators of T cell receptors: qHTS campaign,Confirmatory,,
1358,504937,1,2,,49665790,2662,Inactive,179095.0,6609.0,,Potency,Inhibitors of Secretory Acid Sphingomyelinase (S-ASM): qHTS,Confirmatory,,
1359,510444,7,5,,103181002,2662,Active,754286265.0,443551.0,6.86,IC50,Inhibition of sheep COX1 by spectrophotometry,Confirmatory,20804197.0,
1360,510445,7,5,,103181002,2662,Active,3914304.0,443460.0,0.1,IC50,Inhibition of sheep COX2 by spectrophotometry,Confirmatory,20804197.0,
1361,510446,2,3,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for sheep COX1 to IC50 for sheep COX2",Other,20804197.0,
1362,510449,1,4,,103181002,2662,Unspecified,,,,,Cytotoxicity against human K562 cells assessed as inhibition of cell viability at 10 uM by MTT assay,Other,20804197.0,
1363,510450,1,4,,103181002,2662,Unspecified,,,,,Cytotoxicity against human NCI-H460 cells assessed as inhibition of cell viability at 10 uM by MTT assay,Other,20804197.0,
1364,510451,2,4,,103181002,2662,Unspecified,,,,,Cytotoxicity against human HDF cells assessed as inhibition of cell viability at 100 uM by MTT assay,Other,20804197.0,
1365,510452,4,2,,103181002,2662,Active,,,45.5,IC50,Cytotoxicity against human HT-29 cells by MTT assay,Confirmatory,20804197.0,
1366,512136,7,5,,103181002,2662,Active,3914304.0,443460.0,0.06,IC50,Inhibition of ovine COX2 by chemiluminescence assay,Confirmatory,20691338.0,
1367,512137,7,5,,103181002,2662,Active,754286265.0,443551.0,24.3,IC50,Inhibition of ovine COX1 by chemiluminescence assay,Confirmatory,20691338.0,
1368,512138,2,4,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for ovine COX1 to IC50 for ovine COX2",Other,20691338.0,
1369,514960,7,5,,103181002,2662,Active,5921840.0,808251.0,24.3,IC50,Inhibition of sheep COX1,Confirmatory,20650641.0,
1370,514961,7,3,,103181002,2662,Active,5921855.0,808252.0,0.06,IC50,Inhibition of sheep COX2,Confirmatory,20650641.0,
1371,514962,2,3,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for sheep COX1 to IC50 for COX2",Other,20650641.0,
1372,539226,5,2,,103181002,2662,Unspecified,,,,,Antiinflammatory activity against carrageenan-induced inflammation in Sprague-Dawley rat air pouch model assessed as reduction in PGE2 level administered 3 hrs after carrageenan challenge,Other,21055613.0,
1373,539312,5,2,,103181002,2662,Unspecified,,,,,Analgesic activity against carrageenan-induced thermal hyperalgesia in Sprague-Dawley rat assessed as paw withdrawal latency administered 1 to 3 hrs after carrageenan challenge,Other,21055613.0,
1374,539313,5,2,,103181002,2662,Unspecified,,,,,Antiinflammatory effect in complete Freund's adjuvant-induced Lewis rat arthritis model assessed as reduction in paw swelling by volume displacement plethysmometry,Other,21055613.0,
1375,540253,1,1,,49665790,2662,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
1376,540253,1,1,,49665790,2662,Inactive,5453555.0,5901.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
1377,540253,1,1,,49665790,2662,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
1378,540263,1,1,,49665790,2662,Inconclusive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
1379,540263,1,1,,49665790,2662,Inconclusive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
1380,540267,1,1,,49665790,2662,Inactive,,,,,Small Molecules that selectively kill Giardia lamblia: qHTS,Screening,,
1381,540275,1,1,,49666478,2662,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1,Screening,,
1382,540277,1,1,,49666478,2662,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Potentiators of the Vanilloid Receptor 1,Screening,,
1383,540295,1,1,,49665790,2662,Inactive,119508433.0,4160.0,,,TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R,Screening,,
1384,540299,1,2,,92124698,2662,Inactive,15607688.0,887529.0,,,A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis,Other,20850304.0,
1385,540303,1,1,,49665790,2662,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
1386,540303,1,1,,49665790,2662,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
1387,540303,1,1,,49665790,2662,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
1388,540308,1,1,,49665790,2662,Active,119508433.0,4160.0,,,Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R,Screening,,
1389,540317,1,1,,49665790,2662,Inactive,187960037.0,10951.0,,Potency,HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
1390,540336,1,1,,49665790,2662,Inactive,68474550.0,3639678.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1391,540336,1,1,,49665790,2662,Inactive,68488893.0,3646682.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1392,540364,1,2,,49665790,2662,Inactive,,2395.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the GAA850 frataxin (FXN) promoter,Screening,,
1393,547625,3,1,,103181002,2662,Unspecified,,,,,Antiinflammatory activity in Sprague-Dawley rat assessed as reduction of cotton pellet-induced dry weight of granuloma measured after 7 days,Other,20970223.0,
1394,547626,2,3,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as reduction of carrageenan-induced paw edema at 10 umol/kg, sc administered 1 hr before carrageenan challenge measured after 4 hrs by plethysmometry",Other,20970223.0,
1395,547627,2,3,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as reduction of carrageenan-induced paw edema at 10 umol/kg, sc administered 1 hr before carrageenan challenge measured after 4 hrs by plethysmometry relative to indomethacin",Other,20970223.0,
1396,547628,7,5,,103181002,2662,Active,3915797.0,5743.0,0.3,IC50,Inhibition of human recombinant COX2 after 45 mins,Confirmatory,20970223.0,
1397,547629,7,5,,103181002,2662,Unspecified,317373262.0,5742.0,100.0,IC50,Inhibition of human platelets COX1 after 2 mins,Confirmatory,20970223.0,
1398,547630,2,3,,103181002,2662,Unspecified,,,,,Selectivity ratio of IC50 for human recombinant COX2 to IC50 for human platelets COX1,Other,20970223.0,
1399,547631,2,3,,103181002,2662,Unspecified,,,,,"Gastrointestinal toxicity in albino rat assessed as ulcerogenicity at 30 uM/kg, po bid for 3 days measured after 6 hrs of last post dose",Other,20970223.0,
1400,552127,9,2,,103181002,2662,Unspecified,115449.0,759.0,50.0,Ki,Inhibition of human recombinant CA1 by stopped-flow CO2 hydration assay,Confirmatory,21208801.0,
1401,552128,9,2,,103181002,2662,Active,115456.0,760.0,0.021,Ki,Inhibition of human recombinant CA2 by stopped-flow CO2 hydration assay,Confirmatory,21208801.0,
1402,552129,9,2,,103181002,2662,Inconclusive,116241278.0,765.0,,Ki,Inhibition of human recombinant CA6 by stopped-flow CO2 hydration assay,Confirmatory,21208801.0,
1403,552130,9,1,,103181002,2662,Active,,,0.0342,Ki,Inhibition of Stylophora pistillata carbonic anhydrase by stopped-flow CO2 hydration assay,Confirmatory,21208801.0,
1404,552131,9,1,,103181002,2662,Active,,,0.69,Ki,Inhibition of Stylophora pistillata carbonic anhydrase 2 by stopped-flow CO2 hydration assay,Confirmatory,21208801.0,
1405,560389,5,2,,103181002,2662,Unspecified,,,,,Antibacterial activity against Francisella novicida infected in mouse RAW264.7 cells after 24 hrs by broth microdilution method,Other,19398640.0,
1406,560390,5,2,,103181002,2662,Unspecified,,,,,Antibacterial activity against Francisella tularensis LVS infected in mouse RAW264.7 cells after 48 hrs by broth microdilution method,Other,19398640.0,
1407,560391,5,2,,103181002,2662,Unspecified,,,,,Antibacterial activity against Francisella tularensis SchuS4 infected in mouse RAW264.7 cells after 24 hrs by broth microdilution method,Other,19398640.0,
1408,560392,2,5,,103181002,2662,Inactive,,,,,Antibacterial activity against Salmonella enterica serovar Typhimurium ATCC 14028 infected in mouse RAW264.7 cells at 64 ug/ml after 24 to 48 hrs by broth microdilution method,Other,19398640.0,
1409,560393,2,5,,103181002,2662,Inactive,,,,,Antibacterial activity against Escherichia coli ATCC 25922 infected in mouse RAW264.7 cells at 64 ug/ml after 24 to 48 hrs by broth microdilution method,Other,19398640.0,
1410,560397,4,2,,103181002,2662,Unspecified,,,,,Cytotoxicity against mouse RAW264.7 cells after 8 hrs by MTT assay,Other,19398640.0,
1411,560398,1,5,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for mouse RAW264.7 cells to MIC for Francisella novicida",Other,19398640.0,
1412,560399,2,5,,103181002,2662,Inactive,,,,,Antibacterial activity against Francisella novicida infected in mouse RAW264.7 cells at 64 ug/ml after 24 hrs by broth microdilution method in presence of 10% human serum albumin,Other,19398640.0,
1413,560400,2,5,,103181002,2662,Inactive,,,,,Antibacterial activity against Francisella novicida infected in mouse RAW264.7 cells at 64 ug/ml after 24 hrs by broth microdilution method in presence of 50% human serum albumin,Other,19398640.0,
1414,560401,2,5,,103181002,2662,Inactive,,,,,Antibacterial activity against Francisella novicida infected in mouse RAW264.7 cells at 64 ug/ml after 24 hrs by broth microdilution method in presence of 80% human serum albumin,Other,19398640.0,
1415,560403,2,5,,103181002,2662,Inactive,,,,,Antibacterial activity against Francisella novicida infected in mouse RAW264.7 cells after 24 hrs by broth microdilution method in presence of 10% fetal bovine serum,Other,19398640.0,
1416,560405,2,5,,103181002,2662,Inactive,,,,,Antibacterial activity against Francisella novicida infected in mouse RAW264.7 cells at 64 ug/ml after 24 hrs by broth microdilution method in presence of 80% fetal bovine serum,Other,19398640.0,
1417,560406,2,4,,103181002,2662,Inactive,,,,,Antibacterial activity against Francisella tularensis SchuS4 infected in human THP1 cells at 4 ug/ml after 24 hrs by broth microdilution method,Other,19398640.0,
1418,568555,7,5,,103181002,2662,Active,3915797.0,5743.0,0.04,IC50,Inhibition of human COX2,Confirmatory,21215625.0,
1419,568556,7,5,,103181002,2662,Active,317373262.0,5742.0,15.0,IC50,Inhibition of human COX1,Confirmatory,21215625.0,
1420,568557,2,3,,103181002,2662,Unspecified,,,,,Selectivity ratio of IC50 for human COX1 to IC50 for human COX2,Other,21215625.0,
1421,570436,4,7,,103181002,2662,Unspecified,754286265.0,443551.0,4.0,IC50,Inhibition of ovine purified COX1 after 20 mins,Confirmatory,21318094.0,
1422,570437,7,5,,103181002,2662,Active,548483.0,19225.0,0.03,IC50,Inhibition of mouse purified COX2 after 20 mins,Confirmatory,21318094.0,
1423,570438,7,5,,103181002,2662,Inconclusive,548483.0,19225.0,,IC50,Inhibition of COX2 in mouse LPS-stimulated RAW264.7 cells after 30 mins,Confirmatory,21318094.0,
1424,577526,6,5,,103181002,2662,Unspecified,115449.0,759.0,50.0,Ki,Inhibition of human carbonic anhydrase I by spectrophotometry at pH 7.5,Confirmatory,21251841.0,
1425,577527,6,5,,103181002,2662,Active,115456.0,760.0,0.021,Ki,Inhibition of human carbonic anhydrase II by spectrophotometry at pH 7.5,Confirmatory,21251841.0,
1426,577530,2,4,,103181002,2662,Active,,,0.128,Ki,Inhibition of Brucella suis carbonic anhydrase II by spectrophotometry at pH 8.3,Confirmatory,21251841.0,
1427,577531,2,4,,103181002,2662,Active,,,0.018000000000000002,Ki,Inhibition of Brucella suis carbonic anhydrase I by spectrophotometry at pH 8.3,Confirmatory,21251841.0,
1428,578495,7,5,,103181002,2662,Active,754286265.0,443551.0,8.1,IC50,Inhibition of ovine COX1 assessed as PGF2alpha level by EIA,Confirmatory,21349729.0,
1429,578496,7,5,,103181002,2662,Active,3914304.0,443460.0,0.05,IC50,Inhibition of ovine COX2 assessed as PGF2alpha level by EIA,Confirmatory,21349729.0,
1430,578497,4,2,,103181002,2662,Unspecified,,,10.0,IC50,Inhibition of potato 5-LOX assessed as hydroperoxides production by EIA,Confirmatory,21349729.0,
1431,578498,2,3,,103181002,2662,Unspecified,,,,,Selectivity ratio of IC50 for ovine COX1 to IC50 for ovine COX2,Other,21349729.0,
1432,579473,7,5,,103181002,2662,Active,754286265.0,443551.0,9.4,IC50,Inhibition of ovine COX-1 by fluorescence assay,Confirmatory,21316237.0,
1433,579474,7,5,,103181002,2662,Active,3915797.0,5743.0,0.03,IC50,Inhibition of human recombinant COX-2 by fluorescence assay,Confirmatory,21316237.0,
1434,579475,1,4,,103181002,2662,Unspecified,,,,,Selectivity index ratio of IC50 for ovine COX-1 to IC50 for human recombinant COX-2,Other,21316237.0,
1435,580340,2,7,,103181002,2662,Unspecified,,,,,Inhibition of COX1 at 30 uM,Other,21345672.0,
1436,580341,2,7,,103181002,2662,Unspecified,,,,,Inhibition of COX2 at 30 uM,Other,21345672.0,
1437,580343,7,2,,103181002,2662,Active,,,0.15,IC50,Inhibition of COX2,Confirmatory,21345672.0,
1438,585015,8,1,,103181002,2662,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus ATCC 29213,Other,20937780.0,
1439,585016,8,1,,103181002,2662,Unspecified,,,,,Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 335913,Other,20937780.0,
1440,585017,8,2,,103181002,2662,Unspecified,,,,,Antibacterial activity against Mycobacterium smegmatis MC2 155 ATCC,Other,20937780.0,
1441,585018,2,3,,103181002,2662,Unspecified,,,,,Inhibition of MDR1-mediated vincristine-resistance in Staphylococcus aureus ATCC 29213 assessed as fractional inhibitory concentration index after 24 to 48 hrs in presence of ampicillin,Other,20937780.0,
1442,585019,2,3,,103181002,2662,Unspecified,,,,,Inhibition of MDR1-mediated methicillin-resistant Staphylococcus aureus ATCC 335913 assessed as fractional inhibitory concentration index after 24 to 48 hrs in presence of ampicillin,Other,20937780.0,
1443,585020,2,3,,103181002,2662,Unspecified,,,,,Inhibition of MDR1-mediated Mycobacterium smegmatis MC2 155 ATCC assessed as fractional inhibitory concentration index after 24 to 48 hrs in presence of ampicillin,Other,20937780.0,
1444,585021,2,3,,103181002,2662,Unspecified,,,,,Inhibition of MDR1-mediated vincristine-resistance in Staphylococcus aureus ATCC 29213 assessed as fractional inhibitory concentration index after 24 to 48 hrs in presence of kanamycin,Other,20937780.0,
1445,585022,2,3,,103181002,2662,Unspecified,,,,,Inhibition of MDR1-mediated methicillin-resistant Staphylococcus aureus ATCC 335913 assessed as fractional inhibitory concentration index after 24 to 48 hrs in presence of kanamycin,Other,20937780.0,
1446,585023,2,3,,103181002,2662,Unspecified,,,,,Inhibition of MDR1-mediated Mycobacterium smegmatis MC2 155 ATCC assessed as fractional inhibitory concentration index after 24 to 48 hrs in presence of kanamycin,Other,20937780.0,
1447,585024,2,3,,103181002,2662,Unspecified,,,,,Inhibition of MDR1-mediated vincristine-resistance in Staphylococcus aureus ATCC 29213 assessed as fractional inhibitory concentration index after 24 to 48 hrs in presence of chloramphenicol,Other,20937780.0,
1448,585025,2,3,,103181002,2662,Unspecified,,,,,Inhibition of MDR1-mediated methicillin-resistant Staphylococcus aureus ATCC 335913 assessed as fractional inhibitory concentration index after 24 to 48 hrs in presence of chloramphenicol,Other,20937780.0,
1449,585026,2,3,,103181002,2662,Unspecified,,,,,Inhibition of MDR1-mediated Mycobacterium smegmatis MC2 155 ATCC assessed as fractional inhibitory concentration index after 24 to 48 hrs in presence of chloramphenicol,Other,20937780.0,
1450,585027,2,3,,103181002,2662,Unspecified,,,,,Inhibition of MDR1-mediated vincristine-resistance in Staphylococcus aureus ATCC 29213 assessed as fractional inhibitory concentration index after 24 to 48 hrs in presence of ciprofloxacin,Other,20937780.0,
1451,585028,2,3,,103181002,2662,Unspecified,,,,,Inhibition of MDR1-mediated methicillin-resistant Staphylococcus aureus ATCC 335913 assessed as fractional inhibitory concentration index after 24 to 48 hrs in presence of ciprofloxacin,Other,20937780.0,
1452,585029,2,3,,103181002,2662,Unspecified,,,,,Inhibition of MDR1-mediated Mycobacterium smegmatis MC2 155 ATCC assessed as fractional inhibitory concentration index after 24 to 48 hrs in presence of ciprofloxacin,Other,20937780.0,
1453,585030,3,3,,103181002,2662,Unspecified,,,,,Inhibition of MDR1 in Staphylococcus aureus ATCC 29213 assessed as increase in accumulation of ampicillin by EtBr efflux using flow cytometer,Other,20937780.0,
1454,585031,3,3,,103181002,2662,Unspecified,,,,,Inhibition of MDR1 in methicillin-resistant Staphylococcus aureus ATCC 335913 assessed as increase in accumulation of ampicillin by EtBr efflux using flow cytometer,Other,20937780.0,
1455,585217,3,3,,103181002,2662,Unspecified,,,,,Inhibition of MDR1 in Mycobacterium smegmatis ATCC MC2155 assessed as increase in accumulation of ampicillin by EtBr efflux using flow cytometer,Other,20937780.0,
1456,585218,3,3,,103181002,2662,Unspecified,,,,,Inhibition of MDR1 in Staphylococcus aureus ATCC 29213 assessed as increase in accumulation of kanamycin by EtBr efflux using flow cytometer,Other,20937780.0,
1457,585219,3,3,,103181002,2662,Unspecified,,,,,Inhibition of MDR1 in methicillin-resistant Staphylococcus aureus ATCC 335913 assessed as increase in accumulation of kanamycin by EtBr efflux using flow cytometer,Other,20937780.0,
1458,585220,3,3,,103181002,2662,Unspecified,,,,,Inhibition of MDR1 in Mycobacterium smegmatis ATCC MC2155 assessed as increase in accumulation of kanamycin by EtBr efflux using flow cytometer,Other,20937780.0,
1459,585221,3,3,,103181002,2662,Unspecified,,,,,Inhibition of MDR1 in Staphylococcus aureus ATCC 29213 assessed as increase in accumulation of chloramphenicol by EtBr efflux using flow cytometer,Other,20937780.0,
1460,585222,3,3,,103181002,2662,Unspecified,,,,,Inhibition of MDR1 in methicillin-resistant Staphylococcus aureus ATCC 335913 assessed as increase in accumulation of chloramphenicol by EtBr efflux using flow cytometer,Other,20937780.0,
1461,585223,3,3,,103181002,2662,Unspecified,,,,,Inhibition of MDR1 in Mycobacterium smegmatis ATCC MC2155 assessed as increase in accumulation of chloramphenicol by EtBr efflux using flow cytometer,Other,20937780.0,
1462,585224,3,3,,103181002,2662,Unspecified,,,,,Inhibition of MDR1 in Staphylococcus aureus ATCC 29213 assessed as increase in accumulation of ciprofloxacin by EtBr efflux using flow cytometer,Other,20937780.0,
1463,585225,3,3,,103181002,2662,Unspecified,,,,,Inhibition of MDR1 in methicillin-resistant Staphylococcus aureus ATCC 335913 assessed as increase in accumulation of ciprofloxacin by EtBr efflux using flow cytometer,Other,20937780.0,
1464,585226,3,3,,103181002,2662,Unspecified,,,,,Inhibition of MDR1 in Mycobacterium smegmatis ATCC MC2155 assessed as increase in accumulation of ciprofloxacin by EtBr efflux using flow cytometer,Other,20937780.0,
1465,587232,2,10,,103181002,2662,Unspecified,3915797.0,5743.0,,,Inhibition of human COX2 assessed as PGE2 formation at 46 nM by LC-MS-MS analysis,Other,21261296.0,
1466,587236,2,10,,103181002,2662,Unspecified,3915797.0,5743.0,,,Inhibition of human COX2 assessed as PGE2 formation at 33 uM by LC-MS-MS analysis,Other,21261296.0,
1467,587694,2,3,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity against xylene-induced ear edema in Kunming mouse assessed as reduction in ear swelling weight at 100 mg, ip administered 2 hrs post challenge measured after 30 mins",Other,21295381.0,
1468,587695,2,3,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity against xylene-induced ear edema in Kunming mouse assessed as reduction in ear swelling thickness at 100 mg, ip administered 2 hrs post challenge measured after 30 mins",Other,21295381.0,
1469,588210,2,4,,103181002,2662,Unspecified,,,,,Human drug-induced liver injury (DILI) modelling dataset from Ekins et al,Other,20843939.0,
1470,588211,2,3,,103181002,2662,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
1471,588212,2,3,,103181002,2662,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
1472,588213,2,3,,103181002,2662,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
1473,588334,1,1,,49665790,2662,Inactive,,,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Activator_SinglePoint_HTS_Activity,Screening,,
1474,588335,1,1,,49665790,2662,Inactive,,,,,Counterscreen for inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis: Absorbance-based biochemical high throughput Glycerophosphate Dehydrogenase-Triosephosphate Isomerase (GDH-TPI) full deck assay to identify assay artifacts,Screening,,
1475,588342,1,1,,49666478,2662,Inactive,160794.0,,,Potency,qHTS profiling assay for firefly luciferase inhibitor/activator using purifed enzyme and Km concentrations of substrates (counterscreen for miR-21 project),Confirmatory,,
1476,588352,1,2,,49665790,2662,Inactive,32307126.0,8202.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3),Screening,,
1477,588354,1,1,,49665790,2662,Inactive,22538455.0,8648.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1),Screening,,
1478,588358,1,2,,49665790,2662,Inactive,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies,Screening,,
1479,588391,1,1,,49665790,2662,Inactive,14790033.0,5034.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of Protein Disulfide Isomerase Measured in Biochemical System Using Plate Reader - 2137-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1480,588405,1,1,,49665790,2662,Inactive,78486550.0,171071.0,,,HTS Assay for Peg3 Promoter Inhibitors,Screening,,
1481,588413,1,2,,49665790,2662,Inactive,6009644.0,14632.0,,,uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay,Screening,,
1482,588436,1,1,,49665790,2662,Inactive,,,,,"Cholera Quorum: HTS for inducers of light production in the absence ofautoinducers using BH1578 (luxS deficient, cqsA deficient) Measured in Microorganism System Using Plate Reader - 2132-01_Agonist_SinglePoint_HTS_Activity",Screening,,
1483,588453,1,1,,49665790,2662,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
1484,588456,1,1,,49665790,2662,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
1485,588458,1,1,,49665790,2662,Inactive,4503351.0,1786.0,,,uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay,Screening,,
1486,588473,1,1,,49665790,2662,Inactive,30219.0,1393.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
1487,588473,1,1,,49665790,2662,Inactive,38349113.0,1395.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
1488,588475,1,2,,49665790,2662,Inactive,30219.0,1393.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
1489,588475,1,2,,49665790,2662,Inactive,38349113.0,1395.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
1490,588478,1,2,,124800994,2662,Inactive,4877999.0,51377.0,,,"A screen for small molecule inhibitors of the human deubiquitinating enzyme, UCH37",Other,,
1491,588489,1,1,,49665790,2662,Inactive,46367787.0,26986.0,,,uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay,Screening,,
1492,588492,1,1,,49665790,2662,Inactive,,,,,uHTS identification of small molecule modulators of myocardial damage,Screening,,
1493,588493,1,2,,49665790,2662,Inactive,16306916.0,10213.0,,,uHTS identification of inhibitors of Rpn11 in a Fluorescent Polarization assay,Screening,,
1494,588497,1,2,,49665790,2662,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,16604538.0,
1495,588497,1,2,,49665790,2662,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20035615.0,
1496,588497,1,2,,49665790,2662,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20938917.0,
1497,588499,1,3,,49665790,2662,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,16604538.0,
1498,588499,1,3,,49665790,2662,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20035615.0,
1499,588499,1,3,,49665790,2662,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20938917.0,
1500,588501,1,2,,49665790,2662,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,16604538.0,
1501,588501,1,2,,49665790,2662,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20035615.0,
1502,588501,1,2,,49665790,2662,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20938917.0,
1503,588511,1,2,,49666478,2662,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A),Screening,,
1504,588513,1,1,,17389545,2662,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule antagonists of estrogen receptor alpha signaling,Confirmatory,,
1505,588514,1,1,,17389545,2662,Inconclusive,348019627.0,2099.0,35.4813,Potency,qHTS assay for small molecule agonists of estrogen receptor alpha signaling,Confirmatory,,
1506,588515,1,1,,17389545,2662,Inconclusive,124375976.0,367.0,,Potency,qHTS assay for small molecule agonists of androgen receptor signaling,Confirmatory,,
1507,588516,1,1,,17389545,2662,Inconclusive,124375976.0,367.0,44.6684,Potency,qHTS assay for small molecule antagonists of androgen receptor signaling,Confirmatory,,
1508,588519,1,2,,92124698,2662,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
1509,588526,1,1,,17389545,2662,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule antagonists of farnesoid X receptor signaling,Confirmatory,,
1510,588527,1,1,,17389545,2662,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule agonists of farnesoid X receptor signaling,Confirmatory,,
1511,588532,1,1,,17389545,2662,Inconclusive,311348376.0,2908.0,28.1838,Potency,qHTS assay for small molecule agonists of glucocorticoid receptor signaling,Confirmatory,,
1512,588533,1,1,,17389545,2662,Inconclusive,311348376.0,2908.0,,Potency,qHTS assay for small molecule antagonists of glucocorticoid receptor signaling,Confirmatory,,
1513,588534,1,1,,17389545,2662,Inconclusive,216409690.0,5467.0,35.4813,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
1514,588535,1,1,,17389545,2662,Inconclusive,216409690.0,5467.0,35.4813,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
1515,588536,1,1,,17389545,2662,Inconclusive,216409692.0,5468.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
1516,588537,1,1,,17389545,2662,Inconclusive,216409692.0,5468.0,50.1187,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
1517,588541,1,1,,17389545,2662,Inconclusive,216409708.0,7421.0,,Potency,qHTS assay for small molecule antagonists of vitamin D receptor signaling,Confirmatory,,
1518,588543,1,1,,17389545,2662,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule agonists of vitamin D receptor signaling,Confirmatory,,
1519,588544,1,1,,17389545,2662,Inconclusive,325495497.0,6256.0,22.3872,Potency,qHTS assay for small molecule agonists of retinoid X receptor alpha signaling,Confirmatory,,
1520,588545,1,1,,17389545,2662,Inconclusive,189491771.0,7068.0,10.0,Potency,qHTS assay for small molecule agonists of thyroid hormone receptor beta signaling,Confirmatory,,
1521,588546,1,1,,17389545,2662,Inconclusive,325495497.0,6256.0,,Potency,qHTS assay for small molecule antagonists of retinoid X receptor alpha signaling,Confirmatory,,
1522,588547,1,1,,17389545,2662,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule antagonists of thyroid hormone receptor beta signaling,Confirmatory,,
1523,588549,1,1,,49665790,2662,Inactive,1781172.0,,,,Fluorescence polarization to screen for inhibitor that competite the binding of FadD28 to bisubstrate Measured in Biochemical System Using Plate Reader - 2147-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1524,588579,1,1,,17389545,2662,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1525,588579,1,1,,26747363,2662,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1526,588579,1,1,,49665790,2662,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1527,588590,1,1,,49665790,2662,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
1528,588591,1,1,,49665790,2662,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
1529,588621,1,1,,49665790,2662,Inactive,90652859.0,84867.0,,,uHTS identification of small molecule inhibitors of Striatal-Enriched Phosphatase via a fluorescence intensity assay,Screening,,
1530,588627,1,1,,49666478,2662,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that activate MrgX1 receptor signaling,Screening,,
1531,588664,1,2,,49665790,2662,Inactive,62362414.0,25.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
1532,588664,1,2,,49665790,2662,Inactive,68989256.0,9610.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
1533,588674,1,2,,49665790,2662,Inactive,,,,,Schnurri-3 Inhibitors: specific inducers of adult bone formation Measured in Cell-Based System Using Plate Reader - 2134-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1534,588675,1,1,,49666478,2662,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that allosterically activate MrgX1 receptor signaling,Screening,,
1535,588676,1,1,,49666478,2662,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that antagonize MrgX1 receptor signaling,Screening,,
1536,588689,1,1,,49665790,2662,Inactive,219689243.0,,,IC50,Primary and Confirmatory Screening for Flavivirus Genomic Capping Enzyme Inhibition,Confirmatory,,
1537,588692,2,1,,49665790,2662,Inactive,,,,,Luciferase Reporter Cell Based HTS to identify inhibitors of N-linked Glycosylation Measured in Cell-Based System Using Plate Reader - 2146-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1538,588726,1,2,,49665790,2662,Inactive,15607504.0,886474.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis,Screening,,
1539,588727,1,1,,49665790,2662,Inactive,,,,IC50,"A Cell-Based Confirmatory Screen for Compounds that Inhibit VEEV, TC-83",Confirmatory,,
1540,588795,1,1,,49665790,2662,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
1541,588814,1,3,,49665790,2662,Inactive,37622910.0,1128.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)",Screening,,
1542,588819,1,4,,49665790,2662,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).,Screening,,
1543,588834,2,1,,17389545,2662,Inconclusive,325651834.0,3757.0,50.1187,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
1544,588834,2,1,,144204686,2662,Inconclusive,325651834.0,3757.0,31.6228,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
1545,588850,1,1,,49665790,2662,Inactive,90421313.0,1080.0,,,uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay,Screening,,
1546,588852,1,3,,49665790,2662,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1),Screening,,
1547,588855,1,1,,49665790,2662,Inconclusive,18418623.0,4088.0,35.4813,Potency,qHTS for Inhibitors of TGF-b,Confirmatory,,
1548,588856,1,1,,49665790,2662,Inactive,,,22.3872,Potency,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,Confirmatory,,
1549,588998,1,9,,103181002,2662,Unspecified,206729914.0,10257.0,,,"Inhibitors of transporters of clinical importance in the absorption and disposition of drugs, MRP4",Other,20190787.0,
1550,592801,1,9,,103181002,2662,Unspecified,754286265.0,443551.0,,,Inhibition of ovine COX-1 at 100 uM after 2 mins by fluorescence assay,Other,21434686.0,
1551,592802,6,5,,103181002,2662,Active,3915797.0,5743.0,0.01,IC50,Inhibition of human recombinant COX-2 after 2 mins by fluorescence assay,Confirmatory,21434686.0,
1552,592803,5,5,,103181002,2662,Unspecified,67476665.0,2053.0,1.0,IC50,Inhibition of human recombinant soluble epoxide hydrolase after 10 mins by fluorescent-based assay,Confirmatory,21434686.0,
1553,592805,1,9,,103181002,2662,Unspecified,126407.0,240.0,,,Inhibition of human 5-lipoxygenase at 10 uM,Other,21434686.0,
1554,592808,1,3,,103181002,2662,Active,,,,,"Antiallodynic activity in Sprague-Dawley rat von Frey hair mechanically-stimulated neuropathic pain model assessed as reversal of LPS-induced decrease in paw withdrawal latency at 10 mg/kg, sc administered 60 mins before LPS challenge",Other,21434686.0,
1555,594414,6,5,,103181002,2662,Unspecified,754286265.0,443551.0,100.0,IC50,Inhibition of ovine COX1 after 5 mins by enzyme immunoassay,Confirmatory,21388719.0,
1556,594415,6,5,,103181002,2662,Active,3914304.0,443460.0,0.3,IC50,Inhibition of ovine COX2 after 5 mins by enzyme immunoassay,Confirmatory,21388719.0,
1557,594416,1,5,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for ovine COX1 to IC50 for ovine COX2",Other,21388719.0,
1558,598520,6,5,,103181002,2662,Unspecified,754286265.0,443551.0,50.0,IC50,Inhibition of ovine COX1 assessed as PGF2alpha production from PGH2 after 5 mins by enzyme immunoassay,Confirmatory,21570309.0,
1559,598521,6,5,,103181002,2662,Active,3914304.0,443460.0,0.3,IC50,Inhibition of ovine COX2 assessed as PGF2alpha production from PGH2 after 5 mins by enzyme immunoassay,Confirmatory,21570309.0,
1560,598524,1,4,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for ovine COX1 to IC50 for ovine COX2",Other,21570309.0,
1561,600504,1,3,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for ovine COX1 to IC50 for ovine COX2",Other,19447036.0,
1562,600505,6,5,,103181002,2662,Active,754286265.0,443551.0,24.3,IC50,Inhibition of ovine COX1 by chemiluminescent assay,Confirmatory,19447036.0,
1563,600506,6,5,,103181002,2662,Active,3914304.0,443460.0,0.06,IC50,Inhibition of ovine COX2 by chemiluminescent assay,Confirmatory,19447036.0,
1564,602123,1,1,,49665790,2662,Inactive,16128424.0,945085.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Escherichia coli DNA-binding ATP-dependent protease La (eLon),Screening,,
1565,602141,1,1,,49665790,2662,Inactive,,,,,uHTS determination of small molecule cytotoxicity in a fluorescence assay to identify cystic fibrosis induced NFkb Inhibitors,Screening,,
1566,602162,1,1,,49665790,2662,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set,Screening,,
1567,602163,1,1,,49665790,2662,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify activators of Methionine sulfoxide reductase A (MsrA),Screening,,
1568,602179,1,2,,49665790,2662,Inactive,89573979.0,3417.0,,Potency,qHTS for Inhibitors of mutant isocitrate dehydrogenase 1 (IDH1): qHTS,Confirmatory,,
1569,602229,1,1,,49665790,2662,Inactive,216409728.0,10002.0,,,"Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)",Screening,,
1570,602233,1,1,,49665790,2662,Inactive,115503961.0,4357161.0,,Potency,qHTS Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
1571,602244,1,2,,49665790,2662,Inactive,5730106.0,10663.0,,,uHTS identification of CXCR6 Inhibitors in a B-arrestin luminescence assay,Screening,,
1572,602247,1,2,,49665790,2662,Inactive,,,,,Full deck counterscreen for positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
1573,602248,1,2,,49665790,2662,Inactive,,,,,Full deck counterscreen for agonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
1574,602250,1,2,,49665790,2662,Inactive,,,,,Full deck counterscreen for antagonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective inhibitors and assay artifacts using the parental CHOK1 cell line,Screening,,
1575,602252,1,1,,49665790,2662,Inactive,62868213.0,57120.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1576,602252,1,1,,49665790,2662,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1577,602261,1,1,,49665790,2662,Inactive,41872631.0,2194.0,,,uHTS identification of small molecule inhibitors of  the thioesterase domain of fatty acid synthase via a fluorescence intensity assay,Screening,,
1578,602274,1,2,,49665790,2662,Inactive,,,,,uHTS luminescent assay for identification of compounds that enhance the survival of human induced pluripotent stem cells when cultured as single cells,Screening,,
1579,602281,1,1,,49665790,2662,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
1580,602281,1,1,,49665790,2662,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
1581,602310,1,2,,49665790,2662,Inactive,13399304.0,60489.0,,Potency,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,Confirmatory,,
1582,602313,1,1,,49665790,2662,Inactive,22907044.0,200316.0,,Potency,qHTS for Inhibitors of Vif-A3F Interactions: qHTS,Confirmatory,,
1583,602314,1,2,,92124698,2662,Inactive,151220867.0,,,,A screen for compounds that modulate the activity of the Staphylococcus aureus MgrA protein,Other,,
1584,602329,1,1,,49665790,2662,Inactive,216548193.0,8438.0,,,Identification of inhibitors of RAD54 Measured in Biochemical System Using Plate Reader - 2159-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1585,602332,1,1,,17389545,2662,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1586,602332,1,1,,26747363,2662,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1587,602332,1,1,,49665790,2662,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1588,602340,1,2,,49665790,2662,Inactive,,,,,HTS for suppressors of simvastatin-induced mytoxicity in differentiated C2C12 cells Measured in Cell-Based System Using Plate Reader - 2112-01_Suppressor_SinglePoint_HTS_Activity,Screening,,
1589,602342,2,1,,49665790,2662,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1590,602346,1,1,,49665790,2662,Inactive,9629361.0,155459.0,,,Identification of VIF Inhibitors Measured in Cell-Based System Using Imaging - 2108-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1591,602363,1,1,,49665790,2662,Inactive,,,,,Whole cell Yeast HTS to identify compounds modulating the fidelity of the start codon recognition in eukaryotes. Measured in Whole Organism System Using Plate Reader - 2155-01_Other_SinglePoint_HTS_Activity,Screening,,
1592,602393,1,1,,49665790,2662,Inactive,291463269.0,20586.0,,,Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1593,602396,1,2,,49665790,2662,Inactive,4504343.0,2494.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2),Screening,,
1594,602399,1,2,,49665790,2662,Inactive,15927174.0,,,,uHTS identification of inhibitors of NadD in a Colorimetric assay,Screening,,
1595,602405,1,1,,49665790,2662,Inactive,75495260.0,,,,PgID: DNTB colorimetric HTS to detect inhibitor of PgID Measured in Biochemical System Using Plate Reader - 2164-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1596,602410,1,1,,49665790,2662,Inactive,11093520.0,3777.0,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3,Screening,,
1597,602429,1,1,,49665790,2662,Inactive,1762973.0,7341.0,,,uHTS identification of SUMO1-mediated protein-protein interactions,Screening,,
1598,602438,1,1,,49665790,2662,Inactive,160877737.0,,,,uHTS identification of modulators of interaction between CendR and NRP-1 using Fluorescence Polarization assay,Screening,,
1599,602440,1,1,,49665790,2662,Inactive,262118306.0,123228.0,,,uHTS Fluorescent Assay Using Nedd8 Protein Substrate for Identification of Inhibitors of Sentrin-Specific Protease 8 (SENP8),Screening,,
1600,602449,1,2,,49665790,2662,Inactive,,,,,uHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay,Screening,,
1601,602481,1,1,,49665790,2662,Inactive,378544807.0,,,,Mycobacterium tuberculosis BioA enzyme inhibitor Measured in Biochemical System Using Plate Reader - 2163-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1602,603428,6,5,,103181002,2662,Active,754286265.0,443551.0,7.7,IC50,Inhibition of ovine COX1 by enzyme immuno assay,Confirmatory,21641217.0,
1603,603429,6,5,,103181002,2662,Active,3915797.0,5743.0,0.07,IC50,Inhibition of human recombinant COX2 by enzyme immuno assay,Confirmatory,21641217.0,
1604,603504,4,2,,103181002,2662,Unspecified,,,,,Antiinflammatory activity in po dosed rat assessed as inhibition of carrageenan-induced foot paw edema after 3 hrs,Other,21641217.0,
1605,611752,1,8,,103181002,2662,Unspecified,754286265.0,443551.0,,,Inhibition of sheep COX-1 at 20 uM by cayman colorimetric assay,Other,21724403.0,
1606,611753,1,8,,103181002,2662,Unspecified,3914304.0,443460.0,,,Inhibition of sheep COX-2 at 20 uM by cayman colorimetric assay,Other,21724403.0,
1607,611754,1,3,,103181002,2662,Unspecified,,,,,Selectivity ratio of inhibition for sheep COX-1 to inhibition for sheep COX-2 at 20 uM,Other,21724403.0,
1608,612057,6,5,,103181002,2662,Active,317373262.0,5742.0,7.0,IC50,Inhibition of human whole blood COX-1 assessed as production of TXB2 after 24 hrs by EIA,Confirmatory,21570308.0,
1609,612058,6,5,,103181002,2662,Active,3915797.0,5743.0,0.19,IC50,Inhibition of human whole blood COX-2 assessed as production of PGE2 after 24 hrs by EIA,Confirmatory,21570308.0,
1610,612059,3,3,,103181002,2662,Unspecified,,,90.0,EC50,Membrane permeabilization activity assessed as release of calcein from liposomes after 10 mins by fluorescence assay,Confirmatory,21570308.0,
1611,612060,1,3,,103181002,2662,Unspecified,,,,,Selectivity ratio of IC50 for human COX-1 to IC50 for human COX-2,Other,21570308.0,
1612,612725,6,5,,103181002,2662,Unspecified,115449.0,759.0,50.0,Ki,Inhibition of human recombinant carbonic anhydrase 1 at pH 7.5 by stopped flow CO2 hydration assay,Confirmatory,21757360.0,
1613,612726,6,5,,103181002,2662,Active,115456.0,760.0,0.021,Ki,Inhibition of human recombinant carbonic anhydrase 2 at pH 7.5 by stopped flow CO2 hydration assay,Confirmatory,21757360.0,
1614,612731,3,2,,103181002,2662,Active,,,5.83,Ki,Inhibition of Salmonella Typhimurium recombinant carbonic anhydrase 1 at pH 8.3 by stopped flow CO2 hydration assay,Confirmatory,21757360.0,
1615,612732,3,2,,103181002,2662,Active,,,6.11,Ki,Inhibition of Salmonella Typhimurium recombinant carbonic anhydrase 2 at pH 8.3 by stopped flow CO2 hydration assay,Confirmatory,21757360.0,
1616,613459,1,8,,103181002,2662,Unspecified,48429227.0,6774.0,,,Inhibition of STAT3 SH2 domain phosphorylation at Tyr705 in COX2-negative human HCT116 cells after 1 hr by Western blot analysis,Other,21678971.0,
1617,613460,1,4,,103181002,2662,Inactive,,,,,Inhibition of STAT3 protein expression in COX2-negative human HCT116 cells at 10 to 50 uM after 1 hr by Western blot analysis,Other,21678971.0,
1618,613461,1,8,,103181002,2662,Active,48429227.0,6774.0,,,Inhibition of IL-6-induced STAT3 phosphorylation in human PANC1 cells at 25 to 50 M pretreated 2 hrs prior to IL-6 challenge measured after 30 mins,Other,21678971.0,
1619,613462,1,8,,103181002,2662,Inactive,48429227.0,6774.0,,,Inhibition of interferon gamma induced STAT3 phosphorylation in human PANC1 cells at 25 to 50 M pretreated 2 hrs prior to interferon-gamma challenge measured after 30,Other,21678971.0,
1620,613463,3,2,,103181002,2662,Active,,,43.3,IC50,Anticancer activity against human HCT116 cells after 72 hrs by MTT assay,Confirmatory,21678971.0,
1621,620685,5,5,,103181002,2662,Unspecified,115449.0,759.0,50.0,Ki,Inhibition of human carbonic anhydrase 1-catalyzed CO2 hydration activity by stopped flow assay,Confirmatory,21852133.0,
1622,620686,5,5,,103181002,2662,Active,115456.0,760.0,0.021,Ki,Inhibition of human carbonic anhydrase 2-catalyzed CO2 hydration activity by stopped flow assay,Confirmatory,21852133.0,
1623,620687,5,5,,103181002,2662,Active,83300925.0,768.0,0.016,Ki,Inhibition of human carbonic anhydrase 9-catalyzed CO2 hydration activity by stopped flow assay,Confirmatory,21852133.0,
1624,620688,5,5,,103181002,2662,Active,5915866.0,771.0,0.018000000000000002,Ki,Inhibition of human carbonic anhydrase 12-catalyzed CO2 hydration activity by stopped flow assay,Confirmatory,21852133.0,
1625,620689,1,3,,103181002,2662,Unspecified,,,,,Selectivity ratio of Ki for human carbonic anhydrase 1 to Ki for human recombinant carbonic anhydrase 9 catalytic domain,Other,21852133.0,
1626,620690,1,3,,103181002,2662,Unspecified,,,,,Selectivity ratio of Ki for human carbonic anhydrase 1 to Ki for human recombinant carbonic anhydrase 12 catalytic domain,Other,21852133.0,
1627,620691,1,3,,103181002,2662,Unspecified,,,,,Selectivity ratio of Ki for human carbonic anhydrase 2 to Ki for human recombinant carbonic anhydrase 9 catalytic domain,Other,21852133.0,
1628,620692,1,3,,103181002,2662,Unspecified,,,,,Selectivity ratio of Ki for human carbonic anhydrase 2 to Ki for human recombinant carbonic anhydrase 12 catalytic domain,Other,21852133.0,
1629,622470,4,3,,103181002,2662,Unspecified,,,,,Antiinflammatory activity in po dosed rat assessed as inhibition of carrageenan-induced hind paw edema measured after 3 hrs post dose,Other,21890358.0,
1630,622472,1,5,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for ovine COX1 to IC50 for ovine COX2",Other,21890358.0,
1631,622474,6,5,,103181002,2662,Active,754286265.0,443551.0,7.7,IC50,Inhibition of ovine COX1 by enzyme immuno assay,Confirmatory,21890358.0,
1632,622556,6,5,,103181002,2662,Active,3914304.0,443460.0,0.07,IC50,Inhibition of ovine COX2 by enzyme immuno assay,Confirmatory,21890358.0,
1633,623146,1,3,,103181002,2662,Unspecified,,,,,Inhibition of sodium arachidonate-induced PGE2 production in human SUM149 cells assessed as PGE2 level per 1000 cells at 0.1 uM preincubated for 2 hrs before sodium arachidonate challenge measured after 2 hrs by competitive EIA (Rvb = 3.15 +/- 0.19 pg/mL),Other,21903394.0,
1634,623147,1,3,,103181002,2662,Unspecified,,,,,Inhibition of sodium arachidonate-induced PGE2 production in human SUM149 cells assessed as PGE2 level per 1000 cells at 1 uM preincubated for 2 hrs before sodium arachidonate challenge measured after 2 hrs by competitive EIA (Rvb = 3.15 +/- 0.19 pg/mL),Other,21903394.0,
1635,623148,1,3,,103181002,2662,Unspecified,,,,,Inhibition of sodium arachidonate-induced PGE2 production in human SUM149 cells assessed as PGE2 level per 1000 cells at 10 uM preincubated for 2 hrs before sodium arachidonate challenge measured after 2 hrs by competitive EIA (Rvb = 3.15 +/- 0.19 pg/mL),Other,21903394.0,
1636,623149,1,3,,103181002,2662,Unspecified,,,,,Inhibition of sodium arachidonate-induced PGE2 production in human SUM190 cells assessed as PGE2 level per 1000 cells at 0.1 uM preincubated for 2 hrs before sodium arachidonate challenge measured after 2 hrs by competitive EIA (Rvb = 6.43 +/- 1.87 pg/mL),Other,21903394.0,
1637,623150,1,3,,103181002,2662,Unspecified,,,,,Inhibition of sodium arachidonate-induced PGE2 production in human SUM190 cells assessed as PGE2 level per 1000 cells at 1 uM preincubated for 2 hrs before sodium arachidonate challenge measured after 2 hrs by competitive EIA (Rvb = 6.43 +/- 1.87 pg/mL),Other,21903394.0,
1638,623151,1,3,,103181002,2662,Unspecified,,,,,Inhibition of sodium arachidonate-induced PGE2 production in human SUM190 cells assessed as PGE2 level per 1000 cells at 10 uM preincubated for 2 hrs before sodium arachidonate challenge measured after 2 hrs by competitive EIA (Rvb = 6.43 +/- 1.87 pg/mL),Other,21903394.0,
1639,623870,1,1,,49665790,2662,Inactive,2702319.0,405.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1640,623870,1,1,,49665790,2662,Inactive,5454102.0,10460.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1641,623877,1,1,,49665790,2662,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A),Screening,,
1642,623901,1,1,,49665790,2662,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Activator_SinglePoint_HTS_Activity,Screening,,
1643,624030,1,2,,17389545,2662,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
1644,624031,1,2,,17389545,2662,Inactive,,,,Potency,S16 Schwann cell viability assay (CellTiter-Glo assay),Confirmatory,,
1645,624032,1,2,,17389545,2662,Inconclusive,8393992.0,24660.0,36.1254,Potency,S16 Schwann cell PMP22 intronic element firefly luciferase assay,Confirmatory,,
1646,624037,1,3,,49665790,2662,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1647,624038,1,3,,49665790,2662,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1648,624040,1,3,,49665790,2662,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1649,624044,1,2,,17389545,2662,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element beta-lactamase assay,Confirmatory,,
1650,624101,1,2,,85789333,2662,Inactive,62203298.0,3417.0,,,Development of  IDH1/2 inhibitors (CTD2project) Measured in Biochemical System Using Plate Reader - 2107-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1651,624125,1,4,,49665790,2662,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1652,624126,1,3,,49665790,2662,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1653,624127,1,2,,49665790,2662,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1654,624137,1,1,,85789333,2662,Inactive,881546.0,3400.0,,,SMM ID4 Measured in Biochemical System Using Small Molecule MicroArray - 2128-01_Other_SinglePoint_HTS_Activity,Screening,,
1655,624156,1,1,,85789333,2662,Inactive,,,,,Fluorescence Cell-Based Primary  HTS to Identify Reactive Oxygen Species Inducers in Cancer Cells Measured in Cell-Based System Using Plate Reader and Imaging Combination - 2044-01_Activator_SinglePoint_HTS_Activity,Screening,,
1656,624168,1,1,,49665790,2662,Inactive,47678551.0,9215.0,,,uHTS identification of small molecule activators of alpha dystroglycan glycosylation,Screening,,
1657,624169,1,1,,49665790,2662,Active,27753985.0,15558.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A),Screening,,
1658,624170,1,1,,17389545,2662,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
1659,624170,1,1,,49665790,2662,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
1660,624171,1,1,,49665790,2662,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators,Confirmatory,,
1661,624172,1,1,,17389545,2662,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
1662,624172,1,1,,49665790,2662,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
1663,624173,1,3,,17389545,2662,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
1664,624173,1,3,,49665790,2662,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
1665,624173,1,3,,124890934,2662,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
1666,624178,1,1,,49665790,2662,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
1667,624202,1,1,,49665790,2662,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
1668,624204,1,2,,49665790,2662,Inactive,7657550.0,,,,"uHTS identification of small molecule inhibitors of the catalytic domain of the SUMO protease, SENP1 in a FRET assay",Screening,,
1669,624246,1,1,,49665790,2662,Inactive,343478176.0,2078.0,,Potency,qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction,Confirmatory,,
1670,624256,1,2,,49665790,2662,Inactive,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with MLPCN compound set,Screening,,
1671,624260,1,1,,85789333,2662,Inactive,109633019.0,7468.0,,,NSD2 Inhibitors Measured in Biochemical System Using Plate Reader - 2115-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1672,624263,1,1,,49665790,2662,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
1673,624263,1,1,,49665790,2662,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
1674,624267,1,2,,49665790,2662,Inactive,4506537.0,8767.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
1675,624267,1,2,,49665790,2662,Inactive,119603173.0,64127.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
1676,624268,1,3,,49665790,2662,Inactive,71746704.0,3662741.0,,,Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of Trypanosoma brucei methionyl tRNA synthetase (MetRS),Screening,,
1677,624288,1,1,,49665790,2662,Inactive,52000961.0,2778.0,,Potency,"qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS",Confirmatory,,
1678,624296,1,1,,17389545,2662,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
1679,624296,1,1,,49665790,2662,Inconclusive,7705682.0,51053.0,14.581,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
1680,624297,1,1,,17389545,2662,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
1681,624297,1,1,,49665790,2662,Inactive,7705682.0,51053.0,31.6228,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
1682,624304,1,2,,49665790,2662,Inactive,25148072.0,177343.0,,,uHTS identification of SKN-1 Inhibitors in a fluoresence assay,Screening,,
1683,624330,1,2,,49665790,2662,Inactive,21361397.0,29127.0,,IC50,Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP -  Primary and Confirmatory Screens,Confirmatory,,
1684,624349,1,2,,92124698,2662,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1685,624349,1,2,,92307997,2662,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1686,624349,1,2,,92308914,2662,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1687,624349,1,2,,121362558,2662,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1688,624352,1,1,,49665790,2662,Inactive,40254439.0,2034.0,,,uHTS identification of HIF-2a Inhibitors in a luminesence assay,Screening,,
1689,624354,1,1,,49665790,2662,Inactive,224494019.0,8795.0,,,uHTS identification of Caspase-8 TRAIL sensitizers in a luminesence assay,Screening,,
1690,624377,1,1,,49665790,2662,Inactive,351542238.0,50807.0,,,"Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 (ASAP1)",Screening,,
1691,624380,1,1,,49665790,2662,Active,117940060.0,4988.0,,,Counterscreen for agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A): Luminescence-based cell-based high throughput screening assay to identify agonists of the mu 1 opioid receptor (OPRM1),Screening,,
1692,624381,1,1,,49665790,2662,Active,27753985.0,15558.0,,,Luminescence-based cell-based high throughput confirmation assay for agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A),Screening,,
1693,624414,1,1,,49665790,2662,Inactive,10092597.0,57192.0,,,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
1694,624415,1,2,,49665790,2662,Inactive,10092597.0,57192.0,,,qHTS for Inhibitors of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
1695,624416,1,1,,49665790,2662,Inactive,9629363.0,155971.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify small molecules that bind to the HIV-1-gp120 binding antibody, PG9",Screening,,
1696,624417,1,1,,49665790,2662,Inconclusive,1724069.0,2740.0,28.1838,Potency,qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode),Confirmatory,,
1697,624418,1,1,,49665790,2662,Inactive,,,,Potency,qHTS of GLP-1 Receptor Inverse Agonists: Cytotox Screen,Confirmatory,,
1698,624463,1,1,,49665790,2662,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists,Other,,
1699,624464,1,1,,49665790,2662,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators,Other,,
1700,624465,1,1,,49665790,2662,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists,Other,,
1701,624466,1,3,,49665790,2662,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
1702,624467,1,1,,49665790,2662,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
1703,624476,1,1,,124890934,2662,Inconclusive,,,60.5378,Potency,Cytotoxicity counterscreen for NFkB agonists and antagonists,Confirmatory,,
1704,624478,1,1,,124890934,2662,Inactive,,,,Potency,qHTS Assay for Identification of Small Molecule Agonists for NFkB Signaling Pathway.,Confirmatory,,
1705,624479,1,1,,124890934,2662,Active,,,43.2324,Potency,qHTS Assay for Identification of Small Molecule Antagonists for NFkB Signaling Pathway.,Confirmatory,,
1706,624483,1,1,,49665790,2662,Inactive,,,,,Counterscreen of compound fluorescence effects on High-throughput multiplex microsphere screening for inhibitors of toxin protease,Screening,,
1707,625144,5,5,,103181002,2662,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
1708,625145,4,7,,103181002,2662,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
1709,625146,5,5,,103181002,2662,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
1710,625147,4,7,,103181002,2662,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
1711,625148,4,7,,103181002,2662,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
1712,625149,4,7,,103181002,2662,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
1713,625150,5,5,,103181002,2662,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
1714,625151,4,7,,103181002,2662,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1715,625152,4,7,,103181002,2662,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1716,625153,4,7,,103181002,2662,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1717,625154,4,7,,103181002,2662,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1718,625155,4,7,,103181002,2662,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1719,625156,1,9,,103181002,2662,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
1720,625157,6,2,,103181002,2662,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
1721,625158,3,4,,103181002,2662,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
1722,625159,5,5,,103181002,2662,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
1723,625160,1,9,,103181002,2662,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
1724,625161,4,7,,103181002,2662,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
1725,625162,4,7,,103181002,2662,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
1726,625163,4,7,,103181002,2662,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
1727,625164,1,6,,103181002,2662,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
1728,625165,3,4,,103181002,2662,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
1729,625166,3,4,,103181002,2662,Active,,,9.26,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
1730,625167,5,5,,103181002,2662,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
1731,625168,4,7,,103181002,2662,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
1732,625169,1,6,,103181002,2662,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
1733,625170,3,4,,103181002,2662,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
1734,625171,4,7,,103181002,2662,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
1735,625172,4,7,,103181002,2662,Active,75071465.0,,18.109,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
1736,625173,5,5,,103181002,2662,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
1737,625174,5,5,,103181002,2662,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
1738,625175,5,5,,103181002,2662,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
1739,625176,1,9,,103181002,2662,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
1740,625177,5,5,,103181002,2662,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
1741,625178,5,5,,103181002,2662,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
1742,625179,1,9,,103181002,2662,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
1743,625180,5,5,,103181002,2662,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
1744,625181,5,5,,103181002,2662,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
1745,625182,5,5,,103181002,2662,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
1746,625183,5,5,,103181002,2662,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
1747,625184,5,5,,103181002,2662,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1748,625185,5,5,,103181002,2662,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1749,625186,5,5,,103181002,2662,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1750,625187,5,5,,103181002,2662,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1751,625188,1,9,,103181002,2662,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
1752,625189,1,7,,103181002,2662,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
1753,625190,4,5,,103181002,2662,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
1754,625191,4,7,,103181002,2662,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
1755,625192,4,7,,103181002,2662,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
1756,625193,5,5,,103181002,2662,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
1757,625194,4,7,,103181002,2662,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
1758,625195,4,7,,103181002,2662,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
1759,625196,5,6,,103181002,2662,Active,803374855.0,140.0,24.622,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
1760,625197,3,4,,103181002,2662,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
1761,625198,4,7,,103181002,2662,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
1762,625199,4,7,,103181002,2662,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
1763,625200,4,7,,103181002,2662,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
1764,625201,4,7,,103181002,2662,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
1765,625202,4,7,,103181002,2662,Active,613504690.0,151.0,1.516,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
1766,625203,4,7,,103181002,2662,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
1767,625204,4,7,,103181002,2662,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
1768,625205,4,7,,103181002,2662,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
1769,625206,4,7,,103181002,2662,Active,461604.0,155.0,16.124000000000002,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
1770,625207,4,7,,103181002,2662,Active,128616.0,6530.0,7.308,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
1771,625208,5,5,,103181002,2662,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
1772,625209,4,7,,103181002,2662,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
1773,625210,3,4,,103181002,2662,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
1774,625211,1,6,,103181002,2662,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
1775,625212,3,4,,103181002,2662,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
1776,625213,4,7,,103181002,2662,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
1777,625214,1,9,,103181002,2662,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
1778,625215,3,4,,103181002,2662,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
1779,625216,3,4,,103181002,2662,Active,,,24.601,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
1780,625217,4,7,,103181002,2662,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
1781,625218,4,7,,103181002,2662,Unspecified,112816.0,3358.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
1782,625219,3,4,,103181002,2662,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
1783,625220,4,7,,103181002,2662,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
1784,625221,4,7,,103181002,2662,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
1785,625222,4,7,,103181002,2662,Active,400630.0,6532.0,6.276,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
1786,625223,4,7,,103181002,2662,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
1787,625224,3,4,,103181002,2662,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
1788,625225,3,4,,103181002,2662,Active,,,16.854,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
1789,625226,4,7,,103181002,2662,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
1790,625227,4,7,,103181002,2662,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
1791,625228,4,7,,103181002,2662,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
1792,625229,5,5,,103181002,2662,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
1793,625230,1,6,,103181002,2662,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
1794,625231,4,7,,103181002,2662,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
1795,625232,1,9,,103181002,2662,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
1796,625233,4,7,,103181002,2662,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
1797,625234,3,4,,103181002,2662,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
1798,625235,4,7,,103181002,2662,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
1799,625236,5,5,,103181002,2662,Active,115456.0,760.0,0.18100000000000002,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
1800,625237,4,7,,103181002,2662,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
1801,625238,4,7,,103181002,2662,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
1802,625239,4,7,,103181002,2662,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
1803,625240,1,9,,103181002,2662,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
1804,625241,4,7,,103181002,2662,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
1805,625242,4,7,,103181002,2662,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
1806,625243,5,5,,103181002,2662,Active,317373262.0,5742.0,0.723,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
1807,625244,5,5,,103181002,2662,Active,3915797.0,5743.0,0.484,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
1808,625245,5,5,,103181002,2662,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1809,625246,1,9,,103181002,2662,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
1810,625247,5,5,,103181002,2662,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1811,625248,5,5,,103181002,2662,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1812,625249,5,5,,103181002,2662,Active,84028191.0,1565.0,1.0,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1813,625250,5,5,,103181002,2662,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1814,625251,5,5,,103181002,2662,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
1815,625252,4,7,,103181002,2662,Active,118228.0,1812.0,27.994,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
1816,625253,4,7,,103181002,2662,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1817,625254,4,7,,103181002,2662,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1818,625255,4,7,,103181002,2662,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1819,625256,4,7,,103181002,2662,Active,266667.0,6531.0,2.431,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
1820,625257,4,7,,103181002,2662,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
1821,625258,4,7,,103181002,2662,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
1822,625259,4,7,,103181002,2662,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
1823,625260,3,4,,103181002,2662,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
1824,625261,3,4,,103181002,2662,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
1825,625262,3,4,,103181002,2662,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
1826,625263,4,7,,103181002,2662,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
1827,625264,3,4,,103181002,2662,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
1828,625265,1,6,,103181002,2662,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
1829,625266,3,4,,103181002,2662,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
1830,625267,3,4,,103181002,2662,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
1831,625268,4,2,,103181002,2662,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1832,625268,4,2,,103181002,2662,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1833,625268,4,2,,103181002,2662,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1834,625268,4,2,,103181002,2662,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1835,625269,4,7,,103181002,2662,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
1836,625270,4,7,,103181002,2662,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
1837,625271,5,5,,103181002,2662,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
1838,625272,3,4,,103181002,2662,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
1839,625273,4,6,,103181002,2662,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
1840,625274,1,6,,103181002,2662,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
1841,625275,3,4,,103181002,2662,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
1842,625279,1,3,,103181002,2662,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
1843,625280,1,3,,103181002,2662,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
1844,625281,1,3,,103181002,2662,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
1845,625282,1,3,,103181002,2662,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
1846,625283,1,3,,103181002,2662,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
1847,625284,1,3,,103181002,2662,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
1848,625285,1,3,,103181002,2662,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
1849,625286,1,3,,103181002,2662,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
1850,625287,1,3,,103181002,2662,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
1851,625288,1,3,,103181002,2662,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
1852,625289,1,3,,103181002,2662,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
1853,625290,1,3,,103181002,2662,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
1854,625291,1,3,,103181002,2662,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
1855,625292,1,3,,103181002,2662,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
1856,626160,3,1,,103181002,2662,Unspecified,,,,,Absorptive transport of the compound from apical to basolateral side of transepithelial human Caco2 model,Other,21983446.0,
1857,626161,1,4,,103181002,2662,Unspecified,,,,,Permeability of the compound from apical to basolateral side of transepithelial human Caco2 model assessed as absorptive transport by mass balance study,Other,21983446.0,
1858,626162,3,1,,103181002,2662,Unspecified,,,,,Secretory transport of the compound through transepithelial human Caco2 model,Other,21983446.0,
1859,626163,1,4,,103181002,2662,Unspecified,,,,,Permeability of the compound from basolateral to apical side of transepithelial human Caco2 model assessed as secretory transport by mass balance study,Other,21983446.0,
1860,627513,1,4,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced hind paw edema at 20 mg/kg, po administered 30 mins before carrageenan challenge measured after 3 hrs by plethysmometer",Other,21664130.0,
1861,627514,1,4,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced hind paw edema at 20 mg/kg, po administered 30 mins before carrageenan challenge measured after 5 hrs by plethysmometer",Other,21664130.0,
1862,629712,5,2,,103181002,2662,Active,,,0.12,IC50,Inhibition of COX2 by chemiluminescent enzyme assay,Confirmatory,22000948.0,
1863,629713,5,2,,103181002,2662,Active,,,27.5,IC50,Inhibition of COX1 by chemiluminescent enzyme assay,Confirmatory,22000948.0,
1864,629714,3,2,,103181002,2662,Active,,,40.8,IC50,Antiproliferative activity against human MCF7 cells after 48 hrs by MTT colorimetric assay,Confirmatory,22000948.0,
1865,629716,3,3,,103181002,2662,Unspecified,,,85.6,IC50,Antiproliferative activity against mouse B16F10 cells after 48 hrs by MTT colorimetric assay,Confirmatory,22000948.0,
1866,629717,3,2,,103181002,2662,Active,,,0.1,IC50,Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced PGE2 production,Confirmatory,22000948.0,
1867,629718,3,2,,103181002,2662,Unspecified,,,95.5,IC50,Antiproliferative activity against human HepG2 cells after 48 hrs by MTT colorimetric assay,Confirmatory,22000948.0,
1868,633795,5,5,,103181002,2662,Active,3915797.0,5743.0,0.1,IC50,Inhibition of human recombinant COX-2 assessed as PGF2alpha production by enzyme immunoassay,Confirmatory,22119153.0,
1869,633796,5,5,,103181002,2662,Active,754286265.0,443551.0,34.5,IC50,Inhibition of ovine COX1 assessed as PGF2alpha production by enzyme immunoassay,Confirmatory,22119153.0,
1870,634812,1,5,,103181002,2662,Active,,,,,"Antiinflammatory activity against LPS-induced inflammation in BALB/c mouse acute lung injury model assessed as reduction in total cell count bronchoalveolar lavage fluid at 50 mg/kg, ip administered 1 hr prior to LPS challenge measured after 12 hrs by Wright-Giemsa staining based hemocytometry",Other,22118829.0,
1871,634813,1,5,,103181002,2662,Active,,,,,"Antiinflammatory activity against LPS-induced inflammation in BALB/c mouse acute lung injury model assessed as reduction in neutrophil count in bronchoalveolar lavage fluid at 50 mg/kg, ip administered 1 hr prior to LPS challenge measured after 12 hrs by Wright-Giemsa staining based hemocytometry",Other,22118829.0,
1872,634814,1,5,,103181002,2662,Active,,,,,"Antiinflammatory activity against LPS-induced inflammation in BALB/c mouse acute lung injury model assessed as reduction in macrophage count in bronchoalveolar lavage fluid at 50 mg/kg, ip administered 1 hr prior to LPS challenge measured after 12 hrs by Wright-Giemsa staining based hemocytometry",Other,22118829.0,
1873,634815,1,5,,103181002,2662,Active,,,,,"Antiinflammatory activity against LPS-induced inflammation in BALB/c mouse acute lung injury model assessed as reduction in protein level in bronchoalveolar lavage fluid at 50 mg/kg, ip administered 1 hr prior to LPS challenge measured after 12 hrs by Bradford assay",Other,22118829.0,
1874,634816,1,4,,103181002,2662,Active,,,,,"Antiinflammatory activity against LPS-induced inflammation in BALB/c mouse acute lung injury model assessed as reduction in inflammatory cells infiltration at 50 mg/kg, ip administered 1 hr prior to LPS challenge measured after 12 hrs by hematoxylin and eosin staining based light microscopy",Other,22118829.0,
1875,634817,1,4,,103181002,2662,Active,,,,,"Antiinflammatory activity against LPS-induced inflammation in BALB/c mouse acute lung injury model assessed as increase in alveolar wall thickening at 50 mg/kg, ip administered 1 hr prior to LPS challenge measured after 12 hrs by hematoxylin and eosin staining based light microscopy",Other,22118829.0,
1876,634818,1,4,,103181002,2662,Active,,,,,"Antiinflammatory activity against LPS-induced inflammation in BALB/c mouse acute lung injury model assessed as reduction in wet/dry ratio of lung at 50 mg/kg, ip administered 1 hr prior to LPS challenge measured after 12 hrs",Other,22118829.0,
1877,635997,1,3,,103181002,2662,Inactive,,,,,Antiinflammatory activity in Wistar rat neutrophils assessed as decrease in PGE2 level at 10 nM after 18 hrs by EIA,Other,22071254.0,
1878,635998,1,3,,103181002,2662,Active,,,,,Antiinflammatory activity in Wistar rat neutrophils assessed as decrease in LPS-induced PGE2 secretion at 10 nM after 18 hrs by EIA,Other,22071254.0,
1879,635999,1,9,,103181002,2662,Active,548484.0,29527.0,,,Inhibition of COX-2 in LPS-stimulated rat leukocytes assessed as reduction in PGE2 production from arachidonic acid at 10 nM preincubated for 10 mins by EIA,Other,22071254.0,
1880,639980,5,2,,103181002,2662,Active,,,0.2,IC50,Inhibition of COX2 assessed as inhibition of PGE2 production using arachidonic acid as substrate after 10 mins by ELISA,Confirmatory,22217871.0,
1881,641609,1,9,,103181002,2662,Unspecified,129900.0,19224.0,,,Inhibition of COX-1-mediated PGE2 production in arachidonic acid-stimulated mouse J774 cells at 0.01 uM incubated for 15 mins prior to arachidonic acid-challenge by radioimmunoassay,Other,21992176.0,
1882,641610,1,9,,103181002,2662,Unspecified,129900.0,19224.0,,,Inhibition of COX-1-mediated PGE2 production in arachidonic acid-stimulated mouse J774 cells at 0.1 uM incubated for 15 mins prior to arachidonic acid-challenge by radioimmunoassay,Other,21992176.0,
1883,641611,1,9,,103181002,2662,Unspecified,129900.0,19224.0,,,Inhibition of COX-1-mediated PGE2 production in arachidonic acid-stimulated mouse J774 cells at 1 uM incubated for 15 mins prior to arachidonic acid-challenge by radioimmunoassay,Other,21992176.0,
1884,641612,1,9,,103181002,2662,Unspecified,129900.0,19224.0,,,Inhibition of COX-1-mediated PGE2 production in arachidonic acid-stimulated mouse J774 cells at 10 uM incubated for 15 mins prior to arachidonic acid-challenge by radioimmunoassay,Other,21992176.0,
1885,641613,5,5,,103181002,2662,Active,129900.0,19224.0,3.84,IC50,Inhibition of COX-1-mediated PGE2 production in arachidonic acid-stimulated mouse J774 cells incubated for 15 mins prior to arachidonic acid-challenge by radioimmunoassay,Confirmatory,21992176.0,
1886,641614,1,9,,103181002,2662,Unspecified,548483.0,19225.0,,,Inhibition of COX-2-mediated PGE2 production in LPS-stimulated mouse J774 cells at 0.01 uM after 24 hrs by radioimmunoassay,Other,21992176.0,
1887,641615,1,9,,103181002,2662,Unspecified,548483.0,19225.0,,,Inhibition of COX-2-mediated PGE2 production in LPS-stimulated mouse J774 cells at 0.1 uM after 24 hrs by radioimmunoassay,Other,21992176.0,
1888,641616,1,9,,103181002,2662,Unspecified,548483.0,19225.0,,,Inhibition of COX-2-mediated PGE2 production in LPS-stimulated mouse J774 cells at 1 uM after 24 hrs by radioimmunoassay,Other,21992176.0,
1889,641617,2,8,,103181002,2662,Unspecified,548483.0,19225.0,,,Inhibition of COX-2-mediated PGE2 production in LPS-stimulated mouse J774 cells at 10 uM after 24 hrs by radioimmunoassay,Other,21992176.0,
1890,641618,5,5,,103181002,2662,Active,548483.0,19225.0,0.061,IC50,Inhibition of COX-2-mediated PGE2 production in LPS-stimulated mouse J774 cells after 24 hrs by radioimmunoassay,Confirmatory,21992176.0,
1891,641619,1,4,,103181002,2662,Unspecified,,,,,Selectivity ratio of IC50 for COX1 in mouse J774 cells to IC50 for COX2 in mouse J774 cells,Other,21992176.0,
1892,641770,1,3,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema in Sprague-Dawley rat assessed as paw weight at 10 mg/kg, po administered 4 hrs post challenge measured after 30 mins (Rvb = 61.5+/-3.4 g)",Other,21992176.0,
1893,641771,1,3,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema in Sprague-Dawley rat assessed as paw weight at 10 mg/kg, po administered 4 hrs post challenge measured after 60 mins (Rvb = 61.5+/-3.4 g)",Other,21992176.0,
1894,641772,1,3,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema in Sprague-Dawley rat assessed as paw weight at 10 mg/kg, po administered 4 hrs post challenge measured after 120 mins (Rvb = 61.5+/-3.4 g)",Other,21992176.0,
1895,641774,1,3,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced edema in Sprague-Dawley rat assessed as right hind paw volume at 10 mg/kg, po administered 4 hrs post challenge measured after 60 mins",Other,21992176.0,
1896,641778,5,5,,103181002,2662,Active,317373262.0,5742.0,12.47,IC50,Inhibition of platelet COX1-mediated TXB2 production in LPS-induced human whole blood after 60 mins by radioimmunoassay,Confirmatory,21992176.0,
1897,641779,5,5,,103181002,2662,Active,3915797.0,5743.0,0.54,IC50,Inhibition of COX2-mediated PGE2 production in LPS-induced human whole blood after 60 mins by radioimmunoassay,Confirmatory,21992176.0,
1898,641780,1,3,,103181002,2662,Unspecified,,,,,Selectivity ratio of IC50 for platelet COX1 in human whole blood to IC50 for COX2 in human whole blood,Other,21992176.0,
1899,644379,4,1,,103181002,2662,Active,,,0.732,Ki,Inhibition of GST-tagged astrosclera willeyana Astrosclerin-3 expressed in Escherichia coli after 15 mins preincubation by stopped flow CO2 hydration assay,Confirmatory,22285172.0,
1900,644380,4,5,,103181002,2662,Unspecified,115449.0,759.0,50.0,Ki,Inhibition of human recombinant carbonic anhydrase 1 after 15 mins by stopped flow CO2 hydration assay,Confirmatory,22285172.0,
1901,644381,4,5,,103181002,2662,Active,115456.0,760.0,0.021,Ki,Inhibition of human recombinant carbonic anhydrase 2 after 15 mins by stopped flow CO2 hydration assay,Confirmatory,22285172.0,
1902,644721,1,3,,103181002,2662,Unspecified,,,,,Selectivity ratio of IC50 for human recombinant COX2 to IC50 for ram seminal vesicle COX1,Other,22305614.0,
1903,645642,5,2,,103181002,2662,Active,,,48.0,IC50,Inhibition of recombinant PDK1 using RPRAATF as substrate by scintillation counting,Confirmatory,22266037.0,
1904,647086,1,4,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 mins before carrageenan challenge measured after 3 hrs",Other,22019186.0,
1905,647087,1,4,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 mins before carrageenan challenge measured after 5 hrs",Other,22019186.0,
1906,647091,5,5,,103181002,2662,Active,166897622.0,282022.0,21.61,IC50,Inhibition of bovine COX1 assessed as PGE2 formation preincubated for 10 mins by ELISA,Confirmatory,22019186.0,
1907,647092,5,5,,103181002,2662,Active,3914304.0,443460.0,0.36,IC50,Inhibition of ovine COX2 assessed as PGE2 formation preincubated for 10 mins by ELISA,Confirmatory,22019186.0,
1908,648179,1,4,,103181002,2662,Active,,,0.42100000000000004,Ki,Inhibition of human wild type carbonic anhydrase 2 Asn67Ile mutant expressed in Escherichia coli after 15 mins preincubation by stopped flow CO2 hydration assay,Confirmatory,22386980.0,
1909,648180,1,4,,103181002,2662,Active,,,0.0768,Ki,Inhibition of human wild type carbonic anhydrase 2 Gln92Val mutant expressed in Escherichia coli after 15 mins preincubation by stopped flow CO2 hydration assay,Confirmatory,22386980.0,
1910,648181,1,3,,103181002,2662,Active,,,0.369,Ki,Inhibition of human wild type carbonic anhydrase 2 Leu204Ser mutant expressed in Escherichia coli after 15 mins preincubation by stopped flow CO2 hydration assay,Confirmatory,22386980.0,
1911,648186,5,5,,103181002,2662,Active,754286265.0,443551.0,15.0,IC50,Inhibition of ovine COX1 by fluorescence assay,Confirmatory,22386983.0,
1912,648187,5,5,,103181002,2662,Active,3915797.0,5743.0,0.04,IC50,Inhibition of human recombinant COX2 by fluorescence assay,Confirmatory,22386983.0,
1913,648561,5,5,,103181002,2662,Active,754286265.0,443551.0,10.0,IC50,Competitive inhibition of ovine COX1 by enzyme immunoassay,Confirmatory,22341941.0,
1914,648562,5,5,,103181002,2662,Active,3915797.0,5743.0,0.06,IC50,Competitive inhibition of human recombinant COX2 by enzyme immunoassay,Confirmatory,22341941.0,
1915,649269,5,5,,103181002,2662,Active,754286265.0,443551.0,7.7,IC50,Inhibition of ovine COX-1 by enzyme immuno assay,Confirmatory,22361134.0,
1916,649270,5,5,,103181002,2662,Active,3915797.0,5743.0,0.07,IC50,Inhibition of human recombinant COX-2 by enzyme immuno assay,Confirmatory,22361134.0,
1917,649271,1,5,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for ovine COX-1 to IC50 for human recombinant COX-2",Other,22361134.0,
1918,651548,1,1,,85789333,2662,Inactive,21361095.0,2146.0,,,EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1919,651550,1,1,,49665790,2662,Inactive,60391226.0,207.0,,,HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen,Screening,,
1920,651560,1,1,,49665790,2662,Inactive,1709543.0,52.0,,,"uHTS identification of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay",Screening,,
1921,651572,1,2,,49665790,2662,Inactive,21489979.0,246310.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ADP-ribosylation factor GTPase activating protein 1 (ARFGAP1),Screening,,
1922,651582,1,1,,49665790,2662,Inactive,,,,,uHTS identification of small molecule Triacylglycerol inhbitors in a fluoresence assay,Screening,,
1923,651602,1,1,,49665790,2662,Inactive,16130723.0,947287.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1924,651602,1,1,,49665790,2662,Inactive,16130724.0,947286.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1925,651602,1,1,,49665790,2662,Inactive,16130726.0,947294.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1926,651610,2,1,,49665790,2662,Inactive,,,,,HIV entry: Env-mediated Cell Fusion Measured in Cell-Based System Using Plate Reader - 7013-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1927,651631,4,1,,144204686,2662,Inconclusive,269849759.0,7157.0,29.8493,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
1928,651631,4,1,,144209162,2662,Inconclusive,269849759.0,7157.0,43.1011,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
1929,651631,4,1,,144210916,2662,Inconclusive,269849759.0,7157.0,68.5896,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
1930,651632,4,1,,144204686,2662,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
1931,651632,4,1,,144209162,2662,Inactive,296439460.0,79915.0,54.2611,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
1932,651632,4,1,,144210916,2662,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
1933,651633,4,1,,144204686,2662,Inconclusive,,,29.8493,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
1934,651633,4,1,,144209162,2662,Active,,,54.2611,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
1935,651633,4,1,,144210916,2662,Inconclusive,,,76.9588,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
1936,651634,4,1,,144204686,2662,Active,,,29.8493,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
1937,651634,4,1,,144209162,2662,Active,,,60.882,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
1938,651634,4,1,,144210916,2662,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
1939,651635,1,3,,49665790,2662,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
1940,651636,1,1,,49665790,2662,Inactive,4826706.0,1880.0,,,uHTS identification of small molecule antagonists of the EBI2 receptor via a luminescent beta-arrestin assay,Screening,,
1941,651640,1,1,,49665790,2662,Inactive,,,,,DENV2 CPE-Based HTS Measured in Cell-Based and Microorganism Combination System Using Plate Reader - 2149-01_Other_SinglePoint_HTS_Activity,Screening,,
1942,651644,1,1,,49665790,2662,Inactive,28872817.0,155807.0,,Potency,qHTS Assay for Inhibitors of the HIV-1 protein Vpr,Confirmatory,,
1943,651645,1,1,,124890934,2662,Inactive,,,85.5119,Potency,Cell Proliferation Assay against the TMD8 Cell Line,Confirmatory,,
1944,651646,1,1,,124890934,2662,Inactive,,,,Potency,Cell Proliferation Assay against the HBL1 Cell Line,Confirmatory,,
1945,651647,1,1,,49665790,2662,Inactive,4826834.0,4323.0,,,uHTS identification of inhibitors of MT1-MMP activation in a fluoresence assay,Screening,,
1946,651654,1,1,,49665790,2662,Inactive,,,,,HTS for the detection of C. neoformans cell lysis via adenylate kinase (AK) release Measured in Microorganism System Using Plate Reader - 2162-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1947,651658,1,1,,49665790,2662,Inactive,10190672.0,27006.0,,,Small Molecule Inhibitors of FGF22-Mediated Excitatory Synaptogenesis & Epilepsy Measured in Biochemical System Using RT-PCR - 7012-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1948,651661,2,1,,49665790,2662,Inactive,,,,,Luminescence Cell-Based Primary HTS to identify inhibitors of the oncoprotein EWS/Fli transcriptional activity Measured in Cell-Based System Using Plate Reader - 7014-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1949,651687,1,1,,49665790,2662,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1950,651696,1,1,,124890934,2662,Inactive,,,0.3034,Potency,Cell Proliferation Assay against a hMSC Cell Line,Confirmatory,,
1951,651699,1,1,,49665790,2662,Inactive,4502169.0,8883.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
1952,651699,1,1,,49665790,2662,Inactive,4507791.0,9040.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
1953,651702,1,2,,49665790,2662,Inactive,,,,,Flow Cytometric HTS Screening for Inhibitors of Lytic Granule Exocytosis with MLPCN Compound Library,Screening,,
1954,651704,2,1,,49665790,2662,Inactive,156104889.0,4300.0,,,Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1955,651710,1,1,,49665790,2662,Inactive,109637798.0,5893.0,,,FRET-based HTS for detection of RAD52 Inhibitors Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1956,651711,2,1,,49665790,2662,Inactive,2501205.0,10130.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of ERp5 Measured in Biochemical System Using Plate Reader - 7002-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1957,651712,1,1,,124890934,2662,Inconclusive,,,42.8575,Potency,Cell Proliferation Assay against the TMD8 Cell Line (Caspase readout at 16 hrs),Confirmatory,,
1958,651713,1,1,,124890934,2662,Active,,,53.9544,Potency,Cell Proliferation Assay against the TMD8 Cell Line (Caspase readout at 8 hrs),Confirmatory,,
1959,651718,1,2,,49665790,2662,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA),Screening,,
1960,651719,1,2,,49665790,2662,Inactive,4503907.0,8484.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the Galanin Receptor 3 (GalR3),Screening,,
1961,651723,1,1,,49665790,2662,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Activator_SinglePoint_HTS_Activity,Screening,,
1962,651724,1,1,,49665790,2662,Inactive,1730321.0,5932.0,,,qHTS Assay for Inhibitors of the CtBP/E1A Interaction,Screening,,
1963,651725,1,1,,49665790,2662,Inactive,1246761.0,6495.0,,,qHTS Assay for Inhibitors of the Six1/Eya2 Interaction,Screening,,
1964,651741,1,1,,17389545,2662,Active,20149576.0,4780.0,66.8242,Potency,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
1965,651743,1,1,,17389545,2662,Inactive,269849759.0,7157.0,,Potency,qHTS assay for small molecule activators of the p53 signaling pathway,Confirmatory,,
1966,651749,1,1,,17389545,2662,Inactive,34577122.0,4790.0,,Potency,qHTS assay for small molecule activators of the nuclear factor-kappa B (NF-kB) signaling pathway,Confirmatory,,
1967,651751,1,1,,17389545,2662,Inconclusive,5702233.0,84385.0,56.2341,Potency,qHTS assay for small molecule activators of the rat pregnane X receptor (rPXR) signaling pathway,Confirmatory,,
1968,651754,1,1,,17389545,2662,Active,,,42.1632,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 1 hr assay,Confirmatory,,
1969,651755,1,1,,17389545,2662,Active,,,42.1632,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 5 hr assay,Confirmatory,,
1970,651757,1,1,,17389545,2662,Inactive,25952111.0,7124.0,,Potency,qHTS assay to identify small molecules that stimulate Tumor Necrosis Factor-alpha (TNF-alpha) secretion,Confirmatory,,
1971,651758,1,1,,17389545,2662,Inconclusive,186368.0,3576.0,,Potency,qHTS assay to identify small molecules that stimulate interleukin-8 (IL-8) secretion,Confirmatory,,
1972,651768,1,2,,49665790,2662,Inactive,3719421.0,7486.0,,Potency,qHTS for Inhibitors of WRN Helicase,Confirmatory,,
1973,651777,1,1,,17389545,2662,Inactive,51095037.0,196.0,,Potency,qHTS assay for environmental chemicals that activate the Aryl hydrocarbon Receptor (AhR) signaling pathway,Confirmatory,,
1974,651778,1,1,,17389545,2662,Inactive,3041727.0,5465.0,,Potency,qHTS assay for small molecule agonists of the peroxisome proliferator-activated receptor alpha (PPARalpha) signaling pathway,Confirmatory,,
1975,651800,1,1,,49665790,2662,Inactive,2358024.0,6955.0,,,Fluorescence-based biochemical primary high throughput assay to identify inhibitors of T-cell receptor (TCR)-CD3 interaction using a TAMRA-labeled TCR probe,Screening,,
1976,651802,1,1,,17389545,2662,Active,49066040.0,6097.0,33.4915,Potency,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
1977,651819,1,1,,49665790,2662,Inactive,83758679.0,153562.0,,,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity,Screening,,
1978,651820,1,1,,49665790,2662,Inconclusive,,,10.0,Potency,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),Confirmatory,,
1979,651821,2,4,,49665790,2662,Inactive,,,,,Fluorescence-based biochemical primary high throughput screening assay to identify molecules that bind r(CAG) RNA repeats,Screening,,
1980,651828,1,2,,92308914,2662,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
1981,651828,1,2,,121361138,2662,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
1982,651828,1,2,,121362558,2662,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
1983,651838,1,1,,17389545,2662,Unspecified,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1984,651838,1,1,1.0,17389545,2662,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1985,651838,1,1,2.0,17389545,2662,Inconclusive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1986,651838,1,1,3.0,17389545,2662,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1987,651838,1,1,4.0,17389545,2662,Inconclusive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1988,651838,1,1,5.0,17389545,2662,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1989,651838,1,1,6.0,17389545,2662,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1990,651838,1,1,7.0,17389545,2662,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1991,651838,1,1,8.0,17389545,2662,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1992,651957,1,1,,49665790,2662,Inactive,5729858.0,10499.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2),Screening,,
1993,651958,1,1,,49665790,2662,Inactive,76364066.0,2943075.0,,,Fluorescence-based biochemical high throughput screening primary assay to identify inhibitors of Crimean-Congo Hemorrhagic Fever (CCHF) viral ovarian tumor domain protease (vOTU): Pep-AMC substrate,Screening,,
1994,651965,1,1,,49665790,2662,Inactive,2668494.0,,,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
1995,651999,1,1,,49665790,2662,Inactive,38027923.0,10987.0,,,"uHTS identification of small molecule inhibitors of Csn-mediated Deneddylation of Cullin-Ring Ligases, vis a fluorescence polarization assay",Screening,,
1996,652010,1,1,,49665790,2662,Inactive,5016090.0,190.0,,,"Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1",Screening,,
1997,652017,1,1,,49665790,2662,Inactive,119579215.0,6595.0,,,"Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM)",Screening,,
1998,652025,1,1,,49665790,2662,Inactive,7110653.0,16183.0,,Potency,qHTS of IL-2 Activators,Confirmatory,,
1999,652039,1,1,,49665790,2662,Inactive,21327705.0,5650.0,,,Fluorescence Intensity-based biochemical primary high throughput screening assay to identify activators of kallikrein-7 (K7) zymogen,Screening,,
2000,652048,1,2,,49665790,2662,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
2001,652048,1,2,,144204686,2662,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
2002,652051,1,1,,49665790,2662,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
2003,652051,1,1,,144204686,2662,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
2004,652054,1,1,,49665790,2662,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Antagonist: qHTS,Screening,,
2005,652067,1,4,,49665790,2662,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite H. contortus (hcDAF-12),Screening,,
2006,652104,1,1,,49665790,2662,Inactive,20140568.0,23435.0,,Potency,qHTS of TDP-43 Inhibitors,Confirmatory,,
2007,652105,1,1,,49665790,2662,Inactive,18266879.0,5305.0,,Potency,qHTS for Inhibitors of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K),Confirmatory,,
2008,652106,1,1,,49665790,2662,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
2009,652115,1,1,,49665790,2662,Inactive,38258652.0,23408.0,,,MLPCN SirT-5 Measured in Biochemical System Using Imaging - 7044-01_Inhibitor_SinglePoint_HTS_Activity_Set5,Screening,,
2010,652126,1,3,,49665790,2662,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite S. stercoralis (ssDAF-12),Screening,,
2011,652154,1,1,,49665790,2662,Inactive,998701.0,7849.0,,,HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2012,652162,2,1,,49665790,2662,Inactive,126698238.0,4914074.0,,,C. difficile toxins: HTS for inhibitors of TcdB glycohydrolase activity Measured in Biochemical System Using Plate Reader - 7074-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2013,652163,1,1,,49665790,2662,Inactive,47496637.0,6275.0,,,S100A4: HTS Measured in Biochemical System Using Plate Reader - 7045-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2014,652197,1,1,,49665790,2662,Inactive,21315078.0,51752.0,,,MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2015,652257,1,1,,49665790,2662,Inactive,32425330.0,3276.0,,,Primary biochemical fluorescence polarization-based high throughput screening assay to identify inhibitors of protein arginine methyltransferase 1 (PRMT1),Screening,,
2016,657493,1,8,,103181002,2662,Unspecified,3915797.0,5743.0,,,Inhibition of recombinant human COX2 using arachidonic acid as substrate at 100 nM preincubated for 10 mins prior substrate addition measured after 2 mins by EIA,Other,22494844.0,
2017,657494,1,8,,103181002,2662,Unspecified,548483.0,19225.0,,,Inhibition of LPS-induced COX2-mediated PGF1 production in mouse RAW264.7 cells at 100 nM after 24 hrs by EIA,Other,22494844.0,
2018,657495,2,2,,103181002,2662,Unspecified,,,12090.0,IC50,Inhibition of LPS-induced NO production in mouse RAW264.7 cells after 24 hrs by Griess assay,Confirmatory,22494844.0,
2019,657496,2,2,,103181002,2662,Unspecified,,,11130.0,IC50,Cytotoxicity against mouse RAW264.7 cells assessed as cell viability by propidium iodide staining based FACS-flow cytometry,Confirmatory,22494844.0,
2020,658647,5,5,,103181002,2662,Unspecified,754286265.0,443551.0,50.0,IC50,Inhibition of ovine COX1 by enzyme immuno assay,Confirmatory,22516672.0,
2021,658648,7,2,,103181002,2662,Active,3914304.0,443460.0,0.28,IC50,Inhibition of ovine COX2 by enzyme immuno assay,Confirmatory,22516672.0,
2022,658649,1,2,,103181002,2662,Unspecified,,,,,Selectivity ratio of IC50 for ovine COX1 to IC50 for ovine COX2,Other,22516672.0,
2023,658650,1,2,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced foot paw edema at 100 mg/kg, ip measured after 2 hrs",Other,22516672.0,
2024,658652,1,2,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced foot paw edema at 50 mg/kg, ip measured after 2 hrs",Other,22516672.0,
2025,658653,3,1,,103181002,2662,Unspecified,,,,,Antiinflammatory activity in ip dosed rat assessed as inhibition of carrageenan-induced foot paw edema measured after 2 hrs,Other,22516672.0,
2026,660180,1,3,,103181002,2662,Unspecified,,,,,Inhibition of IL-1beta-induced PGE2 production in human HCA-7 cells at 1 uM after 72 hrs by EIA,Other,22516282.0,
2027,660181,1,5,,103181002,2662,Unspecified,,,,,Inhibition of COX2 at 5 uM by fluorescence assay,Other,22516282.0,
2028,660182,4,2,,103181002,2662,Active,,,0.03,IC50,Inhibition of COX2 by fluorescence assay,Confirmatory,22516282.0,
2029,660183,4,1,,103181002,2662,Active,,,0.00115,EC50,Inhibition of IL-1beta-induced PGE2 production in human HCA-7 cells after 72 hrs by EIA,Confirmatory,22516282.0,
2030,664977,1,3,,103181002,2662,Unspecified,,,,,Ulcerogenic activity in fasted albino rat assessed as ulcer index at 50 mg/kg po administered qd for 3 days measured on day 4,Other,22551678.0,
2031,664978,1,3,,103181002,2662,Unspecified,,,,,Selectivity ratio of IC50 for ovine COX2 to ovine COX1,Other,22551678.0,
2032,665183,5,5,,103181002,2662,Unspecified,754286265.0,443551.0,115.0,IC50,Inhibition of ovine COX1 by enzymatic fluorescence assay,Confirmatory,22560838.0,
2033,665184,5,5,,103181002,2662,Active,3915797.0,5743.0,0.06,IC50,Inhibition of human recombinant COX2 by enzymatic fluorescence assay,Confirmatory,22560838.0,
2034,667791,1,8,,103181002,2662,Unspecified,3915797.0,5743.0,,,Inhibition of recombinant human COX2 assessed as PGE2 formation at 10 uM by enzyme immunoassay,Other,22796043.0,
2035,669115,4,5,,103181002,2662,Active,115456.0,760.0,0.021,Ki,Inhibition of human carbonic anhydrase 2 preincubated for 15 mins measured for 10 to 100 sec by stopped-flow method,Confirmatory,22424239.0,
2036,669116,1,3,,103181002,2662,Active,,,3.056,Ki,Inhibition of Cryptococcus neoformans Can2 preincubated for 15 mins measured for 10 to 100 sec by stopped-flow method,Confirmatory,22424239.0,
2037,669117,1,3,,103181002,2662,Active,,,1.0170000000000001,Ki,Inhibition of Candida albicans CaNce103 preincubated for 15 mins measured for 10 to 100 sec by stopped-flow method,Confirmatory,22424239.0,
2038,669119,1,3,,103181002,2662,Active,,,34.8,Ki,Inhibition of GST-tagged Malassezia globosa ATCC 96807/CBS 7966 MG-CA expressed in Escherichia coli BL21(DE3) cells preincubated for 15 mins measured for 10 to 100 sec by stopped-flow method,Confirmatory,22424239.0,
2039,669515,1,9,,103181002,2662,Unspecified,7387730.0,9536.0,,,Inhibition of mPGES-1 in IL1beta and TNFalpha-stimulated human HeLa cells assessed as PGE2 level after 24 hrs by LC-MS/MS analysis,Other,22449023.0,
2040,669529,1,9,,103181002,2662,Unspecified,3915797.0,5743.0,,,Inhibition of COX2 in LPS-stimulated human whole blood assessed as residual PGE2 level at 5 uM preincubated for 15 mins prior to LPS-stimulation measured after 24 hrs by LC-MS/MS analysis relative to control,Other,22449023.0,
2041,669530,1,9,,103181002,2662,Unspecified,3915797.0,5743.0,,,Inhibition of COX2 in LPS-stimulated human whole blood assessed as residual PGF2alpha level at 5 uM preincubated for 15 mins prior to LPS-stimulation measured after 24 hrs by LC-MS/MS analysis relative to control,Other,22449023.0,
2042,669742,1,8,,103181002,2662,Unspecified,60392839.0,,,,Inhibition of norA-mediated EtBr efflux in Staphylococcus aureus SA1199B overexpressing norA and expressing A116E GrlA mutation at 50 uM by fluorometry,Other,22432682.0,
2043,669743,5,5,,103181002,2662,Unspecified,60392839.0,,40.0,IC50,Inhibition of norA-mediated EtBr efflux in Staphylococcus aureus SA1199B overexpressing norA and expressing A116E GrlA mutation by fluorometry,Confirmatory,22432682.0,
2044,669744,2,2,,103181002,2662,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus SA1199B overexpressing norA and expressing A116E GrlA mutation by microdilution method,Other,22432682.0,
2045,669745,2,2,,103181002,2662,Unspecified,,,,,Antibacterial activity against wild type Staphylococcus aureus SA1199 expressing norA by microdilution method,Other,22432682.0,
2046,669746,2,2,,103181002,2662,Inconclusive,,,,,Antibacterial activity against norA-deficient Staphylococcus aureus SAK1902 by microdilution method,Other,22432682.0,
2047,669747,2,2,,103181002,2662,Inconclusive,,,,,Antibacterial activity against Staphylococcus aureus SAK2378 overexpressing norA by microdilution method,Other,22432682.0,
2048,669748,1,8,,103181002,2662,Inactive,60392839.0,,,,Inhibition of norA in wild type Staphylococcus aureus SA1199 expressing assessed as potentiation of ciprofloxacin MIC by checkerboard assay,Other,22432682.0,
2049,669749,1,8,,103181002,2662,Inactive,60392839.0,,,,Inhibition of norA overexpressed in Staphylococcus aureus SA1199B coexpressing A116E GrlA mutation assessed as potentiation of ciprofloxacin MIC by checkerboard assay,Other,22432682.0,
2050,669752,1,8,,103181002,2662,Active,60392839.0,,,,Inhibition of norA overexpressed in Staphylococcus aureus SA1199B coexpressing A116E GrlA mutation potentiation of EtBr MIC at >6.25 ug/mL by checkerboard assay,Other,22432682.0,
2051,671465,2,2,,103181002,2662,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus ATCC 29213 after 24 hrs by broth microdilution method,Other,22750009.0,
2052,671466,2,2,,103181002,2662,Unspecified,,,,,Antibacterial activity against Staphylococcus epidermidis ATCC 35984 after 24 hrs by broth microdilution method,Other,22750009.0,
2053,671467,2,2,,103181002,2662,Unspecified,,,,,Antiproliferative activity against human HT-29 cells after 24 hrs by MTT assay,Other,22750009.0,
2054,671468,1,3,,103181002,2662,Unspecified,,,,,Selectivity ratio of IC50 for human HT-29 cells to MIC for Staphylococcus aureus ATCC 29213,Other,22750009.0,
2055,671488,1,2,,103181002,2662,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus assessed as log decrease in bacterial CFU at 32 ug/ml after 24 hrs,Other,22750009.0,
2056,673509,5,5,,103181002,2662,Inconclusive,166897622.0,282022.0,,IC50,Inhibition of bovine COX1 assessed as inhibition of calcium ionophore A23187-induced 12-hydroxyheptadecatrienoic acid formation by reverse-phase HPLC analysis,Confirmatory,22749420.0,
2057,673510,5,5,,103181002,2662,Active,3915797.0,5743.0,0.14,IC50,Inhibition of COX2 in human whole blood assessed as inhibition of LPS-induced PGE2 synthesis up to 24 hrs by radioimmunoassay,Confirmatory,22749420.0,
2058,673511,4,5,,103181002,2662,Inconclusive,75066909.0,,,IC50,Inhibition of bovine 5-LOX assessed as inhibition of calcium ionophore A23187-induced leukotriene B4 formation by reversed phase HPLC analysis,Confirmatory,22749420.0,
2059,674712,1,3,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 0.029 mmol/kg, po dosed 1 hr before carrageenan challenge measured 1 hr post carrageenan-induced inflammation",Other,22818041.0,
2060,674713,1,3,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 0.029 mmol/kg, po dosed 2 hrs before carrageenan challenge measured 1 hr post carrageenan-induced inflammation",Other,22818041.0,
2061,674714,1,3,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 0.029 mmol/kg, po dosed 3 hrs before carrageenan challenge measured 1 hr post carrageenan-induced inflammation",Other,22818041.0,
2062,674715,1,3,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 0.029 mmol/kg, po dosed 4 hrs before carrageenan challenge measured 1 hr post carrageenan-induced inflammation",Other,22818041.0,
2063,674721,1,4,,103181002,2662,Unspecified,,,,,"Gastrointestinal toxicity in Wistar albino rat assessed as incidence of stomach ulceration at 0.029 mmol/kg, po",Other,22818041.0,
2064,674724,1,4,,103181002,2662,Unspecified,,,,,"Gastrointestinal toxicity in Wistar albino rat assessed as incidence of stomach ulceration at 0.029 mmol/kg, po followed by another two compound doses in second and third days measured on fourth day post dose by acute ulcerogenicity study",Other,22818041.0,
2065,674725,1,4,,103181002,2662,Unspecified,,,,,"Gastrointestinal toxicity in Wistar albino rat assessed as stomach ulcer index at 0.029 mmol/kg, po followed by another two compound doses in second and third days measured on fourth day post dose by acute ulcerogenicity study",Other,22818041.0,
2066,675695,7,1,,103181002,2662,Active,317373262.0,5742.0,15.0,IC50,Inhibition of COX1,Confirmatory,22263894.0,
2067,675696,7,1,,103181002,2662,Active,3915797.0,5743.0,0.04,IC50,Inhibition of COX2,Confirmatory,22263894.0,
2068,675704,4,5,,103181002,2662,Active,3915797.0,5743.0,0.054000000000000006,IC50,Inhibition of COX-2 in human HNSCC 1483 cells using [14C] arachidonic acid as substrate preincubated for 30 mins before substrate addition measured after 30 mins,Confirmatory,22263894.0,
2069,676453,1,2,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for human COX1 to IC50 for human COX2",Other,22404396.0,
2070,681931,1,7,,103181002,2662,Unspecified,206729914.0,10257.0,,,TP_TRANSPORTER: inhibition of E217betaG in the presence of Celecoxib at a concentration of 50uM in membrane vesicles from MRP4-expressing Sf9 cells,Other,12835412.0,
2071,683132,1,5,,103181002,2662,Unspecified,,,,,Inhibition of COX2 assessed as PGE2 production using arachidonic acid as substrate at 5 nM by EIA,Other,23047231.0,
2072,683133,1,7,,103181002,2662,Active,3914304.0,443460.0,,,Inhibition of ovine COX2 assessed as PGE2 production using arachidonic acid as substrate,Other,23047231.0,
2073,683292,1,2,,103181002,2662,Unspecified,,,,,"Analgesic activity against carrageenan-induced thermal hyperalgesia in Sprague-Dawley rat assessed as paw withdrawal latency at 100 umol/kg, po after 30 mins after 3 hrs",Other,22939234.0,
2074,686940,1,1,,49665790,2662,Inactive,14149746.0,7026.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2),Screening,,
2075,686947,2,2,,124890934,2662,Inactive,4885661.0,7525.0,,Potency,qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen,Confirmatory,23787099.0,
2076,686950,1,1,,124890934,2662,Inactive,,,,Potency,qHTS for small molecule inhibitors of Yes1 kinase: Counter Assay,Other,,
2077,686964,1,1,,49665790,2662,Inactive,21595776.0,8932.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of 5-meCpG-binding domain protein 2 (MBD2)-DBD binding to methylated oligonucleotide,Screening,,
2078,686970,1,2,,49665790,2662,Inconclusive,49168486.0,3417.0,23.1093,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line,Confirmatory,,
2079,686971,1,2,,49665790,2662,Inconclusive,,,29.0929,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line,Confirmatory,,
2080,686978,1,1,,26747363,2662,Inconclusive,79154014.0,55775.0,9.2,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
2081,686978,1,1,,49665790,2662,Inconclusive,79154014.0,55775.0,29.0929,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
2082,686978,1,1,,144204686,2662,Inconclusive,79154014.0,55775.0,11.8856,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
2083,686979,1,1,,26747363,2662,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
2084,686979,1,1,,49665790,2662,Inconclusive,79154014.0,55775.0,29.0929,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
2085,686979,1,1,,144204686,2662,Inconclusive,79154014.0,55775.0,33.4983,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
2086,686992,2,1,,49665790,2662,Inactive,187960042.0,6401.0,,,Identification of agents that induce E-selectin on human endothelial cells Measured in Cell-Based System Using Imaging - 2152-01_Activator_SinglePoint_HTS_Activity,Screening,,
2087,686996,1,1,,49665790,2662,Inactive,13325293.0,839.0,,,VEID(2) R110 Enzymatic Primary HTS to identify Inhibitors of Caspase 6 Measured in Biochemical System Using Plate Reader - 7052-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2088,687014,1,1,,49665790,2662,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the DAF-12 from the parasite H. glycines (hgDAF-12).,Screening,,
2089,687016,1,1,,49665790,2662,Inactive,115430235.0,29128.0,,,Counterscreen for inhibitors of 5-meCpG-binding domain protein 2 (MBD2): TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of binding of ubiquitin-like with PHD and ring finger domains 1 (UHRF1) to methylated oligonucleotide,Screening,,
2090,693434,1,2,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in rat assessed as reduction of carrageenan-induced paw pressure at 10 mg/kg, po after 15 mins post carrageenan-challenge",Other,23131542.0,
2091,693435,1,2,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in rat assessed as reduction of carrageenan-induced paw pressure at 10 mg/kg, po after 30 mins post carrageenan-challenge",Other,23131542.0,
2092,693436,1,2,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in rat assessed as reduction of carrageenan-induced paw pressure at 10 mg/kg, po after 45 mins post carrageenan-challenge",Other,23131542.0,
2093,693437,1,2,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in rat assessed as reduction of carrageenan-induced paw pressure at 10 mg/kg, po after 60 mins post carrageenan-challenge",Other,23131542.0,
2094,693440,1,2,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in rat assessed as reduction of carrageenan-induced oedema in right hind paw at 10 mg/kg, po after 4 hrs post carrageenan-challenge",Other,23131542.0,
2095,693844,1,2,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 25 mg/kg, po after 1 hr (Rvb = 0.85 +/- 0.01%)",Other,23036953.0,
2096,693845,1,2,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 25 mg/kg, po after 2 hrs (Rvb = 1.11 +/- 0.02%)",Other,23036953.0,
2097,693846,1,2,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 25 mg/kg, po after 3 hrs (Rvb = 1.08 +/- 0.41%)",Other,23036953.0,
2098,693847,1,2,,103181002,2662,Unspecified,,,,,"Toxicity in Wistar albino rat assessed as ulcer index at 75 mg/kg/day, po administered for 4 days measured after 12 hrs fasting post-last dose",Other,23036953.0,
2099,694220,3,2,,103181002,2662,Active,,,0.1,IC50,Inhibition of COX-2 by chemiluminescent assay,Confirmatory,23062711.0,
2100,694221,1,2,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for COX-1 to IC50 for COX-2",Other,23062711.0,
2101,694223,3,2,,103181002,2662,Active,,,10.0,IC50,Inhibition of COX-1 by chemiluminescent assay,Confirmatory,23062711.0,
2102,695143,4,5,,103181002,2662,Active,754286265.0,443551.0,15.0,IC50,Inhibition of ovine COX1 using arachidonic acid as substrate incubated for 1 min prior to substrate addition measured for 25 secs by TMPD-based chromogenic assay,Confirmatory,23010270.0,
2103,695144,4,5,,103181002,2662,Active,3915797.0,5743.0,0.042,IC50,Inhibition of human recombinant COX2 expressed in insect cells using arachidonic acid as substrate incubated for 1 min prior to substrate addition measured for 25 secs by TMPD-based chromogenic assay,Confirmatory,23010270.0,
2104,695145,1,2,,103181002,2662,Unspecified,,,,,Selectivity ratio of IC50 for human recombinant COX2 to IC50 for ovine COX1,Other,23010270.0,
2105,697537,1,2,,103181002,2662,Active,,,,,Plasma concentration in human,Other,22780961.0,
2106,697538,1,2,,103181002,2662,Active,,,,,Plasma concentration in rat,Other,22780961.0,
2107,697539,2,2,,103181002,2662,Active,,,40.0,IC50,Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTS assay,Confirmatory,22780961.0,
2108,697540,1,7,,103181002,2662,Unspecified,1705549.0,12552.0,,,Binding affinity to mouse recombinant CDH11 extracellular domain 1-2 by surface plasmon resonance,Other,22780961.0,
2109,699539,1,7,,103181002,2662,Unspecified,12643959.0,10599.0,,,Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting,Other,22541068.0,
2110,699540,1,7,,103181002,2662,Unspecified,27734563.0,28234.0,,,Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
2111,699541,1,7,,103181002,2662,Unspecified,313104012.0,11309.0,,,Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
2112,700996,1,7,,103181002,2662,Unspecified,117020.0,,,,Inhibition of human recombinant COX-2 mediated formation of 12-HHT from arachidonic acid assessed as remaining activity at 10 uM after 5 mins by HPLC analysis,Other,21591611.0,
2113,700999,1,7,,103181002,2662,Inactive,126396.0,246.0,,,Inhibition of 15-lipoxygenase in A23187-stimulated human PMNL assessed as reduction of 15(S)-H(P)ETE formation preincubated 15 mins by RP-HPLC analysis in presence of exogenous arachidonic acid,Other,21591611.0,
2114,701000,1,7,,103181002,2662,Inactive,125987838.0,239.0,,,Inhibition of 12-lipoxygenase in A23187-stimulated human PMNL assessed as reduction of 12(S)-H(P)ETE formation preincubated 15 mins by RP-HPLC analysis in presence of exogenous arachidonic acid,Other,21591611.0,
2115,711032,3,5,,103181002,2662,Active,81671928.0,,7.76,Ki,Inhibition of Mycobacterium tuberculosis recombinant carbonic anhydrase Rv3273 pre-incubated for 15 mins by stopped-flow CO2 hydration method,Confirmatory,23067387.0,
2116,711033,3,5,,103181002,2662,Active,614098999.0,887836.0,0.713,Ki,Inhibition of Mycobacterium tuberculosis recombinant carbonic anhydrase Rv3588c pre-incubated for 15 mins by stopped-flow CO2 hydration method,Confirmatory,23067387.0,
2117,711034,3,5,,103181002,2662,Active,614098993.0,886987.0,10.35,Ki,Inhibition of Mycobacterium tuberculosis recombinant carbonic anhydrase Rv1284 pre-incubated for 15 mins by stopped-flow CO2 hydration method,Confirmatory,23067387.0,
2118,711035,3,5,,103181002,2662,Active,8928036.0,23632.0,0.6890000000000001,Ki,Inhibition of human recombinant CA14 catalytic domain pre-incubated for 15 mins by stopped-flow CO2 hydration method,Confirmatory,23067387.0,
2119,711036,3,5,,103181002,2662,Active,30580350.0,377677.0,0.098,Ki,Inhibition of human recombinant CA13 catalytic domain pre-incubated for 15 mins by stopped-flow CO2 hydration method,Confirmatory,23067387.0,
2120,711037,3,5,,103181002,2662,Active,83300925.0,768.0,0.016,Ki,Inhibition of human recombinant CA9 catalytic domain pre-incubated for 15 mins by stopped-flow CO2 hydration method,Confirmatory,23067387.0,
2121,711038,3,5,,103181002,2662,Active,5915866.0,771.0,0.018000000000000002,Ki,Inhibition of human recombinant CA12 catalytic domain pre-incubated for 15 mins by stopped-flow CO2 hydration method,Confirmatory,23067387.0,
2122,711039,3,5,,103181002,2662,Active,1168744.0,766.0,2.17,Ki,Inhibition of human recombinant full length CA7 pre-incubated for 15 mins by stopped-flow CO2 hydration method,Confirmatory,23067387.0,
2123,711040,3,5,,103181002,2662,Active,116241278.0,765.0,0.094,Ki,Inhibition of human recombinant full length CA6 pre-incubated for 15 mins by stopped-flow CO2 hydration method,Confirmatory,23067387.0,
2124,711041,3,5,,103181002,2662,Active,8928041.0,11238.0,0.09300000000000001,Ki,Inhibition of human recombinant full length CA5B pre-incubated for 15 mins by stopped-flow CO2 hydration method,Confirmatory,23067387.0,
2125,711042,3,5,,103181002,2662,Active,461680.0,763.0,0.794,Ki,Inhibition of human recombinant full length CA5A pre-incubated for 15 mins by stopped-flow CO2 hydration method,Confirmatory,23067387.0,
2126,711043,3,5,,103181002,2662,Active,115465.0,762.0,0.88,Ki,Inhibition of human recombinant full length CA4 pre-incubated for 15 mins by stopped-flow CO2 hydration method,Confirmatory,23067387.0,
2127,711044,3,5,,103181002,2662,Active,134047703.0,761.0,7.4,Ki,Inhibition of human recombinant full length CA3 pre-incubated for 15 mins by stopped-flow CO2 hydration method,Confirmatory,23067387.0,
2128,711045,3,5,,103181002,2662,Active,115456.0,760.0,0.021,Ki,Inhibition of human recombinant full length CA2 pre-incubated for 15 mins by stopped-flow CO2 hydration method,Confirmatory,23067387.0,
2129,711046,3,5,,103181002,2662,Unspecified,115449.0,759.0,50.0,Ki,Inhibition of human recombinant full length CA1 pre-incubated for 15 mins by stopped-flow CO2 hydration method,Confirmatory,23067387.0,
2130,711212,1,2,,103181002,2662,Unspecified,,,1.0,Ki,Inhibition of recombinant Vibrio cholerae carbonic anhydrase expressed in Escherichia coli (DE3) preincubated for 15 mins by stopped-flow CO2 hydrase assay,Confirmatory,23181552.0,
2131,711213,3,5,,103181002,2662,Active,115456.0,760.0,0.021,Ki,Inhibition of human recombinant carbonic anhydrase 2 preincubated for 15 mins by stopped-flow CO2 hydrase assay,Confirmatory,23181552.0,
2132,711214,3,5,,103181002,2662,Unspecified,115449.0,759.0,50.0,Ki,Inhibition of human recombinant carbonic anhydrase 1 preincubated for 15 mins by stopped-flow CO2 hydrase assay,Confirmatory,23181552.0,
2133,711533,1,2,,103181002,2662,Unspecified,,,,,Half life in rat,Other,21413808.0,
2134,717363,1,2,,103181002,2662,Unspecified,,,,,Selectivity ratio of ovine COX1 to ovine COX2 at 20 uM,Other,23146282.0,
2135,717364,1,7,,103181002,2662,Unspecified,3914304.0,443460.0,,,Inhibition of ovine COX2 peroxidase activity assessed as TMPD oxidation at 20 uM by colorimetric analysis,Other,23146282.0,
2136,717365,1,7,,103181002,2662,Unspecified,754286265.0,443551.0,,,Inhibition of ovine COX1 peroxidase activity assessed as TMPD oxidation at 20 uM by colorimetric analysis,Other,23146282.0,
2137,719859,1,2,,103181002,2662,Unspecified,,,,,Antiinflammatory activity in rat assessed as inhibition of carageenaan-induced paw edema relative to control,Other,22546204.0,
2138,720504,1,1,,49665790,2662,Inactive,21359873.0,5347.0,,Potency,qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen,Confirmatory,,
2139,720508,1,1,,49665790,2662,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
2140,720509,1,1,,49665790,2662,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
2141,720511,1,1,,49665790,2662,Inactive,89348172.0,1080.0,,,Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity,Screening,,
2142,720516,2,1,,144204686,2662,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
2143,720516,2,1,,144209162,2662,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
2144,720516,2,1,,144210916,2662,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
2145,720532,1,1,,26747363,2662,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2146,720532,1,1,,144204686,2662,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2147,720533,1,1,,26747363,2662,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2148,720533,1,1,,144204686,2662,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2149,720542,1,2,,49665790,2662,Inactive,23496270.0,810891.0,,Potency,qHTS for Inhibitors of AMA1-RON; Towards Development of Antimalarial Drug Lead: Primary Screen,Confirmatory,,
2150,720543,1,1,,49665790,2662,Inactive,326937491.0,105501.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of alpha/beta hydrolase domain containing 4 (ABHD4).,Screening,,
2151,720551,1,2,,49665790,2662,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS,Confirmatory,,
2152,720552,2,1,,144204686,2662,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
2153,720552,2,1,,144209162,2662,Inconclusive,269849759.0,7157.0,65.7389,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
2154,720552,2,1,,144210916,2662,Inconclusive,269849759.0,7157.0,68.5896,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
2155,720553,1,2,,49665790,2662,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS,Confirmatory,,
2156,720554,1,3,,121362558,2662,Inactive,52423132.0,3087402.0,,,Inhibition of the Burkholderia mallei acyl-homoserine lactone synthase BmaI1,Other,,
2157,720579,2,1,,26747363,2662,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
2158,720579,2,1,,49665790,2662,Inconclusive,222762.0,3707576.0,15.8489,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
2159,720580,1,1,,26747363,2662,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
2160,720580,1,1,,49665790,2662,Inconclusive,222762.0,3707576.0,11.2202,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
2161,720582,1,1,,49665790,2662,Inactive,2393947.0,102.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.,Screening,,
2162,720596,1,1,,49665790,2662,Inactive,4506113.0,5621.0,,,TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC),Screening,,
2163,720634,2,1,,144204686,2662,Active,,,11.8832,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
2164,720634,2,1,,144209162,2662,Active,,,12.1476,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
2165,720634,2,1,,144210916,2662,Active,,,30.6379,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
2166,720635,2,1,,144204686,2662,Active,,,11.8832,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
2167,720635,2,1,,144209162,2662,Active,,,7.6646,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
2168,720635,2,1,,144210916,2662,Active,,,21.6899,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
2169,720636,1,1,,17389545,2662,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,Confirmatory,,
2170,720637,2,1,,144204686,2662,Inconclusive,,,13.8548,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
2171,720637,2,1,,144209162,2662,Inconclusive,,,11.6902,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
2172,720637,2,1,,144210916,2662,Inconclusive,,,33.082,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
2173,720641,1,2,,92307997,2662,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
2174,720641,1,2,,92308914,2662,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
2175,720647,1,2,,49665790,2662,Inactive,,,,,Bursicon-induced LGR2 mediated cAMP production in LGR-2/CRE6x-Luciferase co-transfected HEK293 cells Inhibition,Screening,,
2176,720648,1,1,,49665790,2662,Inactive,73747889.0,6868.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.,Screening,,
2177,720652,1,1,,17389545,2662,Inconclusive,,,74.97800000000001,Potency-Replicate_1,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
2178,720653,1,1,,17389545,2662,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity - cell viability counter screen,Confirmatory,,
2179,720659,1,1,,17389545,2662,Active,325495557.0,8856.0,5.6234,Potency-Replicate_1,qHTS assay for small molecule activators of the human pregnane X receptor (PXR) signaling pathway,Confirmatory,,
2180,720674,2,2,,144204686,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
2181,720674,2,2,,144209162,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
2182,720674,2,2,,144210916,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
2183,720675,2,2,,144204686,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
2184,720675,2,2,,144209162,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
2185,720675,2,2,,144210916,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
2186,720678,2,1,,144204686,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
2187,720678,2,1,,144209162,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
2188,720678,2,1,,144210916,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
2189,720679,2,1,,144204686,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
2190,720679,2,1,,144209162,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
2191,720679,2,1,,144210916,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
2192,720680,2,1,,144204686,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
2193,720680,2,1,,144209162,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
2194,720680,2,1,,144210916,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
2195,720681,2,1,,144204686,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
2196,720681,2,1,,144209162,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
2197,720681,2,1,,144210916,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
2198,720682,2,1,,144204686,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
2199,720682,2,1,,144209162,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
2200,720682,2,1,,144210916,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
2201,720683,2,1,,144204686,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
2202,720683,2,1,,144209162,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
2203,720683,2,1,,144210916,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
2204,720684,2,1,,144204686,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
2205,720684,2,1,,144209162,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
2206,720684,2,1,,144210916,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
2207,720685,2,1,,144204686,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
2208,720685,2,1,,144209162,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
2209,720685,2,1,,144210916,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
2210,720686,2,1,,144204686,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
2211,720686,2,1,,144209162,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
2212,720686,2,1,,144210916,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
2213,720687,2,2,,144204686,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
2214,720687,2,2,,144209162,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
2215,720687,2,2,,144210916,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
2216,720691,4,1,,144204686,2662,Inconclusive,311348376.0,2908.0,16.9301,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2217,720691,4,1,,144209162,2662,Inconclusive,311348376.0,2908.0,54.7327,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2218,720691,4,1,,144210916,2662,Inconclusive,311348376.0,2908.0,54.941,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2219,720692,3,1,,144204686,2662,Inconclusive,311348376.0,2908.0,15.089,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2220,720692,3,1,,144209162,2662,Inconclusive,311348376.0,2908.0,54.7327,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2221,720692,3,1,,144210916,2662,Inconclusive,311348376.0,2908.0,54.941,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2222,720693,3,1,,144204686,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
2223,720693,3,1,,144209162,2662,Active,,,54.7327,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
2224,720693,3,1,,144210916,2662,Inconclusive,,,61.6448,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
2225,720700,1,4,,49665790,2662,Inactive,223459640.0,5335.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).,Screening,,
2226,720702,1,1,,49665790,2662,Inactive,23510348.0,51567.0,,,Epi Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of human tyrosyl-DNA phosphodiesterase 2 (TDP2),Screening,,
2227,720704,1,4,,49665790,2662,Inactive,148745659.0,5331.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-beta3).,Screening,,
2228,720707,1,2,,49665790,2662,Inactive,317373593.0,10411.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
2229,720708,1,2,,49665790,2662,Inconclusive,32171491.0,11069.0,44.6684,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 2 (EPAC2): primary screen,Confirmatory,,
2230,720709,1,2,,49665790,2662,Inactive,317373593.0,10411.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
2231,720711,1,2,,49665790,2662,Inactive,32171491.0,11069.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 4 (EPAC2): primary screen,Confirmatory,,
2232,720717,1,3,,92124698,2662,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
2233,720717,1,3,,92307997,2662,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
2234,720717,1,3,,92308914,2662,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
2235,720719,2,1,,144204686,2662,Inconclusive,311348376.0,2908.0,28.4224,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2236,720719,2,1,,144209162,2662,Inconclusive,311348376.0,2908.0,12.2531,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2237,720719,2,1,,144210916,2662,Inconclusive,311348376.0,2908.0,54.941,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2238,720725,2,1,,144204686,2662,Active,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2239,720725,2,1,,144209162,2662,Inconclusive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2240,720725,2,1,,144210916,2662,Inconclusive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2241,724441,1,2,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for ovine COX1 to IC50 for human recombinant COX2",Other,23200247.0,
2242,724443,2,5,,103181002,2662,Active,754286265.0,443551.0,7.7,IC50,Inhibition of ovine COX1,Confirmatory,23200247.0,
2243,724444,2,5,,103181002,2662,Active,3915797.0,5743.0,0.07,IC50,Inhibition of human recombinant COX2,Confirmatory,23200247.0,
2244,725955,2,5,,103181002,2662,Unspecified,115449.0,759.0,50.0,Ki,Inhibition of human recombinant carbonic anhydrase 1 by stopped flow CO2 hydration assay,Confirmatory,23391336.0,
2245,725956,2,5,,103181002,2662,Active,115456.0,760.0,0.021,Ki,Inhibition of human recombinant carbonic anhydrase 2 by stopped flow CO2 hydration assay,Confirmatory,23391336.0,
2246,726232,1,2,,103181002,2662,Active,,,0.0911,Ki,Inhibition of Trypanosoma cruzi CL Brener recombinant alpha-carbonic anhydrase expressed in insect Sf9 cell Baculovirus system by stopped flow CO2 hydration assay,Confirmatory,23391336.0,
2247,733373,1,2,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Sprague-Dawley/Wistar rat assessed as decrease in carrageenan-induced paw edema at 3 mg/kg, po administered 3 hrs 30 mins after carrageenan-challenge measured after 60 mins (Rvb = 2.48 +/- 0.06 mL)",Other,23534442.0,
2248,733809,1,2,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Sprague-Dawley/Wistar rat assessed as decrease in carrageenan-induced paw edema at 10 mg/kg, po administered 3 hrs 30 mins after carrageenan-challenge measured after 60 mins (Rvb = 2.48 +/- 0.06 mL)",Other,23534442.0,
2249,733812,1,2,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Sprague-Dawley/Wistar rat assessed as decrease in carrageenan-induced hyperalgesia at 3 mg/kg, po administered 4 hrs after carrageenan-challenge measured after 120 mins (Rvb = 31.4 +/- 3.7 g)",Other,23534442.0,
2250,733813,1,2,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Sprague-Dawley/Wistar rat assessed as decrease in carrageenan-induced hyperalgesia at 3 mg/kg, po administered 4 hrs after carrageenan-challenge measured after 60 mins (Rvb = 33.9 +/- 3.7 g)",Other,23534442.0,
2251,733814,1,2,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Sprague-Dawley/Wistar rat assessed as decrease in carrageenan-induced hyperalgesia at 3 mg/kg, po administered 4 hrs after carrageenan-challenge measured after 30 mins (Rvb = 34.8 +/- 3.0 g)",Other,23534442.0,
2252,733815,1,2,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Sprague-Dawley/Wistar rat assessed as decrease in carrageenan-induced hyperalgesia at 10 mg/kg, po administered 4 hrs after carrageenan-challenge measured after 120 mins (Rvb = 31.4 +/- 3.7 g)",Other,23534442.0,
2253,733816,1,2,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Sprague-Dawley/Wistar rat assessed as decrease in carrageenan-induced hyperalgesia at 10 mg/kg, po administered 4 hrs after carrageenan-challenge measured after 60 mins (Rvb = 33.9 +/- 3.7 g)",Other,23534442.0,
2254,733817,1,2,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Sprague-Dawley/Wistar rat assessed as decrease in carrageenan-induced hyperalgesia at 10 mg/kg, po administered 4 hrs after carrageenan-challenge measured after 30 mins (Rvb = 34.8 +/- 3.0 g)",Other,23534442.0,
2255,733824,1,2,,103181002,2662,Unspecified,,,,,Antinociceptive activity in po dosed Swiss albino mouse assessed as reduction in number of acetic acid-induced writhing counted 5 mins after acetic acid challenge counted for 10 mins,Other,23534442.0,
2256,734521,2,5,,103181002,2662,Active,548483.0,19225.0,0.12,IC50,Inhibition of COX-2 in mouse RAW264.7 cells assessed as decrease in LPS-induced PGE2 production,Confirmatory,23353741.0,
2257,734522,2,5,,103181002,2662,Active,3915797.0,5743.0,0.1,IC50,Inhibition of COX-2 (unknown origin) by chemiluminescence assay,Confirmatory,23353741.0,
2258,734524,1,3,,103181002,2662,Unspecified,,,85.9,IC50,Antitumor activity against mouse B16F10 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay,Confirmatory,23353741.0,
2259,734525,2,5,,103181002,2662,Active,317373262.0,5742.0,27.5,IC50,Inhibition of COX-1 (unknown origin) by chemiluminescence assay,Confirmatory,23353741.0,
2260,734526,1,2,,103181002,2662,Active,,,15.6,IC50,Antitumor activity against human A549 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay,Confirmatory,23353741.0,
2261,734527,1,2,,103181002,2662,Active,,,40.8,IC50,Antitumor activity against human MCF7 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay,Confirmatory,23353741.0,
2262,738674,1,2,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for COX1 in human blood to IC50 for COX2 in human blood",Other,23473947.0,
2263,738675,2,5,,103181002,2662,Active,3915797.0,5743.0,0.87,IC50,Inhibition of COX2 in human blood assessed as TxB2 level after 1 hr by enzyme immunoassay,Confirmatory,23473947.0,
2264,738676,2,5,,103181002,2662,Active,317373262.0,5742.0,6.65,IC50,Inhibition of COX1 in human blood assessed as PGE2 level incubated for 15 mins prior to LPS-challenge measured after 24 hrs by enzyme immunoassay,Confirmatory,23473947.0,
2265,742598,2,2,,103181002,2662,Active,3915797.0,5743.0,,,Cyclooxygenase-2 inhibitor,Other,,
2266,743012,3,1,,144204686,2662,Active,,,23.7101,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
2267,743012,3,1,,144209162,2662,Inconclusive,,,68.3107,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
2268,743012,3,1,,144210916,2662,Active,,,27.305999999999997,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
2269,743014,3,1,,144204686,2662,Active,,,21.1317,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
2270,743014,3,1,,144209162,2662,Active,,,54.2611,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
2271,743014,3,1,,144210916,2662,Active,,,24.3365,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
2272,743015,3,1,,144204686,2662,Active,,,29.8493,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
2273,743015,3,1,,144209162,2662,Active,,,54.2611,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
2274,743015,3,1,,144210916,2662,Active,,,24.3365,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
2275,743033,3,1,,144204686,2662,Inconclusive,,,23.9145,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
2276,743033,3,1,,144209162,2662,Active,,,34.534,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
2277,743033,3,1,,144210916,2662,Active,,,43.6412,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
2278,743035,2,1,,144204686,2662,Active,124375976.0,367.0,23.9145,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2279,743035,2,1,,144209162,2662,Inconclusive,124375976.0,367.0,54.7327,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2280,743035,2,1,,144210916,2662,Inconclusive,124375976.0,367.0,61.6448,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2281,743036,2,1,,144204686,2662,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2282,743036,2,1,,144209162,2662,Inconclusive,124375976.0,367.0,48.7806,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2283,743036,2,1,,144210916,2662,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2284,743040,3,1,,144204686,2662,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2285,743040,3,1,,144209162,2662,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2286,743040,3,1,,144210916,2662,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2287,743041,3,1,,144204686,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
2288,743041,3,1,,144209162,2662,Inconclusive,,,68.3107,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
2289,743041,3,1,,144210916,2662,Inconclusive,,,68.5896,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
2290,743042,3,1,,144204686,2662,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2291,743042,3,1,,144209162,2662,Active,124375976.0,367.0,60.882,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2292,743042,3,1,,144210916,2662,Active,124375976.0,367.0,68.5896,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2293,743053,2,1,,144204686,2662,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2294,743053,2,1,,144209162,2662,Inconclusive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2295,743053,2,1,,144210916,2662,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2296,743054,2,1,,144204686,2662,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
2297,743054,2,1,,144209162,2662,Inconclusive,124375976.0,367.0,60.882,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
2298,743054,2,1,,144210916,2662,Inconclusive,124375976.0,367.0,68.5896,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
2299,743063,2,1,,144204686,2662,Inconclusive,124375976.0,367.0,23.0141,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2300,743063,2,1,,144209162,2662,Inconclusive,124375976.0,367.0,15.1326,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2301,743063,2,1,,144210916,2662,Inconclusive,124375976.0,367.0,16.0903,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2302,743064,3,1,,144204686,2662,Active,,,26.6032,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
2303,743064,3,1,,144209162,2662,Active,,,48.3603,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
2304,743064,3,1,,144210916,2662,Inconclusive,,,76.9588,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
2305,743065,3,1,,144204686,2662,Active,399498506.0,24831.0,23.7101,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2306,743065,3,1,,144209162,2662,Active,399498506.0,24831.0,30.5133,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2307,743065,3,1,,144210916,2662,Active,399498506.0,24831.0,54.4827,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2308,743066,3,1,,144204686,2662,Inconclusive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2309,743066,3,1,,144209162,2662,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2310,743066,3,1,,144210916,2662,Inconclusive,399498506.0,24831.0,10.8707,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2311,743067,2,1,,144204686,2662,Inconclusive,399498506.0,24831.0,25.6016,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
2312,743067,2,1,,144209162,2662,Inconclusive,399498506.0,24831.0,28.4766,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
2313,743067,2,1,,144210916,2662,Inconclusive,399498506.0,24831.0,44.9702,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
2314,743069,2,1,,144204686,2662,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2315,743069,2,1,,144209162,2662,Inconclusive,348019627.0,2099.0,27.4313,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2316,743069,2,1,,144210916,2662,Active,348019627.0,2099.0,54.941,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2317,743074,2,1,,144204686,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
2318,743074,2,1,,144209162,2662,Active,,,43.4757,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
2319,743074,2,1,,144210916,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
2320,743075,2,1,,144204686,2662,Active,348019627.0,2099.0,23.8911,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2321,743075,2,1,,144209162,2662,Inconclusive,348019627.0,2099.0,2.7431,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2322,743075,2,1,,144210916,2662,Inactive,348019627.0,2099.0,0.1949,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2323,743077,2,1,,144204686,2662,Active,348019627.0,2099.0,23.8911,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2324,743077,2,1,,144209162,2662,Inconclusive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2325,743077,2,1,,144210916,2662,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2326,743078,2,1,,144204686,2662,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2327,743078,2,1,,144209162,2662,Inconclusive,348019627.0,2099.0,27.4313,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2328,743078,2,1,,144210916,2662,Active,348019627.0,2099.0,61.6448,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2329,743079,3,1,,144204686,2662,Active,348019627.0,2099.0,7.4978,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2330,743079,3,1,,144209162,2662,Inconclusive,348019627.0,2099.0,76.6459,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2331,743079,3,1,,144210916,2662,Inconclusive,348019627.0,2099.0,19.3312,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2332,743080,3,1,,144204686,2662,Inactive,348019627.0,2099.0,6.6824,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2333,743080,3,1,,144209162,2662,Inconclusive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2334,743080,3,1,,144210916,2662,Inconclusive,348019627.0,2099.0,21.6899,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2335,743081,3,1,,144204686,2662,Inconclusive,,,9.4392,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
2336,743081,3,1,,144209162,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
2337,743081,3,1,,144210916,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
2338,743083,3,1,,144204686,2662,Active,119597822.0,1588.0,29.8493,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
2339,743083,3,1,,144209162,2662,Active,119597822.0,1588.0,30.5133,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
2340,743083,3,1,,144210916,2662,Inconclusive,119597822.0,1588.0,68.5896,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
2341,743084,3,1,,144204686,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
2342,743084,3,1,,144209162,2662,Active,,,54.2611,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
2343,743084,3,1,,144210916,2662,Inconclusive,,,68.5896,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
2344,743085,3,1,,144204686,2662,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
2345,743085,3,1,,144209162,2662,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
2346,743085,3,1,,144210916,2662,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
2347,743086,3,1,,144204686,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
2348,743086,3,1,,144209162,2662,Inconclusive,,,68.3107,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
2349,743086,3,1,,144210916,2662,Inconclusive,,,68.5896,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
2350,743091,2,1,,144204686,2662,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
2351,743091,2,1,,144209162,2662,Inconclusive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
2352,743091,2,1,,144210916,2662,Inconclusive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
2353,743094,3,1,,144204686,2662,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
2354,743094,3,1,,144209162,2662,Inconclusive,216409692.0,5468.0,21.7895,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
2355,743094,3,1,,144210916,2662,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
2356,743122,2,1,,144204686,2662,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
2357,743122,2,1,,144209162,2662,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
2358,743122,2,1,,144210916,2662,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
2359,743126,1,1,,49665790,2662,Inactive,119580345.0,50487.0,,,QFRET-based biochemical high throughput primary assay to identify inhibitors of human group III secreted phospholipase A2 enzyme (HGIII-sPLA2),Screening,,
2360,743139,2,1,,144204686,2662,Inconclusive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
2361,743139,2,1,,144209162,2662,Inconclusive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
2362,743139,2,1,,144210916,2662,Inconclusive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
2363,743140,2,1,,144204686,2662,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
2364,743140,2,1,,144209162,2662,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
2365,743140,2,1,,144210916,2662,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
2366,743191,3,1,,144209162,2662,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
2367,743191,3,1,,144210916,2662,Inconclusive,216409692.0,5468.0,54.941,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
2368,743191,3,1,,170464693,2662,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
2369,743194,3,1,,144209162,2662,Inconclusive,,,61.4111,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
2370,743194,3,1,,144210916,2662,Inconclusive,,,61.6448,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
2371,743194,3,1,,170464693,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
2372,743199,2,1,,144209162,2662,Inconclusive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
2373,743199,2,1,,144210916,2662,Inconclusive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
2374,743199,2,1,,170464693,2662,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
2375,743202,4,1,,144209162,2662,Inconclusive,20149576.0,4780.0,68.3107,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
2376,743202,4,1,,144210916,2662,Inconclusive,20149576.0,4780.0,30.6379,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
2377,743202,4,1,,170464693,2662,Active,20149576.0,4780.0,26.6011,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
2378,743203,3,1,,144209162,2662,Inconclusive,,,68.3107,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
2379,743203,3,1,,144210916,2662,Active,,,61.1306,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
2380,743203,3,1,,170464693,2662,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
2381,743209,3,1,,144209162,2662,Inconclusive,,,54.7327,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
2382,743209,3,1,,144210916,2662,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
2383,743209,3,1,,170464693,2662,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
2384,743210,4,1,,144209162,2662,Inconclusive,4504517.0,3315.0,54.7327,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
2385,743210,4,1,,144210916,2662,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
2386,743210,4,1,,170464693,2662,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
2387,743211,3,1,,144209162,2662,Inconclusive,,,54.7327,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
2388,743211,3,1,,144210916,2662,Active,,,54.941,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
2389,743211,3,1,,170464693,2662,Inconclusive,,,33.4889,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
2390,743212,3,1,,144209162,2662,Inconclusive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
2391,743212,3,1,,144210916,2662,Inconclusive,216409690.0,5467.0,3.0896,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
2392,743212,3,1,,170464693,2662,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
2393,743213,3,1,,144209162,2662,Inconclusive,,,48.7806,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
2394,743213,3,1,,144210916,2662,Inconclusive,,,61.6448,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
2395,743213,3,1,,170464693,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
2396,743215,3,1,,144209162,2662,Inconclusive,216409690.0,5467.0,0.0274,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
2397,743215,3,1,,144210916,2662,Inconclusive,216409690.0,5467.0,54.941,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
2398,743215,3,1,,170464693,2662,Inconclusive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
2399,743217,3,1,,144209162,2662,Inconclusive,325495553.0,9971.0,61.4111,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
2400,743217,3,1,,144210916,2662,Inconclusive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
2401,743217,3,1,,170464693,2662,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
2402,743218,3,1,,144209162,2662,Inconclusive,,,48.7806,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
2403,743218,3,1,,144210916,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
2404,743218,3,1,,170464693,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
2405,743219,3,1,,144209162,2662,Active,20149576.0,4780.0,14.859000000000002,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
2406,743219,3,1,,144210916,2662,Active,20149576.0,4780.0,13.6854,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
2407,743219,3,1,,170464693,2662,Inconclusive,20149576.0,4780.0,26.6011,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
2408,743220,3,1,,144209162,2662,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
2409,743220,3,1,,144210916,2662,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
2410,743220,3,1,,170464693,2662,Inconclusive,325495553.0,9971.0,2.9847,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
2411,743221,3,1,,144209162,2662,Inconclusive,,,54.7327,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
2412,743221,3,1,,144210916,2662,Inconclusive,,,27.5357,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
2413,743221,3,1,,170464693,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
2414,743222,3,1,,144209162,2662,Inconclusive,216409708.0,7421.0,15.4258,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
2415,743222,3,1,,144210916,2662,Inconclusive,216409708.0,7421.0,2.7536,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
2416,743222,3,1,,170464693,2662,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
2417,743223,3,1,,144209162,2662,Inconclusive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
2418,743223,3,1,,144210916,2662,Inconclusive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
2419,743223,3,1,,170464693,2662,Inconclusive,216409708.0,7421.0,30.1065,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
2420,743224,3,1,,144209162,2662,Inconclusive,,,54.7327,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
2421,743224,3,1,,144210916,2662,Inconclusive,,,54.941,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
2422,743224,3,1,,170464693,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
2423,743225,3,1,,144209162,2662,Active,,,48.7806,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
2424,743225,3,1,,144210916,2662,Inconclusive,,,54.941,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
2425,743225,3,1,,170464693,2662,Inconclusive,,,26.8325,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
2426,743226,2,1,,144209162,2662,Inconclusive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
2427,743226,2,1,,144210916,2662,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
2428,743226,2,1,,170464693,2662,Inconclusive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
2429,743227,2,1,,144209162,2662,Inconclusive,216409690.0,5467.0,59.099,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
2430,743227,2,1,,144210916,2662,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
2431,743227,2,1,,170464693,2662,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
2432,743228,3,1,,144209162,2662,Inconclusive,4504517.0,3315.0,54.7327,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
2433,743228,3,1,,144210916,2662,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
2434,743228,3,1,,170464693,2662,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
2435,743238,1,1,,49665790,2662,Inactive,,,,,High Content Cell-Based Imaging Primary HTS to Identify Small Molecules Involved in X-Chromosome Reactivation and Reprogramming Measured in Cell-Based System Using Imaging - 7015-01_Activator_SinglePoint_HTS_Activity_Set2,Screening,,
2436,743239,2,1,,144209162,2662,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
2437,743239,2,1,,144210916,2662,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
2438,743239,2,1,,170464693,2662,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
2439,743240,2,1,,144209162,2662,Inconclusive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
2440,743240,2,1,,144210916,2662,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
2441,743240,2,1,,170464693,2662,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
2442,743241,2,1,,144209162,2662,Inconclusive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
2443,743241,2,1,,144210916,2662,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
2444,743241,2,1,,170464693,2662,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
2445,743242,2,1,,144209162,2662,Inconclusive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
2446,743242,2,1,,144210916,2662,Inconclusive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
2447,743242,2,1,,170464693,2662,Inconclusive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
2448,743244,1,1,,124890934,2662,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
2449,743244,1,1,,144204686,2662,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
2450,743247,1,2,,49665790,2662,Inactive,,,,,Inhibition of Alexa 488-Fibronectin deposition #on AH1F cell monolayers Measured in Cell-Based System Using Plate Reader - 7059-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2451,743255,1,1,,49665790,2662,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Primary Screen,Confirmatory,,
2452,743266,1,2,,49665790,2662,Inactive,296080761.0,5745.0,,Potency,qHTS of PTHR Inhibitors: Primary Screen,Confirmatory,,
2453,743268,1,1,,172080831,2662,Inactive,,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of the NIH Clinical Collection: biochemical high-throughput screening assay to identify compounds that enhance or quench fluorescence of a Cy5-labeled substrate oligonucliotide bound to E. coli SSB,Screening,,
2454,743269,1,1,,49665790,2662,Inactive,2853980.0,,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
2455,743269,1,1,,49665790,2662,Inactive,6708281.0,11168.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
2456,743270,1,1,,172080831,2662,Inactive,125541954.0,,,,Fluorescence polarization based primary biochemical high throughput screening  assay of the NIH Clinical Collections to identify inhibitors of hepatitis C non-structural protein 3 helicase,Screening,,
2457,743271,1,1,,172080831,2662,Inactive,,,,,Biochemical high throughput counterscreening assay of the NIH Clinical Collection for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): fluorescence polarization based assay to identify compounds that can displace E. coli single stranded binding protein,Screening,,
2458,743272,1,1,,172080831,2662,Inactive,,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of the NIH Clinical Collection: a biochemical high-throughput screening assay to identify compounds that cause fluorescent interference,Screening,,
2459,743279,1,2,,49665790,2662,Inactive,10835145.0,3553.0,,,qHTS for Inhibitors of Inflammasome Signaling:  IL-1-beta AlphaLISA Primary Screen,Screening,,
2460,743288,1,1,,17389545,2662,Inactive,,,,Potency,qHTS assay for cell viability of HEK293 cells,Confirmatory,,
2461,743292,1,1,,17389545,2662,Inactive,,,,Potency,qHTS assay for cell viability of the p53RE-bla HCT-116 cell line,Confirmatory,,
2462,743322,2,1,,124890934,2662,Inactive,,,,Potency,qHTS profiling for inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
2463,743322,2,1,,174007280,2662,Inactive,,,,Potency,qHTS profiling for inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
2464,743323,2,1,,124890934,2662,Inactive,,,,Potency,qHTS profiling for inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
2465,743323,2,1,,174007280,2662,Inactive,,,11.8754,Potency,qHTS profiling for inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
2466,743324,2,1,,124890934,2662,Inactive,,,,Potency,qHTS profiling for inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
2467,743324,2,1,,174007280,2662,Inactive,,,,Potency,qHTS profiling for inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
2468,743344,1,1,,174007280,2662,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
2469,743345,1,1,,174007280,2662,Inactive,,,9.4329,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
2470,743346,1,1,,174007280,2662,Inactive,,,10.5839,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation (Rep 2),Confirmatory,,
2471,743347,1,1,,174007280,2662,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
2472,743397,1,1,,49665790,2662,Inactive,,,,,HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2473,743398,1,1,,49665790,2662,Inactive,,,,,Wnt/Beta-catenin HTS Measured in Cell-Based System Using Plate Reader - 2161-01_Activator_SinglePoint_HTS_Activity,Screening,,
2474,743512,1,1,,103181002,2662,Active,,,0.0069,Ki,Inhibition of Sulfurihydrogenibium yellowstonense YO3AOP1 recombinant carbonic anhydrase preincubated for 15 mins by CO2 hydration stopped-flow assay,Confirmatory,22883029.0,
2475,743513,1,1,,103181002,2662,Inconclusive,,,,Ki,Inhibition of Helicobacter pylori recombinant alpha carbonic anhydrase preincubated for 15 mins by CO2 hydration stopped-flow assay,Confirmatory,22883029.0,
2476,743514,2,3,,103181002,2662,Active,115456.0,760.0,0.021,Ki,Inhibition of human recombinant carbonic anhydrase 2 preincubated for 15 mins by CO2 hydration stopped-flow assay,Confirmatory,22883029.0,
2477,743515,2,3,,103181002,2662,Unspecified,115449.0,759.0,50.0,Ki,Inhibition of human recombinant carbonic anhydrase 1 preincubated for 15 mins by CO2 hydration stopped-flow assay,Confirmatory,22883029.0,
2478,744415,1,1,,103181002,2662,Active,,,0.11599999999999999,Ki,Inhibition of recombinant full length Candida glabrata NCE103 expressed in Escherichia coli BL21 preincubated for 15 mins by stopped-flow CO2 hydrase assay,Confirmatory,23511020.0,
2479,744750,1,2,,103181002,2662,Unspecified,,,,,Antiinflammatory activity in ip dosed Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw edema measured after 2 hrs plethysmometric analysis,Other,23528298.0,
2480,744751,1,2,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for ovine COX1 to IC50 for ovine COX2",Other,23528298.0,
2481,744752,2,3,,103181002,2662,Active,3914304.0,443460.0,0.26,IC50,Inhibition of ovine COX2-mediated prostaglandin alpha production by enzyme immuno assay,Confirmatory,23528298.0,
2482,744753,2,3,,103181002,2662,Unspecified,754286265.0,443551.0,100.0,IC50,Inhibition of ovine COX1-mediated prostaglandin alpha production by enzyme immuno assay,Confirmatory,23528298.0,
2483,746180,1,1,,103181002,2662,Active,,,6.0,IC50,Inhibition of hyaluronan-induced CD44 antigen variant exon 6 activity in mouse APC10.1 cells expressing Has2 assessed as decrease in cell survival after 18 hrs by MTS assay,Confirmatory,23517721.0,
2484,746181,1,1,,103181002,2662,Active,,,17.5,IC50,Inhibition of hyaluronan-induced CD44 antigen variant exon 6 activity in human HCA-7 cells expressing Has2 assessed as decrease in cell survival after 18 hrs by MTS assay,Confirmatory,23517721.0,
2485,746182,1,1,,103181002,2662,Active,,,18.3,IC50,Inhibition of hyaluronan-induced CD44 antigen variant exon 6 activity in human HT-29 cells expressing Has2 assessed as decrease in cell survival after 18 hrs by MTS assay,Confirmatory,23517721.0,
2486,746183,1,2,,103181002,2662,Active,,,2.0,IC50,Cytotoxicity against human HCA-7 cells assessed as decrease in cell survival after 18 hrs by MTS assay,Confirmatory,23517721.0,
2487,746184,1,1,,103181002,2662,Active,,,3.0,IC50,Cytotoxicity against human HT-29 cells assessed as decrease in cell survival after 18 hrs by MTS assay,Confirmatory,23517721.0,
2488,746187,1,2,,103181002,2662,Active,,,4.2,IC50,Cytotoxicity against mouse APC10.1 cells assessed as decrease in cell survival after 18 hrs by MTS assay,Confirmatory,23517721.0,
2489,746188,1,2,,103181002,2662,Unspecified,,,,,Cytotoxicity against human HCA-7 cells assessed as growth inhibition after 18 hrs by MTS assay,Other,23517721.0,
2490,746189,1,1,,103181002,2662,Unspecified,,,,,Cytotoxicity against human HT-29 cells assessed as growth inhibition after 18 hrs by MTS assay,Other,23517721.0,
2491,746190,1,1,,103181002,2662,Unspecified,,,,,Inhibition of hyaluronan-induced CD44 antigen variant exon 6 activity in mouse APC10.1 cells assessed as cell growth inhibition after 18 hrs by MTS assay,Other,23517721.0,
2492,746193,1,2,,103181002,2662,Active,,,,,Inhibition of hyaluronan-induced CD44 antigen variant exon 6 activity in human HT29 cells assessed as decrease in 5-LOX expression at 10 uM,Other,23517721.0,
2493,746194,1,2,,103181002,2662,Active,,,,,Inhibition of hyaluronan-induced CD44 antigen variant exon 6 activity in human HT29 cells assessed as decrease in COX-2 expression at 10 uM,Other,23517721.0,
2494,753948,1,1,,103181002,2662,Unspecified,,,,,Selectivity ratio of IC50 for platelet COX1 in human whole blood to IC50 for monocyte COX2 in human whole blood,Other,23680444.0,
2495,753949,4,2,,103181002,2662,Unspecified,317373262.0,5742.0,12530.0,IC50,Inhibition of platelet COX1 in human whole blood assessed as inhibition of serum TXB2 production after 1 hr by radioimmunoassay,Confirmatory,23680444.0,
2496,753950,4,2,,103181002,2662,Unspecified,3915797.0,5743.0,390.0,IC50,Inhibition of monocyte COX2 in human whole blood assessed as inhibition of LPS-induced plasma PGE2 production after 24 hrs by radioimmunoassay,Confirmatory,23680444.0,
2497,753951,1,1,,103181002,2662,Unspecified,,,,,"Analgesic activity in Swiss albino mouse inflammatory pain model assessed as inhibition of acetic acid-induced writhing at 40 mg/kg, po administered 30 mins prior to acetic acid challenge relative to vehicle-treated control",Other,23680444.0,
2498,753952,1,1,,103181002,2662,Unspecified,,,,,"Analgesic activity in Swiss albino mouse inflammatory pain model assessed as inhibition of acetic acid-induced writhing at 20 mg/kg, po administered 30 mins prior to acetic acid challenge relative to vehicle-treated control",Other,23680444.0,
2499,753953,1,1,,103181002,2662,Unspecified,,,,,"Analgesic activity in Swiss albino mouse inflammatory pain model assessed as inhibition of acetic acid-induced writhing at 10 mg/kg, po administered 30 mins prior to acetic acid challenge relative to vehicle-treated control",Other,23680444.0,
2500,753954,1,1,,103181002,2662,Unspecified,,,,,"Analgesic activity in Swiss albino mouse inflammatory pain model assessed as inhibition of acetic acid-induced writhing at 5 mg/kg, po administered 30 mins prior to acetic acid challenge relative to vehicle-treated control",Other,23680444.0,
2501,753955,1,1,,103181002,2662,Unspecified,,,,,"Analgesic activity in Swiss albino mouse inflammatory pain model assessed as inhibition of acetic acid-induced writhing at 1 mg/kg, po administered 30 mins prior to acetic acid challenge relative to vehicle-treated control",Other,23680444.0,
2502,753958,1,1,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for COX1 in mouse J774 cells to IC50 for COX2 in mouse J774 cells",Other,23680444.0,
2503,753959,2,3,,103181002,2662,Active,548483.0,19225.0,0.061,IC50,Inhibition of COX2 in mouse J774 cells assessed as inhibition of LPS-induced PGE2 production by radioimmunoassay,Confirmatory,23680444.0,
2504,753960,2,3,,103181002,2662,Active,129900.0,19224.0,3.84,IC50,Inhibition of COX1 in mouse J774 cells using arachidonic acid as substrate assessed as inhibition of PGE2 production incubated for 15 mins prior to substrate addition measured after 30 mins by radioimmunoassay,Confirmatory,23680444.0,
2505,755519,1,2,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for ovine COX1 to IC50 for human recombinant COX2",Other,23706267.0,
2506,755520,2,3,,103181002,2662,Unspecified,754286265.0,443551.0,1.0,IC50,Inhibition of ovine COX1 by fluorescence assay,Confirmatory,23706267.0,
2507,755521,2,3,,103181002,2662,Active,3915797.0,5743.0,0.02,IC50,Inhibition of human recombinant COX2 by fluorescence assay,Confirmatory,23706267.0,
2508,757858,2,3,,103181002,2662,Active,17380162.0,5170.0,48.0,IC50,Inhibition of PDK1-mediated Akt activation in human PC3 cells after 2 hrs by Western blotting analysis,Confirmatory,23735281.0,
2509,762999,1,5,,103181002,2662,Unspecified,3914304.0,443460.0,,,Inhibition of ovine COX2 assessed as PGF2alpha production by reduction of PGH2 with stannous chloride at 40 uM by enzyme immunoassay relative to control,Other,23914900.0,
2510,763000,1,5,,103181002,2662,Unspecified,754286265.0,443551.0,,,Inhibition of ovine COX1 assessed as PGF2alpha production by reduction of PGH2 with stannous chloride at 40 uM by enzyme immunoassay relative to control,Other,23914900.0,
2511,763514,1,1,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for ovine COX1 to IC50 for ovine COX2",Other,23769654.0,
2512,763515,2,3,,103181002,2662,Active,3914304.0,443460.0,0.15,IC50,Inhibition of ovine COX2 using arachidonic acid as substrate assessed as production of PGF2alpha preincubated for 10 mins followed by substrate addition measured after 2 mins by EIA in presence of stannous chloride,Confirmatory,23769654.0,
2513,763516,2,3,,103181002,2662,Unspecified,754286265.0,443551.0,30.0,IC50,Inhibition of ovine COX1 using arachidonic acid as substrate assessed as production of PGF2alpha preincubated for 10 mins followed by substrate addition measured after 2 mins by EIA in presence of stannous chloride,Confirmatory,23769654.0,
2514,763517,1,5,,103181002,2662,Unspecified,3914304.0,443460.0,,,Inhibition of ovine COX2 using arachidonic acid as substrate assessed as production of PGF2alpha at 30 uM preincubated for 10 mins followed by substrate addition measured after 2 mins by EIA in presence of stannous chloride relative to control,Other,23769654.0,
2515,763518,1,5,,103181002,2662,Unspecified,754286265.0,443551.0,,,Inhibition of ovine COX1 using arachidonic acid as substrate assessed as production of PGF2alpha at 30 uM preincubated for 10 mins followed by substrate addition measured after 2 mins by EIA in presence of stannous chloride relative to control,Other,23769654.0,
2516,764717,2,3,,103181002,2662,Active,1168744.0,766.0,2.17,Ki,Inhibition of human cytosolic carbonic anhydrase 7 preincubated for 15 mins by stopped flow CO2 hydration assay,Confirmatory,23867389.0,
2517,764718,2,3,,103181002,2662,Active,115456.0,760.0,0.021,Ki,Inhibition of human cytosolic carbonic anhydrase 2 preincubated for 15 mins by stopped flow CO2 hydration assay,Confirmatory,23867389.0,
2518,764719,2,3,,103181002,2662,Unspecified,115449.0,759.0,50.0,Ki,Inhibition of human cytosolic carbonic anhydrase 1 preincubated for 15 mins by stopped flow CO2 hydration assay,Confirmatory,23867389.0,
2519,770581,1,1,,103181002,2662,Unspecified,,,,,Selectivity ratio of Ki for human carbonic anhydrase 2 to Ki for human carbonic anhydrase 9,Other,23965175.0,
2520,770582,2,3,,103181002,2662,Active,5915866.0,771.0,0.018000000000000002,Ki,Inhibition of human membrane bound carbonic anhydrase 12 preincubated for 15 mins at room temperature followed by 72 hrs at 4 degC by stopped flow CO2 hydration assay,Confirmatory,23965175.0,
2521,770583,2,3,,103181002,2662,Active,83300925.0,768.0,0.016,Ki,Inhibition of human membrane bound carbonic anhydrase 9 preincubated for 15 mins at room temperature followed by 72 hrs at 4 degC by stopped flow CO2 hydration assay,Confirmatory,23965175.0,
2522,770584,2,3,,103181002,2662,Active,1168744.0,766.0,2.17,Ki,Inhibition of human cytosolic carbonic anhydrase 7 preincubated for 15 mins at room temperature followed by 72 hrs at 4 degC by stopped flow CO2 hydration assay,Confirmatory,23965175.0,
2523,770585,2,3,,103181002,2662,Active,115456.0,760.0,0.021,Ki,Inhibition of human cytosolic carbonic anhydrase 2 preincubated for 15 mins at room temperature followed by 72 hrs at 4 degC by stopped flow CO2 hydration assay,Confirmatory,23965175.0,
2524,770586,2,3,,103181002,2662,Unspecified,115449.0,759.0,50.0,Ki,Inhibition of human cytosolic carbonic anhydrase 1 preincubated for 15 mins at room temperature followed by 72 hrs at 4 degC by stopped flow CO2 hydration assay,Confirmatory,23965175.0,
2525,778725,1,1,,103181002,2662,Active,,,0.705,Ki,Inhibition of recombinant Leishmania donovani chagasi beta-carbonic anhydrase expressed in baculovirus infected insect Sf9 cells incubated for 15 mins prior to testing by stopped flow CO2 hydrase assay,Confirmatory,23977960.0,
2526,925142,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: R031014,Other,,
2527,925143,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: R031014,Other,,
2528,925144,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: R031014,Other,,
2529,925145,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: R031014,Other,,
2530,925146,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: R031014,Other,,
2531,925147,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: R031014,Other,,
2532,925148,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: R031014,Other,,
2533,925149,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: R031014,Other,,
2534,925150,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: R031014,Other,,
2535,925151,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: R031014,Other,,
2536,925152,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: R031014,Other,,
2537,925153,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: R031014,Other,,
2538,925154,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: R031014,Other,,
2539,925155,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: R031014,Other,,
2540,936301,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: R031014,Other,,
2541,936302,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: R031014,Other,,
2542,936303,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: R031014,Other,,
2543,936304,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: R031014,Other,,
2544,936305,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: R031014,Other,,
2545,936306,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: R031014,Other,,
2546,936307,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: R031014,Other,,
2547,936308,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: R031014,Other,,
2548,936309,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: R031014,Other,,
2549,936310,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: R031014,Other,,
2550,936311,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: R031014,Other,,
2551,936312,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: R031014,Other,,
2552,936313,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: R031014,Other,,
2553,936314,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: R031014,Other,,
2554,936315,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: R031014,Other,,
2555,936316,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: R031014,Other,,
2556,936317,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: R031014,Other,,
2557,936318,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: R031014,Other,,
2558,936319,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: R031014,Other,,
2559,936320,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: R031014,Other,,
2560,936321,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: R031014,Other,,
2561,936322,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: R031014,Other,,
2562,936323,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: R031014,Other,,
2563,936324,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: R031014,Other,,
2564,936325,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: R031014,Other,,
2565,936326,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: R031014,Other,,
2566,936327,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: R031014,Other,,
2567,936328,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: R031014,Other,,
2568,957778,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: R031014,Other,,
2569,957779,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: R031014,Other,,
2570,957780,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: R031014,Other,,
2571,957781,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: R031014,Other,,
2572,957782,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: R031014,Other,,
2573,957783,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: R031014,Other,,
2574,957784,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: R031014,Other,,
2575,957785,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: R031014,Other,,
2576,957786,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: R031014,Other,,
2577,957787,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: R031014,Other,,
2578,957788,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: R031014,Other,,
2579,957789,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: R031014,Other,,
2580,957790,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: R031014,Other,,
2581,957791,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: R031014,Other,,
2582,957792,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: R031014,Other,,
2583,968847,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: R031014,Other,,
2584,968848,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: R031014,Other,,
2585,968849,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: R031014,Other,,
2586,968850,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: R031014,Other,,
2587,968851,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: R031014,Other,,
2588,968852,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: R031014,Other,,
2589,968853,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: R031014,Other,,
2590,968854,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: R031014,Other,,
2591,968855,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: R031014,Other,,
2592,968856,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: R031014,Other,,
2593,968857,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: R031014,Other,,
2594,968858,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: R031014,Other,,
2595,968859,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: R031014,Other,,
2596,969491,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: R031014,Other,,
2597,969492,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: R031014,Other,,
2598,969493,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: R031014,Other,,
2599,969494,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: R031014,Other,,
2600,969495,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: R031014,Other,,
2601,969496,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: R031014,Other,,
2602,969497,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: R031014,Other,,
2603,969498,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: R031014,Other,,
2604,969499,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: R031014,Other,,
2605,971522,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: R031014,Other,,
2606,971523,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: R031014,Other,,
2607,971524,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: R031014,Other,,
2608,971525,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: R031014,Other,,
2609,971526,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: R031014,Other,,
2610,971527,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: R031014,Other,,
2611,971528,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: R031014,Other,,
2612,971529,1,3,,103181002,2662,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: R031014,Other,,
2613,977599,1,1,,103181002,2662,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
2614,977602,1,2,,103181002,2662,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
2615,977608,3,1,,46392808,2662,Active,47168469.0,,0.021,IC50,Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB,Other,14736236.0,
2616,1053175,2,1,,178126925,2662,Inactive,,,,,A screen for compounds that inhibit growth of Escherichia coli,Other,,
2617,1053194,1,1,,124890934,2662,Inactive,,,,Potency,Cell Proliferation Assay Versus the ED40515 IL2 Independent  ATL cell lines,Confirmatory,,
2618,1053195,1,1,,124890934,2662,Inactive,,,,Potency,Cell Proliferation Assay Versus the ED40515 IL2 Dependent  ATL cell lines,Confirmatory,,
2619,1053197,1,1,,49665790,2662,Inactive,74734243.0,54414.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of sialic acid acetylesterase (SIAE),Screening,,
2620,1053259,1,4,,103181002,2662,Unspecified,118206.0,1813.0,,,Antagonist activity at human recombinant dopamine D2 long receptor expressed in CHOK1 cells coexpressing mitochondrial apoaequorin assessed as inhibition of agonist-induced effect at 8 uM after 15 mins by luminometric analysis relative to haloperidol,Other,24088053.0,
2621,1053261,1,4,,103181002,2662,Unspecified,118206.0,1813.0,,,Agonist activity at human recombinant dopamine D2 long receptor expressed in CHOK1 cells coexpressing mitochondrial apoaequorin at 8 uM by luminometric analysis relative to quinpirol,Other,24088053.0,
2622,1053263,1,4,,103181002,2662,Unspecified,118228.0,1812.0,,,Antagonist activity at human recombinant dopamine D1 receptor expressed in CHOK1 cells assessed as inhibition of agonist-induced cAMP accumulation at 8 uM preincubated for 10 mins prior to agonist addition measured after 30 mins by HTRF assay relative to SCH23390,Other,24088053.0,
2623,1053265,1,4,,103181002,2662,Unspecified,118228.0,1812.0,,,Agonist activity at human recombinant dopamine D1 receptor expressed in CHOK1 cells assessed as stimulation of cAMP accumulation at 8 uM after 30 mins by HTRF assay relative to SKF81297,Other,24088053.0,
2624,1055834,1,2,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for COX1 (unknown origin) to IC50 for human recombinant COX2",Other,24211633.0,
2625,1055837,2,3,,103181002,2662,Unspecified,3915797.0,5743.0,,IC50,Inhibition of human recombinant COX2 expressed in insect cell expression system using TMPD and arachidonic acid as substrate incubated for 1 min prior to substrate addition by spectrophotometry,Confirmatory,24211633.0,
2626,1055838,2,3,,103181002,2662,Active,317373262.0,5742.0,25.74,IC50,Inhibition of COX1 (unknown origin),Confirmatory,24211633.0,
2627,1057592,1,4,,103181002,2662,Unspecified,3915797.0,5743.0,,,Inhibition of human recombinant COX2 using arachidonic acid as substrate at 10 uM incubated 5 mins prior to substrate addition measured after 5 mins by HPLC analysis,Other,24171493.0,
2628,1057593,1,4,,103181002,2662,Unspecified,754286265.0,443551.0,,,Inhibition of ovine COX1 using arachidonic acid as substrate at 10 uM incubated 5 mins prior to substrate addition measured after 5 mins by HPLC analysis,Other,24171493.0,
2629,1057875,1,4,,103181002,2662,Unspecified,3915797.0,5743.0,,,Inhibition of LPS-stimulated COX2 in human whole blood assessed as reduction in PGF2alpha production by measuring remaining activity at 5 uM preincubated for 15 mins followed by LPS addition measured after 24 hrs by LC-MS/MS analysis,Other,24183739.0,
2630,1057877,1,4,,103181002,2662,Unspecified,3915797.0,5743.0,,,Inhibition of LPS-stimulated COX2 in human whole blood assessed as reduction in PGE2 production by measuring remaining activity at 5 uM preincubated for 15 mins followed by LPS addition measured after 24 hrs by LC-MS/MS analysis,Other,24183739.0,
2631,1057882,1,2,,103181002,2662,Unspecified,,,,,Cytotoxicity against IL-1beta/TNFalpha-stimulated human HeLa cells assessed as cell viability at 100 uM after 24 hrs by WST-1 assay,Other,24183739.0,
2632,1057883,1,2,,103181002,2662,Unspecified,,,,,Cytotoxicity against IL-1beta/TNFalpha-stimulated human HeLa cells assessed as cell viability up to 10 uM after 24 hrs by WST-1 assay,Other,24183739.0,
2633,1057885,1,4,,103181002,2662,Inactive,7387730.0,9536.0,,,Inhibition of mPGES-1 in human HeLa cells using PGH2 as substrate assessed as inhibition of IL-1beta/TNFalpha-stimulated PGE2 production at 1 to 10 uM after 24 hrs by LC-MS/MS analysis,Other,24183739.0,
2634,1057886,1,4,,103181002,2662,Active,7387730.0,9536.0,,,Inhibition of mPGES-1 in human HeLa cells using PGH2 as substrate assessed as inhibition of IL-1beta/TNFalpha-stimulated PGE2 production at 100 uM after 24 hrs by LC-MS/MS analysis,Other,24183739.0,
2635,1060765,2,3,,103181002,2662,Active,1168744.0,766.0,2.17,Ki,Inhibition of human recombinant carbonic anhydrase 7 preincubated for 15 mins by stopped flow CO2 hydration assay,Confirmatory,24287559.0,
2636,1060940,1,1,,103181002,2662,Unspecified,,,,,Ratio of IC50 for COX-2 positive mouse APC10.1 cells overexpressing HAS-2 to IC50 for COX-2 positive mouse APC10.1 cells transfected with CD44v6shRNA overexpressing HAS-2,Other,24295787.0,
2637,1060941,1,1,,103181002,2662,Unspecified,,,,,Ratio of IC50 for COX-2 positive human HCA-7 cells to IC50 for COX-2 positive human HCA-7 cells transfected with CD44v6shRNA,Other,24295787.0,
2638,1060942,1,2,,103181002,2662,Unspecified,,,,,Ratio of IC50 for COX-2 positive human HT-29 cells to IC50 for COX-2 positive human HT-29 cells transfected with CD44v6shRNA,Other,24295787.0,
2639,1060946,1,1,,103181002,2662,Active,,,,,Inhibition of hyaluronan-induced CD44v6 in human HCA-7 cells transfected with Has2cDNA assessed as downregulation of 5-LOX protein expression at 5 uM after 24 hrs by Western blotting analysis,Other,24295787.0,
2640,1060947,1,1,,103181002,2662,Active,,,,,Inhibition of hyaluronan-induced CD44v6 in human HCA-7 cells transfected with Has2cDNA assessed as downregulation of COX-2 protein expression at 5 uM after 24 hrs by Western blotting analysis,Other,24295787.0,
2641,1060948,1,1,,103181002,2662,Active,,,,,Inhibition of hyaluronan-induced CD44v6 in human HCA-7 cells transfected with Has2cDNA assessed as downregulation of COX-1 protein expression at 5 uM after 24 hrs by Western blotting analysis,Other,24295787.0,
2642,1060954,1,1,,103181002,2662,Active,,,1.3,IC50,Cytotoxicity against COX-2 positive mouse APC10.1 cells transfected with CD44v6shRNA overexpressing HAS-2 assessed as growth inhibition after 48 hrs by MTT assay,Confirmatory,24295787.0,
2643,1060955,1,1,,103181002,2662,Active,,,0.75,IC50,Cytotoxicity against COX-2 positive human HCA-7 cells transfected with CD44v6shRNA assessed as growth inhibition after 48 hrs by MTT assay,Confirmatory,24295787.0,
2644,1060956,1,2,,103181002,2662,Active,,,0.7,IC50,Cytotoxicity against COX-2 positive human HT-29 cells transfected with CD44v6shRNA assessed as growth inhibition after 48 hrs by MTT assay,Confirmatory,24295787.0,
2645,1060957,1,2,,103181002,2662,Active,,,6.9,IC50,Cytotoxicity against COX-2 negative human SW480 cells assessed as growth inhibition by CellTiter-96 AQueous assay,Confirmatory,24295787.0,
2646,1060958,1,1,,103181002,2662,Active,,,4.9,IC50,Cytotoxicity against COX-2 positive human HCA-7 cells assessed as growth inhibition by CellTiter-96 AQueous assay,Confirmatory,24295787.0,
2647,1060959,1,1,,103181002,2662,Active,,,13.4,IC50,Cytotoxicity against COX-2 positive mouse APC10.1 cells overexpressing HAS-2 assessed as growth inhibition by CellTiter-96 AQueous assay,Confirmatory,24295787.0,
2648,1060960,1,2,,103181002,2662,Active,,,5.7,IC50,Cytotoxicity against COX-2 positive human HT-29 cells assessed as growth inhibition by CellTiter-96 AQueous assay,Confirmatory,24295787.0,
2649,1060962,2,3,,103181002,2662,Active,3915797.0,5743.0,0.057,IC50,Inhibition of COX-2 (unknown origin) by ELISA,Confirmatory,24295787.0,
2650,1060963,2,3,,103181002,2662,Active,754286265.0,443551.0,22.9,IC50,Inhibition of ram seminal vesicle COX-1 assessed as conversion of arachidonic acid to PGH2,Confirmatory,24295787.0,
2651,1061066,2,3,,103181002,2662,Active,75109031.0,,0.265,Ki,Inhibition of Thalassiosira weissflogii delta carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay,Confirmatory,24314394.0,
2652,1061067,1,1,,103181002,2662,Active,,,0.16899999999999998,Ki,Inhibition of Porphyromonas gingivalis recombinant gamma-carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay,Confirmatory,24314394.0,
2653,1061068,1,1,,103181002,2662,Active,,,0.705,Ki,Inhibition of Leishmania donovani chagasi recombinant beta-carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay,Confirmatory,24314394.0,
2654,1061069,2,3,,103181002,2662,Active,115456.0,760.0,0.021,Ki,Inhibition of human recombinant carbonic anhydrase 2 preincubated for 15 mins by stopped flow CO2 hydration assay,Confirmatory,24314394.0,
2655,1061169,1,1,,103181002,2662,Active,,,0.14,Ki,Inhibition of recombinant Methanosarcina thermophila gamma-CA CAM by stopped flow CO2 hydration assay,Confirmatory,24316122.0,
2656,1061170,1,1,,103181002,2662,Active,,,0.16899999999999998,Ki,Inhibition of Porphyromonas gingivalis gamma-carbonic anhydrase expressed in Escherichia coli preincubated for 15 mins by stopped flow CO2 hydration assay,Confirmatory,24316122.0,
2657,1061772,1,1,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for ovine COX1 to IC50 for human recombinant COX2",Other,24332492.0,
2658,1061773,2,3,,103181002,2662,Active,754286265.0,443551.0,15.0,IC50,Inhibition of ovine COX1 using arachidonic acid as substrate incubated for 10 mins prior to substrate addition measured after 2 mins by spectrophotometry,Confirmatory,24332492.0,
2659,1061774,2,3,,103181002,2662,Active,3915797.0,5743.0,0.04,IC50,Inhibition of human recombinant COX2 using arachidonic acid as substrate incubated for 10 mins prior to substrate addition measured after 2 mins by spectrophotometry,Confirmatory,24332492.0,
2660,1063669,2,3,,103181002,2662,Active,754286265.0,443551.0,24.3,IC50,Inhibition of ovine COX1 using arachidonic acid as substrate by chemiluminescence assay,Confirmatory,24361187.0,
2661,1063670,2,3,,103181002,2662,Active,3914304.0,443460.0,0.06,IC50,Inhibition of ovine COX2 using arachidonic acid as substrate by chemiluminescence assay,Confirmatory,24361187.0,
2662,1063671,1,1,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for ovine COX1 to IC50 for ovine COX2",Other,24361187.0,
2663,1064077,1,1,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for COX-1 to IC50 for COX-2 in human whole blood",Other,24373735.0,
2664,1064080,2,3,,103181002,2662,Active,3915797.0,5743.0,0.54,IC50,Inhibition of COX-2 in human whole blood assessed as prostaglandin E2 production by RIA,Confirmatory,24373735.0,
2665,1064082,2,3,,103181002,2662,Active,317373262.0,5742.0,12.47,IC50,Inhibition of COX-1 in human whole blood assessed as thromboxane B2 production by RIA,Confirmatory,24373735.0,
2666,1064089,1,1,,103181002,2662,Unspecified,,,,,Analgesic activity in po dosed Swiss albino mouse assessed as reduction of acetic acid-induced writhing measured every 10 mins after 5 mins of administration,Other,24373735.0,
2667,1064091,1,1,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Swiss albino mouse assessed as reduction in carrageenan-induced paw edema at 10 mg/kg, po relative to control",Other,24373735.0,
2668,1064094,1,1,,103181002,2662,Unspecified,,,,,"Antihyperalgesic activity in Swiss albino mouse assessed as reduction in carrageenan-induced inflammation at 10 mg/kg, po after 120 mins relative to control",Other,24373735.0,
2669,1064095,1,1,,103181002,2662,Unspecified,,,,,"Antihyperalgesic activity in Swiss albino mouse assessed as reduction in carrageenan-induced inflammation at 10 mg/kg, po after 90 mins relative to control",Other,24373735.0,
2670,1064096,1,1,,103181002,2662,Unspecified,,,,,"Antihyperalgesic activity in Swiss albino mouse assessed as reduction in carrageenan-induced inflammation at 10 mg/kg, po after 60 mins relative to control",Other,24373735.0,
2671,1064097,1,1,,103181002,2662,Unspecified,,,,,"Antihyperalgesic activity in Swiss albino mouse assessed as reduction in carrageenan-induced inflammation at 10 mg/kg, po after 30 mins relative to control",Other,24373735.0,
2672,1064115,1,1,,103181002,2662,Unspecified,,,,,"Analgesic activity in Swiss albino mouse assessed as reduction of acetic acid-induced writhing at 10 mg/kg, po measured every 10 mins after 5 mins of administration relative to control",Other,24373735.0,
2673,1067225,1,1,,103181002,2662,Unspecified,,,,,Selectivity ratio of Ki for human transmembrane carbonic anhydrase 2 to Ki for human cytosolic carbonic anhydrase 12,Other,24513184.0,
2674,1067226,1,1,,103181002,2662,Unspecified,,,,,Selectivity ratio of Ki for human transmembrane carbonic anhydrase 2 to Ki for human cytosolic carbonic anhydrase 9,Other,24513184.0,
2675,1067227,2,3,,103181002,2662,Active,5915866.0,771.0,0.018000000000000002,Ki,Inhibition of human transmembrane carbonic anhydrase 12 by stopped-flow CO2 hydration assay,Confirmatory,24513184.0,
2676,1067228,2,3,,103181002,2662,Active,83300925.0,768.0,0.016,Ki,Inhibition of human transmembrane carbonic anhydrase 9 by stopped-flow CO2 hydration assay,Confirmatory,24513184.0,
2677,1067229,2,3,,103181002,2662,Active,115456.0,760.0,0.021,Ki,Inhibition of human cytosolic carbonic anhydrase 2 by stopped-flow CO2 hydration assay,Confirmatory,24513184.0,
2678,1067230,2,3,,103181002,2662,Unspecified,115449.0,759.0,50.0,Ki,Inhibition of human cytosolic carbonic anhydrase 1 by stopped-flow CO2 hydration assay,Confirmatory,24513184.0,
2679,1067405,1,4,,103181002,2662,Unspecified,3914304.0,443460.0,,,Inhibition of ovine COX2 at 50 uM by peroxidase activity-based colorimetric assay,Other,24531199.0,
2680,1067406,2,3,,103181002,2662,Active,3914304.0,443460.0,0.28,IC50,Inhibition of ovine COX2 by peroxidase activity-based colorimetric assay,Confirmatory,24531199.0,
2681,1067408,1,4,,103181002,2662,Unspecified,754286265.0,443551.0,,,Inhibition of ovine COX1 at 50 uM by peroxidase activity-based colorimetric assay,Other,24531199.0,
2682,1069512,3,1,,103181002,2662,Unspecified,,,,,"Plasma concentration in Wistar rat lambda carrageenan-induced pleurisy model at 20 mg/kg, ip pretreated for 30 mins followed by lambda carrageenan-challenge measured after 4 hrs by SPE-HPLC analysis",Other,24440378.0,
2683,1069513,3,1,,103181002,2662,Unspecified,,,,,"Plasma concentration in Wistar rat lambda carrageenan-induced pleurisy model at 10 mg/kg, ip pretreated for 30 mins followed by lambda carrageenan-challenge measured after 4 hrs by SPE-HPLC analysis",Other,24440378.0,
2684,1069514,3,1,,103181002,2662,Unspecified,,,,,"Plasma concentration in Wistar rat lambda carrageenan-induced pleurisy model at 5 mg/kg, ip pretreated for 30 mins followed by lambda carrageenan-challenge measured after 4 hrs by SPE-HPLC analysis",Other,24440378.0,
2685,1069515,1,1,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Wistar rat lambda carrageenan-induced pleurisy model assessed as decrease in number of leukocytes in pleural space at 20 mg/kg, ip pretreated for 30 mins followed by lambda carrageenan-challenge measured after 4 hrs relative to control",Other,24440378.0,
2686,1069516,1,1,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Wistar rat lambda carrageenan-induced pleurisy model assessed as decrease in number of leukocytes in pleural space at 10 mg/kg, ip pretreated for 30 mins followed by lambda carrageenan-challenge measured after 4 hrs relative to control",Other,24440378.0,
2687,1069517,1,1,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Wistar rat lambda carrageenan-induced pleurisy model assessed as decrease in number of leukocytes in pleural space at 5 mg/kg, ip pretreated for 30 mins followed by lambda carrageenan-challenge measured after 4 hrs relative to control",Other,24440378.0,
2688,1069518,1,1,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Wistar rat lambda carrageenan-induced pleurisy model assessed as decrease in exudate volume at 20 mg/kg, ip pretreated for 30 mins followed by lambda carrageenan-challenge measured after 4 hrs relative to control",Other,24440378.0,
2689,1069519,1,1,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Wistar rat lambda carrageenan-induced pleurisy model assessed as decrease in exudate volume at 10 mg/kg, ip pretreated for 30 mins followed by lambda carrageenan-challenge measured after 4 hrs relative to control",Other,24440378.0,
2690,1069520,1,1,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Wistar rat lambda carrageenan-induced pleurisy model assessed as decrease in exudate volume at 5 mg/kg, ip pretreated for 30 mins followed by lambda carrageenan-challenge measured after 4 hrs relative to control",Other,24440378.0,
2691,1069521,1,1,,103181002,2662,Unspecified,,,,,Selectivity ratio of IC50 for COX-1 in human whole blood to IC50 for COX-2 in human whole blood,Other,24440378.0,
2692,1069522,2,3,,103181002,2662,Active,3915797.0,5743.0,0.35,IC50,Inhibition of COX-2 in human whole blood assessed as PGE2 level in plasma after 5 mins by enzyme immunoassay,Confirmatory,24440378.0,
2693,1069523,2,3,,103181002,2662,Active,317373262.0,5742.0,2.6,IC50,Inhibition of COX-1 in human whole blood assessed as thromboxane B2 level in serum after 5 mins by enzyme immunoassay,Confirmatory,24440378.0,
2694,1071432,1,4,,103181002,2662,Inactive,754286265.0,443551.0,,,Inhibition of ovine COX1 using TMPD as substrate at 20 uM incubated for 5 mins prior to substrate addition measured after 5 mins by colorimetry,Other,24412499.0,
2695,1071433,1,4,,103181002,2662,Unspecified,3914304.0,443460.0,,,Inhibition of ovine COX2 using TMPD as substrate at 20 uM incubated for 5 mins prior to substrate addition measured after 5 mins by colorimetry,Other,24412499.0,
2696,1071434,1,1,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 1 hr prior to carrageenan challenge measured after 24 hrs relative to vehicle-treated control",Other,24412499.0,
2697,1071435,1,1,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 1 hr prior to carrageenan challenge measured after 4 hrs relative to vehicle-treated control",Other,24412499.0,
2698,1071436,1,1,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 1 hr prior to carrageenan challenge measured after 3 hrs relative to vehicle-treated control",Other,24412499.0,
2699,1071437,1,1,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 1 hr prior to carrageenan challenge measured after 2 hrs relative to vehicle-treated control",Other,24412499.0,
2700,1071438,1,1,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 1 hr prior to carrageenan challenge measured after 1 hr relative to vehicle-treated control",Other,24412499.0,
2701,1077200,1,1,,103181002,2662,Unspecified,,,,,Selectivity ratio of IC50 for human COX1 to IC50 for human COX2,Other,24602792.0,
2702,1077203,2,3,,103181002,2662,Active,3915797.0,5743.0,0.04,IC50,Inhibition of human COX2 using arachidonic acid as substrate assessed as PGE2 formation incubated for 10 mins prior to substrate addition measured after 10 mins by ELISA,Confirmatory,24602792.0,
2703,1077204,2,3,,103181002,2662,Active,317373262.0,5742.0,15.0,IC50,Inhibition of human COX1 using arachidonic acid as substrate assessed as PGE2 formation incubated for 10 mins prior to substrate addition measured after 10 mins by ELISA,Confirmatory,24602792.0,
2704,1077234,1,1,,103181002,2662,Unspecified,,,,,"Ulcerogenic effect in fasted Wistar albino rat at 50 mg/kg, po measured 2 hrs post last dose",Other,24607877.0,
2705,1077235,1,1,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of formalin-induced paw edema at 50 mg/kg, po administered 1 hr prior to formalin challenge measured after 3 hrs relative to control",Other,24607877.0,
2706,1077236,1,1,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of formalin-induced paw edema at 50 mg/kg, po administered 1 hr prior to formalin challenge measured after 2 hrs relative to control",Other,24607877.0,
2707,1077237,1,1,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of formalin-induced paw edema at 50 mg/kg, po administered 1 hr prior to formalin challenge measured after 1 hr relative to control",Other,24607877.0,
2708,1077238,1,1,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of formalin-induced paw edema at 50 mg/kg, po administered 1 hr prior to formalin challenge measured after 30 mins relative to control",Other,24607877.0,
2709,1077239,1,1,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for ovine COX1 to IC50 for human recombinant COX2",Other,24607877.0,
2710,1077240,2,3,,103181002,2662,Active,3915797.0,5743.0,0.28,IC50,Inhibition of human recombinant COX2 using arachidonic acid as substrate incubated for 10 mins prior to substrate addition measured after 2 mins by enzyme immunoassay,Confirmatory,24607877.0,
2711,1077241,1,4,,103181002,2662,Unspecified,754286265.0,443551.0,50.0,IC50,Inhibition of ovine COX1 using arachidonic acid as substrate incubated for 10 mins prior to substrate addition measured after 2 mins by enzyme immunoassay,Confirmatory,24607877.0,
2712,1077380,1,2,,103181002,2662,Unspecified,,,,,Half life in rat,Other,,
2713,1079931,1,1,,103181002,2662,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
2714,1079932,1,1,,103181002,2662,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
2715,1079933,1,1,,103181002,2662,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
2716,1079934,1,1,,103181002,2662,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
2717,1079935,1,1,,103181002,2662,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
2718,1079936,1,1,,103181002,2662,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
2719,1079937,1,1,,103181002,2662,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
2720,1079938,1,1,,103181002,2662,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
2721,1079939,1,1,,103181002,2662,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
2722,1079940,1,1,,103181002,2662,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
2723,1079941,1,1,,103181002,2662,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
2724,1079942,1,1,,103181002,2662,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
2725,1079943,1,1,,103181002,2662,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
2726,1079944,1,1,,103181002,2662,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
2727,1079945,1,1,,103181002,2662,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
2728,1079946,1,1,,103181002,2662,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
2729,1079947,1,1,,103181002,2662,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
2730,1079948,1,1,,103181002,2662,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
2731,1079949,1,1,,103181002,2662,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
2732,1084670,1,2,,103181002,2662,Unspecified,,,,,Toxicity in ip dosed Mus musculus (mouse) after 24 hr,Other,,
2733,1084671,1,2,,103181002,2662,Unspecified,,,,,"Gastrointestinal toxicity in Rattus norvegicus albino (rat) assessed as ulcer index at 25 mg/kg, po for 3 days measured 2 hr after last dose",Other,,
2734,1084672,1,2,,103181002,2662,Unspecified,,,,,"Analgesic activity in Mus musculus (mouse) assessed as inhibition of p-benzoquinone-induced writhing at 25 mg/kg, ip pretreated 30 min prior to carrageenan administration measured 4 hr after carrageenan challenge (Rvb = 0%)",Other,,
2735,1084673,1,2,,103181002,2662,Unspecified,,,,,"Analgesic activity in Mus musculus (mouse) assessed as inhibition of p-benzoquinone-induced writhing at 25 mg/kg, ip pretreated 30 min prior to carrageenan administration measured 3 hr after carrageenan challenge (Rvb = 0%)",Other,,
2736,1084674,1,2,,103181002,2662,Unspecified,,,,,"Analgesic activity in Mus musculus (mouse) assessed as inhibition of p-benzoquinone-induced writhing at 25 mg/kg, ip pretreated 30 min prior to carrageenan administration measured 2 hr after carrageenan challenge (Rvb = 0%)",Other,,
2737,1084675,1,2,,103181002,2662,Unspecified,,,,,"Analgesic activity in Mus musculus (mouse) assessed as inhibition of p-benzoquinone-induced writhing at 25 mg/kg, ip pretreated 30 min prior to carrageenan administration measured 1 hr after carrageenan challenge (Rvb = 0%)",Other,,
2738,1084676,1,2,,103181002,2662,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus albino (rat) assessed as inhibition of carrageenan-induced paw edema at 25 mg/kg, ip pretreated 30 min prior to carrageenan administration measured 4 hr after carrageenan challenge (Rvb = 0%)",Other,,
2739,1084677,1,2,,103181002,2662,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus albino (rat) assessed as inhibition of carrageenan-induced paw edema at 25 mg/kg, ip pretreated 30 min prior to carrageenan administration measured 3 hr after carrageenan challenge (Rvb = 0%)",Other,,
2740,1084678,1,2,,103181002,2662,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus albino (rat) assessed as inhibition of carrageenan-induced paw edema at 25 mg/kg, ip pretreated 30 min prior to carrageenan administration measured 2 hr after carrageenan challenge (Rvb = 0%)",Other,,
2741,1084679,1,2,,103181002,2662,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus albino (rat) assessed as inhibition of carrageenan-induced paw edema at 25 mg/kg, ip pretreated 30 min prior to carrageenan administration measured 1 hr after carrageenan challenge (Rvb = 0%)",Other,,
2742,1085305,1,2,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for Ovis aries (sheep) COX1 to IC50 for Ovis aries (sheep) COX2",Other,,
2743,1085306,2,3,,103181002,2662,Active,754286265.0,443551.0,24.3,IC50,Inhibition of Ovis aries (sheep) COX1 using arachidonic acid as substrate using cyclic naphthalene hydrazide by chemiluminescence assay,Confirmatory,,
2744,1085307,2,3,,103181002,2662,Active,3914304.0,443460.0,0.06,IC50,Inhibition of Ovis aries (sheep) COX2 using arachidonic acid as substrate using cyclic naphthalene hydrazide by chemiluminescence assay,Confirmatory,,
2745,1085308,1,2,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for Ovis aries (sheep) COX1 to IC50 for Ovis aries (sheep) COX2",Other,,
2746,1085309,2,3,,103181002,2662,Active,3914304.0,443460.0,0.06,IC50,Inhibition of Ovis aries (sheep) COX2 using arachidonic acid as substrate using cyclic naphthalene hydrazide by chemiluminescence assay,Confirmatory,,
2747,1085310,2,3,,103181002,2662,Active,754286265.0,443551.0,24.3,IC50,Inhibition of Ovis aries (sheep) COX1 using arachidonic acid as substrate using cyclic naphthalene hydrazide by chemiluminescence assay,Confirmatory,,
2748,1085484,1,4,,103181002,2662,Unspecified,3914304.0,443460.0,,,"Inhibition of Ovis aries (sheep) COX-2 assessed as appearance of oxidized N,N,N',N'-tetramethyl-p-phenylenediamine at 20 uM by colorimetric analysis",Other,,
2749,1085485,1,4,,103181002,2662,Unspecified,754286265.0,443551.0,,,"Inhibition of Ovis aries (sheep) COX-1 assessed as appearance of oxidized N,N,N',N'-tetramethyl-p-phenylenediamine at 20 uM by colorimetric analysis",Other,,
2750,1087306,1,2,,103181002,2662,Unspecified,,,,,"Ulcerogenicity in Rattus norvegicus albino (rat) at 9 mg/kg/day, po qd for 3 successive days",Other,,
2751,1087307,1,2,,103181002,2662,Unspecified,,,,,"Anti-inflammatory activity inRattus norvegicus albino (rat) assessed as reduction in carrageenan-induced paw edema at 10 mg/kg, ip administered 1 hr prior to carrageenan-induced measured 1 to 4 hr post challenge relative to indomethacin",Other,,
2752,1087308,1,2,,103181002,2662,Unspecified,,,,,"Anti-inflammatory activity carrageenan-induced paw edema in Rattus norvegicus albino (rat) at 9 mg/kg, ip administered 1 hr prior to carrageenan-induced measured 1 to 4 hr post challenge relative to control",Other,,
2753,1087314,1,2,,103181002,2662,Unspecified,,,,,"Anti-inflammatory activity carrageenan-induced paw edema in Rattus norvegicus albino (rat) assessed as paw thickness at 9 mg/kg, ip administered 1 hr prior to carrageenan-induced measured 4 hr post challenge",Other,,
2754,1087315,1,2,,103181002,2662,Unspecified,,,,,"Anti-inflammatory activity carrageenan-induced paw edema inRattus norvegicus albino (rat) assessed as paw thickness at 9 mg/kg, ip administered 1 hr prior to carrageenan-induced measured 3 hr post challenge",Other,,
2755,1087316,1,2,,103181002,2662,Unspecified,,,,,"Anti-inflammatory activity carrageenan-induced paw edema inRattus norvegicus albino (rat) assessed as paw thickness at 9 mg/kg, ip administered 1 hr prior to carrageenan-induced measured 2 hr post challenge",Other,,
2756,1087317,1,2,,103181002,2662,Unspecified,,,,,"Anti-inflammatory activity carrageenan-induced paw edema inRattus norvegicus albino (rat) assessed as paw thickness at 9 mg/kg, ip administered 1 hr prior to carrageenan-induced measured 1 hr post challenge",Other,,
2757,1095017,1,2,,103181002,2662,Unspecified,,,,,"Gastrointestinal toxicity in Rattus norvegicus albino (rat) assessed as incidence of gastric ulceration at 0.9 mg/100 g body weight, po qd",Other,,
2758,1095018,1,2,,103181002,2662,Unspecified,,,,,"Gastrointestinal toxicity in Rattus norvegicus albino (rat) assessed as ulcer index at 0.9 mg/100 g body weight, po qd",Other,,
2759,1095019,1,2,,103181002,2662,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus albino (rat) assessed as reduction of carrageenan-induced paw edema thickness at 0.9 mg/100 g body weight, ip administered 1 hr before carrageenan-challenge measured after 4 hr (Rvb = 0.88 +/- 0.03 mm)",Other,,
2760,1095020,1,2,,103181002,2662,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus albino (rat) assessed as reduction of carrageenan-induced paw edema thickness at 0.9 mg/100 g body weight, ip administered 1 hr before carrageenan-challenge measured after 3 hr (Rvb = 0.88 +/- 0.03 mm)",Other,,
2761,1095021,1,2,,103181002,2662,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus albino (rat) assessed as reduction of carrageenan-induced paw edema thickness at 0.9 mg/100 g body weight, ip administered 1 hr before carrageenan-challenge measured after 2 hr (Rvb = 0.88 +/- 0.03 mm)",Other,,
2762,1095022,1,2,,103181002,2662,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus albino (rat) assessed as reduction of carrageenan-induced paw edema thickness at 0.9 mg/100 g body weight, ip administered 1 hr before carrageenan-challenge measured after 1 hr (Rvb = 0.77 +/- 0.02 mm)",Other,,
2763,1095209,1,2,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for Bos taurus (bovine) COX-1 to IC50 for Bos taurus (bovine) COX-2",Other,,
2764,1095210,2,3,,103181002,2662,Active,3914301.0,282023.0,0.06,IC50,Inhibition of Bos taurus (bovine) COX-2 by Chemoiluminescence assay,Confirmatory,,
2765,1095211,2,3,,103181002,2662,Active,166897622.0,282022.0,24.3,IC50,Inhibition of Bos taurus (bovine) COX-1 by Chemoiluminescence assay,Confirmatory,,
2766,1096893,1,2,,103181002,2662,Unspecified,,,,,"Anti-inflammatory activity inRattus norvegicus albino (rat) assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, po administered 3 hr prior challenge measured after 1 hr post challenge",Other,,
2767,1096894,1,2,,103181002,2662,Unspecified,,,,,"Anti-inflammatory activity inRattus norvegicus albino (rat) assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, po administered 2 hr prior challenge measured after 1 hr post challenge",Other,,
2768,1096895,1,2,,103181002,2662,Unspecified,,,,,"Anti-inflammatory activity inRattus norvegicus albino (rat) assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, po administered 1 hr prior challenge measured after 1 hr post challenge",Other,,
2769,1107026,1,2,,103181002,2662,Unspecified,,,,,Anti-inflammatory activity in Rattus norvegicus Wistar albino (rat) assessed as inhibition of carrageenan-induced paw edema at 0.05 mmol/kg administered 30 min prior to carrageenan-challenge measured after 5 hr relative to control,Other,,
2770,1107027,1,2,,103181002,2662,Unspecified,,,,,Anti-inflammatory activity in Rattus norvegicus Wistar albino (rat) assessed as inhibition of carrageenan-induced paw edema at 0.05 mmol/kg administered 30 min prior to carrageenan-challenge measured after 3 hr relative to control,Other,,
2771,1107227,2,3,,103181002,2662,Active,3915797.0,5743.0,0.057,IC50,Inhibition of COX2 (unknown origin),Confirmatory,,
2772,1107309,1,2,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for Ovis aries (sheep) COX-1 to IC50 for Ovis aries (sheep) COX-2",Other,,
2773,1107310,2,3,,103181002,2662,Active,3914304.0,443460.0,0.057,IC50,Inhibition of Ovis aries (sheep) COX-2 assessed as decrease in PGF2a production from PGH2 upon reduction with stannous chloride using arachidonic acid as substrate pre-incubated with enzyme for 5 min prior to substrate addition by enzyme immunoassay,Confirmatory,,
2774,1107313,2,3,,103181002,2662,Active,754286265.0,443551.0,23.0,IC50,Inhibition of Ovis aries (sheep) COX-1 assessed as decrease in PGF2a production from PGH2 upon reduction with stannous chloride using arachidonic acid as substrate pre-incubated with enzyme for 5 min prior to substrate addition by enzyme immunoassay,Confirmatory,,
2775,1115574,1,2,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for Ovis aries (sheep) cyclooxygenase-1 to IC50 for ovine cyclooxygenase-2",Other,,
2776,1115575,2,3,,103181002,2662,Active,3914304.0,443460.0,0.06,IC50,Inhibition of Ovis aries (sheep) cyclooxygenase-2 using arachidonic acid as substrate by chemiluminescent assay,Confirmatory,,
2777,1115576,2,3,,103181002,2662,Active,754286265.0,443551.0,24.3,IC50,Inhibition of Ovis aries (sheep) cyclooxygenase-1 using arachidonic acid as substrate by chemiluminescent assay,Confirmatory,,
2778,1116760,1,2,,103181002,2662,Unspecified,,,,,Selectivity ratio of IC50 for Ovis aries (sheep) COX2 to IC50 for ovine COX1,Other,,
2779,1116762,1,2,,103181002,2662,Unspecified,,,,,"Ulcerogenic activity against fasted albino Rattus norvegicus (rat) assessed as ulcer index at 50 mg/kg, po administered QD for 3 days measured on day 4",Other,,
2780,1117298,1,2,,170464693,2662,Inactive,,,44.6684,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 green channel",Confirmatory,,
2781,1117301,1,2,,170464693,2662,Inactive,,,15.8489,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 blue channel",Confirmatory,,
2782,1117302,1,2,,170464693,2662,Inactive,,,35.4813,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen1 green channel",Confirmatory,,
2783,1117303,1,2,,170464693,2662,Inactive,,,11.23,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 ratio channel",Confirmatory,,
2784,1117304,1,2,,170464693,2662,Active,,,39.8107,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel",Confirmatory,,
2785,1117305,1,2,,170464693,2662,Inactive,,,39.8107,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 ratio channel",Confirmatory,,
2786,1117310,1,1,,170464693,2662,Inactive,,,44.6684,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, green channel",Confirmatory,,
2787,1117311,1,1,,170464693,2662,Inactive,,,15.8489,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, blue channel",Confirmatory,,
2788,1117312,1,1,,170464693,2662,Active,,,39.8107,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen2, ratio channel",Confirmatory,,
2789,1117314,1,1,,170464693,2662,Inactive,,,39.8107,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, blue channel",Confirmatory,,
2790,1117315,1,1,,170464693,2662,Inactive,,,35.4813,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, green channel",Confirmatory,,
2791,1117318,1,1,,170464693,2662,Active,,,11.2202,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, ratio channel",Confirmatory,,
2792,1117326,1,1,,170464693,2662,Inactive,,,,,nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-screen,Screening,,
2793,1117329,1,1,,170464693,2662,Inactive,,,,,insulin secretion from INS-1E cells in the presence of 5 mM glucose-screen,Screening,,
2794,1117336,1,1,,170464693,2662,Inactive,,,,,GSK3B-pretreated HCT116 viability from Cell TiterGlo-screen,Screening,,
2795,1117340,1,1,,170464693,2662,Inactive,,,,,VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-screen,Screening,,
2796,1117341,1,1,,170464693,2662,Inactive,,,,,GLP1 secretion from NCI-H716 cells-screen,Screening,,
2797,1117342,1,1,,170464693,2662,Inactive,,,,,HCT116 viability from Cell TiterGlo-screen,Screening,,
2798,1117343,1,1,,170464693,2662,Active,,,,,SW480 viability from Cell TiterGlo-screen,Screening,,
2799,1117346,1,1,,170464693,2662,Active,,,,,DLD-1 viability from Cell TiterGlo-screen,Screening,,
2800,1125015,2,2,,103181002,2662,Unspecified,754286265.0,443551.0,30.0,IC50,Inhibition of ovine COX1 using arachidonic acid as substrate assessed as conversion of PGH2 to PGF2alpha after 10 mins by EIA,Confirmatory,24631365.0,
2801,1125016,1,3,,103181002,2662,Active,3914304.0,443460.0,0.22,IC50,Inhibition of ovine COX2 using arachidonic acid as substrate assessed as conversion of PGH2 to PGF2alpha after 10 mins by EIA,Confirmatory,24631365.0,
2802,1125017,1,1,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for ovine COX1 to IC50 for ovine COX2",Other,24631365.0,
2803,1125124,1,1,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 0.28 mmol/kg, po administered 30 mins before carrageenan challenge measured after 1 hr relative to control",Other,24631895.0,
2804,1125125,1,1,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 0.28 mmol/kg, po administered 30 mins before carrageenan challenge measured after 2 hrs relative to control",Other,24631895.0,
2805,1125126,1,1,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 0.28 mmol/kg, po administered 30 mins before carrageenan challenge measured after 3 hrs relative to control",Other,24631895.0,
2806,1125127,1,1,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 0.28 mmol/kg, po administered 30 mins before carrageenan challenge measured after 4 hrs relative to control",Other,24631895.0,
2807,1125128,1,1,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 0.28 mmol/kg, po administered 30 mins before carrageenan challenge measured after 5 hrs relative to control",Other,24631895.0,
2808,1125129,1,1,,103181002,2662,Unspecified,,,,,"Ulcerogenic effect in albino rat assessed as ulcer index at 0.28 mmol/kg, po",Other,24631895.0,
2809,1125532,1,1,,103181002,2662,Unspecified,,,50.0,EC50,Membrane permeabilizing activity of the compound in calcein-loaded egg phosphatidylcholine liposomes assessed as release of calcein from liposomes at pH 6.8 after 10 mins by fluorescence assay,Confirmatory,24650702.0,
2810,1125533,2,2,,103181002,2662,Unspecified,754286265.0,443551.0,117.0,IC50,Inhibition of purified ovine COX-1 by enzyme immunoassay,Confirmatory,24650702.0,
2811,1125534,1,3,,103181002,2662,Active,3915797.0,5743.0,0.07,IC50,Inhibition of human recombinant COX-2 by enzyme immunoassay,Confirmatory,24650702.0,
2812,1125535,1,1,,103181002,2662,Unspecified,,,,,Selectivity ratio of IC50 for ovine COX-1 to IC50 for human recombinant COX-2,Other,24650702.0,
2813,1125536,1,1,,103181002,2662,Unspecified,,,,,Ratio of EC50 for membrane permeabilization to IC50 for human recombinant COX-2,Other,24650702.0,
2814,1125683,1,3,,103181002,2662,Active,548483.0,19225.0,0.0087,IC50,Inhibition of COX-2 in mouse RAW264.7 cells assessed as decrease in LPS-induced PGE2 production treated prior to LPS challenge by enzyme immunoassay,Confirmatory,24656662.0,
2815,1125684,1,3,,103181002,2662,Unspecified,754286265.0,443551.0,1.0,IC50,Inhibition of ovine COX-1 assessed as decrease in PGH2 production using arachidonic acid as substrate treated with enzyme for 10 mins prior to substrate challenge for 2 mins by enzyme immunoassay,Confirmatory,24656662.0,
2816,1125685,1,3,,103181002,2662,Active,3915797.0,5743.0,0.07200000000000001,IC50,Inhibition of human recombinant COX-2 assessed as decrease in PGH2 production using arachidonic acid as substrate treated with enzyme for 10 mins prior to substrate challenge for 2 mins by enzyme immunoassay,Confirmatory,24656662.0,
2817,1125686,1,1,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for ovine COX-1 to IC50 for human recombinant COX-2",Other,24656662.0,
2818,1125894,1,3,,103181002,2662,Unspecified,3915797.0,5743.0,,,Inhibition of COX2 (unknown origin) at 100 uM by colorimetric method,Other,24661847.0,
2819,1125895,1,3,,103181002,2662,Unspecified,317373262.0,5742.0,,,Inhibition of COX1 (unknown origin) at 100 uM by colorimetric method,Other,24661847.0,
2820,1125896,1,3,,103181002,2662,Active,3915797.0,5743.0,2.66,IC50,Inhibition of COX2 (unknown origin) by colorimetric method,Confirmatory,24661847.0,
2821,1126478,1,1,,103181002,2662,Active,,,1.84,IC50,Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 18 hrs by griess reaction analysis,Confirmatory,24679441.0,
2822,1126479,1,1,,103181002,2662,Active,,,1.28,IC50,Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha secretion after 18 hrs by sandwich ELISA,Confirmatory,24679441.0,
2823,1139263,1,1,,103181002,2662,Unspecified,,,,,Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced PGE2 production at 20 uM administered 1 hr prior to LPS challenge measured after 20 hrs by EIA relative to control,Other,24689881.0,
2824,1140775,1,3,,103181002,2662,Active,3914292.0,24693.0,15.0,IC50,Inhibition of rat seminal vesicle COX-1 using arachidonic acid as substrate assessed as reduction of PGG2 to PGH2 incubated for 1 min prior to substrate addition measured after 25 secs by chromogenic assay,Confirmatory,24745964.0,
2825,1140776,1,3,,103181002,2662,Active,3915797.0,5743.0,0.04,IC50,Inhibition of human recombinant COX-2 expressed in insect cell system using arachidonic acid as substrate assessed as reduction of PGG2 to PGH2 incubated for 1 min prior to substrate addition measured after 25 secs by chromogenic assay,Confirmatory,24745964.0,
2826,1140777,1,1,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for human recombinant COX-2 to IC50 for rat seminal vesicle COX-1",Other,24745964.0,
2827,1141096,1,3,,103181002,2662,Unspecified,754286265.0,443551.0,,,Inhibition of ovine COX1 peroxidase activity assessed as reduction of PGG2 to PGH2 by measuring oxidized TMPD level at 10 ug/ml by colorimetric assay relative to control,Other,24751552.0,
2828,1141097,1,3,,103181002,2662,Active,3914304.0,443460.0,0.04,IC50,Inhibition of ovine COX2 peroxidase activity assessed as reduction of PGG2 to PGH2 by measuring oxidized TMPD level by colorimetric assay,Confirmatory,24751552.0,
2829,1141098,1,3,,103181002,2662,Active,754286265.0,443551.0,14.0,IC50,Inhibition of ovine COX1 peroxidase activity assessed as reduction of PGG2 to PGH2 by measuring oxidized TMPD level by colorimetric assay,Confirmatory,24751552.0,
2830,1141099,1,3,,103181002,2662,Unspecified,3914304.0,443460.0,,,Inhibition of ovine COX2 peroxidase activity assessed as reduction of PGG2 to PGH2 by measuring oxidized TMPD level at 10 ug/ml by colorimetric assay relative to control,Other,24751552.0,
2831,1141756,1,3,,103181002,2662,Unspecified,754286265.0,443551.0,30.0,IC50,Inhibition of ovine COX1 using arachidonic acid as substrate preincubated for 10 mins before substrate addition measured after 5 mins by EIA,Confirmatory,24763362.0,
2832,1141757,1,3,,103181002,2662,Active,3914304.0,443460.0,0.15,IC50,Inhibition of ovine COX2 using arachidonic acid as substrate preincubated for 10 mins before substrate addition measured after 5 mins by EIA,Confirmatory,24763362.0,
2833,1141758,1,1,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for ovine COX1 to IC50 for ovine COX2",Other,24763362.0,
2834,1142444,2,2,,103181002,2662,Unspecified,754286265.0,443551.0,100.0,IC50,Inhibition of ovine COX1 after 2 mins by EIA,Confirmatory,24780593.0,
2835,1142445,1,3,,103181002,2662,Active,3915797.0,5743.0,0.28,IC50,Inhibition of human recombinant COX2 after 2 mins by EIA,Confirmatory,24780593.0,
2836,1142446,1,1,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for ovine COX1 to IC50 for human recombinant COX2",Other,24780593.0,
2837,1142447,1,1,,103181002,2662,Unspecified,,,,,Antiinflammatory activity in po dosed albino rat assessed as inhibition of carrageenan-induced paw edema administered 1 hr prior challenge measured 2 hrs post challenge,Other,24780593.0,
2838,1142833,1,3,,103181002,2662,Unspecified,115449.0,759.0,50.0,Ki,Inhibition of human carbonic anhydrase-1 by stopped-flow CO2 hydration assay,Confirmatory,24792813.0,
2839,1142834,1,3,,103181002,2662,Active,115456.0,760.0,0.021,Ki,Inhibition of human carbonic anhydrase-2 by stopped-flow CO2 hydration assay,Confirmatory,24792813.0,
2840,1142836,1,1,,103181002,2662,Active,,,0.99,Ki,Inhibition of Legionella pneumophilia subsp. Pneumophila strain Philadelphia-1 carbonic anhydrase-1 assessed as CO2 hydrase activity by stopped-flow assay,Confirmatory,24792813.0,
2841,1142837,1,1,,103181002,2662,Active,,,0.42100000000000004,Ki,Inhibition of Legionella pneumophilia subsp. Pneumophila strain Philadelphia-1 carbonic anhydrase-2 assessed as CO2 hydrase activity by stopped-flow assay,Confirmatory,24792813.0,
2842,1142838,1,1,,103181002,2662,Inconclusive,,,,Ki,Inhibition of Helicobacter pylori carbonic anhydrase by stopped-flow CO2 hydration assay,Confirmatory,24792813.0,
2843,1143086,1,1,,103181002,2662,Unspecified,,,,,Antiinflammatory activity in ip dosed Sprague-Dawley rat assessed as inhibition of carrageenan-induced foot paw edema after 1 hr by plethysmometer analysis,Other,24794773.0,
2844,1143087,1,1,,103181002,2662,Unspecified,,,,,Antiinflammatory activity in ip dosed Sprague-Dawley rat assessed as inhibition of carrageenan-induced foot paw edema after 2 hrs by plethysmometer analysis,Other,24794773.0,
2845,1143088,1,1,,103181002,2662,Unspecified,,,,,Antiinflammatory activity in ip dosed Sprague-Dawley rat assessed as inhibition of carrageenan-induced foot paw edema after 3 hrs by plethysmometer analysis,Other,24794773.0,
2846,1143089,1,1,,103181002,2662,Unspecified,,,,,Toxicity in ip dosed mouse assessed as behavioral changes and death during observation up to 72 hrs,Other,24794773.0,
2847,1143090,1,3,,103181002,2662,Unspecified,754286265.0,443551.0,,,Inhibition of ovine COX1 at 5 uM,Other,24794773.0,
2848,1143091,1,3,,103181002,2662,Unspecified,3914304.0,443460.0,,,Inhibition of ovine COX2 at 5 uM,Other,24794773.0,
2849,1143092,1,1,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of ovine COX2 to ovine COX1",Other,24794773.0,
2850,1143093,1,1,,103181002,2662,Unspecified,,,,,"Gastrointestinal toxicity in albino rat assessed as ulcer index at 100 mg/kg, po qd for 3 days measured 6 hrs after last dose",Other,24794773.0,
2851,1143094,1,1,,103181002,2662,Unspecified,,,,,Analgesic activity in ip dosed albino Swiss mouse after 0.5 hrs by hot plate test,Other,24794773.0,
2852,1143095,1,1,,103181002,2662,Unspecified,,,,,Analgesic activity in ip dosed albino Swiss mouse after 1 hr by hot plate test,Other,24794773.0,
2853,1143096,1,1,,103181002,2662,Unspecified,,,,,Analgesic activity in ip dosed albino Swiss mouse after 2 hrs by hot plate test,Other,24794773.0,
2854,1143523,1,1,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Albino Wistar rat assessed as inhibition of carrageenan-induced hind paw edema at 0.05 mmol/kg, po treated 1 hr before carrageenan challenge measured 5 hrs post-carrageenan injection by plethysmometer analysis",Other,24836072.0,
2855,1143524,1,1,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Albino Wistar rat assessed as inhibition of carrageenan-induced hind paw edema at 0.05 mmol/kg, po treated 1 hr before carrageenan challenge measured 3 hrs post-carrageenan injection by plethysmometer analysis",Other,24836072.0,
2856,1143526,1,2,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced hind paw Albino Wistar rat model assessed as reduction in serum IL-1 beta level at 0.05 mmol/kg, po treated 1 hr before carrageenan challenge by ELISA",Other,24836072.0,
2857,1143527,1,2,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced hind paw Albino Wistar rat model assessed as reduction in serum TNF-alpha level at 0.05 mmol/kg, po treated 1 hr before carrageenan challenge by ELISA",Other,24836072.0,
2858,1143528,1,2,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced hind paw Albino Wistar rat model assessed as reduction in serum COX2 level at 0.05 mmol/kg, po treated 1 hr before carrageenan challenge by ELISA",Other,24836072.0,
2859,1143529,1,3,,103181002,2662,Active,317373262.0,5742.0,20.4,IC50,Inhibition of COX-1 (unknown origin),Confirmatory,24836072.0,
2860,1143530,1,3,,103181002,2662,Active,3915797.0,5743.0,0.27,IC50,Inhibition of COX-2 (unknown origin),Confirmatory,24836072.0,
2861,1143531,1,1,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for COX-1 (unknown origin) to IC50 for COX-2 (unknown origin)",Other,24836072.0,
2862,1143533,1,1,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced hind paw Albino Wistar rat model assessed as reduction in nitric oxide level in hind paw at 0.05 mmol/kg, po treated 1 hr before carrageenan challenge measured per mg of wet tissue by griess reagent based microplate reader analysis",Other,24836072.0,
2863,1143534,1,1,,103181002,2662,Unspecified,,,,,"Antioxidant activity in carrageenan-induced hind paw Albino Wistar rat model assessed as increase in GSH level in hind paw joint at 0.05 mmol/kg, po treated 1 hr before carrageenan challenge measured per gm of tissue by plate reader analysis (Rvb = 0.58 +/-0.02 ug)",Other,24836072.0,
2864,1143535,1,1,,103181002,2662,Unspecified,,,,,"Antioxidant activity in carrageenan-induced hind paw Albino Wistar rat model assessed as inhibition of lipid peroxidation by measuring TBARS level in hind paw at 0.05 mmol/kg, po treated 1 hr before carrageenan challenge by microplate reader analysis",Other,24836072.0,
2865,1143536,1,1,,103181002,2662,Unspecified,,,,,"Antinociceptive activity in mouse assessed as inhibition of acetic acid-induced writhing at 0.05 mmol/kg, po administered 30 mins prior to acetic acid challenge measured for 20 mins after acetic acid injection",Other,24836072.0,
2866,1143538,1,1,,103181002,2662,Active,,,,,"Antiinflammatory activity against carrageenan-induced hind paw Albino Wistar rat model assessed as reduction in nitric oxide level in hind paw at 0.05 mmol/kg, po treated 1 hr before carrageenan challenge by griess reagent based microplate reader analysis",Other,24836072.0,
2867,1143905,1,3,,103181002,2662,Unspecified,3915797.0,5743.0,,,Inhibition of human recombinant COX2 assessed as residual activity preincubated at 5 uM for 5 mins by HPLC analysis,Other,24871899.0,
2868,1153843,1,3,,103181002,2662,Inconclusive,754286265.0,443551.0,,,Inhibition of ovine COX-1 using arachidonic acid as substrate assessed as residual activity at 10 uM preincubated for 5 mins followed by substrate addition measured after 5 mins by HPLC analysis relative to control,Other,24844534.0,
2869,1153845,1,3,,103181002,2662,Unspecified,3915797.0,5743.0,,,Inhibition of human recombinant COX-2 using arachidonic acid as substrate assessed as residual activity at 5 uM preincubated for 5 mins followed by substrate addition measured after 5 mins by HPLC analysis relative to control,Other,24844534.0,
2870,1154873,1,3,,103181002,2662,Unspecified,754286265.0,443551.0,,,Inhibition of ovine COX1 using arachidonic acid as substrate at 10 uM,Other,24900871.0,
2871,1154874,1,3,,103181002,2662,Unspecified,3915797.0,5743.0,,,Inhibition of human recombinant COX2 using arachidonic acid as substrate at 10 uM,Other,24900871.0,
2872,1154875,1,1,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for ovine COX1 to IC50 for human recombinant COX2",Other,24900871.0,
2873,1154876,1,1,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as reduction in carrageenan-induced hind paw volume at 12.5 mg/kg, ip administered 10 mins after carrageenan-challenge measured up to 3 hrs",Other,24900871.0,
2874,1154877,1,1,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as reduction in carrageenan-induced hind paw volume at 25 mg/kg, ip administered 10 mins after carrageenan-challenge measured up to 3 hrs",Other,24900871.0,
2875,1154878,1,3,,103181002,2662,Active,754286265.0,443551.0,27.25,IC50,Inhibition of ovine COX1 using arachidonic acid as substrate,Confirmatory,24900871.0,
2876,1154879,1,3,,103181002,2662,Active,3915797.0,5743.0,0.29,IC50,Inhibition of human recombinant COX2 using arachidonic acid as substrate,Confirmatory,24900871.0,
2877,1154880,1,1,,103181002,2662,Unspecified,,,,,Selectivity for human recombinant COX2 to ovine COX1,Other,24900871.0,
2878,1156826,1,1,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity against albino rat assessed as inhibition of carrageenan-induced paw edema at 0.28 mmol/kg, po administered 30 mins prior to carrageenan challenge measured after 1 hr relative to control",Other,24983538.0,
2879,1156827,1,1,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity against albino rat assessed as inhibition of carrageenan-induced paw edema at 0.28 mmol/kg, po administered 30 mins prior to carrageenan challenge measured after 2 hrs relative to control",Other,24983538.0,
2880,1156828,1,1,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity against albino rat assessed as inhibition of carrageenan-induced paw edema at 0.28 mmol/kg, po administered 30 mins prior to carrageenan challenge measured after 3 hrs relative to control",Other,24983538.0,
2881,1156829,1,1,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity against albino rat assessed as inhibition of carrageenan-induced paw edema at 0.28 mmol/kg, po administered 30 mins prior to carrageenan challenge measured after 4 hrs relative to control",Other,24983538.0,
2882,1156830,1,1,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity against albino rat assessed as inhibition of carrageenan-induced paw edema at 0.28 mmol/kg, po administered 30 mins prior to carrageenan challenge measured after 5 hrs relative to control",Other,24983538.0,
2883,1156832,1,1,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity against albino rat assessed as inhibition of carrageenan-induced paw edema at 0.28 mmol/kg, po administered 30 mins prior to carrageenan challenge measured after 3 hrs relative to celecoxib",Other,24983538.0,
2884,1156833,1,1,,103181002,2662,Unspecified,,,,,"Gastric toxicity in rat assessed as ulcer index at 0.28 mmol/kg, po",Other,24983538.0,
2885,1159387,1,2,,103181002,2662,Unspecified,,,,,"ASTRAZENECA: Octan-1-ol/water (pH7.4) distribution coefficent measured  by a shake flask method described in J. Biomol. Screen. 2011, 16, 348-355. Experimental range -1.5 to 4.5",Other,,
2886,1159388,1,2,,103181002,2662,Unspecified,,,,,"ASTRAZENECA: Solubility in pH7.4 buffer using solid starting material using the method described in J. Assoc. Lab. Autom. 2011, 16, 276-284. Experimental range 0.10 to 1500 uM",Other,,
2887,1159389,1,2,,103181002,2662,Unspecified,,,,,"ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole human plasma  at 37C for >5hrs.  Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound.",Other,,
2888,1159396,1,2,,103181002,2662,Unspecified,,,,,"ASTRAZENECA: Intrinsic clearance measured in human hepatocytes following incubation at 37C. Experimental range <3 to >150 microL/min/1E6 cells. Rapid Commun. Mass Spectrom. 2010, 24, 1730-1736.",Other,,
2889,1159509,1,1,,144209162,2662,Inconclusive,119626539.0,4790.0,54.7327,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
2890,1159509,1,1,,144210916,2662,Inconclusive,119626539.0,4790.0,61.6448,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
2891,1159509,1,1,,170464693,2662,Inconclusive,119626539.0,4790.0,4.7716,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
2892,1159510,3,1,,124890934,2662,Active,,,48.0869,Potency,Immunotoxin (HA22) sensitization/mitigation study. Vehicle arm (PBS),Confirmatory,,
2893,1159511,3,1,,124890934,2662,Active,,,27.0412,Potency,Immunotoxin (SS1P) sensitization/mitigation study - treatment arm,Confirmatory,,
2894,1159512,3,1,,124890934,2662,Active,,,24.1005,Potency,Immunotoxin (HA22) sensitization/mitigation study - treatment arm (low dose),Confirmatory,,
2895,1159513,3,1,,124890934,2662,Active,,,38.1968,Potency,Immunotoxin (SS1P) sensitization/mitigation study. Vehicle arm (DMEM),Confirmatory,,
2896,1159515,1,1,,144209162,2662,Inconclusive,,,61.4111,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
2897,1159515,1,1,,144210916,2662,Inconclusive,,,61.6448,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
2898,1159515,1,1,,170464693,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
2899,1159516,1,1,,144209162,2662,Inconclusive,119611100.0,22926.0,54.7327,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
2900,1159516,1,1,,144210916,2662,Inconclusive,119611100.0,22926.0,4.3641,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
2901,1159516,1,1,,170464693,2662,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
2902,1159517,1,1,,144209162,2662,Inconclusive,,,54.7327,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
2903,1159517,1,1,,144210916,2662,Inconclusive,,,61.6448,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
2904,1159517,1,1,,170464693,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
2905,1159518,1,1,,144209162,2662,Inconclusive,119626539.0,4790.0,57.9758,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
2906,1159518,1,1,,144210916,2662,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
2907,1159518,1,1,,170464693,2662,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
2908,1159519,1,1,,144209162,2662,Inconclusive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
2909,1159519,1,1,,144210916,2662,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
2910,1159519,1,1,,170464693,2662,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
2911,1159520,1,1,,144209162,2662,Active,,,60.882,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
2912,1159520,1,1,,144210916,2662,Active,,,54.4827,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
2913,1159520,1,1,,170464693,2662,Inconclusive,,,33.4915,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
2914,1159521,1,1,,144209162,2662,Active,15928672.0,19885.0,19.2526,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
2915,1159521,1,1,,144210916,2662,Inconclusive,15928672.0,19885.0,30.6379,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
2916,1159521,1,1,,170464693,2662,Inconclusive,15928672.0,19885.0,14.9601,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
2917,1159523,1,1,,144209162,2662,Inconclusive,15928672.0,19885.0,25.6737,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
2918,1159523,1,1,,144210916,2662,Inconclusive,15928672.0,19885.0,28.924,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
2919,1159523,1,1,,170464693,2662,Inconclusive,15928672.0,19885.0,26.6032,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
2920,1159524,1,1,,26747363,2662,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
2921,1159524,1,1,,49665790,2662,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
2922,1159525,1,1,,144209162,2662,Active,,,48.7806,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
2923,1159525,1,1,,144210916,2662,Active,,,54.941,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
2924,1159525,1,1,,170464693,2662,Inconclusive,,,26.8325,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
2925,1159526,1,1,,144209162,2662,Inconclusive,119627033.0,3725.0,48.7806,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
2926,1159526,1,1,,144210916,2662,Inconclusive,119627033.0,3725.0,48.9662,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
2927,1159526,1,1,,170464693,2662,Inconclusive,119627033.0,3725.0,23.9145,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
2928,1159527,1,1,,144209162,2662,Inconclusive,325495497.0,6256.0,43.4757,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
2929,1159527,1,1,,144210916,2662,Inconclusive,325495497.0,6256.0,0.309,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
2930,1159527,1,1,,170464693,2662,Inconclusive,325495497.0,6256.0,2.3914,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
2931,1159528,1,1,,144209162,2662,Inconclusive,119627033.0,3725.0,23.8917,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
2932,1159528,1,1,,144210916,2662,Inconclusive,119627033.0,3725.0,13.8006,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
2933,1159528,1,1,,170464693,2662,Inconclusive,119627033.0,3725.0,19.7391,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
2934,1159529,1,1,,144209162,2662,Active,,,48.7806,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
2935,1159529,1,1,,144210916,2662,Active,,,21.8724,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
2936,1159529,1,1,,170464693,2662,Inconclusive,,,23.9145,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
2937,1159530,2,1,,124890934,2662,Active,,,,Potency,Immunotoxin (HA22) sensitization/mitigation study - treatment arm (High Dose),Confirmatory,,
2938,1159531,1,1,,144209162,2662,Inconclusive,325495497.0,6256.0,2.61967,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
2939,1159531,1,1,,144210916,2662,Inconclusive,325495497.0,6256.0,0.291673,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
2940,1159531,1,1,,170464693,2662,Inconclusive,325495497.0,6256.0,2.68325,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
2941,1159550,3,1,,252401678,2662,Inactive,12653201.0,5226.0,,,Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening,Screening,26479318.0,
2942,1159551,1,1,,144209162,2662,Active,,,60.882,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
2943,1159551,1,1,,144210916,2662,Inconclusive,,,76.9588,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
2944,1159551,1,1,,170464693,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
2945,1159552,1,1,,144209162,2662,Active,325495463.0,5914.0,43.1011,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
2946,1159552,1,1,,144210916,2662,Active,325495463.0,5914.0,27.305999999999997,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
2947,1159552,1,1,,170464693,2662,Active,325495463.0,5914.0,29.8493,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
2948,1159553,2,1,,144209162,2662,Inconclusive,325495463.0,5914.0,19.2526,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
2949,1159553,2,1,,144210916,2662,Inconclusive,325495463.0,5914.0,68.5896,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
2950,1159553,2,1,,170464693,2662,Inconclusive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
2951,1159555,1,1,,144209162,2662,Inconclusive,325495463.0,5914.0,33.4571,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
2952,1159555,1,1,,144210916,2662,Active,325495463.0,5914.0,26.278000000000002,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
2953,1159555,1,1,,170464693,2662,Inconclusive,325495463.0,5914.0,29.8493,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
2954,1159580,2,1,,268734967,2662,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
2955,1159583,2,1,,178126925,2662,Inactive,,,,,High throughput screen for small molecule inhibitors of a hypoxia-regulated fluorescent biosensor in Mycobacterium tuberculosis,Other,,
2956,1159606,1,1,,49665790,2662,Inactive,,,,,"uHTS identification of small molecule inhibitors of TWEAK-Fn14 interactions, using a cell-based reporter assay",Other,,
2957,1159607,2,1,,312310333,2662,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
2958,1159614,1,2,,170464693,2662,Inactive,22328079.0,2581.0,,Potency,A Novel Cell-Based Assay to Identify Small Molecules for B -Galactocerebrosidase,Confirmatory,,
2959,1159620,1,1,,103181002,2662,Active,,,,,Summary of drug indications.,Other,,
2960,1164048,1,2,,103181002,2662,Unspecified,754286265.0,443551.0,,,Inhibition of ovine COX1 assessed as reduction in PGF2alpha formation at 10 uM incubated for 18 hrs by enzyme immunoassay,Other,25219899.0,
2961,1164049,1,2,,103181002,2662,Unspecified,3914304.0,443460.0,,,Inhibition of ovine COX2 assessed as reduction in PGF2alpha formation at 10 uM incubated for 18 hrs by enzyme immunoassay,Other,25219899.0,
2962,1164050,1,2,,103181002,2662,Inconclusive,754286265.0,443551.0,,IC50,Inhibition of ovine COX1 assessed as reduction in PGF2alpha formation incubated for 18 hrs by enzyme immunoassay,Confirmatory,25219899.0,
2963,1164051,1,2,,103181002,2662,Active,3914304.0,443460.0,0.15,IC50,Inhibition of ovine COX2 assessed as reduction in PGF2alpha formation incubated for 18 hrs by enzyme immunoassay,Confirmatory,25219899.0,
2964,1164052,1,1,,103181002,2662,Inconclusive,,,,,"Selectivity index, ratio of IC50 for ovine COX1 to IC50 for ovine COX2",Other,25219899.0,
2965,1164053,1,1,,103181002,2662,Unspecified,,,,,"Anti-inflammatory activity in Sprague-Dawley rat model of carrageenan-induced paw edema assessed as inhibition of paw edema volume at 150 umol/kg, po dosed 1 hr before carrageenan challenge and measured 1 hr post carrageenan challenge",Other,25219899.0,
2966,1164054,1,1,,103181002,2662,Unspecified,,,,,"Anti-inflammatory activity in Sprague-Dawley rat model of carrageenan-induced paw edema assessed as inhibition of paw edema volume at 150 umol/kg, po dosed 1 hr before carrageenan challenge and measured 3 hrs post carrageenan challenge",Other,25219899.0,
2967,1164055,1,1,,103181002,2662,Unspecified,,,,,"Anti-inflammatory activity in Sprague-Dawley rat model of carrageenan-induced paw edema assessed as inhibition of paw edema volume at 150 umol/kg, po dosed 1 hr before carrageenan challenge and measured 5 hrs post carrageenan challenge",Other,25219899.0,
2968,1164201,1,2,,103181002,2662,Active,754286265.0,443551.0,30.0,IC50,"Inhibition of purified ovine COX1 pre-treated for 1 hr before 10-acetyl-3,7-dihydroxyphenoxazin substrate addition in absence of porcine liver esterase by fluorescence assay",Confirmatory,25221653.0,
2969,1164203,1,2,,103181002,2662,Active,3915797.0,5743.0,0.05,IC50,"Inhibition of human recombinant COX2 pre-treated for 1 hr before 10-acetyl-3,7-dihydroxyphenoxazin substrate addition in absence of porcine liver esterase by fluorescence assay",Confirmatory,25221653.0,
2970,1164209,1,1,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for purified ovine COX1 in presence of porcine liver esterase to IC50 for human recombinant COX2 in presence of porcine liver esterase",Other,25221653.0,
2971,1168407,1,1,,103181002,2662,Unspecified,,,,,Anti-inflammatory activity in carrageenan-induced rat foot paw edema model assessed as reduction in paw volume at 20 mg/kg dosed 30 mins before carrageenan injection and measured 1 hr after carrageenan challenge,Other,25304893.0,
2972,1168408,1,1,,103181002,2662,Unspecified,,,,,Anti-inflammatory activity in carrageenan-induced rat foot paw edema model assessed as reduction in paw volume at 20 mg/kg dosed 30 mins before carrageenan injection and measured 3 hrs after carrageenan challenge,Other,25304893.0,
2973,1168409,1,1,,103181002,2662,Unspecified,,,,,Anti-inflammatory activity in carrageenan-induced rat foot paw edema model assessed as reduction in paw volume at 20 mg/kg dosed 30 mins before carrageenan injection and measured 5 hrs after carrageenan challenge,Other,25304893.0,
2974,1168907,1,1,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in albino Wistar rat paw edema model assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 1 hr prior to carrageenan challenge measured after 3 to 5 hrs by plethysmometry relative to vehicle-treated control",Other,25311566.0,
2975,1168908,1,2,,103181002,2662,Unspecified,3915797.0,5743.0,,,Inhibition of human recombinant COX-2 expressed in insect cell system using arachidonic acid as substrate assessed as rate of TMPD oxidation incubated for 1 min prior to substrate addition by spectrophotometry,Other,25311566.0,
2976,1168909,1,1,,103181002,2662,Unspecified,,,,,Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha release at 20 uM after 24 hrs by ELISA,Other,25311566.0,
2977,1168911,1,1,,103181002,2662,Unspecified,,,,,"Toxicity in rat assessed as ulceration at 60 mg/kg, po after 5 hrs",Other,25311566.0,
2978,1168912,1,2,,103181002,2662,Unspecified,,,,,"Toxicity in rat assessed as damage to epithelial layer of stomach at 60 mg/kg, po after 5 hrs",Other,25311566.0,
2979,1169135,1,1,,103181002,2662,Unspecified,,,,,Antiinflammatory activity in orally dosed Sprague-Dawley rat model of carrageenan-induced air pouch inflammation assessed as reduction in PGE2 level by ELISA method,Other,25313331.0,
2980,1169136,1,1,,103181002,2662,Unspecified,,,,,Antiinflammatory activity in orally dosed Sprague-Dawley rat model of carrageenan-induced foot paw edema assessed as reduction in edema by plethysmometry,Other,25313331.0,
2981,1169137,1,1,,103181002,2662,Unspecified,,,,,Antinociceptive activity in orally dosed Sprague-Dawley rat model of carrageenan-induced foot paw hyperalgesia assessed as paw withdrawal latency,Other,25313331.0,
2982,1169138,1,1,,103181002,2662,Unspecified,,,,,Antiarthritic activity in Lewis rat model of adjuvant-induced arthritis administrated by oral gavage once daily,Other,25313331.0,
2983,1172862,1,2,,103181002,2662,Active,754286265.0,443551.0,32.0,IC50,Inhibition of ovine COX1,Confirmatory,25444084.0,
2984,1172863,1,2,,103181002,2662,Active,3914304.0,443460.0,0.3,IC50,Inhibition of ovine COX2,Confirmatory,25444084.0,
2985,1172864,1,1,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for ovine COX1 to IC50 for ovine COX2",Other,25444084.0,
2986,1177822,1,2,,103181002,2662,Unspecified,754286265.0,443551.0,50.0,IC50,Inhibition of ovine COX1 assessed as reduction in PGH2-dervied PGF2alpha production using arachidonic acid substrate by enzyme immunoassay,Confirmatory,24576797.0,
2987,1177823,1,2,,103181002,2662,Active,3914304.0,443460.0,0.28,IC50,Inhibition of ovine COX2 assessed as reduction in PGH2-dervied PGF2alpha production using arachidonic acid substrate by enzyme immunoassay,Confirmatory,24576797.0,
2988,1177824,1,1,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for ovine COX1 to IC50 for ovine COX2",Other,24576797.0,
2989,1177984,1,2,,103181002,2662,Active,754286265.0,443551.0,15.0,IC50,Inhibition of ovine COX-1 assessed as decrease in prostaglandin production using arachidonic acid as substrate incubated with enzyme for 10 mins prior to substrate challenge by enzyme immunoassay,Confirmatory,24631898.0,
2990,1177989,1,2,,103181002,2662,Active,3915797.0,5743.0,0.04,IC50,Inhibition of human recombinant COX-2 assessed as decrease in prostaglandin production using arachidonic acid as substrate incubated with enzyme for 10 mins prior to substrate challenge by enzyme immunoassay,Confirmatory,24631898.0,
2991,1177990,1,1,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for ovine COX-1 to IC50 for human recombinant COX-2",Other,24631898.0,
2992,1177996,1,2,,103181002,2662,Unspecified,3915797.0,5743.0,,,Binding affinity to COX-2 (unknown origin) by ESI mass spectrometry,Other,24631898.0,
2993,1179976,1,2,,103181002,2662,Active,317373262.0,5742.0,15.03,IC50,Inhibition of COX1 (unknown origin) by solid phase ELISA method,Confirmatory,24934992.0,
2994,1179977,1,2,,103181002,2662,Active,3915797.0,5743.0,0.04,IC50,Inhibition of COX2 (unknown origin) by solid phase ELISA method,Confirmatory,24934992.0,
2995,1179978,1,1,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for COX1 (unknown origin) to IC50 for COX2 (unknown origin)",Other,24934992.0,
2996,1183331,1,2,,103181002,2662,Unspecified,754286265.0,443551.0,,,Inhibition of ovine COX1 using fluorometric substrate at 100 uM by fluorescent inhibitor screening assay,Other,25016374.0,
2997,1183335,1,2,,103181002,2662,Unspecified,3915797.0,5743.0,,,Inhibition of human recombinant COX2 using fluorometric substrate at 10 mM by fluorescent inhibitor screening assay,Other,25016374.0,
2998,1188134,1,2,,103181002,2662,Unspecified,115449.0,759.0,50.0,Ki,Inhibition of human recombinant Carbonic anhydrase 1 compound preincubated for 15 mins by stopped flow CO2 hydrase assay method,Confirmatory,25129169.0,
2999,1188135,1,2,,103181002,2662,Active,115456.0,760.0,0.021,Ki,Inhibition of human recombinant Carbonic anhydrase 2 compound preincubated for 15 mins by stopped flow CO2 hydrase assay method,Confirmatory,25129169.0,
3000,1188136,1,1,,103181002,2662,Inconclusive,,,,Ki,Inhibition of Helicobacter pylori Beta-carbonic anhydrase compound preincubated for 15 mins by stopped flow CO2 hydrase assay method,Confirmatory,25129169.0,
3001,1188137,1,1,,103181002,2662,Active,,,4.15,Ki,Inhibition of Porphyromonas gingivalis Beta-carbonic anhydrase compound preincubated for 15 mins by stopped flow CO2 hydrase assay method,Confirmatory,25129169.0,
3002,1188138,1,1,,103181002,2662,Active,,,0.16899999999999998,Ki,Inhibition of Porphyromonas gingivalis Gamma-carbonic anhydrase compound preincubated for 15 mins by stopped flow CO2 hydrase assay method,Confirmatory,25129169.0,
3003,1188169,1,1,,103181002,2662,Unspecified,,,,,Cytotoxicity against human MDA-MB-231 cells assessed as cell viability at 10 ug/ml after 24 to 48 hrs by trypan blue exclusion assay (Rvb = 87.54 +/- 2.11%),Other,25131536.0,
3004,1188170,1,1,,103181002,2662,Unspecified,,,,,Cytotoxicity against human MDA-MB-231 cells assessed as cell viability at 100 ug/ml after 24 to 48 hrs by trypan blue exclusion assay (Rvb = 86.21 +/- 1.80%),Other,25131536.0,
3005,1188171,1,1,,103181002,2662,Unspecified,,,,,Cytotoxicity against human MDA-MB-231 cells assessed as optical density after 24 hrs by MTT assay (Rvb =2.43 +/- 0.05 nm),Other,25131536.0,
3006,1188777,1,2,,103181002,2662,Unspecified,754286265.0,443551.0,50.0,IC50,Inhibition of ovine COX1 assessed as reduction in PGH2 production using arachidonic acid substrate by enzyme immunoassay,Confirmatory,25147154.0,
3007,1188778,1,2,,103181002,2662,Active,3914304.0,443460.0,0.28,IC50,Inhibition of ovine COX2 assessed as reduction in PGH2 production using arachidonic acid substrate by enzyme immunoassay,Confirmatory,25147154.0,
3008,1188779,1,1,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for ovine COX1 to IC50 for ovine COX2",Other,25147154.0,
3009,1190063,1,2,,103181002,2662,Unspecified,115449.0,759.0,50.0,Ki,Inhibition of human recombinant carbonic anhydrase 1 by stopped-flow CO2 hydration assay,Confirmatory,25533402.0,
3010,1190064,1,2,,103181002,2662,Active,115456.0,760.0,0.021,Ki,Inhibition of human recombinant carbonic anhydrase 2 by stopped-flow CO2 hydration assay,Confirmatory,25533402.0,
3011,1190065,1,1,,103181002,2662,Active,,,0.217,Ki,Inhibition of Plasmodium falciparum Eta-carbonic anhydrase pre-incubated for 15 mins before CO2 substrate addition by stopped-flow CO2 hydration assay,Confirmatory,25533402.0,
3012,1190067,1,1,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of Ki for human recombinant carbonic anhydrase 1 to Ki for Plasmodium falciparum Eta-carbonic anhydrase",Other,25533402.0,
3013,1192235,1,2,,103181002,2662,Unspecified,754286265.0,443551.0,,,Inhibition of ovine COX1 at 10 uM by TMPD oxidation based colorimetric assay,Other,25708616.0,
3014,1192236,1,2,,103181002,2662,Unspecified,3915797.0,5743.0,,,Inhibition of human recombinant COX2 at 10 uM by TMPD oxidation based colorimetric assay,Other,25708616.0,
3015,1192615,1,1,,103181002,2662,Unspecified,,,,,"Analgesic activity in Swiss albino mouse model assessed as reduction of acetic acid-induced writhes at 10 mg/kg, po administered 30 mins prior to acetic acid challenge measured after 5 mins for 10 mins relative to vehicle-treated control",Other,25596758.0,
3016,1193925,1,2,,103181002,2662,Unspecified,115449.0,759.0,50.0,Ki,Inhibition of human recombinant CA-1 after 15 mins by stopped-flow CO2 hydrase assay,Confirmatory,25766630.0,
3017,1193926,1,2,,103181002,2662,Active,115456.0,760.0,0.021,Ki,Inhibition of human recombinant CA-2 after 15 mins by stopped-flow CO2 hydrase assay,Confirmatory,25766630.0,
3018,1193927,1,2,,103181002,2662,Active,1168744.0,766.0,2.17,Ki,Inhibition of human recombinant CA-7 after 15 mins by stopped-flow CO2 hydrase assay,Confirmatory,25766630.0,
3019,1193928,1,2,,103181002,2662,Active,83300925.0,768.0,0.016,Ki,Inhibition of human recombinant CA-9 after 15 mins by stopped-flow CO2 hydrase assay,Confirmatory,25766630.0,
3020,1193929,1,2,,103181002,2662,Active,5915866.0,771.0,0.018000000000000002,Ki,Inhibition of human recombinant CA-12 after 15 mins by stopped-flow CO2 hydrase assay,Confirmatory,25766630.0,
3021,1194024,1,2,,103181002,2662,Unspecified,115449.0,759.0,50.0,Ki,Inhibition of human recombinant carbonic anhydrase 1 by stopped flow CO2 hydrase assay,Confirmatory,25773015.0,
3022,1194025,1,2,,103181002,2662,Active,115456.0,760.0,0.021,Ki,Inhibition of human recombinant carbonic anhydrase 2 by stopped flow CO2 hydrase assay,Confirmatory,25773015.0,
3023,1194026,1,1,,103181002,2662,Active,,,0.14,Ki,Inhibition of recombinant Methanosarcina thermophila gamma-carbonic anhydrase by stopped flow CO2 hydrase assay,Confirmatory,25773015.0,
3024,1194027,1,1,,103181002,2662,Active,,,0.16899999999999998,Ki,Inhibition of recombinant Porphyromonas gingivalis gamma-carbonic anhydrase by stopped flow CO2 hydrase assay,Confirmatory,25773015.0,
3025,1194028,1,1,,103181002,2662,Active,,,0.0876,Ki,Inhibition of recombinant Nostoc commune gamma-carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydrase assay,Confirmatory,25773015.0,
3026,1194587,1,2,,103181002,2662,Unspecified,754286265.0,443551.0,78.4,IC50,Inhibition of ovine COX1 using fluorometric substrate after 15 mins,Confirmatory,25819096.0,
3027,1194588,1,2,,103181002,2662,Active,3915797.0,5743.0,0.019,IC50,Inhibition of human recombinant COX2 using fluorometric substrate after 15 mins,Confirmatory,25819096.0,
3028,1195369,1,2,,103181002,2662,Unspecified,115449.0,759.0,50.0,Ki,Inhibition of human carbonic anhydrase 1 pre-incubated for 15 mins by stopped-flow CO2 hydration assay,Confirmatory,25882523.0,
3029,1195370,1,2,,103181002,2662,Active,115456.0,760.0,0.021,Ki,Inhibition of human carbonic anhydrase 2 pre-incubated for 15 mins by stopped-flow CO2 hydration assay,Confirmatory,25882523.0,
3030,1195371,1,2,,103181002,2662,Active,74781045.0,1272966.0,0.17300000000000001,Ki,Inhibition of Anopheles gambiae carbonic anhydrase pre-incubated for 15 mins by stopped-flow CO2 hydration assay,Confirmatory,25882523.0,
3031,1196112,1,2,,103181002,2662,Unspecified,754286265.0,443551.0,100.0,IC50,Inhibition of ovine COX1 assessed as inhibition of PGF2alpha production from PGH2 preincubated for 5 mins before arachidonic acid addition measured after 2 mins by enzyme immunoassay,Confirmatory,25549551.0,
3032,1196113,1,2,,103181002,2662,Active,3914304.0,443460.0,0.26,IC50,Inhibition of ovine COX2 assessed as inhibition of PGF2alpha production from PGH2 preincubated for 5 mins before arachidonic acid addition measured after 2 mins by enzyme immunoassay,Confirmatory,25549551.0,
3033,1196114,1,1,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for ovine COX1 to IC50 for ovine COX2",Other,25549551.0,
3034,1196115,1,1,,103181002,2662,Unspecified,,,,,Antiinflammatory activity in ip dosed Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw edema measured 2 hrs post dose by displacement plethysmometer analysis,Other,25549551.0,
3035,1196116,1,1,,103181002,2662,Unspecified,,,,,Analgesic activity in ip dosed albino Swiss mouse assessed as licking or blowing latency time measured 60 mins post dose by hot plate method,Other,25549551.0,
3036,1198995,1,1,,103181002,2662,Active,,,4.56,IC50,Antiproliferative activity against mouse B16F10 cells after 24 hrs by MTT assay,Confirmatory,25866240.0,
3037,1198996,1,1,,103181002,2662,Active,,,5.94,IC50,Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay,Confirmatory,25866240.0,
3038,1198997,1,1,,103181002,2662,Active,,,7.35,IC50,Antiproliferative activity against human HeLa cells after 24 hrs by MTT assay,Confirmatory,25866240.0,
3039,1198998,1,2,,103181002,2662,Active,317373262.0,5742.0,32.6,IC50,Inhibition of human recombinant COX1 by ELISA,Confirmatory,25866240.0,
3040,1198999,1,2,,103181002,2662,Active,3915797.0,5743.0,0.052000000000000005,IC50,Inhibition of human recombinant COX2 by ELISA,Confirmatory,25866240.0,
3041,1199000,1,2,,103181002,2662,Unspecified,,,72.42,CC50,Cytotoxicity against human 293T cells after 24 hrs by MTT assay,Confirmatory,25866240.0,
3042,1204106,1,1,,103181002,2662,Active,,,2.425,Ki,Inhibition of recombinant Streptococcus mutans UA159 beta-carbonic anhydrase expressed in Escherichia coli Arctic cells preincubated for 15 mins by stopped flow CO2 hydrase assay,Confirmatory,25913199.0,
3043,1204712,1,2,,103181002,2662,Unspecified,754286265.0,443551.0,81.7,IC50,Inhibition of ovine COX1 pre-incubated for 15 mins followed by addition of heme and fluorometric substrate and further incubated for 15 mins in presence of arachidonic acid by fluorescence based assay,Confirmatory,25980909.0,
3044,1204713,1,2,,103181002,2662,Active,3915797.0,5743.0,0.016,IC50,Inhibition of human recombinant COX2 pre-incubated for 15 mins followed by addition of heme and fluorometric substrate and further incubated for 15 mins in presence of arachidonic acid by fluorescence based assay,Confirmatory,25980909.0,
3045,1206369,1,1,,103181002,2662,Active,,,,,"Reversal of complete freund's adjuvant-induced thermal hypersensitivity in Sprague-Dawley rat at 30 mg/kg, po measured after 30 to 180 mins",Other,25850459.0,
3046,1217704,1,2,,103181002,2662,Unspecified,117144.0,1544.0,,,Time dependent inhibition of CYP1A2 (unknown origin) at 100 uM by LC/MS system,Other,21467212.0,
3047,1217707,1,2,,103181002,2662,Unspecified,60416369.0,1557.0,,,Time dependent inhibition of CYP2C19 in human liver microsomes at 100 uM by LC/MS system,Other,21467212.0,
3048,1217710,1,2,,103181002,2662,Unspecified,,,,,Covalent binding in human liver microsomes measured per mg of protein using radiolabelled compound at 10 uM after 1 hr incubation by liquid scintillation counting,Other,21467212.0,
3049,1217711,1,2,,103181002,2662,Unspecified,,,,,Metabolic activation in human liver microsomes assessed as [3H]GSH adduct formation rate measured per mg of protein at 100 uM by [3H]GSH trapping assay,Other,21467212.0,
3050,1217712,1,2,,103181002,2662,Unspecified,117225.0,1558.0,,,Time dependent inhibition of CYP2C8 (unknown origin) at 100 uM by LC/MS system,Other,21467212.0,
3051,1217713,1,2,,103181002,2662,Unspecified,116241312.0,1576.0,,,Time dependent inhibition of CYP3A4 (unknown origin) at 10 uM by LC/MS system,Other,21467212.0,
3052,1217717,1,2,,103181002,2662,Unspecified,6686268.0,1559.0,,,Time dependent inhibition of CYP2C9 (unknown origin) at 30 uM by LC/MS system,Other,21467212.0,
3053,1217724,1,2,,103181002,2662,Unspecified,84028191.0,1565.0,,,Time dependent inhibition of CYP2D6 (unknown origin) at 30 uM by LC/MS system,Other,21467212.0,
3054,1217727,1,2,,103181002,2662,Unspecified,,,,,Intrinsic clearance for reactive metabolites formation per mg of protein in human liver microsomes based on [3H]GSH adduct formation rate at 100 uM by [3H]GSH trapping assay,Other,21467212.0,
3055,1217728,1,1,,103181002,2662,Unspecified,,,,,Intrinsic clearance for reactive metabolites formation per mg of protein based on cytochrome P450 (unknown origin) inactivation rate by TDI assay,Other,21467212.0,
3056,1217729,1,1,,103181002,2662,Unspecified,,,,,Intrinsic clearance for reactive metabolites formation assessed as summation of [3H]GSH adduct formation rate-based reactive metabolites formation and cytochrome P450 (unknown origin) inactivation rate-based reactive metabolites formation,Other,21467212.0,
3057,1217730,1,2,,103181002,2662,Unspecified,117205.0,1555.0,,,Time dependent inhibition of CYP2B6 (unknown origin) at 30 uM by LC/MS system,Other,21467212.0,
3058,1222793,1,1,,103181002,2662,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,23454828.0,
3059,1224818,1,1,,312344531,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway - cell viability counter screen,Confirmatory,,
3060,1224819,1,1,,312344531,2662,Inconclusive,325495545.0,2101.0,16.7855,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway,Confirmatory,,
3061,1224820,1,1,,312344531,2662,Inactive,325495545.0,2101.0,16.7855,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway,Confirmatory,,
3062,1224821,1,1,,312344531,2662,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC),Confirmatory,,
3063,1224822,1,1,,312344531,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) ### cell viability counter screen,Confirmatory,,
3064,1224823,1,1,,312344531,2662,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC),Confirmatory,,
3065,1224824,1,1,,174007280,2662,Inactive,,,8.3328,Potency,High-throughput drug toxicity screening in the BPDCN cell line Gen2.2,Confirmatory,,
3066,1224825,1,1,,174007280,2662,Inactive,,,,Potency,High-throughput drug toxicity screening in the BPDCN cell line Cal-1,Confirmatory,,
3067,1224834,3,1,,144209162,2662,Active,,,48.3603,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
3068,1224834,3,1,,144210916,2662,Active,,,61.1306,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
3069,1224834,3,1,,170464693,2662,Inconclusive,,,29.8493,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
3070,1224835,1,1,,144209162,2662,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
3071,1224835,1,1,,144210916,2662,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
3072,1224835,1,1,,170464693,2662,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
3073,1224836,1,1,,144209162,2662,Active,,,48.3603,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3074,1224836,1,1,,144210916,2662,Inconclusive,,,68.5896,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3075,1224836,1,1,,170464693,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3076,1224837,1,1,,144209162,2662,Inconclusive,,,60.882,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3077,1224837,1,1,,144210916,2662,Active,,,61.1306,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3078,1224837,1,1,,170464693,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3079,1224838,1,1,,144209162,2662,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3080,1224838,1,1,,144210916,2662,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3081,1224838,1,1,,170464693,2662,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3082,1224839,1,1,,144209162,2662,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3083,1224839,1,1,,144210916,2662,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3084,1224839,1,1,,170464693,2662,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3085,1224840,3,1,,144209162,2662,Active,,,54.2611,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
3086,1224840,3,1,,144210916,2662,Active,,,54.4827,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
3087,1224840,3,1,,170464693,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
3088,1224841,3,1,,144209162,2662,Active,325495545.0,2101.0,60.882,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3089,1224841,3,1,,144210916,2662,Inconclusive,325495545.0,2101.0,68.5896,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3090,1224841,3,1,,170464693,2662,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3091,1224842,3,1,,144209162,2662,Inactive,325495545.0,2101.0,60.882,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3092,1224842,3,1,,144210916,2662,Inactive,325495545.0,2101.0,68.5896,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3093,1224842,3,1,,170464693,2662,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3094,1224843,1,1,,144209162,2662,Active,119601739.0,7253.0,48.3603,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3095,1224843,1,1,,144210916,2662,Active,119601739.0,7253.0,34.3762,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3096,1224843,1,1,,170464693,2662,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3097,1224844,1,1,,144209162,2662,Active,,,48.7806,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
3098,1224844,1,1,,144210916,2662,Active,,,54.941,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
3099,1224844,1,1,,170464693,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
3100,1224845,1,1,,144209162,2662,Inconclusive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
3101,1224845,1,1,,144210916,2662,Inconclusive,344243002.0,100757539.0,113.00399999999999,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
3102,1224845,1,1,,170464693,2662,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
3103,1224846,1,1,,144209162,2662,Inconclusive,11995455.0,3091.0,54.7327,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
3104,1224846,1,1,,144210916,2662,Inconclusive,11995455.0,3091.0,54.941,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
3105,1224846,1,1,,170464693,2662,Inconclusive,11995455.0,3091.0,26.8325,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
3106,1224847,1,1,,144209162,2662,Active,,,100.34700000000001,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
3107,1224847,1,1,,144210916,2662,Active,,,113.00399999999999,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
3108,1224847,1,1,,170464693,2662,Inconclusive,,,61.9315,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
3109,1224848,3,1,,144209162,2662,Active,325495545.0,2101.0,27.195,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3110,1224848,3,1,,144210916,2662,Active,325495545.0,2101.0,61.1306,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3111,1224848,3,1,,170464693,2662,Inconclusive,325495545.0,2101.0,29.8493,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3112,1224849,3,1,,144209162,2662,Inactive,325495545.0,2101.0,27.195,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3113,1224849,3,1,,144210916,2662,Inactive,325495545.0,2101.0,61.1306,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3114,1224849,3,1,,170464693,2662,Inactive,325495545.0,2101.0,29.8493,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3115,1224857,2,1,,170464693,2662,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
3116,1224857,2,1,,174007280,2662,Inactive,,,5.2576,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
3117,1224857,2,1,,312344531,2662,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
3118,1224859,2,1,,170464693,2662,Inactive,,,35.4813,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
3119,1224859,2,1,,174007280,2662,Inactive,,,37.2212,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
3120,1224863,1,1,,176484222,2662,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
3121,1224863,1,1,,176484922,2662,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
3122,1224863,1,1,,316919155,2662,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
3123,1224865,1,2,,49665790,2662,Inactive,578162.0,,,,Identify inhibitors of HNF4 alpha protein binding to DNA,Screening,,
3124,1224867,1,1,,144209162,2662,Active,,,48.7806,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
3125,1224867,1,1,,144210916,2662,Active,,,48.9662,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
3126,1224867,1,1,,170464693,2662,Inconclusive,,,30.1065,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
3127,1224868,1,1,,144209162,2662,Active,,,38.7478,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
3128,1224868,1,1,,144210916,2662,Active,,,30.8956,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
3129,1224868,1,1,,170464693,2662,Inconclusive,,,26.8325,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
3130,1224869,1,1,,144209162,2662,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
3131,1224869,1,1,,144210916,2662,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
3132,1224869,1,1,,170464693,2662,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
3133,1224870,1,1,,144209162,2662,Inconclusive,,,61.4111,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
3134,1224870,1,1,,144210916,2662,Active,,,48.9662,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
3135,1224870,1,1,,170464693,2662,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
3136,1224871,1,1,,144209162,2662,Active,,,54.7327,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
3137,1224871,1,1,,144210916,2662,Active,,,54.941,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
3138,1224871,1,1,,170464693,2662,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
3139,1224872,1,1,,144209162,2662,Active,,,38.7478,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
3140,1224872,1,1,,144210916,2662,Active,,,27.5357,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
3141,1224872,1,1,,170464693,2662,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
3142,1224873,1,1,,144209162,2662,Active,,,48.7806,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
3143,1224873,1,1,,144210916,2662,Active,,,48.9662,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
3144,1224873,1,1,,170464693,2662,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
3145,1224874,1,1,,144209162,2662,Active,,,21.7895,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
3146,1224874,1,1,,144210916,2662,Active,,,30.8956,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
3147,1224874,1,1,,170464693,2662,Inconclusive,,,26.8325,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
3148,1224875,1,1,,144209162,2662,Inconclusive,,,54.7327,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
3149,1224875,1,1,,144210916,2662,Inconclusive,,,54.941,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
3150,1224875,1,1,,170464693,2662,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
3151,1224876,1,1,,144209162,2662,Active,,,48.7806,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
3152,1224876,1,1,,144210916,2662,Active,,,43.6412,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
3153,1224876,1,1,,170464693,2662,Inconclusive,,,26.8325,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
3154,1224877,1,1,,144209162,2662,Inconclusive,,,54.7327,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
3155,1224877,1,1,,144210916,2662,Active,,,48.9662,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
3156,1224877,1,1,,170464693,2662,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
3157,1224878,1,1,,144209162,2662,Active,,,19.4199,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
3158,1224878,1,1,,144210916,2662,Active,,,48.9662,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
3159,1224878,1,1,,170464693,2662,Inconclusive,,,26.8325,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
3160,1224879,1,1,,144209162,2662,Active,,,48.7806,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
3161,1224879,1,1,,144210916,2662,Active,,,48.9662,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
3162,1224879,1,1,,170464693,2662,Inconclusive,,,26.8325,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
3163,1224880,1,1,,144209162,2662,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
3164,1224880,1,1,,144210916,2662,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
3165,1224880,1,1,,170464693,2662,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
3166,1224881,1,1,,144209162,2662,Inconclusive,,,54.7327,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
3167,1224881,1,1,,144210916,2662,Active,,,48.9662,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
3168,1224881,1,1,,170464693,2662,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
3169,1224882,1,1,,144209162,2662,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
3170,1224882,1,1,,144210916,2662,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
3171,1224882,1,1,,170464693,2662,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
3172,1224883,1,1,,144209162,2662,Active,,,48.7806,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
3173,1224883,1,1,,144210916,2662,Active,,,48.9662,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
3174,1224883,1,1,,170464693,2662,Inconclusive,,,26.8325,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
3175,1224884,1,1,,144209162,2662,Inconclusive,,,54.7327,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
3176,1224884,1,1,,144210916,2662,Inconclusive,,,61.6448,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
3177,1224884,1,1,,170464693,2662,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
3178,1224885,1,1,,144209162,2662,Active,,,48.7806,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
3179,1224885,1,1,,144210916,2662,Active,,,43.6412,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
3180,1224885,1,1,,170464693,2662,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
3181,1224886,1,1,,144209162,2662,Active,,,38.7478,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
3182,1224886,1,1,,144210916,2662,Active,,,30.8956,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
3183,1224886,1,1,,170464693,2662,Inconclusive,,,30.1065,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
3184,1224887,1,1,,144209162,2662,Active,,,43.4757,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
3185,1224887,1,1,,144210916,2662,Active,,,30.8956,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
3186,1224887,1,1,,170464693,2662,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
3187,1224888,1,1,,144209162,2662,Inconclusive,,,54.7327,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
3188,1224888,1,1,,144210916,2662,Inconclusive,,,54.941,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
3189,1224888,1,1,,170464693,2662,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
3190,1224889,1,1,,144209162,2662,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
3191,1224889,1,1,,144210916,2662,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
3192,1224889,1,1,,170464693,2662,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
3193,1224890,1,1,,144209162,2662,Inconclusive,,,54.7327,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
3194,1224890,1,1,,144210916,2662,Active,,,54.941,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
3195,1224890,1,1,,170464693,2662,Inconclusive,,,26.8325,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
3196,1224892,1,1,,144209162,2662,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3197,1224892,1,1,,144210916,2662,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3198,1224892,1,1,,170464693,2662,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3199,1224893,1,1,,144209162,2662,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3200,1224893,1,1,,144210916,2662,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3201,1224893,1,1,,170464693,2662,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3202,1224894,1,1,,144209162,2662,Inconclusive,11995455.0,3091.0,54.7327,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
3203,1224894,1,1,,144210916,2662,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
3204,1224894,1,1,,170464693,2662,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
3205,1224895,1,1,,144209162,2662,Active,119601739.0,7253.0,49.7724,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3206,1224895,1,1,,144210916,2662,Active,119601739.0,7253.0,40.8562,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3207,1224895,1,1,,170464693,2662,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3208,1224896,1,1,,144209162,2662,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
3209,1224896,1,1,,144210916,2662,Inconclusive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
3210,1224896,1,1,,170464693,2662,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
3211,1224905,2,1,,92308914,2662,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
3212,1224905,2,1,,92308914,2662,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
3213,1224905,2,1,,121361138,2662,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
3214,1224905,2,1,,121361138,2662,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
3215,1224923,1,1,,103181002,2662,Active,,,,,Summary of drugs withdrawn.,Other,,
3216,1226814,1,1,,103181002,2662,Active,754286265.0,443551.0,15.0,IC50,Inhibition of ovine COX-1 assessed as PGF2alpha formation using arachidonic acid as substrate pretreated with compound for 20 mins prior to substrate addition by spectrophotometric analysis,Confirmatory,25956953.0,
3217,1226815,1,1,,103181002,2662,Active,3915797.0,5743.0,0.04,IC50,Inhibition of human recombinant COX-2 assessed as PGF2 alpha formation using arachidonic acid as substrate pretreated with compound for 20 mins prior to substrate addition by spectrophotometric analysis,Confirmatory,25956953.0,
3218,1226816,1,1,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for ovine COX-1 to human recombinant COX-2",Other,25956953.0,
3219,1238183,1,1,,103181002,2662,Unspecified,754286265.0,443551.0,100.0,IC50,"Inhibition of ovine COX-1 assessed as reduction of prostaglandin-G2 to prostaglandin-H2 and oxidation of 10-acetyl-3,7-dihydroxyphenoxazine to resorufin after 5 mins by fluorescence based assay",Confirmatory,26081289.0,
3220,1238184,1,1,,103181002,2662,Active,3915797.0,5743.0,0.13,IC50,"Inhibition of recombinant human COX-2 assessed as reduction of prostaglandin-G2 to prostaglandin-H2 and oxidation of 10-acetyl-3,7-dihydroxyphenoxazine to resorufin after 5 mins by fluorescence based assay",Confirmatory,26081289.0,
3221,1238185,1,1,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for ovine COX-1 to IC50 for recombinant human COX-2",Other,26081289.0,
3222,1240214,1,1,,103181002,2662,Active,,,0.0876,Ki,Inhibition of Nostoc commune gamma carbonic anhydrase by CO2 hydration assay,Confirmatory,26174556.0,
3223,1240215,1,1,,103181002,2662,Active,,,0.7609999999999999,Ki,Inhibition of Pseudoalteromonas haloplanktis gamma carbonic anhydrase by CO2 hydration assay,Confirmatory,26174556.0,
3224,1240216,1,1,,103181002,2662,Active,,,0.14,Ki,Inhibition of Methanosarcina thermophila recombinant gamma carbonic anhydrase by stopped flow CO2 hydrase assay method,Confirmatory,26174556.0,
3225,1240217,1,1,,103181002,2662,Active,115456.0,760.0,0.021,Ki,Inhibition of human recombinant carbonic anhydrase-2 by stopped flow CO2 hydrase assay method,Confirmatory,26174556.0,
3226,1241378,1,1,,103181002,2662,Unspecified,754286265.0,443551.0,,,Inhibition of ovine COX1 using arachidonic acid as substrate at 1 uM preincubated for 5 mins measured after 2 mins by colorimetric analysis,Other,26277757.0,
3227,1241379,1,1,,103181002,2662,Unspecified,3915797.0,5743.0,,,Inhibition of human recombinant COX2 using arachidonic acid as substrate at 1 uM preincubated for 5 mins measured after 2 mins by colorimetric analysis,Other,26277757.0,
3228,1241380,1,1,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of inhibition of human recombinant COX2 to inhibition of ovine COX1",Other,26277757.0,
3229,1241381,1,1,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced hind paw edema at 20 mg/kg, po after 1 hr by plethysmometer",Other,26277757.0,
3230,1241382,1,1,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced hind paw edema at 20 mg/kg, po after 3 hrs by plethysmometer",Other,26277757.0,
3231,1241383,1,1,,103181002,2662,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced hind paw edema at 20 mg/kg, po after 5 hrs by plethysmometer",Other,26277757.0,
3232,1241384,1,1,,103181002,2662,Unspecified,,,,,"Toxicity in Wistar albino rat assessed as ulcer index at 20 mg/kg, po qd for 3 days measured after 6 hrs of last dose",Other,26277757.0,
3233,1244900,1,1,,103181002,2662,Unspecified,,,,,"Antihyperalgesic effect in Swiss mouse assessed as inhibition of CFA-induced paw withdrawal threshold at 300 mg/kg, po after 2 hrs",Other,26263246.0,
3234,1244901,1,1,,103181002,2662,Unspecified,,,,,Antihyperalgesic effect in po dosed Swiss mouse assessed as inhibition of CFA-induced paw withdrawal threshold after 2 hrs,Other,26263246.0,
3235,1244904,1,1,,103181002,2662,Unspecified,,,,,"Antiedematogenic effect in Swiss mouse assessed as inhibition of CFA-induced paw edema at 300 mg/kg, po after 2 hrs",Other,26263246.0,
3236,1244906,1,1,,103181002,2662,Active,,,,,"Antihyperalgesic effect in Swiss mouse assessed as inhibition of CFA-induced paw withdrawal threshold at 300 mg/kg, po after 0.5 to 6 hrs",Other,26263246.0,
3237,1250473,1,1,,103181002,2662,Unspecified,754286265.0,443551.0,78.4,IC50,Inhibition of ovine COX-1 using arachidonic acid after 15 mins by fluorescence based assay,Confirmatory,26316467.0,
3238,1250474,1,1,,103181002,2662,Active,3915797.0,5743.0,0.019,IC50,Inhibition of human recombinant COX-2 using arachidonic acid after 15 mins by fluorescence based assay,Confirmatory,26316467.0,
3239,1251002,1,1,,103181002,2662,Active,,,6.88,IC50,Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay,Confirmatory,26346367.0,
3240,1251003,1,1,,103181002,2662,Active,,,7.55,IC50,Antiproliferative activity against human HeLa cells incubated for 48 hrs by MTT assay,Confirmatory,26346367.0,
3241,1251004,1,1,,103181002,2662,Active,,,2.15,IC50,Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay,Confirmatory,26346367.0,
3242,1251005,1,1,,103181002,2662,Active,,,0.76,IC50,Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay,Confirmatory,26346367.0,
3243,1251008,1,1,,103181002,2662,Unspecified,,,54.38,CC50,Cytotoxicity against HEK293T cells incubated for 48 hrs by MTT assay,Confirmatory,26346367.0,
3244,1253839,1,1,,103181002,2662,Unspecified,754286265.0,443551.0,100.0,IC50,Inhibition of ovine COX-1 using arachidonic acid after 5 mins by colorimetric method,Confirmatory,26455657.0,
3245,1253840,1,1,,103181002,2662,Active,3914304.0,443460.0,0.56,IC50,Inhibition of ovine COX-2 using arachidonic acid after 5 mins by colorimetric method,Confirmatory,26455657.0,
3246,1253841,1,1,,103181002,2662,Unspecified,,,,,"Selectivity index, ratio of IC50 for ovine COX-1 to IC50 for ovine COX-2",Other,26455657.0,
3247,1256041,1,1,,103181002,2662,Unspecified,,,,,Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production at 10 uM preincubated for 30 mins followed by LPS stimulation measured after 24 hrs by Griess assay relative to control,Other,26444098.0,
3248,1256042,1,1,,103181002,2662,Active,,,1.6,IC50,Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 30 mins followed by LPS stimulation measured after 24 hrs by Griess assay,Confirmatory,26444098.0,
3249,1257341,1,1,,103181002,2662,Unspecified,5921694.0,100135490.0,10.6,IC50,Inhibition of Cav1.2 calcium current measured using whole Cell patch clamp in guinea pig ventricular myocytes,Confirmatory,,
3250,1257978,1,1,,103181002,2662,Active,17380162.0,5170.0,48.0,IC50,"BindingDB_Patents: In Vitro Kinase Assay. PDK-1 kinase activity This in vitro assay was performed using a PDK-1 kinase assay kit (Upstate, Lake Placid, N.Y.) according to the vendor's instructions. This cell-free assay is based on the ability of recombinant PDK-1, in the presence of DMSO vehicle or the test agent, to activate its downstream kinase serum- and glucocorticoid-regulated kinase (SGK.) which, in turn, phosphorylates the Akt/SGK-specific peptide substrate RPRAATF with [ inverted question mark-32]-ATP. The [32P]-phosphorylated peptide substrate was then separated from the residual [ inverted question mark-32P]-ATP using PS1 phosphocellulose paper and quantitated by a scintillation counter after three washes with 0.75% phosphoric acid.",Confirmatory,,
3251,1259241,1,1,,144209162,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
3252,1259241,1,1,,144210916,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
3253,1259241,1,1,,170464693,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
3254,1259242,1,1,,144209162,2662,Inconclusive,,,68.3107,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
3255,1259242,1,1,,144210916,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
3256,1259242,1,1,,170464693,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
3257,1259243,1,1,,144209162,2662,Active,124375976.0,367.0,54.2611,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
3258,1259243,1,1,,144210916,2662,Active,124375976.0,367.0,68.5896,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
3259,1259243,1,1,,170464693,2662,Inconclusive,124375976.0,367.0,33.4915,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
3260,1259244,1,1,,144209162,2662,Inconclusive,348019627.0,2099.0,60.882,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
3261,1259244,1,1,,144210916,2662,Inconclusive,348019627.0,2099.0,61.1306,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
3262,1259244,1,1,,170464693,2662,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
3263,1259247,1,1,,144209162,2662,Inconclusive,124375976.0,367.0,58.5898,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
3264,1259247,1,1,,144210916,2662,Inconclusive,124375976.0,367.0,68.5896,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
3265,1259247,1,1,,170464693,2662,Inconclusive,124375976.0,367.0,33.4915,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
3266,1259248,1,1,,144209162,2662,Active,348019627.0,2099.0,71.5301,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
3267,1259248,1,1,,144210916,2662,Inconclusive,348019627.0,2099.0,61.1306,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
3268,1259248,1,1,,170464693,2662,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
3269,1259252,1,1,,174007280,2662,Active,169655958.0,,4.1763,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (RDES),Confirmatory,,
3270,1259253,1,1,,174007280,2662,Active,169655958.0,,13.2066,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC71),Confirmatory,,
3271,1259255,1,1,,174007280,2662,Active,169655958.0,,20.930999999999997,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (EW8),Confirmatory,,
3272,1259256,1,1,,174007280,2662,Active,169655958.0,,11.7704,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC32),Confirmatory,,
3273,1259309,1,1,,178126925,2662,Inactive,,,,,A screen for compounds that are lethal to S. aureus RN4220 with the processive glycosyltransferase UgtP deleted,Other,,
3274,1259310,1,1,,104170206,2662,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
3275,1259310,1,1,,321946832,2662,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
3276,1259310,1,1,,333473336,2662,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
3277,1259311,1,1,,178126925,2662,Inactive,,,,,A screen for compounds that are lethal to S. aureus RN4220,Other,,
3278,1259313,1,1,,49665790,2662,Inactive,,,,,uHTS identification of small molecule modulators of NR3A,Screening,,
3279,1259318,1,1,,49665790,2662,Inactive,,,,,uHTS identification of small molecule modulators of Rev-erb Alpha.,Screening,,
3280,1259325,1,2,,336954409,2662,Inactive,4504843.0,3763.0,,,Discovering small molecule activators of G protein-gated inwardly-rectifying potassium subunit 2 (GIRK2) containing channels utilizing methyl-2 4-pentanediol (MPD) for partial channel activation during screening,Screening,,
3281,1259344,1,1,,144204686,2662,Inactive,,,,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
3282,1259355,1,1,,144204686,2662,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-1,Confirmatory,,
3283,1259356,1,1,,144204686,2662,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-2,Confirmatory,,
3284,1259357,1,1,,124890934,2662,Inconclusive,,,0.0021,Potency,"Identifying Small Molecule Inhibitors of Pancreatic Cancer Stem Cells (A2780, Spheroid)",Confirmatory,,
3285,1259358,1,1,,124890934,2662,Inconclusive,,,60.5378,Potency,"Identifying Small Molecule Inhibitors of Pancreatic Cancer Stem Cells (SN12C, Adherent)",Confirmatory,,
3286,1259359,1,1,,124890934,2662,Inconclusive,,,,Potency,"Identifying Small Molecule Inhibitors of Pancreatic Cancer Stem Cells (Panc1, Spheroid)",Confirmatory,,
3287,1259360,1,1,,124890934,2662,Inconclusive,,,60.5378,Potency,"Identifying Small Molecule Inhibitors of Pancreatic Cancer Stem Cells (SN12C, Spheroid)",Confirmatory,,
3288,1259361,1,1,,124890934,2662,Inconclusive,,,107.38600000000001,Activity at 9.921 uM,"Identifying Small Molecule Inhibitors of Pancreatic Cancer Stem Cells (A278, Adherent)",Confirmatory,,
3289,1259362,1,1,,124890934,2662,Inconclusive,,,,Potency,"Identifying Small Molecule Inhibitors of Pancreatic Cancer Stem Cells (Panc1, Adherent)",Confirmatory,,
3290,1259364,1,1,,144209162,2662,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
3291,1259364,1,1,,144210916,2662,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
3292,1259364,1,1,,170464693,2662,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
3293,1259365,1,1,,144209162,2662,Inconclusive,,,60.882,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
3294,1259365,1,1,,144210916,2662,Inconclusive,,,54.4827,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
3295,1259365,1,1,,170464693,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
3296,1259366,1,1,,144209162,2662,Active,,,60.882,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3297,1259366,1,1,,144210916,2662,Active,,,61.1306,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3298,1259366,1,1,,170464693,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3299,1259367,1,1,,144209162,2662,Active,,,54.2611,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3300,1259367,1,1,,144210916,2662,Active,,,61.1306,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3301,1259367,1,1,,170464693,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3302,1259368,1,1,,144209162,2662,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3303,1259368,1,1,,144210916,2662,Inactive,109731339.0,2737.0,68.5896,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3304,1259368,1,1,,170464693,2662,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3305,1259369,1,1,,144209162,2662,Active,109731339.0,2737.0,21.6017,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3306,1259369,1,1,,144210916,2662,Active,109731339.0,2737.0,13.6854,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3307,1259369,1,1,,170464693,2662,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3308,1259370,2,2,,124637194,2662,Inactive,312803.0,1017.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
3309,1259370,2,2,,124637194,2662,Inactive,510604.0,890.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
3310,1259370,2,2,,124637194,2662,Inactive,14602917.0,994.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
3311,1259377,1,1,,144209162,2662,Inconclusive,54288833.0,2100.0,68.3107,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3312,1259377,1,1,,144210916,2662,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3313,1259377,1,1,,170464693,2662,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3314,1259378,1,1,,144209162,2662,Inconclusive,54288833.0,2100.0,68.3107,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3315,1259378,1,1,,144210916,2662,Inconclusive,54288833.0,2100.0,68.5896,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3316,1259378,1,1,,170464693,2662,Inconclusive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3317,1259379,1,1,,144209162,2662,Inconclusive,,,76.6459,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3318,1259379,1,1,,144210916,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3319,1259379,1,1,,170464693,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3320,1259380,1,1,,144209162,2662,Active,,,60.882,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3321,1259380,1,1,,144210916,2662,Active,,,34.3762,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3322,1259380,1,1,,170464693,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3323,1259381,1,1,,144209162,2662,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
3324,1259381,1,1,,144210916,2662,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
3325,1259381,1,1,,170464693,2662,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
3326,1259382,1,1,,144209162,2662,Active,,,54.2611,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3327,1259382,1,1,,144210916,2662,Active,,,61.1306,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3328,1259382,1,1,,170464693,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3329,1259383,1,1,,144209162,2662,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
3330,1259383,1,1,,144210916,2662,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
3331,1259383,1,1,,170464693,2662,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
3332,1259384,1,1,,144209162,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
3333,1259384,1,1,,144210916,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
3334,1259384,1,1,,170464693,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
3335,1259385,1,1,,144209162,2662,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3336,1259385,1,1,,144210916,2662,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3337,1259385,1,1,,170464693,2662,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3338,1259386,1,1,,144209162,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3339,1259386,1,1,,144210916,2662,Inconclusive,,,24.3365,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3340,1259386,1,1,,170464693,2662,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3341,1259387,1,1,,144209162,2662,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
3342,1259387,1,1,,144210916,2662,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
3343,1259387,1,1,,170464693,2662,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
3344,1259388,1,1,,144209162,2662,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
3345,1259388,1,1,,144210916,2662,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
3346,1259388,1,1,,170464693,2662,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
3347,1259389,1,1,,124637194,2662,Inactive,,,,,HIV1_TAR : FRET assay measuring displacement of FAM and TAMRA-labeled Tat peptide from HIV-1 TAR RNA.,Screening,,
3348,1259390,1,1,,144209162,2662,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3349,1259390,1,1,,144210916,2662,Inconclusive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3350,1259390,1,1,,170464693,2662,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3351,1259391,1,1,,144209162,2662,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
3352,1259391,1,1,,144210916,2662,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
3353,1259391,1,1,,170464693,2662,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
3354,1259392,1,1,,144209162,2662,Inconclusive,109731339.0,2737.0,22.0202,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3355,1259392,1,1,,144210916,2662,Active,109731339.0,2737.0,14.4963,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3356,1259392,1,1,,170464693,2662,Inconclusive,109731339.0,2737.0,31.618000000000002,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3357,1259393,1,1,,144209162,2662,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
3358,1259393,1,1,,144210916,2662,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
3359,1259393,1,1,,170464693,2662,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
3360,1259394,1,1,,144209162,2662,Inconclusive,54288833.0,2100.0,72.3584,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3361,1259394,1,1,,144210916,2662,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3362,1259394,1,1,,170464693,2662,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3363,1259395,1,1,,144209162,2662,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3364,1259395,1,1,,144210916,2662,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3365,1259395,1,1,,170464693,2662,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3366,1259396,1,1,,144209162,2662,Inconclusive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3367,1259396,1,1,,144210916,2662,Inconclusive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3368,1259396,1,1,,170464693,2662,Inconclusive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3369,1259400,1,1,,170464693,2662,Inactive,166209887.0,59350.0,,,qHTS Assay for Antagonists of the Relaxin Receptor RXFP1,Screening,,
3370,1259401,1,1,,144209162,2662,Inconclusive,325495545.0,2101.0,55.525,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3371,1259401,1,1,,144210916,2662,Inconclusive,325495545.0,2101.0,68.5896,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3372,1259401,1,1,,170464693,2662,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3373,1259402,1,1,,144209162,2662,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3374,1259402,1,1,,144210916,2662,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3375,1259402,1,1,,170464693,2662,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3376,1259403,1,1,,144209162,2662,Inconclusive,325495545.0,2101.0,30.5133,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3377,1259403,1,1,,144210916,2662,Inconclusive,325495545.0,2101.0,58.82899999999999,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3378,1259403,1,1,,170464693,2662,Inconclusive,325495545.0,2101.0,29.8493,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3379,1259404,1,1,,144209162,2662,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3380,1259404,1,1,,144210916,2662,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3381,1259404,1,1,,170464693,2662,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3382,1259406,1,1,,363920409,2662,Unspecified,,,,,BK Channel Variant Modulator Selectivity Assay,Screening,,
3383,1259406,1,1,1.0,363920409,2662,Inactive,26638650.0,3778.0,0.0569696,LogChange(F380Y),BK Channel Variant Modulator Selectivity Assay,Screening,,
3384,1259406,1,1,2.0,363920409,2662,Inactive,4758626.0,3779.0,-0.0387384,LogChange(F380Y/beta1),BK Channel Variant Modulator Selectivity Assay,Screening,,
3385,1259406,1,1,3.0,363920409,2662,Inactive,5031823.0,10242.0,-0.0191525,LogChange(F380Y/beta2Delta),BK Channel Variant Modulator Selectivity Assay,Screening,,
3386,1259406,1,1,4.0,363920409,2662,Inactive,26051275.0,27345.0,0.016699099999999998,LogChange(F380Y/beta4),BK Channel Variant Modulator Selectivity Assay,Screening,,
3387,1259406,1,1,5.0,363920409,2662,Inactive,160410009.0,389816.0,-0.0326585,LogChange(F380Y/Slo1WT/gamma1),BK Channel Variant Modulator Selectivity Assay,Screening,,
3388,1259406,1,1,6.0,363920409,2662,Inactive,26638650.0,3778.0,-0.009426299999999999,LogChange(R275C),BK Channel Variant Modulator Selectivity Assay,Screening,,
3389,1259406,1,1,7.0,363920409,2662,Inactive,4758626.0,3779.0,0.0119804,LogChange(R275C/beta1),BK Channel Variant Modulator Selectivity Assay,Screening,,
3390,1259406,1,1,8.0,363920409,2662,Inactive,5031823.0,10242.0,-0.0273959,LogChange(R275C/beta2Delta),BK Channel Variant Modulator Selectivity Assay,Screening,,
3391,1259406,1,1,9.0,363920409,2662,Inactive,26051275.0,27345.0,-0.00588398,LogChange(R275C/beta4),BK Channel Variant Modulator Selectivity Assay,Screening,,
3392,1259406,1,1,10.0,363920409,2662,Inactive,5031823.0,10242.0,-0.0384816,LogChange(R275C/Slo1WT/beta2),BK Channel Variant Modulator Selectivity Assay,Screening,,
3393,1259409,1,1,,363906628,2662,Unspecified,,,,,CCRIS tumor inhibitor studies,Other,,
3394,1259409,1,1,,363907276,2662,Unspecified,,,,,CCRIS tumor inhibitor studies,Other,,
3395,1259413,1,2,,104170206,2662,Inactive,47605623.0,173990.0,,,Modulators of fzo-1,Other,,
3396,1259415,1,1,,49665790,2662,Inactive,,,,,qHTS Assay for inhibitors of the human cytomegalovirus (HCMV),Screening,,
3397,1259416,1,2,,340079670,2662,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
3398,1259416,1,2,,375174629,2662,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
3399,1259418,1,1,,375174629,2662,Active,56786138.0,3458.0,22.18,AC50_uM,Toxoplasma gondii at dose in the presence of IFN-y,Confirmatory,,
3400,1259420,1,1,,375174629,2662,Inactive,56786138.0,3458.0,,AC50_uM,Toxoplasma gondii at dose in the absence of IFN-y,Confirmatory,,
3401,1259421,1,1,,340079670,2662,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
3402,1259421,1,1,,375174629,2662,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
3403,1259423,1,2,,354987648,2662,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
3404,1259423,1,2,,354992960,2662,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
